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Abstract 
Introduction: Hypoglycaemia has been strongly associated with 
cardiovascular death in trials of intensive glycaemic control in type 2 
diabetes (T2DM) patients at high cardiovascular risk for up to 90 days 
afterwards. Hypoglycaemia may increase cardiovascular mortality via: i) 
proarrhythmic effects due to abnormal cardiac repolarisation and 
autonomic function; and ii) prothrombotic effects via platelet 
hyperreactivity and altered fibrin clot properties. It was hypothesised this 
may be mediated by both acute and mechanisms downstream of the 
hypoglycaemic event and these were tested experimentally. 
Methods: The risk of cardiac arrhythmias was examined during 
spontaneous hypoglycaemia, as captured via continuous interstitial glucose 
and Holter monitoring in insulin-treated T2DM patients. This was 
complemented by hyperinsulinaemic hypoglycaemic clamp studies, where 
cardiovascular parameters were measured acutely and up to 7 days later in 
T2DM and nondiabetic subjects. Autonomic function was analysed using 
heart rate variability and spontaneous baroreceptor sensitivity, whilst 
effects on thrombosis were analysed using platelet function assays, 
turbidimetric and lysis assays, and scanning electron microscopy of fibrin 
clots.  
Results: During spontaneous prolonged hypoglycaemia, an 8-fold increase 
in bradyarrhythmias was observed. Vagal re-activation following initial 
transient withdrawal was observed during spontaneous as well as 
experimental hypoglycaemia, that only occurred in T2DM subjects. 
Hypoglycaemia was found to increase platelet activation and aggregation 
acutely, whilst also increasing fibrin clot density and depressing fibrinolysis 
for up to 7 days, an effect that occurred in T2DM subjects but not 
nondiabetic controls. 
Conclusions: Hypoglycaemia may override the benefits of intensive glucose 
control via proarrhythmic and prothrombotic mechanisms. These effects 
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may persist beyond the acute episode and mediate short term increases in 
cardiovascular mortality. Hypoglycaemia should be minimised in high 
cardiovascular risk patients through individualised glucose lowering 
strategies.  
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Chapter 1 - Introduction 
Diabetes mellitus is defined as a metabolic disorder characterised by raised 
blood glucose, and currently affects 4% of the UK population with numbers 
expected to reach half a billion worldwide by 2030. The consequences of 
chronic hyperglycaemia include microvascular complications (nephropathy, 
retinopathy, neuropathy) and macrovascular complications (cardiovascular, 
peripheral arterial and cerebrovascular disease).  The leading cause of 
death is cardiovascular disease (CVD) which accounts for 50% of all deaths 
of diabetic individuals (Morrish et al., 2001), and of these, sudden cardiac 
death (SCD) is the first presentation of CVD in half of all cases. In 400 BC, 
Hippocrates noted that ‘sudden death is more common in those who are 
naturally fat than in the lean’, and epidemiological studies have shown that 
the risk of SCD is increased by two- to three-fold among subjects with type 
2 diabetes (T2DM) compared with nondiabetic individuals (Curb et al., 
1995).  
Current prevention of cardiovascular complications is dependent on a 
multifactorial approach, addressing risk factors such as hypertension, 
hyperlipidaemia and lifestyle factors, and glycaemic control. Intensive 
glycaemic control reduces microvascular complications and was 
demonstrated in the landmark United Kingdom Prospective Diabetes Study 
(UKPDS), where levels were reduced by a quarter (UK Prospective Diabetes 
Study Group, 1998a, b).  The potential of intensive glycaemic control to 
reduce the incidence of CVD is less established and has been tested 
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recently by three international randomised controlled trials - Action to 
Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and 
Vascular Disease: Preterax and Diamicron Modified Release Controlled 
Evaluation (ADVANCE) and Veteran Administration Diabetes Trial  (VADT). 
These trials were designed to examine the effect of intensive glycaemic 
treatment versus conventional treatment on cardiovascular endpoints, 
including major adverse cardiovascular events and  death (Duckworth et 
al., 2009; Gerstein et al., 2008; Patel et al., 2008). A total of nearly 25,000 
T2DM patients worldwide with existing CVD or two or more cardiovascular 
risk factors were randomised into an intensive glycaemic control group 
(target glycated haemoglobin A1c, HbA1c <6.0% in ACCORD and VADT, 
<6.5% in ADVANCE) versus a group receiving standard glycaemic therapy. 
My research question was prompted by the premature termination of the 
ACCORD trial in 2008 due to excess mortality in the intensive glucose 
lowering arm. 
In this introductory chapter, the pathophysiological mechanisms of T2DM 
and SCD will be outlined, and the relationship between T2DM, glycaemia 
and an increased risk of CVD will be explored, together with the 
paradoxical effectiveness of intensive glucose lowering strategies in CVD 
prevention. Evidence from large scale trials of intensive glycaemic control 
in T2DM will be presented that implicate hypoglycaemia as a causal factor 
in increased risk of cardiovascular death, a key observation which has 
prompted this research. The existing literature on cardiovascular effects of 
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hypoglycaemia and potential mechanistic links between hypoglycaemia 
and SCD will be reviewed. Finally, I will present the research question 
based on current gaps in the knowledge and the overall aims of my thesis. 
1.1 Pathogenesis of Type 2 Diabetes 
Diabetes mellitus describes a group of metabolic disorders characterised by 
hyperglycaemia, either as a result of deficient insulin secretion, resistance 
to the action of insulin, or a combination of both. The World Health 
Organization  (WHO) has defined the glucose thresholds for diagnosis: 
fasting plasma glucose >7 mmol/L; random plasma glucose >11.1 mmol/L, 
or a 2 hour plasma glucose >11.1 mmol during 75 g oral glucose tolerance 
test (2009). While these definitions are widely accepted, the aetiological 
classification of diabetes is not straightforward, particularly as the 
understanding of pathogenesis of diabetes has increased.  T2DM, which 
accounts for 90-95% of diabetes, is a heterogeneous disorder, where 
individuals may present with a range of defects, from predominantly 
insulin resistance with relative insulin deficiency, to predominantly a 
secretory defect with insulin resistance (2009).  
It has previously been assumed that insulin resistance is the primary defect 
in T2DM, leading to eventual beta cell failure as a result of compensatory 
hyperinsulinaemia. However, current evidence challenges this view. T2DM 
develops as a consequence of a progressive, largely genetically 
determined, decline in beta cell function in addition to acquired insulin 
resistance secondary to factors such as physical activity and obesity (Alsahli 
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M, 2010). In the pre-diabetic state, individuals are at least as insulin 
resistant as patients with T2DM, and normally there is a hyperbolic 
relationship between insulin secretion and insulin sensitivity. Individuals 
with T2DM fall off this curve and have inadequate insulin secretion in the 
face of insulin resistance (Figure 1-1).  In the United Kingdom Prospective 
Diabetes Study (UKPDS), the use of a mathematical model relating insulin 
and glucose measurements through homeostatic model assessment 
(HOMA), indicated that there is already a 50% loss of beta cell function at 
the point of diagnosis (1995). Both glucotoxicity secondary to 
hyperglycaemia and lipotoxicity from free fatty acids (FFA), impair the 
capacity of beta-cell for glucose sensing, regeneration and the propensity 
for apoptosis (Alsahli M, 2010). There is growing evidence that 
endoplasmic reticulum stress induced apoptosis and cytokines, such as 
interleukin-1 (IL1), may be implicated in beta-cell decline. 
 
Figure 1-1: Relationship between insulin secretion and insulin sensitivity 
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The curvilinear relationship between beta cell function (as represented by the acute 
insulin response) and insulin sensitivity as measured during a hyperinsulinaemic clamp. 
Individuals with normal glucose tolerance (NGT) remain on the curvilinear line, whereas 
progressors went on to develop impaired glucose tolerance  (IGT) and eventually diabetes 
(DM), failing to demonstrate adequate beta cell compensation for insulin resistance.  
Modified from (Alsahli M, 2010). 
Insulin resistance is defined as the inability of insulin to exert its normal 
biological actions. The molecular mechanisms of insulin resistance are 
incompletely understood. There are multiple intramyocellular defects 
concerning insulin action, including impaired glucose transport and 
phosphorylation, reduced glycogen synthesis, and decreased glucose 
oxidation (Defronzo, 2009). However, a notable abnormality is the 
impaired ability of insulin to phosphorylate the insulin receptor substrate 1 
(IRS-1), which leads to the reduced activation of phosphatidylinositol-3-
kinase (PI3K). PI3K normally mediates insulin-stimulated muscle glycogen 
synthase activity and insulin stimulated glucose disposal (DeFronzo, 2004). 
The key sites of insulin resistance, with respect to glucose homeostasis, are 
the liver and muscle. Hepatic insulin resistance leads to the inability of 
insulin to suppress basal hepatic glucose production and fasting 
hyperglycaemia. Skeletal muscle is responsible of 80% of the total body 
glucose uptake, whereas adipose tissue is responsible for only 5% of 
glucose disposal. Muscle insulin resistance has been demonstrated in lean 
and obese T2DM individuals, and impaired glucose uptake by leg muscles 
has been shown to occur in response to physiological increases in plasma 
insulin (DeFronzo, 2004). 
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Insulin resistance is clearly associated with obesity, and in epidemiological 
studies, there is a clear association between total body fat and insulin 
resistance across a broad range of body mass indices and  ethnic groups 
(Buse et al., 2011). Central adiposity is more closely linked to insulin 
resistance and there is considerable evidence that fat distribution and 
adipocyte metabolism are involved in the pathogenesis of T2DM. Insulin is 
normally an antilipolytic hormone which restrains the release of FFA 
release from adipocytes via hormone-sensitive lipase. The impaired 
antilipolytic effect of insulin leads to chronic FFA elevation, and FFA has 
been shown to induce hepatic and muscle insulin resistance. Furthermore, 
it is now thought that fat cells are not merely sites of lipid storage but in 
fact active endocrine organs. Dysfunctional adipocytes have been shown to 
produce excessive amount of proinflammatory, insulin-resistance inducing 
adipocytokines, such as tumour necrosis factor alpha (TNF-α) and 
interleukin 6 (IL-6), and reduced amounts of protective adipocytokines, 
such as adiponectin. The pathogenesis of T2DM is clearly multifactorial and 
complex.  Defronzo (2009) described the ‘ominous octet’, where in 
addition to beta cell dysfunction and liver and muscle insulin resistance, 
other factors, including accelerated lipolysis of fat cells,  incretin 
deficiency/resistance, hyperglucagonaemia, increased renal glucose 
reabsorption and brain insulin resistance leading to altered appetite 
regulation, all contribute to disease pathogenesis. 
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1.2 Pathophysiology of Sudden Cardiac Death  
SCD is defined as death attributed to cardiac causes occurring suddenly or 
unexpectedly within one hour of the onset of symptoms (Myerburg and 
Wellens, 2006). The incidence of SCD is 0.1-0.2% per year in the adult 
population (Myerburg and Wellens, 2006), which amounts to 50,000-
70,000 people annually in the UK (NICE, 2007).  The terminal event in SCD 
is usually due to fatal ventricular tachycardia (VT) or ventricular fibrillation 
(VF). In Western countries, the underlying cause in 80% of cases is coronary 
artery disease, with cardiomyopathies and ion channel abnormalities 
accounting for the remaining 20% of cases. SCD is often the first expression 
of ischaemic heart disease and accounts for 50% of all deaths due to 
ischaemic heart disease.  
Diabetes has been associated with an increased risk of SCD (Balkau et al., 
1999) but whether the risk increases beyond that attributed to CVD  is 
debated (Kucharska-Newton et al., 2010; Suarez et al., 2005). In the 
Rochester diabetic neuropathy study, 21 SCDs were reported during a 15 
year follow up, all of whom had coronary or myocardial disease (Suarez et 
al., 2005). In the Honolulu heart programme, a 23 year follow up of over 
800 patients found that diabetes conferred an increased relative risk of 
SCD of 2.76 (Curb et al., 1995). Similarly, a population based case control 
study found that high glucose levels were associated with an increased risk 
of SCD irrespective of microvascular complications (Jouven et al., 2005). 
The Framingham study also revealed a strong association between 
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diabetes and SCD in women (Kannel and McGee, 1985). In the Paris 
Prospective Study 1, diabetes was an independent risk factor for SCD even 
after adjusting for other risk factors (Balkau et al., 1999). 
The pathophysiology of SCD is notoriously difficult to study, as these are 
sudden, unheralded events, and it is increasingly recognised that SCD 
involves an underlying substrate and a transient trigger. The 
pathophysiology of SCD is a multifactorial process involving: 1) 
conventional risk factors promoting atherogenesis; 2) rupture of the 
vulnerable plaque; 3) activation of the thrombotic cascade; and 4) a final 
transient trigger, such as autonomic balance in patients with an 
electrophysiological predisposition for arrhythmia (Myerburg and Wellens, 
2006)  
 
 
 
 
 
 
 
 
Figure 1-2). The pathogenesis of SCD in diabetic patients is likely to be 
multifactorial due to the combination of atherosclerosis as well as specific 
thrombosis and plaque-related and electrophysiological factors that 
enhance the risk. In the following section an overview of the 
pathophysiological processes underpinning the evolution of SCD is 
discussed. 
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Figure 1-2: Multifactorial cascade leading to SCD 
General risk factors, such as diabetes and hypertension promote atherogenesis. The 
transition from a stable to a vulnerable plaque is driven by diffuse subclinical 
inflammation.  Clotting factors and the fibrinolytic balance determine the fate of a 
ruptured plaque and the development of coronary thrombosis. Transient factors, such as 
an altered sympathovagal balance and cardiac repolarisation abnormalities, can trigger 
the final fatal event of a ventricular tachyarrythmia. DM  - diabetes mellitus, HTN  - 
hypertension, CRP  - C reactive protein, vWF  - von Willebrand factor, IL-6  - interleukin 6, 
PAI-1  - plasminogen activator 1, tPA  - tissue plasminogen activator. 
1.2.1 Atherogenesis 
Atherogenesis is a chronic inflammatory condition characterised by 
endothelial injury, modified lipoproteins and immune cells (Boyle, 2007). 
Low density lipoprotein (LDL) cholesterol is deposited across the vascular 
endothelium, mediated by angiotensin II, and oxidation of LDL cholesterol 
leads to a chain of metabolic responses, which attract monocytes to the 
subendothelial compartment. These monocytes differentiate into 
macrophages under the influence of IL1 and turn into foam cells secreting 
cytokines, such as interleukin 2 (IL-2) and TNFα, which drive the expression 
of vascular cell adhesion molecules (VCAM) on the endothelial surface. In 
turn, these adhesion molecules attract T lymphocytes which secrete 
interferon-gamma (IFN-γ) and stimulate smooth muscle proliferation 
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(Boyle, 2007). There is eventual elaboration of the extracellular matrix 
which turns into a fibrous cap overlying the atheroma.  
1.2.2 Vulnerable Plaques 
Acute myocardial infarction (AMI) and unstable angina are the result of 
acute plaque disruption and subsequent thrombosis overlying the plaque, 
leading to coronary vascular occlusion. An understanding of the concept of 
the ‘vulnerable plaque’ is fundamental to the current concept of acute 
coronary syndromes (ACS). One of the factors thought to promote 
transitioning from a stable to a vulnerable plaque is subclinical 
inflammation (Libby, 2008). Markers of subclinical inflammation, such as 
high C reactive protein (CRP) levels, predicted a 2-fold increase in SCD risk 
over a 17 year follow up period in men (Albert and Cobbe, 2006), whilst 
elevated levels of von Willebrand factor (vWF) and IL-6 predicted an 
increased risk of a fatal over that of a nonfatal coronary event (Empana et 
al., 2010; Kucharska-Newton et al., 2009).  
1.2.3 Thrombosis and Coronary Occlusion 
Plaque rupture precipitates a series of events leading to the formation of a 
thrombus over the eroded or ruptured plaque causing ACS. In a large post 
mortem study of SCD victims, 74% had evidence of intramural thrombosis 
(Davies and Thomas, 1984). Activation of the thrombotic cascade is a 
critical event in the precipitation of SCD and involves both cellular and fluid 
phases of the coagulation system. Platelets are involved in the initial 
response by adhering to the ruptured plaque, which is followed by the 
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activation of the thrombotic cascade and the generation of a platelet rich 
fibrin mesh (Grant, 2007). The fate of a ruptured plaque and whether it 
becomes a sustained occlusive thrombus is dictated by the fibrinolytic 
balance. Increased levels of hepatic derived coagulation factors promote 
clot formation, while impaired fibrinolysis can result from a decrease in 
fibrinolytic enzymes or an increase in endogenous inhibitors, such as 
plasminogen-activator-inhibitor-1 (PAI-1).  
1.2.4 Cardiac Electrical Instability and Arrhythmogenesis 
The final event in SCD in 80% of cases is a fatal ventricular tachyarrhthmia. 
Based on observational studies, SCD stratifiers with prognostic value in 
patients with established cardiac disease fall into 3 categories (Spooner, 
2008): 
1) Structural - left ventricular ejection fraction (LVEF) <30-35%, left 
ventricular hypertrophy 
2) Markers of enhanced sympathetic activity - heart rate variability (HRV) 
3) Markers of electrical instability - prolonged QTc, arrhythmia 
inducibility during invasive electrophysiological studies 
Left ventricular hypertrophy of any cause is one of the strongest predictors 
of SCD, and the risk of SCD post myocardial infarction is increased by left 
ventricular dysfunction (Solomon et al., 2005). Autonomic function has a 
strong contributory influence on SCD. Impaired baroreceptor sensitivity 
(BRS) and HRV are strongly associated with an increased SCD risk in cohort 
studies (La Rovere et al., 1998). The risk of SCD is highest during the first 3 
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hours after waking, coinciding with maximal sympathetic activation (Albert 
and Cobbe, 2006). In prospective studies among T2DM patients, those with 
a depressed cardiac vagal function were 1.5 to 2 times more likely to suffer 
a SCD (Kataoka et al., 2004; Wheeler et al., 2002). 
Arrhythmias can result from abnormal automaticity, triggered activity, or 
both. Triggered activity may be caused by early or delayed 
afterdepolarisations (EAD and DAD), which are secondary repolarisations 
during or after the repolarisation phase, respectively. Long QT syndromes 
(LQTS), both congenital and acquired have provided a paradigm for the 
understanding of the relationship between abnormal cardiac repolarisation 
and ventricular arrhythmias. In LQTS, changes in cardiac ion channels lead 
to altered repolarisation currents and a prolonged cardiac repolarisation 
phase (Goldenberg et al., 2008) (Figure 1-3). It has been hypothesised that 
increased dispersion creates pockets of inexcitable tissue predisposed to 
re- entrant arrhythmias and a polymorphic form of VT (Taggart et al., 1990).  
Transmural and apical basal heterogeneity are responsible for the 
morphology of the T wave on surface electrocardiogram (ECG). QT 
parameters have been shown to be accurate predictors of cardiac mortality 
in newly diagnosed T2DM patients (Naas et al., 1998).  Another study has 
shown that QT interval abnormalities present at diagnosis and were better 
predictors of cardiac death than the ankle brachial pressure index and 
autonomic function tests in type 2 diabetes patients (Rana et al., 2011). 
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Figure 1-3: Ionic basis of abnormal cardiac repolarisation in LQTS and relation 
to ECG morphology  
(A) The top panel shows the phases of a normal cardiac action potential (AP).  In phase 0, 
rapid depolarisation occurs caused by an influx of Na
+
 via the ina channel. In phase 1, 
inactivation of ina and the movement of K
+
 via ito result in a transient net outward current 
and the notch appearance of the AP. The plateau phase (2) is mainly sustained by the 
opening of type l calcium channels which results in a net inward current. During phase 3, 
rapid repolarisation occurs via rapid delayed inward rectifying K
+
 current, ikr. The ikr 
channels close when the membrane is repolarised to its resting potential (phase 4). The 
QT interval corresponds to the total duration from depolarisation to repolarisation of a 
cardiac AP (bottom). T wave morphology is affected by gradients of repolarisation across 
the myocardium. (B) The AP in LQTSs is abnormally prolonged in the plateau phase due to 
a decrease in repolarisation currents (e.g. Mutated ikr) or an increase in depolarising 
currents (e.g.  Mutation in ina). This leads to a prolonged AP as well as QT interval. The 
prolonged plateau phase increases the risk of early after depolarisations (EAD) (dotted 
line) which predisposes to re-entrant arrhythmias and VT. Adapted from (2004). 
1.3 Type 2 Diabetes and Cardiovascular Disease: Role of 
Glycaemia and Other Risk Factors 
The relationship between type 2 diabetes and CVD is well established, 
however, the relative contribution of individual risk factors is debated.  
Unlike type 1 diabetes where macrovascular risk is primarily mediated by 
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hyperglycaemia, in T2DM other factors including insulin resistance, 
adiposity, dyslipidaemia, hypertension and subclinical inflammation are 
also implicated. The present section briefly outlines the role of these risk 
factors followed by a discussion of endothelial, thrombotic and myocardial 
mechanisms of diabetic cardiovascular disease. This section prefaces the 
subsequent section on the rationale for intensive glucose lowering 
therapies in reduction of CVD. 
1.3.1 Risk Factors for Cardiovascular Disease in Type 2 Diabetes 
T2DM is associated with a 2- to 4-fold increase in cardiovascular mortality 
compared to nondiabetic subjects (Laakso, 2010). These findings have been 
confirmed in several cohorts, including the European Prospective 
Investigation of Cancer and Nutrition (EPIC Norfolk) (Khaw et al., 2001) and 
the Atherosclerosis Risk in Communities (ARIC) studies (Selvin et al., 2010). 
Laakso and colleagues compared the seven year incidence of fatal and 
nonfatal myocardial infarction in 1373 nondiabetic and 1059 T2DM 
subjects (Haffner et al., 1998). In nondiabetic subjects the 10 year risk of 
myocardial infarction was 3.5%. However, in those with a history of 
previous myocardial infarction, the risk increased to 19%, whilst in diabetic 
patients the 10 year risk of myocardial infarction was 20% even those with 
no with  prior history of CVD.  This gave rise to the concept of diabetes as a 
‘coronary heart disease equivalent’. Similar findings have been replicated 
in other cohorts (Juutilainen et al., 2005).  
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Traditional risk factors (low levels of high density lipoprotein (HDL), high 
levels of LDL cholesterol, obesity and hypertension), together with non-
traditional or diabetes specific risk factors (hyperglycaemia, insulin 
resistance, inflammation, and nephropathy), are involved in thed 
development of CVD in T2DM. It is important to note that these factors 
tend to cluster and do not occur in isolation. Stern (1995) originally 
proposed the ‘common soil hypothesis’ that both diabetes and CVD arise 
from common antecedents, and Reaven (1988) described the components 
of the insulin resistance syndrome, or the metabolic syndrome, which 
associates insulin resistance with obesity, hyperglycaemia, high plasma 
triglycerides, low HDL cholesterol and hypertension. Subsequent to its 
original description, there is strong epidemiological data to support the 
association of the metabolic syndrome with CVD (Fonseca et al., 2004). 
However, it is not always easy to dissect the individual contribution of each 
of these factors since they tend to aggregate.  Figure 1-4 depicts the 
interaction between these factors and their role in pathogenesis of CVD. 
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Figure 1-4: Interaction of risk factors in T2DMand development of CVD 
 
With respect to hyperglycaemia, epidemiological studies indicate a clear 
association between glucose levels and cardiovascular risk, and a 
systematic review of 26 cohort studies showed  that 1% increase in HbA1c 
was associated with a relative risk of 1.15 95% confidence intervals (CI, 
1.11-1.20) for all causes of mortality and 1.15 95% CI (1.05-1.17) for CVD. 
There is evidence of a dose response relationship appearing to extend to 
within the normoglycaemic range (Zhang et al., 2010).  The Honolulu Heart 
Programme demonstrated a predictive correlation between fasting plasma 
glucose levels (nondiabetic, impaired glucose tolerance, and diabetic 
ranges) and cardiovascular events and mortality (Donahue et al., 1987), 
whilst Levitan et al. (2004) found that hyperglycaemia in the nondiabetic 
range was associated with an increase in CVD in  a linear fashion for two 
hour post-prandial glucose and fasting glucoses above 5.6 mmol/L.  
Brownlee (2005) proposed that hyperglycaemia may mediate tissue 
damage through a unifying pathway via overproduction of reactive oxygen 
species (ROS) by the mitochondrial electron transport chain. These then 
activate four damaging pathways: the polyol, hexoamine, and protein 
kinase C (PKC) pathways and the formation of advanced glycation end 
products (AGEs). Production of ROS leads to the up-regulation of nuclear 
factor kappa B (NF-κB) and transcription of proinflammatory cell adhesion 
molecules and monocyte chemoattractant protein-1 (MCP-1), which attract 
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immune cells to the endothelium. Activation of the PKC pathways also 
decreases endothelial nitric oxide (NO) availability and induces endothelial 
dysfunction. Further hyperglycaemia has been associated with the 
abnormal post-translational modification of plasma coagulation proteins 
and altered clot properties (Grant, 2007). 
The increased cardiovascular risk appears to begin prior to the 
development of frank hyperglycaemia (Laakso, 2010).In the UKPDS the risk 
of coronary heart disease was increased even at normal or low HbA1c with 
CVD risk being substantially higher compared with microvascular 
complications such as retinopathy at the equivalent HbA1c level (UK 
Prospective Diabetes Study Group, 1998b).  The risk of coronary heart 
disease and stroke is already substantially elevated at the time of diagnosis 
of T2DM. Haffner et al. (1990) developed the ‘ticking clock’ hypothesis of 
complications, asserting that the clock for microvascular risk starts ticking 
at the onset of hyperglycaemia, while the clock for macrovascular risk 
starts ticking at some antecedent point . It is thought that insulin resistance 
may explain the accumulation of cardiovascular risk factors in the years 
before diagnosis  (FizeI'ova et al., 2014) (Figure 1-5). 
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Figure 1-5: Relative risk of CVD in normoglycaemia, pre-diabetes and T2DM and 
relative contribution of insulin resistance and hyperglycaemia 
Modified from (Laakso, 2010) 
In the following section, the mechanisms involved in the development of 
diabetic CVD will be described, together with the contributory roles of the 
above risk factors.  
1.3.2 Mechanisms of Diabetic Cardiovascular Disease 
T2DM is associated with multiple pathophysiological abnormalities that 
predispose to an increased risk of CVD.  Figure 1-6 summarises the 
constellation of cardiovascular abnormalities which culminate in a 
vulnerable individual with T2DM, who is at a significantly increased risk of 
cardiovascular complications as further detailed below. 
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Figure 1-6: The vulnerable T2DM patient - mechanisms of increased 
cardiovascular risk  
Modified from (Hess et al., 2012b) 
1.3.2.1 Atherogenesis 
Patients with T2DM exhibit accelerated atherosclerosis compared to 
nondiabetic individuals.  One of the earliest events in the pathogenesis of 
atherosclerotic lesions is impaired endothelial function. It is well known 
that individuals with T2DM exhibit impaired nitric-oxide mediated 
vasodilatation.   In the Hoorn study, markers of endothelial dysfunction, 
such as vWF and the endothelial cell adhesion molecule 1 (ECAM-1) 
explained 43% of the increase in cardiovascular mortality in T2DM (De 
Jager et al., 2005).  Hyperglycaemia also increases vascular smooth muscle 
cell proliferation and macrophage migration into the media, promoting 
fatty streak formation within atherosclerotic lesions (Moreno and Fuster, 
2004).  
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T2DM patients tend to have more diffuse and distal coronary artery lesion, 
and advanced techniques, such as intravenous ultrasound-virtual histology, 
studies have found that diabetes patients have more thin-cap 
fibroatheroma, which have a higher propensity to rupture and cause 
coronary thrombosis (Hess et al., 2012b). Both subclinical inflammation 
from adipose tissue and hyperglycaemia-related oxidative stress, have 
been linked to the development of thin cap fibroatheroma. Higher levels of 
inflammatory mediators originating from adipose tissue and systemically, 
and as well as increased numbers of monocytes, can contribute to the 
weakening of the fibrous cap in T2DM (Viswanathan and Zaman, 2012). 
Diabetes-induced oxidative stress has been linked to adventitial 
inflammation in porcine coronary arteries, with cytokines such as IL-6 and 
TNF-α, MCP-1 and adhesive molecules playing a role (Zhang et al., 2003a).  
1.3.2.2 Platetet Hyperactivity 
Hyperactive platelets contribute to CVD through triggering thrombus 
formation, microcapillary embolisation, and the release of cytokines that 
can accelerate the progression of vascular lesions (Kakouros et al., 2011). 
Platelets in T2DM are hyperactive and demonstrate greater aggregation 
responses compared to controls for given concentration of agonists. A 
fundamental characteristic of the diabetic platelet is higher baseline 
intracellular calcium levels and reduced levels of cyclic adenosine 
monophosphate (cAMP); thus the platelet is capable of activation at lower 
level of agonist stimulation. Many of these changes are associated with 
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hyperglycaemia, which is capable of inducing markers of platelet 
activation, including P-selectin and the CD40 ligand even in nondiabetic 
individuals (Kakouros et al., 2011). Platelets respond to sub-threshold 
stimuli under hyperglycaemic conditions and this results in increased 
platelet turnover (Hess et al., 2012b). T2DM platelets are larger and 
possess more integrin receptors (GP1b/GPIIb/IIIa) responsible for 
formation of the platelet plug which correlates with a level of glycaemic 
control (Kakouros et al., 2011). Hyperglycaemia can also induce 
thromboxane synthesis, mimicking conditions of shear stress and 
consequent platelet activation (Hess et al., 2012b).  
1.3.2.3 Altered Fibrin Clot Characteristics and Hypofibrinolysis 
Haemostatic abnormalities are also observed in type 2 diabetes which may 
contribute to increased coronary thrombosis. There are quantitative 
changes to level of coagulation proteins such as tissue factor and Factor VII 
which are key initiators of clot formation  (Alzahrani and Ajjan, 2010). 
Thrombin levels are increased which produces denser, less permeable 
clots. IL6 production and elevated fibrinogen levels predict CVD (Alzahrani 
and Ajjan, 2010). Fibrinolysis is also impaired as high levels of PAI-1, a key 
inhibitor in the fibrinolysis pathway is feature of T2DM (Alzahrani and 
Ajjan, 2010). Type 2 diabetes individuals display both quantitative and 
qualitatitive changes to clot structure. An analysis of plasma-purified 
fibrinogen clots from type 2 diabetes patients showed increased fibre 
thickness, a more compact structure, smaller pore size and increased 
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number of fibrinogen branching points compared with healthy controls 
(Dunn et al., 2005).Qualitatively, hyperglycaemia has been shown to 
increase post-translational glycation of fibrinogen leading to more compact 
clots (Alzahrani and Ajjan, 2010). At the same time clots in type 2 diabetes 
patients are slower to lyse, due to decrease in plasminogen binding to 
fibrin networks and decreased plasmin generation  (Alzahrani and Ajjan, 
2010).  
1.3.2.4 Cardiac Metabolism 
The effect of an occlusion of the coronary artery leads to disparate clinical 
courses in different patients, ranging from silent ischaemia to SCD (Hess et 
al., 2012b), and these outcomes are probably influenced by a number of 
myocardial characteristics. Factors associated with atherosclerosis-
dependent ischemia, such as perfusion, myocardial viability and wall 
motion abnormalities, as well as those independent of ischaemia, e.g. 
sympathetic hyperactivity, left ventricular hypertrophy and cardiac 
repolarisation abnormalities, may play critical roles (Naghavi et al., 2003). 
In the presence of insulin resistance there is a shift in substrate utilisation 
from glucose to FFA within cardiac myocytes. This energetic inflexibility 
leads to increases in oxygen demand, which is reflected in a larger infarct 
size in response to a comparable ischemic insult in diabetic patients 
compared to nondiabetic individuals (Hess et al., 2012b). Although the 
increased risk of heart failure in diabetes is in part linked to ischaemic 
cardiomyopathy, some individuals develop a distinct diabetic 
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cardiomyopathy (Boudina and Abel, 2010) as a result of remodelling, 
apoptosis of cardiac myocytes and interstitial fibrosis.  
1.3.2.5 Cardiac Autonomic Neuropathy 
Diabetes can ‘attack’ the cardiovascular autonomic system due to either 
functional or structural nerve damage (Vinik and Ziegler, 2007). Whilst the 
pathogenesis of diabetic autonomic neuropathy is incompletely 
understood, it is thought to be part of a polyneuropathy that parallels the 
development of peripheral neuropathy. Metabolic insults and oxidative 
stress, neurovascular insufficiency and a deficiency in neurohormonal 
growth factors, have all been thought to contribute (Vinik and Ziegler, 
2007). CAN may range from asymptomatic depression of autonomic 
reflexes that are only present on testing to devastating syndromes such as 
postural hypotension and nocturnal diarrhoea. Cardiac autonomic 
neuropathy (CAN) can increase the risk of SCD via a number of mechanisms. 
These include sympathetic over-activity and the loss of vagal inhibition 
leading to an increased propensity for tachyarrhythmias, regional 
dysinnervation leading to an intracardiac sympathetic imbalance, silent 
ischaemia, abnormal repolarisation, adverse cardiac remodelling leading to 
systolic and diastolic dysfunction.  
1.3.2.6 Prolonged QT Interval 
There is a higher prevalence of QT abnormalities, an index of cardiac 
repolarisation in T2DM patients compared with normal subjects (Veglio et 
al., 2002), and this appears to be present at the time of diagnosis of T2DM 
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(Rana et al., 2011).  One of the characteristics of abnormal repolarisation is 
an intracellular calcium overload within cardiac myocytes. Impaired 
ventricular relaxation can lead to consecutive diastolic calcium overload 
(Hess et al., 2012b), and there is evidence that impaired calcium handling is 
linked to insulin resistance. Fasting insulin concentrations have been 
associated with QT independent of obesity-related parameters (Kazumi et 
al., 1999). In animal studies, the L-type calcium current displays defective 
inactivation in obese insulin-resistant rats (Lin et al., 2012). There is 
decreased expression of calcium transporters, such as the 
sarco/endoplastic reticulum calcium ATPase (SERCA2), and other 
alterations of the persistent sodium current are linked to down-regulation 
of PI3K (Lu et al., 2013).  The overall effect is an abnormal repolarisation 
substrate that is more vulnerable to stressors, such as ischemia, electrolyte 
disturbances, autonomic imbalance, triggering afterdepolarisations and 
cardiac arrhythmias. 
1.3.3 The Contribution of Glycaemia to CVD in Type 2 Diabetes 
From the above discussion, several points are worthy of consideration 
before approaching the subject of the effect of intensive glycaemic control 
on cardiovascular mortality in T2DM in clinical trials. Firstly, CVD in T2DM is 
multifactorial with a clustering of risk factors and hyperglycaemia partly 
contributing, but the majority of cardiovascular risk may be accumulated 
secondary to insulin-resistance- related factors while blood glucose is in 
the pre-diabetic range. Thus patients are likely to have accumulated a 
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significant atherogenic burden at the time of presentation, and this may 
account for the lack of cardiovascular benefit from intensive glucose 
lowering during advanced disease. Secondly, hyperglycaemia can impact 
on different stages in the evolution of CVD.  Hyperglycaemia can have an 
early influence in the atherogenic process through oxidative stress and 
endothelial dysfunction, but can also impact on more proximate 
mechanisms, such as increased thrombogenicity and myocardial 
metabolism.  Thirdly, not only the absolute glucose concentration, but 
degree of fluctuation has been associated with cardiovascular risk (Esposito 
et al., 2004) (Monnier et al., 2012) (Hanefeld et al., 2004), and this may be 
influenced by patient factors and the type of glucose lowering therapy 
employed.  Finally, pharmacological and non-pharmacological 
interventions, even if its primary aim is glucose lowering, can have 
pleiotropic effects where it may simultaneously modify other risk factors, 
such as weight and inflammation, in a protective or adverse manner.  
1.4 Intensive Glycaemic Control and Cardiovascular Mortality 
in Type 2 diabetes 
The association between hyperglycaemia and CVD reported both in 
observational studies and epidemiological analyses of trials has formed the 
rationale for interventional trials of intensive glucose lowering to reduce 
macrovascular complications in T2DM (Stratton et al., 2000). The landmark 
UKPDS randomised 5102 newly diagnosed T2DM patients to receive either 
conventional therapy (dietary restriction) or intensive therapy (either 
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sulphonylurea or insulin, or in overweight patients metformin) for glucose 
control (UK Prospective Diabetes Study Group, 1998a, b). Over 10 years 
HbA1c averaged 7.0% (6.2-8.2) in the intensive group compared to 7.9% 
(6.9-8.8) in the conventional group, and overall, there was a reduction in 
12% for any diabetes-related endpoint, together with a significant 
reduction of 25% for microvascular complications. In addition, there was a 
trend towards a non-significant reduction in myocardial infarction by 16% 
(p=0.052). The study was limited by the duration of the follow up (median 
10.7 years when published in 1998) and the sample size was not adequate 
to test the effects of intensive glycaemic control on CVD. However, at 10 
year followup, risk reduction in myocardial infarction emerged with time 
(15% p=0.01) despite loss of glycaemic differences between arms after the 
first year(Holman et al., 2008). 
Three multicentre international randomised controlled trials were designed 
to test the hypothesis that intensive glucose therapy reduces mortality as 
the primary outcome in T2DM. The ACCORD, ADVANCE and VADT 
randomised 24,000 patients with a high cardiovascular risk to intensive 
glycaemic control or standard control groups (Duckworth et al., 2009; 
Gerstein et al., 2008; Patel et al., 2008). The characteristics of these three 
trials are summarised in Table 1-1. 
 
 
52 
 
Table 1-1: Summary of ACCORD, ADVANCE and VADT characteristics 
 ACCORD ADVANCE VADT 
n 10 251 11 140 1791 
Mean age 
(years) 
62 66 60 
Sex 
(%male/female) 
39/61 42/58 97/3 
Duration of 
diabetes (years) 
10 8 11.5 
History of CVD 
(%) 
35 32 40 
Median 
baseline HbA1c 
(%) 
8.1 7.2 9.4 
Target HbA1c 
(%)* 
<6.0 vs 7.0-7.9 
<6.5 vs based on 
local guidelines 
<6.0 vs planned separation of 
1.5 
Achieved 
HbA1c (%)* 
6.4 vs 7.5 6.3 vs 7.0 6.9 vs 8.5 
Median follow 
up (years) 
3.5 5 5.6 
On Insulin at 
end of study* 
(%) 
75 vs 55 40 vs 24 89 vs 74 
On TZD at end 
of study* (%) 
91 vs 58 17 vs 11 53 vs 42 
Weight 
change* (kg) 
+3.5 vs +0.4 -0.1 vs -1.0 +7.8 vs + 3.4 
Severe 
hypoglycaemia 
* (%) 
16.2 vs 5.1 2.7 vs 1.5 21.2 vs 9.9 
Definition of 
primary 
outcome 
Nonfatal MI, 
nonfatal stroke, 
CVD death 
Microvascular and 
macrovascular 
outcomes 
Nonfatal MI, nonfatal stroke, 
CVD death, hospitalisation for 
heart failure, 
revascularisation 
HR for primary 
outcome (95% 
CI) 
0.90 (0.78-1.04) 
0.9 (0.82-0.98); 
macrovascular 
0.94 (0.84-1.06) 
0.88 (0.74-1.05) 
HR for 
mortality 
findings (95% 
CI) 
1.22 (1.01-1.46) 0.93 (0.83-1.06) 1.07 (0.81-1.42) 
 
In all three trials no significant benefit in overall mortality or cardiovascular 
events was observed in the intensively treated groups.  Furthermore, in 
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2008 the diabetes community was alarmed by the premature termination 
of the ACCORD trial due to the excess number of deaths that had occurred 
within the intensive treatment arm of the trial (Hazard ratio, HR 1.22 95% 
CI 1.01-1.46, p=0.04, Figure 1-7). 
 
Figure 1-7: Differences in survival following intensive and standard glycaemic 
therapy in the ACCORD trial 
Adapted from (Gerstein et al., 2008) 
Cardiovascular deaths accounted for a third of all deaths in the ACCORD 
and VADT studies (Duckworth et al., 2009; Gerstein et al., 2008) and half of 
all deaths in the ADVANCE trial (Patel et al., 2008). In the ACCORD study, 
there was an excess of fatal cardiovascular events in the intensive 
treatment group, and in particular, there was an excess of SCDs which 
accounted for 46% of all the excess cardiovascular deaths associated with 
the intensive control group. In the VADT, SCDs were 3-fold higher in the 
intensive treatment group as compared to the standard arm. However, 
although the overall rates of fatal cardiovascular deaths were greater in the 
intensive arm, this did not apply to nonfatal events, as the rates of nonfatal 
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myocardial infarction were lower in the intensive treatment group (HR 
0.76, 95% CI 0.67-0.92, p = 0.004). Similar findings have been reported in a 
meta-analysis of randomised controlled trials of intensive glycaemic control 
in T2DM (Boussageon et al., 2011). Thus, there may be some evidence that 
intensive glycaemic control appears to selectively promote fatal 
cardiovascular events, in particular SCD, over nonfatal events. 
A further paradoxical observation is that although intensive glycaemic 
control had no apparent benefit or increased the risk of death overall, it 
may have had protective effects in subgroups with a low atherogenic 
burden based on post hoc analyses.  In the ACCORD study, a significant 
reduction in the primary cardiovascular endpoint was observed in patients 
with no prior cardiovascular events (Gerstein et al., 2008). This view is 
supported by an ancillary analysis of the VADT that showed intensive 
glycaemic therapy reduced future CVD events in those patients with low 
baseline coronary artery calcium scores (Duckworth et al., 2009).  In the 10 
year follow up of the UKPDS trial, patients randomised to intensive 
glycaemic control group who at the time of diagnosis had a low 
atherogenic burden were protected from cardiovascular events beyond the 
period of the intervention (Holman et al., 2008). The benefits of intensive 
glycaemic control may be due to a reduction in hyperglycaemia, which is 
linked to increased oxidative stress as outlined earlier (Laakso, 1999). This 
supports the notion of a ‘hyperglycaemic memory’, where even transient 
exposures to high glucose can cause persistent damage to the vasculature. 
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Thus early intervention in the course of T2DM may be cardioprotective but 
the benefits may not extend to those with established CVD. 
These two paradoxical observations raise the possibility that although 
intensive glycaemic therapy may reduce adverse effects of hyperglycaemia 
through mechanisms such as oxidative stress (Laakso, 1999), it may also 
increase the risk of fatal cardiovascular events, including SCD, by another 
mechanism in those with established CVD.  A number of explanations have 
been proposed, including greater weight gain or medication effects, and a 
high proportion of patients were reported to be taking thiazeliediones, 
which have been associated with heart failure and excess cardiovascular 
mortality (Gerstein et al., 2008). However, a strong candidate was the 
effect of hypoglycaemia, since this was 3-fold higher in frequency in the 
intensive arm of the study (Gerstein et al., 2008) (Figure 1-8). The 
increased likelihood of hypoglycaemia during strict glycaemic control is  not 
unexpected (Turnbull et al., 2009), particularly during a strategy in which 
the overall aim was to lower HbA1c levels to below 6.5% as rapidly as 
possible.  
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Figure 1-8: Percentage of patients with at least one episode of severe 
hypoglycaemia in trials of intensive glycaemic control in T2DM patients  
Adapted from (Frier et al., 2011) 
In the following section it will be argued that hypoglycaemia is a strong 
causal explanation for an increase in cardiovascular mortality. 
1.5 Can Hypoglycaemia be a Potential Mechanism for 
Increased Cardiovascular Death Observed with Intensive 
Glycaemic Control in Type 2 Diabetes Patients 
There has been considerable controversy concerning the question of 
whether hypoglycaemia is causal in the increase in cardiovascular mortality 
in trials of intensive glycaemic control in T2DM (Yakubovich and Gerstein, 
2011).  One issue is that many of the subsequent analyses are based on 
post hoc analyses, which were not designed a priori to test the effect of 
hypoglycaemia on cardiovascular outcomes. Additional limitations include 
the lack of uniform definitions of hypoglycaemia and variable reporting of 
hypoglycaemic events. In the ACCORD, ADVANCE and VADT studies, a 
history of hypoglycaemia was consistently associated with an increase in 
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subsequent cardiovascular mortality (Bonds et al., 2010; Duckworth et al., 
2009; Zoungas et al., 2010). Even though this relationship was attenuated 
after adjusting for multiple covariates, it nevertheless remained significant, 
and the crucial question is whether a true causal relationship exists 
between hypoglycaemia and mortality.  The possibility cannot be excluded 
that the association between hypoglycaemia and death could, at least in 
part, be an artefact of residual confounding factors and is simply a marker 
for vulnerability. Goto et al. (2013) conducted a bias analysis to evaluate 
the effect of severe comorbid illness as a confounding factor on the 
association between severe hypoglycaemia and the risk of CVD. Their 
analysis indicated that comorbid illness alone is unlikely to explain the 
association, as it requires a severe morbid illness to be ten times more 
prevalent in individuals with a history of hypoglycaemia compared to those 
without, which is unlikely.  
The Bradford Hill criteria defines a list of factors to be considered when 
trying to determine whether an association is truly causal (Hill, 1965). 
These include the strength of an association, the temporal relationship, 
dose-response relationship, consistency with other studies, specificity, 
biological plausibility, reversibility, coherence, and analogy. Evidence for 
and against hypoglycaemia as a causal factor for increased cardiovascular 
mortality will now be discussed in the context of these criteria. 
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1.5.1 Strength of Association 
In the ACCORD trial patients who had experienced one or more severe 
hypoglycaemic episodes had higher mortality rates than those with no 
hypoglycaemia across both study arms  (Bonds et al., 2010). One third of all 
deaths were attributed to CVD and hypoglycaemia was associated with a 
higher cardiovascular mortality. A similar pattern was also reported in an 
analysis of the ADVANCE trial (Zoungas et al., 2010), where patients with a 
history of hypoglycaemia had higher rates of cardiovascular death with an 
adjusted HR of 3.79 (2.36-6.08). In the VADT, a recent severe 
hypoglycaemic event was the strongest independent predictor of death at 
90 days (Duckworth et al., 2009). In both intensive and standard treatment 
arms, patients who experienced severe hypoglycaemia, sufficient to cause 
an impairment in consciousness, had an 88% increase in primary 
cardiovascular events and a 3-fold increase in cardiovascular death 
(Duckworth, 2009). Recent severe hypoglycaemia was associated with a HR 
of 3.7 for cardiovascular death (p=0.01) and Figure 1-9  demonstrates the 
association between severe hypoglycaemia and mortality. 
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Figure 1-9: Association between severe hypoglycaemia and mortality in the 
ACCORD and ADVANCE studies 
HR for death by any cause in patients with at least one severe episode of hypoglycaemia 
versus no hypoglycaemia.  
1.5.2 Consistency with Other Studies 
The association between hypoglycaemia and cardiovascular mortality has 
also been reported in trials of intensive insulin therapy in critical care 
patients. A study by van den Berghe et al. (2001) demonstrated that 
intensive insulin therapy resulted in a reduction in mortality in surgical 
critical care patients. However, subsequent studies have reported no 
change or an increase in mortality when intensive insulin therapy has been 
applied in other medical or mixed intensive care settings (Brunkhorst et al., 
2008; Finfer et al., 2009; Van den Berghe et al., 2006), with the risk of 
hypoglycaemia being increased by up to 6-fold in some reports in the 
intensive treatment arm. Hypoglycaemia was also observed to be an 
independent risk factor for death following adjustment for disease severity 
ACCORD	
All-cause	deaths	
CVD	deaths	
Standard	arm	
ADVANCE	
All	cause	deaths	
201(2.8%)	 	53(1.2%)	
176	(3.7%)	 21	(1.0%)	
45	(19.5%)	 986	(9.0%)	
22	(9.5%)	 520	(4.8%)	
Events	
Number	(%)	of	pa ents	with	event	
SH:	Yes	
	
SH:	No	
	
Adjusted	Hazard	ra o	
(95%	CI)	
1.41(1.03-1.93)	
3.27	(2.29–4.65)	
3.79	(2.36–6.08)	
Non-CVD	deaths	
23	(10.0%)	 466	(4.3%)	 2.80	(1.64–4.79)	
1.0	0.1	 10.0	
Hazard	ra o	
Zoungas	et	al.	N	Eng	J	Med	2010		
2.30(1.46-3.65)	
Intensive	arm	
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(Brunkhorst et al., 2008; Griesdale et al., 2009; Van den Berghe et al., 
2006). 
1.5.3 Dose Response  
There is some evidence for a dose-response relationship between the 
severity of a hypoglycaemic event and the subsequent risk of 
cardiovascular death.  In a post hoc analysis of the ORGIN trial which 
compared the addition of glargine versus standard therapy, the HR 
between cardiovascular death and hypoglycaemia was stronger for severe 
than for nonsevere hypoglycaemia in both treatment groups (HR 1.38 vs 
1.08 for severe vs nonsevere hypoglycaemia in the glargine group, HR 2.89 
versus 0.95 in standard group ) (Mellbin et al., 2013). In the NICE-SUGAR 
study, the adjusted HRs for death among patients was stronger for those 
with moderate or severe hypoglycaemia, compared to those with no 
hypoglycaemia (HR 1.41 (1.21 to 1.62; P<0.001) and 2.10 (95% CI, 1.59 to 
2.77; P<0.001), respectively). Furthermore, the association with death was 
increased among patients who had moderate hypoglycaemia on more than 
one day (Finfer et al., 2012). 
In the ACCORD trial, although hypoglycaemia was associated with an 
increased risk of death in both study arms, the relationship was stronger in 
the standard therapy group than the intensive arm (Gerstein et al., 2008), 
and similar observations have been reported in other studies (Mellbin et 
al., 2013). This counterintuitive observation has been used as an argument 
against  hypoglycaemia as a causal explanation for increased cardiovascular 
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mortality (Yakubovich and Gerstein, 2011). However, the ACCORD study 
group have further analysed the frequency of self-monitored blood glucose 
(SMBG) <3.9 mmol in the seven days prior to the four month study visit, 
and found that there was a lower risk of death (HR 0.68 95% CI 0.36-1.24) 
in subjects randomly assigned to the intensive treatment group who 
experienced frequent episodes of low blood glucose determine through 
self-monitoring during the previous week (Seaquist et al., 2012). This 
relationship was more pronounced in subjects with a history of severe 
hypoglycaemia requiring medical assistance in the intensive treatment 
group. Similarly, in a post hoc analysis of the ADVANCE trial, the risks of 
major macrovascular outcomes and death were reduced among patients 
reporting minor hypoglycaemia compared to those who did not report 
such episodes (Zoungas et al., 2010). The fact that the association between 
hypoglycaemia and cardiovascular death was weaker in the intensive 
treatment arm may be explained by more frequent asymptomatic 
hypoglycaemia.  Repeated episodes of hypoglycaemia result in blunting the 
sympathodrenal response (Heller and Cryer, 1991). However, this weaker 
association in the intensive treatment arm does not itself negate a 
potential causal association between hypoglycaemia and cardiovascular 
death. 
1.5.4 Specificity 
Some analyses have examined the specific cause of death associated with 
hypoglycaemia. For example, in the NICE-SUGAR study of intensive insulin 
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therapy in critically ill patients, the strongest association found for 
hypoglycaemia was cardiovascular death, particularly due to distributive 
shock  (HR 4.35, p<0.001) (Finfer et al., 2012). In the ORIGIN study, an 
increase in arrhythmic death was associated with severe hypoglycaemia 
(adjusted HR 1.77, 1.17-2.67, p<0.007) (Mellbin et al., 2013). In  post hoc 
analyses of the ADVANCE trial, severe hypoglycaemia was associated with 
an increase in major macrovascular events (HR 2.88, 2.01-4.12), 
cardiovascular death (HR 2.69, 1.72-4.19), and total mortality (HR 2.69, 
1.97-3.67) all p<0.001 (Zoungas et al., 2010). However, hypoglycaemia was 
also related to death due to seemingly unrelated nonvascular causes in the 
ADVANCE trial, such as skin disorders (adjusted HR 4.73, 1.96-11.40) and 
respiratory disorders (adjusted HR 2.4, 1.43-2.43), casting doubt on the 
specificity of the association and suggesting the possibility of residual 
confounding factors. 
1.5.5 Temporal Relationship 
In the ACCORD study, of the 74 participants who reported any 
hypoglycaemic event, six died with 30 days of the event, whilst only one 
death in the intensive treatment group was identified as definitely related 
to hypoglycaemia. Therefore hypoglycaemia was identified as having a 
probable role in only 0.7% of deaths. A post hoc analysis of the NICE-
SUGAR study found excess mortality in the intensive treatment group, with 
the median time to death from the occurrence of a hypoglycaemic event 
being seven days for moderate hypoglycaemia and eight days for severe 
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hypoglycaemia (Finfer et al., 2012). However, pathogenic mechanisms in 
critically ill patients may be different compared to those in individuals with 
T2DM and ‘stable’ CVD.  It has been difficult to identify a direct immediate 
link between hypoglycaemia and cardiovascular death. However, given the 
high prevalence of asymptomatic hypoglycaemia and the variability in self-
monitoring of blood glucose, it is possible that hypoglycaemia could have 
been unrecognised, even if it was contributory. Furthermore, if a death is 
unexpected, it would be difficult to determine if hypoglycaemia had 
occurred immediately before death.  
Most studies have reported that the risk of death associated with severe 
hypoglycaemia was not immediate; rather it increased in the months 
following the event.  In the VADT, severe hypoglycaemia predicted death at 
90 days (Duckworth, 2009). In the ADVANCE study, Zoungas et al. (2010) 
examined the incident of vascular outcomes in patients with severe 
hypoglycaemia, and found that the HR for cardiovascular death at three 
months was 5.35 (p<0.01); this was attenuated at 6 months (HR 3.57) but 
remained significant (p=0.01).   
The risk of a cardiovascular event is also elevated following other 
conditions, such as after a systemic respiratory infection (Smeeth et al., 
2004). In a case control study, acute respiratory-tract infections were 
associated with an increased risk of a first ever AMI in low cardiovascular 
risk patients for a period of about two weeks (Meier et al., 1998).There has 
been a burgeoning of the literature in the past 15 years linking systemic 
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sepsis and inflammation to increased arterial thrombotic events within 30 
days (Donze et al., 2014). Thus the fact that hypoglycaemia at the time of 
the event may not have been an immediate precipitant of cardiovascular 
death, does not negate a potential causal role further downstream. 
Hypoglycaemia has been associated with increases in proinflammatory 
markers and impairment in autonomic function for at least 24 hours after 
the event (Adler et al., 2009; Wright et al., 2010). However, whether there 
are other mechanisms that can promote a sustained elevation for the risk 
of CVD in the weeks to months after the event is a question which remains 
to be answered. 
1.5.6 Reversibility, Analogy, Coherence, and Biological Plausibility 
The question of reversibility is difficult to address since the risk of 
hypoglycaemia is inherent in glycaemic management and is not an 
exposure that can simply be removed. Although there is currently little 
evidence linking hypoglycaemia and SCD in T2DM, there is circumstantial 
evidence linking hypoglycaemia to sudden nocturnal deaths in T1DM. 
Tattersall and Gill (1991) published a series of investigations into 50 cases 
of sudden deaths among young adults with T1DM, and in 22 cases there 
was a similar mode of death, whereby the patient was found in an 
undisturbed bed having been well the day before, and the term ‘dead-in-
bed’ syndrome was coined to describe the clinical picture (Campbell, 1991). 
Subsequent cohorts in Sweden and Australia have reported similar findings 
(Sartor and Dahlquist, 1995; Tu et al., 2008).  
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There is evidence linking hypoglycaemia and the dead-in-bed syndrome, as 
in Tattersall and Gill’s original study, fourteen out of the 50 patients had 
known problems with recurrent nocturnal hypoglycaemia. Another cohort 
study of T1DM patients found that sudden overnight death was more 
common in the last three years of the study (1988-1980), coinciding with 
the greater use of intensive insulin therapy (Thordarson and Søvik, 1995). 
Recently, Tanenberg et al. (2009) described a 23 year old with T1DM who 
was experiencing recurrent nocturnal hypoglycaemia and was fitted with 
an insulin pump and a continuous glucose monitoring system (CGMS). He 
was then found dead in an disturbed bed 20 hours after the fitting of the 
continuous glucose monitor, and his recorded glucose was <30 mg/dL or 
1.8 mmol/L around the time of his death (Fig1-10) . Thus, there is 
circumstantial evidence linking sudden deaths in T1DM to nocturnal 
hypoglycaemia, although it is unknown whether this could also happen in 
T2DM.  
 
Figure 1-10: Low interstitial glucose at the time of death as captured by 
continuous glucose monitoring in a T1DM subject  
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A 23 year old patient with T1DM  had a continuous glucose monitor fitted and 
subsequently died suddenly overnight. The time of death is estimated between 5-8 am, at 
which point he was severely hypoglycaemic. Source:  (Tanenberg et al., 2009) 
An association between hypoglycaemia and SCD is biologically plausible, as 
hypoglycaemia provokes sympathoadrenal activation that can result in 
cardiac ischaemia, changes in the cardiac autonomic balance, abnormal 
cardiac repolarisation, and an increased risk of arrhythmic death (Chow 
and Heller, 2012). Hypoglycaemia can also be prothrombotic via increased 
platelet activation and aggregation, an increase in coagulant factors and 
pro-inflammatory molecules. In addition, hypoglycaemia has also been 
shown to impair autonomic responses to hypotensive stress for at least 24 
hours after an event (Adler et al., 2009). Much of the evidence for this has 
been obtained from nondiabetic and T1DM individuals, but remains 
plausible in patients with T2DM. In the following sections, the physiology of 
hypoglycaemia will be reviewed, followed by the postulation of a number 
of mechanisms by which hypoglycaemia can increase SCD in T2DM.    
1.6  The Physiology of Hypoglycaemia 
1.6.1 Epidemiology 
The problem of hypoglycaemia has been under-recognised in patients with 
T2DM, as it has traditionally been thought that the risk of hypoglycaemia is 
low in comparison to T1DM.  The risks associated with metformin and 
incretin based therapies is low, and in the UKPDS, only 0.3%  metformin 
treated newly diagnosed T2DM patients reported one or more episodes of 
hypoglycaemia per year (Amiel et al., 2008). T2DM patients on insulin for 
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>5 years are at a significant risk of hypoglycaemia occurring in 25% of 
subjects and at rates similar to patients with recently diagnosed T1DM 
(Group, 2007). A number of factors predispose those with T2DM to 
hypoglycaemia, including advancing age, as counter-regulatory responses 
to hypoglycaemia decrease, even in nondiabetic individuals (Zammitt and 
Frier, 2005). Counter-regulatory responses also diminish with the duration 
of disease, as glucagon release during hypoglycaemia is reduced as patients 
become progressively insulin deficient (Segel et al., 2002). Renal failure 
reduces the clearance of many glucose lowering agents, including insulin, 
and predicts hypoglycaemic risk (Bruderer et al., 2014). Impaired 
hypoglycaemia awareness has not been intensively studied in the T2DM 
population, but it is well known that the elderly may experience a different 
symptom profile that can often be confused with strokes. There is a high 
prevalence of comorbid conditions, such as cognitive dysfunction, which 
impairs the ability to recognise and self-treat. Interestingly, epidemiology 
studies have shown no association between rates of hypoglycaemia and 
HbA1c (Akram et al., 2006), although some reports indicate a relationship 
with glycaemic variability (Zammitt and Frier, 2005). It is estimated that 
28% of severe hypoglycaemia results in admission to hospital, with the 
associated healthcare costs amounting to around £1000 per admission 
(Leese et al., 2003). T2DM patients experience longer hospitals stays due to 
a greater burden of morbidity compared to T1DM patients (Zammitt and 
Frier, 2005). 
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1.6.2 Counter-regulatory Responses in Hypoglycaemia 
Homeostatic mechanisms exist to maintain the glucose concentration 
within narrow limits because of the dependence of the central nervous 
system on glucose. A complex network of biochemical, functional and 
haemodynamic changes can restore glucose concentrations and produce 
symptoms which protect the body from the effects of hypoglycaemia. The 
body responds to hypoglycaemia in two ways: 1) increased endogenous 
glucose production through glycogenolysis and gluconeogenesis; and 2) 
behavioural responses to prompt an individual to eat. At the same time, 
energy is diverted to vital organs, such as the brain and liver, and away 
from less essential organs, such as the kidneys, during acute 
hypoglycaemia. 
Counter-regulatory hormones are released in a hierarchical response at 
reproducible thresholds in normal humans (Figure 1-11). When plasma 
glucose levels fall to around 4.6 mmol/L, the first physiological defence is a 
decrease in insulin secretion by pancreatic beta cells (Cryer et al., 2003). 
Experiments have been performed to determine the relative importance of 
these hormones by producing isolated deficiencies of these hormones in 
response to insulin-induced hypoglycaemia (Rizza et al., 1979). When 
glucose falls to 3.8 mmol/L, the secondary defence of secreting glucagon by 
pancreatic alpha cells is initiated in an attempt to restore glucose level 
(Cryer, 2008). A third line of defence is adrenomedullary secretion of 
adrenaline secondary to the activation of the autonomic nervous system.  
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Adrenaline has a variety of metabolic effects, including increasing 
glycogenolysis and gluconeogenesis, reducing glucose utilisation 
peripherally, and inhibiting insulin secretion (Macdonald and King, 2007).  
Adrenomedullary adrenaline secretion becomes more relevant when 
glucagon is deficient, as in the case of T1DM and advanced T2DM. Growth 
hormone and cortisol secretion occur during more prolonged periods of 
hypoglycaemia lasting longer than one hour. The depth and duration of 
hypoglycaemia determines the magnitude of counter-regulatory response 
(Davis et al., 1997), but the overall resultant effect is an increase in hepatic 
glucose production and the limitation of glucose utilisation by non-neural 
tissues. 
 
Figure 1-11: Thresholds for counter-regulatory responses and symptoms during 
hypoglycaemia in a nondiabetic adult 
Counter-regulatory responses to hypoglycaemia have been extensively 
studied in normal subjects and in T1DM, but less systematically 
investigated in T2DM. Adrenaline  secretion is preserved in individuals with 
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T2DM, although the glucagon response has been reported in different 
studies as either modestly diminished or preserved (Zammitt and Frier, 
2005). In a study comparing nondiabetic, non-insulin treated, and insulin 
treated diabetic subjects, the glucagon response was almost absent in the 
insulin-treated group but intact in the others (Segel et al., 2002). Counter-
regulatory hormonal release in some T2DM patients occur at higher 
glucose levels than in nondiabetic controls or T1DM patients (Korzon-
Burakowska et al., 1998; Levy et al., 1998; Spyer et al., 2000).  
The autonomic nervous system is responsible for neurogenic symptoms, 
such as sweating or tremor, as well as haemodynamic changes observed 
during hypoglycaemia. Hypoglycaemia is accompanied by a number of 
haemodynamic changes that include an increase in heart rate, systolic 
blood pressure, myocardial contractility, and cardiac output mediated via 
β-1 adrenoreceptors and a decline in peripheral resistance (Fisher et al., 
1990). Changes in regional blood flow also occur, such as an increase in 
cerebral and splanchnic blood flow, thereby enhancing the delivery of 
substrates to vital organs. Experiments by Fagius et al. (1986) showed that 
during hypoglycaemia, muscle sympathetic activity increases after insulin is 
injected, peaking after 25-30 minutes, which coincides with a glucose nadir 
and persists for 90 minutes after euglycaemia is restored.  
Recent antecedent hypoglycaemia causes attenuation in sympathoadrenal 
activation against subsequent hypoglycaemic episodes, leading to reduced 
neurogenic symptoms and hypoglycaemic unawareness (Dagogo-Jack et 
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al., 1993; Heller and Cryer, 1991),  However, it can be reversed by 
scrupulous avoidance of hypoglycaemia for as little as two to three weeks 
(Dagogo-Jack et al., 1994). There is evidence that this phenomenon is not 
limited to T1DM, as Segel et al. (2002) demonstrated antecedent 
hypoglycaemia resulted in lower glucose thresholds required to activate 
glucagon, catecholamine and symptomatic responses in advanced T2DM 
and that these responses were attenuated in subsequent hypoglycaemia. 
The mechanisms underlying this impairment of counterregulation are 
uncertain, however it is likely to be centrally mediated. Based on brain 
imaging studies, the paraventricular nuclus of the thalamus has been 
implicated in the habituation of sympathoadrenal responses following 
hypoglycaemia. Other groups have reported alterations in glucose sensing 
by glucose excitatory and gluose inhibitory neurones in ventomedial 
hypothalamus (Cryer, 2013) . A number of studies have found 
augmentation of sympathoadrenal responses to repeated hypoglycaemia 
with selective serotonin reuptake inhibitors, alpha and beta blockade, 
opiate antagonists and selective KATP agonists suggesting multiple 
mediators and complex neural circuitry are involved (Cryer, 2013). 
1.7 Potential Mechanisms of Hypoglycaemia-Related Sudden 
Cardiac Death 
In the above section, I have argued that hypoglycaemia may be causal 
factor in the increase in cardiovascular mortality during intensive glycaemic 
control in T2DM patients. Mechanisms by which hypoglycaemia can exert 
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adverse CV events are incompletely understood. Early studies have 
investigated the effects of transient hypoglycaemia induced by an insulin 
bolus. Subsequen studies have examined the effects of more sustained 
hypoglycaemia using hyperinsulianemic clamps. However, most studies 
have been in T1DM and nondiabetic individuals with few studies in T2DM 
patients. The purpose of this section is to review the existing literature on 
CV effects of hypoglycaemia and propose putative mechanisms by which 
hypoglycaemia may predispose to CV events in T2DM individuals. 
1.7.1 Endothelial Function and Atherogenesis 
Human and animal studies have indicated the mechanisms by which 
hypoglycaemia might contribute to early atherogenesis.  Human 
endothelial cells, when exposed to acute hypoglycaemia, show a rapid 
reduction in NO availability (Wang et al., 2011). There is some data to 
suggest that acute hypoglycaemia can impair flow-mediated dilatation by 
both NO-dependent and -independent mechanisms in people with T2DM 
(Gogitidze Joy et al., 2011). Acute hypoglycaemia can also induce the 
release of potent vasoconstrictors, such as endothelin (Wright et al., 2007).   
Atherogenic cell adhesion molecules appear to be up-regulated following 
hypoglycaemia. VCAMs and intracellular cell adhesion molecules (ICAMs) 
are higher during hyperinsulinaemic hypoglycaemia in both healthy 
individuals and people with T1DM (Gogitidze Joy et al., 2010). Rats that 
were exposed to repetitive episodes of hypoglycaemia had an increased 
number of adherent monocytes in the aorta (Jin et al., 2011). The effect of 
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hypoglycaemia on leukocyte trafficking has also been studied, with Wright 
et al. (2010) reporting an increase in CD40 ligand and platelet monocyte 
adhesion in both healthy participants and those with T1DM diabetes. Some 
of these mechanisms may be mediated by adrenaline, as adrenergic 
blockade prevents the up-regulation of ICAM and VCAM induced by 
hypoglycaemia in a rat model of diabetes (Jin et al., 2011). Clinically, there 
is evidence that  people with T1DM diabetes and a history of recurrent 
hypoglycaemia have increased carotid and femoral intima-media thickness 
suggesting early atherosclerosis, compared with individuals with a similar 
duration of disease and matched risk factors (Gimenez et al., 2011).   
1.7.2 Inflammation 
Diffuse inflammation is important in promoting transition to a vulnerable 
plaque that may rupture. Inflammatory markers, such as CRP and IL-6, are 
strong predictors of the risk of ACS in cohort studies (Packard and Libby, 
2008). In one study, CRP increased for 24 hours after transient insulin 
induced hypoglycaemia in T1DM subjects and healthy volunteers (Galloway 
et al., 2000). During insulin tolerance tests performed on normal 
individuals, a rise in TNF-α and interleukin 8 (IL-8) has been observed that 
is likely to be adrenaline mediated, along with a later rise in IL-1 that is 
likely to be cortisol mediated. Gogitidze Joy et al. (2010) reported an 
increase in IL-6 during acute hypoglycaemia in T1DM and healthy 
individuals. However, the effect of acute hypoglycaemia on 
proinflammatory cytokines has not always been consistent, as Wright et al. 
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(2010) reported significant increases in hsCRP in healthy but not T1DM 
subjects following insulin-induced hypoglycaemia. Furthermore, the 
authors reported rises in IL-6 that occurred during both hyperinsulinaemic 
euglycaemia and hypoglycaemia. These discrepancies may be due to 
differences in the method of inducing experimental hypoglycaemia and the 
biological variability of these markers.  
1.7.3 Platelet Activation and Aggregation 
Platelets make important contributions to the atherothrombotic process, 
as they adhere to the damaged endothelium and contribute to the 
development of atherosclerotic lesions. Activated platelets also contribute 
to the onset of arterial thrombosis following plaque rupture. In human 
studies, platelet activation occurs in response to acute hypoglycaemia, 
resulting in the release of beta-thromboglobulin from platelet granules and 
the expression of cell surface receptors, such as P-selectin (Gogitidze Joy et 
al., 2010; Trovati et al., 1986). These changes are inhibited by the alpha-2-
adrenoreceptor blockade (Kishikawa et al., 1987). Hypoglycaemia has also 
been shown to potentiate platelet aggregation induced by other agonists, 
such as adenosine diphosphate (ADP) and collagen (Trovati et al., 1986) via 
an alpha-2 adrenergic mechanism (Kishikawa et al., 1987). 
1.7.4 Coagulation and Fibrinolysis 
Hypoglycaemia is associated with an increase in procoagulant factors, such 
as  factor VIII activity (Grant et al., 1987). Receptor blockade with 
propranolol prevents a rise in factor VIII associated with hypoglycaemia, 
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which suggests that this is mediated by adrenergic control (Grant, 1990). 
vWF, an endothelial-derived factor that promotes thrombosis, is increased 
in response to hypoglycaemia and is raised in patients with diabetes (Fisher 
et al., 1991), whilst a reduction in activated partial thromboplastin time 
(APTT) was observed following insulin-induced hypoglycaemia (Dalsgaard-
Nielsen et al., 1982). 
In contrast, some studies suggest that the fibrinolytic system is activated in 
response to hypoglycaemia induced by an insulin bolus. An increase in 
tissue plasminogen activator (tPA), plasminogen activator activity, and a 
decrease in inhibitory factors, such as PAI-1 (Fisher et al., 1991; Wieczorek 
et al., 1993), have been reported during hypoglycaemia. Most of these 
earlier studies did not control for the effects of insulin and it is unclear 
whether these observations were due to the effects of insulin per se. 
Hypoglycaemia stimulated by an insulin bolus was highly unphysiological 
does not represent hypoglycaemia in a diabetic individual during therapy. 
Preliminary data published by my collaborators have showed increases in 
clot lysis times during sustained hyperinsulinaemic hypoglycaemia in T1DM 
subjects (Ajjan et al., 2009; Gogitidze Joy et al., 2010). However, more 
studies are needed to delineate the role of hypoglycaemia in coagulation 
and fibrinolysis. 
1.7.5 Cardiac Ischemia 
Hypoglycaemia is accompanied by sympathoadrenal activation and 
catecholamine release, which can have widespread effects on the 
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cardiovascular system, including a transient increase in heart rate 
mediated by beta-adrenoreceptors (Fisher et al., 1990; Russell et al., 2001). 
Cardiac output increases during hypoglycaemia, mainly via increased 
myocardial contractility stimulated by β1-adrenergic receptors (Fisher et 
al., 1987). The demand for myocardial oxygen would be expected to rise 
with this increase in workload, and under normal circumstances there 
should be a matched increase in myocardial blood flow; however, there is 
evidence that myocardial blood flow may be reduced during insulin-
induced hypoglycaemia. This has been observed in healthy volunteers and 
people with T1DM without known coronary artery disease (Rana et al., 
2011). Release of potent vasoconstrictors into the coronary circulation can 
mediate this effect, and in patients with diabetes and existing flow-limiting 
disease, it is possible that such a reduction in flow leads to myocardial 
ischemia or even infarction. In an experimental canine model of coronary 
artery occlusion, the area of early myocardial necrosis increased by nearly 
50% following exposure to hypoglycaemia (Libby et al., 1975). 
There have been isolated reports of myocardial ischemia observed during 
diabetic hypoglycaemic comas (Ben-Ami et al., 1999; Markel et al., 1994), 
but given the intense haemodynamic changes associated with 
hypoglycaemia, one would expect ischaemia to be more frequently 
observed. De Desouza et al. (2003) monitored 19 individuals with T2DM 
with a history of frequent hypoglycaemia and coronary artery disease. 
Patients underwent 72 hour continuous glucose monitoring (CGM) with 
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simultaneous cardiac Holter monitoring for ischemia. Among the 54 
recorded episodes of hypoglycaemia, 10 were associated with symptoms of 
chest pain and 4 with ischaemic ECG changes. Silent ischaemia is more 
common in patients with diabetes, and there have been several case 
reports of silent myocardial infarctions associated with hypoglycaemia 
where low glucose was the presenting feature (Chang et al., 2007; 
Pladziewicz and Nesto, 1989). Therefore, cardiac ischemia secondary to 
hypoglycaemia may occur more commonly than is recognised. 
1.7.6 Cardiac Arrhythmias 
There are anecdotal reports of a variety of arrhythmias precipitated by 
hypoglycaemia. Atrial fibrillation has been commonly reported, and is 
reversible through the administration of intravenous dextrose (Baxter et 
al., 1990; Collier et al., 1987; Odeh et al., 1990). There have also been other 
reports of premature ventricular contractions (Shimada et al., 1984) and 
atrioventricular junctional tachycardia (Pezzarossa et al., 1993), although  
VT has rarely been reported, perhaps because such events are usually fatal 
(Chelliah, 2000). Hypoglycaemia has also been associated with 
bradyarrhythmias in several reports (Gill et al., 2009; Navarro-Gutiérrez et 
al., 2003; Pollock et al., 1996). This appears counterintuitive given that 
sympathoadrenal activation is expected to increase the heart rate (see 
discussion below). In a study by Gill et al. (2009), 25 T1DM patients 
underwent ambulatory ECG monitoring with CGM. Thirteen episodes of 
nocturnal hypoglycaemia occurred and eight were associated with cardiac 
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arrhythmias, including bradycardia, ventricular ectopics, atrial ectopics and 
P wave abnormalities.  
1.7.7 Arrhythmia Mechanisms: Autonomic 
It is well established that hypoglycaemia is accompanied by neural-
mediated activation of the sympathetic nervous system and adrenaline 
release. As alluded to above, there is strong evidence to support a 
sympathovagal imbalance as a risk factor for SCD. Several studies have 
examined the effect of hypoglycaemia on the sympathovagal balance using 
spectral analysis of HRV. Koivikko and colleagues studied six T1DM 
diabetics and eight healthy subjects over a two day single blinded cross 
over design of euglycaemic clamps and hypoglycaemic clamps one week 
apart (Koivikko et al., 2005). Cardiac vagal activity, as reflected by the high 
frequency (HF) component of the spectral analysis, decreased progressively 
during hypoglycaemia in both controls and diabetic subjects. The increase 
in heart rate and decrease in high-frequency power were not related to an 
increase in adrenaline or noradrenaline. This suggests that 
adrenomedullary sympathoexcitation was not the primary cause of the 
altered HRV, but were most likely a result of reduced cardiac vagal outflow 
caused by the hypoglycaemia itself. Laitinen et al. (2003) performed serial 
euglycaemic clamps (target glucose 5 mmol/L for 2 hours) followed by 
hypoglycaemic clamps (target glucose 3 mmol/L for 2 hours) on 18 healthy 
subjects, and reported a  trend towards a decrease in the HF component 
while the low frequency (LF) band remained the same during 
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hypoglycaemia. However, conflicting results were reported by Schachinger 
et al. (2004), who found an increase in HRV and vagal activity during 
hypoglycaemia in healthy volunteers. This discrepancy may be attributed 
to shorter HRV recordings in the Schachinger study which are less accurate 
and differences in the hypoglycaemic clamp protocols. Consequently, 
further studies are required to investigate if similar autonomic changes 
occur in T2DM patients during hypoglycaemia.  
1.7.8 Arrhythmia Mechanisms: Repolarisation 
Hypoglycaemia can affect repolarisation characteristics and the action 
potential duration of cardiac cells. Low glucose may reduce the 
repolarisation reserve by a direct effect on the main repolarising potassium 
channels in cardiac cells (Zhang et al., 2003b). In normal subjects, 
hypoglycaemia produced by an insulin infusion resulted in lengthening of 
the QT interval (Eckert and Agardh, 1998). This also occurs in T1DM and 
T2DM patients (Marques et al., 1997). Observational studies suggest a 
lengthening of the QT interval occurs during nocturnal hypoglycaemia in 
T1DM subjects (Gill et al., 2009; Murphy et al., 2004; Robinson et al., 2004).  
There have been relatively few studies on the effect of hypoglycaemia on 
changes in QT interval in T2DM subjects. Marques et al. (1997) performed 
controlled hypoglycaemia on seven noninsulin dependent individuals with 
T2DM and eight insulin dependent T1DM subjects with no CVD, and the 
subjects participated in hyperinsulinaemic hypoglycaemic clamps with a 
target glucose of 3 mmol/L for 120 minutes. In the non-insulin dependent 
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diabetics, the QT interval increased after 60 minutes of hypoglycaemia and 
continued to increase for 120 minutes. This was paralleled by an increase 
in adrenaline. T1DM subjects had a similar degree of QT prolongation, but 
QT plateaued by 120 minutes of hypoglycaemia. Another study by 
Landstedt-Hallin et al. (1999) examined 13 patients with T2DM on insulin 
and glibenclamide with a mean HbA1c 7.6% and mean duration of diabetes 
of 9 years. An increase in the QT interval and QT dispersion (QTd) were 
found following 60 minutes of hypoglycaemic clamp with at blood glucose 
of 2.5-3.0 mmol/L. 
Increases in catecholamine levels appear to be the main driver of QT 
prolongation. Adrenaline causes QT lengthening when infused into humans 
in a dose dependent manner, while a beta-blockade with atenolol 
prevented hypoglycaemia induced QTc and QTd lengthening in healthy 
humans (Robinson et al., 2003). Pre-treatment of a group of T1DM subjects 
with atenolol similarly attenuated the QTc lengthening induced by 
hypoglycaemia in physiological studies (Lee et al., 2005). QT lengthening 
seems to occur independently of a fall in extracellular potassium as QT 
increases were observed in hyperinsulinaemic hypoglycaemia despite 
potassium clamping (Robinson et al., 2003). Thus adrenaline may have a 
direct effect on the myocardium independent of potassium. 
1.7.9 Effects of Hypoglycaemia beyond the Acute Episode 
The cardiovascular effects of hypoglycaemia in the hours and weeks that 
follow an acute episode remain largely uninvestigated. Hypoglycaemia-
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associated autonomic failure is a term that has been coined to describe the 
attenuation of counter-regulatory responses mediated by the autonomic 
nervous system, following an episode of hypoglycaemia (Cryer, 2005). Our 
group has shown that impaired counter-regulatory responses can persist 
for at least several days following an episode of hypoglycaemia (George et 
al., 1995). However, autonomic impairment caused by hypoglycaemia may 
be more generalised and not limited to hypoglycaemic responses alone. 
One study examined the effect of antecedent hypoglycaemia on cardiac 
autonomic function in healthy participants, and found that two episodes of 
insulin-induced hypoglycaemia lasting 60 minutes resulted in decreased 
baroreceptor sensitivity, cardiovagal function, and autonomic responses to 
hypotensive stress for at least one day (Adler et al., 2009). In rats, 
antecedent hypoglycaemia also reduced the subsequent adrenaline 
responses to non-hypoglycaemic stimuli, such as hypotension, by 2- to 3-
fold (Herlein et al., 2006). Cardiac autonomic impairment can increase the 
risk of fatal arrhythmias and reduce the response to physiological stressors. 
In people with existing diabetic autonomic neuropathy, this risk might be 
further increased. This highlights a plausible pathological pathway which 
might increase cardiovascular risk in the long-term. 
The cardiovascular effects of recurrent hypoglycaemia are not known, and 
recurrent episodes may exert a cumulative effect on atherothrombotic risk 
(Jin et al., 2011). Alternatively, sympathoadrenal responses are attenuated 
by repeated episodes of hypoglycaemia and this might actually protect 
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against the cardiovascular effects mediated by adrenergic mechanisms. In a 
recent analysis of the ACCORD study, although mortality was higher in the 
intensively treated group, those with the highest number of recurrent 
hypoglycaemic episodes exhibited a slightly lower risk of death, which 
would be consistent with this hypothesis (Seaquist et al., 2012). A summary 
of the potential mechanisms by which hypoglycaemia may predispose to 
SCD are shown in Figure 1-12.  
 
Figure 1-12:  Potential mechanisms of hypoglycaemia-related SCD 
Hypoglycaemia is accompanied by sympathoadrenal activation which can promote 
inflammation and platelet aggregation and hence the development of a vulnerable 
plaque. These effects are likely to be cumulative over months to years. The effect of 
hypoglycaemia on coagulation and fibrinolysis can contribute to acute coronary 
thrombosis and can affect autonomic function during an acute episode but also cause 
more sustained impairment. This in conjunction with abnormal repolarisation that is 
associated with acute hypoglycaemia, which may act as a final pathophysiological trigger 
for a fatal tachyarrhythmia. 
1.8 Summary 
To summarise, T2DM is associated with an increased risk of CVD through 
multiple pathways involving premature atherosclerosis, increased 
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thrombogenicity and altered myocardial metabolism and function. 
Hyperglycaemia may be responsible for some but not all of the excess risk, 
and clearly insulin resistance, dyslipidaemia, hypertension, and adipocity-
related inflammation can contribute even in the pre-diabetic state. 
Intensive glycaemic control reduces microvascular complications, but has 
not consistently reduced cardiovascular mortality in subjects at known high 
cardiovascular risk (Duckworth et al., 2009; Patel et al., 2008);  in one trial 
there was increased mortality (Gerstein et al., 2008) including an excess of 
SCDs. Hypoglycaemia, which was increased in the intensive treatment arm, 
was one of the strongest predictors of mortality in post hoc analyses.  
Although the association could be due to shared confounding factors, the 
relationship is strong and has been consistently observed in other settings.   
Experimental studies in T1DM and nondiabetic individuals have shown that 
hypoglycaemia is capable of inducing a wide range of adverse 
cardiovascular effects, many of which can predispose to SCD, thereby 
making the association biologically plausible.    
Given the global epidemic of T2DM which is set to rise in coming decades, 
it is a pressing question as to the optimal glycaemic strategy for CVD 
reduction.  Since the publication of the ACCORD, ADVANCE and VADT 
studies, there has been considerable controversy as to ‘how low to go’.  
Whether hypoglycaemia, which is unfortunately a common iatrogenic 
complication of some glucose lowering therapies, is causal in increasing the 
risk of cardiovascular death, is an important question which cannot easily 
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be answered from observational studies and trial data. Therefore exploring 
mechanisms by which hypoglycaemia can increase the risk of SCD using 
experimental studies may help answer these questions.   
1.9 Aims of the Thesis 
There is a dearth of experimental studies on the cardiovascular effects of 
hypoglycaemia in T2DM patients. Nearly all the studies mentioned earlier 
have been performed in nondiabetic and T1DM individuals and 
consequently the results must be extrapolated with some caution to T2DM 
populations, as there are physiological differences. In general, T2DM 
patients have preserved adrenaline responses to hypoglycaemia compared 
to T1DM individuals (Segel et al., 2002; Zammitt and Frier, 2005). 
Furthermore, counter-regulation may occur at a higher threshold 
compared to T1DM or nondiabetic individuals (Spyer et al., 2000). The 
magnitude of the adrenaline released is expected to be greater for the 
same level of hypoglycaemia, thus catecholamine-mediated adverse 
cardiovascular effects may be even more pronounced in T2DM individuals.  
Insulin resistance that characterises T2DM is associated with 
prothrombotic and proinflammatory effects (Grant, 2007), for example 
endogenous levels of PAI-1 are known to be higher in T2DM patients 
(Grant, 2007). The prevalence of ischaemia and cardiac structural 
abnormalities are higher than in T1DM or nondiabetic populations and 
provide further substrates for SCD in T2DM individuals.  
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Secondly, existing experimental studies have concentrated on the 
cardiovascular effects of acute hypoglycaemia up to 24 hours, yet there is 
ample evidence to suggest that acute hypoglycaemia may have 
downstream effects.  In the ACCORD trial, few deaths were judged to have 
occurred at the time of acute hypoglycaemia (Bonds et al., 2010).  Instead, 
hypoglycaemia appears to predict the risk of death in the weeks and 
months following an episode. In the VADT study, hypoglycaemia was the 
strongest independent predictor of mortality at 90 days (Duckworth et al., 
2009). Therefore an important and novel aspect of this work is to explore 
whether hypoglycaemia exerts more sustained effects on the 
cardiovascular system beyond the immediate episode. I will investigate 
whether autonomic, thrombotic and inflammatory changes may persist up 
to seven days after an episode of hypoglycaemia.   
The choice of mechanisms to investigate is based on theoretical and 
practical considerations. It is known that the increase in mortality 
associated with intensive glucose lowering occurs in patients with 
established CVD but not in those with a low atherogenic burden; 
furthermore, there was an excess of fatal myocardial infarcts over nonfatal 
myocardial infarcts in those receiving intensive glycaemic therapy. Thus the 
more proximate mechanisms of acute coronary thrombosis, transient 
autonomic imbalance and abnormal repolarisation, as triggers for fatal 
arrhythmias, may be more relevant than earlier processes of endothelial 
dysfunction and atherogenesis. The acute effects of hypoglycaemia on 
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cardiac ischaemia are clearly important; however, there are ethical 
considerations of experimentally inducing hypoglycaemia in T2DM patients 
with established ischaemic heart disease. Thus the main mechanisms 
chosen to be investigated are the effects of hypoglycaemia on thrombosis 
(platelet function, fibrin clot formation and lysis), cardiac autonomic 
function, and cardiac repolarisation. 
1.9.1 Aims and Hypothesis 
Aim: To explore potential mechanisms of hypoglycaemia-related SCD in 
T2DM 
Hypothesis: Hypoglycaemia predisposes to SCD in patients with T2DM 
through the following mechanisms: 
i) Adverse effects on thrombosis - increases in platelet reactivity, 
fibrin network characteristics and hypofibrinolysis 
ii) Adverse effects on  cardiac autonomic function 
iii) Abnormal cardiac repolarisation  
The effects of hypoglycaemia are aimed to be investigated   over the 
course of an acute hypoglycaemic episode and up to seven days after an 
episode of hypoglycaemia. 
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Chapter 2 - Research Design and Methodology 
The purpose of this chapter is to justify the choice of the experimental 
method and the reasoning behind using complementary approaches for 
studying both spontaneous and experimentally induced hypoglycaemia. 
The choice of study population will be discussed together with the 
advantages and limitations of each approach.  The design of the 
hyperinsulinaemic clamp protocol will be presented and in addition the 
choice of electrophysiological and atherothrombotic outcome measures, 
including the theoretical underpinnings for each will be discussed.     
2.1 Overview of the Study Design 
The aims of the thesis were to investigate the acute and downstream 
effects of hypoglycaemia on: 1) fibrin characteristics and fibrinolysis; 2) 
cardiac autonomic function; and 3) cardiac repolarisation. Hypoglycaemia 
is difficult to study as it occurs relatively rarely, even in tightly controlled 
individuals with diabetes, and is mostly self-treated before presentation to 
a health professional. The introduction of CGMS has allowed the capture of 
spontaneous hypoglycaemia in ambulatory patients which can be 
combined with ambulatory ECG monitoring. Synchronous monitoring 
allows the determination of arrhythmias, non-invasive indices of 
autonomic function and cardiac repolarisation at the time of the episode. 
Furthermore, patients at high cardiovascular risk or with a history of CVD 
may be studied who otherwise may be unsuitable for more invasive 
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investigations employing experimentally induced hypoglycaemia. However, 
this is dependent on capturing sporadic, unpredictable episodes of 
spontaneous hypoglycaemia and it is not be possible to take biochemical 
measurements of thrombosis and counter-regulatory hormones at the 
time of an event. It is also impossible to control for the time, depth and 
duration of spontaneous hypoglycaemia, as well as the environmental 
conditions surrounding a hypoglycaemic episode.  
The advantage of experimentally induced hypoglycaemia is that the 
intensity and duration of the hypoglycaemic stimulus can be controlled, 
together with the environmental conditions that may influence 
cardiovascular parameters. In addition, physiological measurements can be 
taken under stable glucose conditions and the exact timing of biochemical 
measurements for thrombosis and counter-regulatory hormones can be 
controlled and recorded at the time of hypoglycaemia, as well as at 
intervals after the episode.  The hyperinsulinaemic hypoglycaemic clamp is 
a well-established method of simulating an episode of experimental 
hypoglycaemia under controlled conditions (DeFronzo et al., 1979). 
However, supraphysiological doses of insulin are used and this induces 
larger electrolyte fluxes and counter-regulatory responses than clinical 
episodes. The nature of experimental hypoglycaemia may be different as 
subjects are resting and supine as opposed to spontaneous hypoglycaemia 
when subjects are mostly ambulant, at least during the day. Further, the 
hyperinsulinaemic clamp technique is invasive and can only be performed 
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in a relatively small number of subjects, and it would be unethical to 
subject T2DM patients with high cardiovascular risk to experimental 
hypoglycaemia, who are the group of interest in this study.  
It was therefore decided to use complementary approaches of ambulatory 
monitoring to investigate the acute electrophysiological response to 
hypoglycaemia in T2DM patients at high cardiovascular risk (study 1)  and 
using experimentally induced hypoglycaemia (study 2) to examine the 
electrophysiological and thrombotic effects effects in patients with no CVD 
both during and after an episode. An overview of the two studies is 
presented below.  
2.2  Study 1: Cardiac Electrophysiological Response to 
Spontaneous Hypoglycaemia in Individuals with Type 2 
Diabetes and with a Cardiovascular Risk  
2.2.1 Overview of the Study 
The primary outcome of this study is the frequency of arrhythmia during 
spontaneous hypoglycaemia compared to euglycaemia in T2DM patients 
with known cardiovascular risk. Changes in cardiac autonomic function, as 
shown by heart rate variability (HRV), and changes in cardiac 
repolarisation, as shown by QTc intervals, were investigated as potential 
mechanisms that can predispose to arrhythmias. 
Patients with T2DM taking insulin for > 4 years and with a history of CVD or 
at high CV risk were recruited to the study. Following a baseline 
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assessment which included autonomic function testing, all subjects 
underwent simultaneous continuous interstitial glucose (IG) and 
ambulatory ECG monitoring for five days. The frequency of arrhythmias, 
HRV and corrected QT were compared between hypoglycaemia and 
euglycaemia matched for the time of day. A hypoglycaemic episode was 
defined as interstitial glucose (IG) <3.5 mmol/L for at least 20 minutes and 
euglycaemia as 5-10 mmol/L.  To account for diurnal variation in cardiac 
electrophysiology and counter-regulatory responses, episodes were further 
divided into daytime and nocturnal (2300 to 0700 hours) episodes for the 
analyses.  
2.2.2 Study Participants 
T2DM patients were recruited from Sheffield Teaching Hospitals diabetes 
outpatient clinics. Subjects who had been treated with insulin for at least 
four years were recruited, as these individuals were at highest risk of 
hypoglycaemia due to disease duration. In a recent clinical observational 
study, 25% of T2DM patients on insulin >5 years experienced one or more 
episodes of low IG <2.2 mmol/L during the study week, as recorded by 
CGM (Group, 2007). In this present study, the inclusion criteria were 
chosen such that patients had either established CVD or two or more CVD 
risk factors and were designed to mirror the characteristics of the ACCORD 
study cohort (Gerstein et al., 2008).  
Inclusion criteria: 
 T2DM patients on insulin treatment for 4 or more years 
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 History of CVD (ischemic heart disease, peripheral vascular or 
cerebrovascular disease) and/or two additional cardiovascular risk 
factors (hypertension and dyslipidaemia, both defined as requiring 
medication, a current smoker, obesity) 
Exclusion criteria: 
 Pregnancy 
 Bundle branch block on resting ECG  
 Permanent atrial fibrillation 
 Prescription of QT prolonging drugs  
 Severe diabetic complications (e.g. blindness) affecting the ability to 
participate in the study 
 Myocardial infarction or coronary artery bypass graft <12 months 
ago 
 Inability to communicate in English 
 Inability to provide informed consent 
2.2.3 Research Governance 
Informed consent was obtained from all the participants according to the 
principles of good clinical practice. The study received local ethics approval 
(Appendix 3). 
2.2.4 Baseline Assessment 
Baseline data were obtained from patients, including age, sex, BMI, 
duration of diabetes, and duration of insulin treatment. Past medical 
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history and information on diabetes treatment and other medications were 
also obtained and a baseline 12 lead ECG was recorded. Blood pressure 
was measured using an automatic oscillometric sphygmomanometer 
(DINAMAP® GE Medical Systems Information technologies, Inc.) after lying 
supine for five minutes. For HbA1c, venous blood was collected into tubes 
containing ethylenedimiaminetetraacetic acid (EDTA) (BD Vacutainer™ 
K3E) and analysed via ion exchange high performance liquid 
chromatography (HPLC) techniques at Sheffield Teaching Hospital central 
laboratories.  Blood (2 mL) was collected into tubes with a clot accelerator 
and separation gel (BD Vacutainer® SST™ Advance) and subjected to 
centrifugation at 300 ×g at room temperature for 10 minutes. The resulting 
serum was analysed for urea and electrolytes using an automated system 
(Cobas® analyser, Roche Diagnostics, UK) at Sheffield Teaching Hospital 
laboratories. 
2.2.5 Cardiac Autonomic Reflex Tests 
Cardiac autonomic reflex testing was performed to determine the presence 
of cardiac autonomic neuropathy (CAN) at baseline. The cardiovascular 
reflex tests were performed to assess the integrity cardiovagal and 
sympathoeffector responses via reflex pathways triggered by physiological 
manoeuvres. They consisted of three tests which predominantly assess 
cardiovagal function (heart rate to deep breathing, the Valsava manoeuvre, 
and heart rate response to standing) and two tests for sympathetic 
function (blood pressure response to standing and change in diastolic 
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blood pressure (DBP) in response to a sustained handgrip).  Participants 
rested for three minutes before each test and the results were compared 
against age-adjusted normal ranges (O'Brien et al., 1986), with results 
below the 95% confidence limits regarded as abnormal. These simple 
bedside tests have been validated for diagnosis and staging, and as trial 
endpoints in CAN (Tesfaye et al., 2010; Vinik and Ziegler, 2007). Based on 
the most recent consensus (Tesfaye et al., 2010), the presence of  two or 
more abnormal cardiovagal tests were defined as definite CAN and these 
participants excluded from the trial. A number of factors are known to 
influence autonomic function and these were controlled for.  Venous 
glucose was concurrently measured to ensure participants were 
euglycaemic during the tests, and all participants were asked to avoid 
caffeine or smoking on the day of the tests and vigorous exertion 24 hours 
prior to the tests. The tests were performed according to the standardised 
protocols outlined below. 
ECG signals were obtained using a three lead ECG monitor (Ivy Cardiac 
Trigger Monitor 3000, Ivy Biomedical Systems Inc., Branford CT, USA), 
which generates a synchronised pulse at the peak of each R wave. This was 
connected to the WR TestWorks™ Analogue Interface (WR Medical 
Electronics Company, Maplewood, USA) and ECG signals was digitised 
using a sampling frequency of 1000 Hz via a data acquisition device (NI-
DAQCard-6062E, National Instruments™, UK) connected to a laptop 
computer (Toshiba Satellite 1800-S274). Data were recorded and analysed 
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using the WR-TestWorks™ software (version 2.4.0, WR Medical Electronics 
Co., Maplewood, USA). This software contained dedicated modules for the 
heart rate response to deep breathing, Valsava, and standing. A marker 
was placed on the ECG recording denoting the beginning of the manoeuvre 
and R-R intervals (measured in ms) were generated within the programme, 
with the tests results calculated according to definitions below. 
2.2.5.1 Heart Rate Response to Deep Breathing 
The subjects remained supine and breathed deeply at the rate of one 
breath per 10 seconds (i.e. six breaths per minute) for one minute while 
being monitored by ECG. Reproducibility was improved by visual cues and 
the participants breathed in and out according to a timed light display. The 
heart rate increases on inspiration and falls with expiration (sinus 
arrhythmia), and the expiration:inspiration (E:I) ratio is the ratio of the 
mean of the longest R-R intervals during deep expirations to the mean of 
the shortest R-R intervals during deep inspirations.  
2.2.5.2 Heart Rate Response to the Valsalva Manoeuvre 
The supine patient was connected to an ECG monitor and asked to forcibly 
exhale into a modified sphygmomanometer to a pressure of 40 mmHg for 
15 seconds. Once the Valsalva was released, the subjects were asked to lie 
still without talking and recording continued for a further 45 seconds.  This 
was repeated three times with one minute of rest in between. Normally, 
the reflex response to the Valsalva manoeuvre includes tachycardia and 
peripheral vasoconstriction during strain, followed by an overshoot in 
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blood pressure and bradycardia after release of the strain. The response to 
the performance of the Valsalva manoeuvre has four phases: 
Phase I: Transient rise in blood pressure and a fall in heart rate due to 
compression of the aorta and propulsion of blood into the peripheral 
circulation. Haemodynamic changes are mostly secondary to mechanical 
factors. 
Phase II: Early fall in blood pressure with a subsequent recovery of blood 
pressure later in the phase. Blood pressure changes are accompanied by 
an increase in heart rate, and there is a fall in cardiac output due to 
impaired venous return causing compensatory cardiac acceleration, 
increased muscle sympathetic activity, and peripheral resistance. 
Phase III: Blood pressure falls and heart rate increases with the 
cessation of expiration. 
Phase IV: Blood pressure increases above the baseline value (overshoot) 
because of residual vasoconstriction and restored normal venous return 
and cardiac output. 
The Valsalva ratio is the longest R-R divided by the shortest R-R occurring 
within 45 seconds of the peak heart rate. The mean ratios from three 
attempts were recorded. 
2.2.5.3 Heart Rate Response to Standing 
Participants remained supine for at least five minutes and then stood to a 
full upright position. The normal response is a characteristic and rapid 
96 
increase in heart rate in response to standing that is maximal at 
approximately the 15th beat after standing, followed by a relative 
bradycardia that is maximal at approximately the 30th beat after standing. 
Because the maximum and minimum R-R intervals may not always occur at 
exactly the 15th or 30th beats after standing, the  30:15 ratio has been 
redefined as the longest R-R interval during beats 20–40 divided by the 
shortest R-R interval during beats 5–25 (Ziegler et al., 1992).  
2.2.5.4 Systolic Blood Pressure Response to Standing 
Blood pressure was measured using an automatic sphygmomanometer 
with the patient having remained supine for >5 minutes and then repeated 
one minute after standing. A drop of systolic blood pressure (SBP) <10 
mmHg was classified as normal, 10-30 mmHg as borderline, and >30 mmHg 
as abnormal. A drop in DBP >10 mmHg was also considered abnormal.  
2.2.6 Continuous Glucose and Ambulatory ECG Monitoring  
All patients underwent five days of simultaneous 12 lead Holter and 
interstitial CGM. Patients carried on with their usual daily activities and 
diabetes treatments. Twelve lead ambulatory ECGs (Lifecard 12, Spacelabs 
Healthcare, Hertford, UK) were recorded at a sampling rate of 128 Hz with 
electrodes in a Mason-Likar configuration. IG was monitored using a CGMS 
which employed a wired enzyme electrochemical method of glucose 
detection (Freestyle Navigator Continuous Glucose Monitoring System, 
Abbott Diabetes Care, Maidenhead, UK) (Heller and Feldman, 2010). 
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Calibrations against capillary blood glucose were performed at least four 
times during the study week according to the manufacturer's instructions.  
This calibration was performed to convert sensor-detected currents into 
glucose readings and to deduce blood glucose levels from glucose values 
measured in interstitial fluid  (Vaddiraju et al., 2010). One of the limitations 
of CGM is its reduced accuracy in the hypoglycaemic range due to a low 
sensor signal. A further limitation is that changes in IG lag behind that of 
blood glucose by 12-20 minutes. This has implications for the accuracy of 
calibration; hence the device has built-in functions which only permit 
calibration when IG is stable within a pre-specified range. The accuracy of 
CGM devices has been tested in hyperinsulinaemic clamps against 
arterialised blood glucose (Clarke et al., 2005). Mindful of the limitations of 
CGM, a system was selected that has been reported to follow the descent 
in blood glucose to the hypoglycaemic nadir (Clarke et al., 2005), with a 
lowest detection limit of 1.1 mmol/L (20 mg/dL).  
IG was measured every minute by the CGM and 10 minute averages were 
reported (CoPilot Healthcare, Abbott Diabetes Care, Maidenhead, UK), 
with hypoglycaemia defined as IG ≤ 3.5 mmol/L in accordance with 
previously published studies (Gill et al., 2009), euglycaemia as 5-10 
mmol/L, and hyperglycaemia defined as IG ≥ 15 mmol/L. These glycaemic 
thresholds were designed to allow for a margin of error in the CGM. 
Predictive alarms were switched off and participants were instructed not to 
view the glucose values except during calibrations. Patients were also 
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asked to keep a record of any symptomatic hypoglycaemia. An episode of 
low IG <3.5 mmol/L on CGM without the simultaneous self-reporting of 
symptoms was regarded as asymptomatic.   
2.2.7 Arrhythmia Analysis 
The 12 lead ambulatory ECG data was analysed with the Pathfinder 
Ambulatory ECG analysis system (v. 8.701, Delmar Reynolds Medical Ltd, 
Edinburgh & Hertford, UK). Leads I, II and V5 were used for analysis as they 
represented the orthogonal leads. Normal and aberrant beats were 
labelled by the Pathfinder system using a commercial algorithm with pre-
set sensitivity to optimise the trade-off between preserving useful 
information versus eliminating artefacts. The ECG was manually screened 
for gross arrhythmias, whilst the software automatically detected 
arrhythmic events according to predetermined event definitions, which 
included atrial ectopic beats, bradycardia (defined as four or more 
consecutive beats at less than 45 beats per minute), ventricular premature 
beats (VPB) and complex VPB (bigeminy, trigeminy, couplet, Salvos and 
VT). Definitions of these terms are described in Appendix 1. All identified 
arrhythmic events were manually verified for accuracy, with investigators 
blinded to glucose values during arrhythmia analysis. Hourly counts for 
each type of arrhythmia were paired against hourly mean IG, which was 
categorised into hypoglycaemia (IG ≤ 3.5 mmol/L), hyperglycaemia (IG ≥ 15 
mmol/L) and euglycaemia (5 mmol/L < IG < 10 mmol/L). Analyses were 
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separated into day and night (2300-0700 hours) in order to take into 
account diurnal variation. 
2.2.8 Heart Rate Variability  
Direct recordings of cardiac sympathetic and vagal neural activity are 
difficult to measure in the conscious human, thus non-invasive assessment 
of cardiac autonomic balance relies on measuring the efferent activity of 
end organs, such as the heart.  At rest, short term heart rate changes are 
predominantly influenced by neural inputs from sympathetic and 
parasympathetic traffic, and the right atrial stretch.  The R-R interval and 
fluctuations are linearly related to vagal cardiac activity, and this has been 
validated in anaesthetised dogs where the R-R interval has been shown to 
be prolonged in direct proportion to right vagal stimulation (Eckberg and 
Sleight, 1992). There are limited data for humans, but Carlsten et al. (1957) 
performed vagal stimulation in six patients undergoing radical neck surgery 
for cancer and found that the R-R interval increased linearly with 
stimulation frequency and plateaus at a higher range. Vagal activity leads 
to rapid changes in heart periods as the acetylcholine is rapidly hydrolysed. 
There is general accepted that rapid changes in the R-R interval are almost 
entirely mediated by changes in vagal cardiac activity (Eckberg and Sleight, 
1992; Fouad et al., 1984). 
Different computational methods may be applied to represent the 
variation in R-R intervals over time. The time domain measures include the 
standard deviation of 5-minute averages of normal R-R intervals (SDNN), 
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and the root-mean square of the difference of successive R-R intervals 
(RMSSD), which represent long and short term variations in 
parasympathetic activity. HRV can also be studied using power spectral 
density analysis, which describes how variance is distributed as a function 
of frequency (Figure 2-1).  As mentioned previously, the vagus nerve acts 
rapidly on the sinus node. Therefore fluctuations of the heart rate at a HF 
(0.15-0.4 Hz) are thought to represent parasympathetic activity. In dogs 
and humans, parasympathetic blockade by atropine eliminates most heart 
rate fluctuations above 0.15 Hz (Parati et al., 1995) 
The interpretation of the low frequency component (0.04-0.15 Hz) of HRV 
is a matter of great controversy, and the concept of normalised LF as a 
measure of relative sympathetic contribution was introduced by the 
Malliani group (Pagani et al., 1986). In healthy subjects who underwent a 
graded tilt, there was an observed correlation between the degree of tilt 
and the LF and HF power expressed as a proportion of the total power 
(LFnorm and HF norm) in the spectra, and the LF-to-HF ratio. However, 
there was no correlation between the tilt angle and the absolute values of 
LF power (Montano et al., 1994).  Rather than increasing or decreasing 
fluctuations in heart rate, sympathetic activity appears to act as a low-pass 
filter 
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Figure 2-1: Power spectra of heart rate variability 
The variation in R-R interval is mathematically transformed using the Fourier 
transformation into a power spectrum.  Power spectra are further divided according to 
frequency domains: Low frequency LF (0.04-0.15 Hz) and high frequency HF (0.15-0.4 Hz). 
(Bernardi et al., 2011). Thus during sympathetic activation (e.g. upright 
posture, exercise or heart failure), the increasing sympathetic contribution 
reduces the respiratory-mediated HF component and there is a global 
reduction in total power in the heart rate spectra. However, the relative 
contribution of LF power to the total power is increased, thus LF expressed 
only in normalised units is meaningful for expressing the sympathovagal 
balance (Bernardi et al., 2011). Another important concept to bear in mind 
is that HRV measures fluctuations in autonomic inputs to the heart, rather 
than the mean level of autonomic inputs. 
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There are a number of limitations to the use of LF as a measure of cardiac 
sympathetic activity. In animals, heart rate fluctuations in the LF domain 
are affected by electrical stimulation of both the vagal and sympathetic 
cardiac nerves. In humans, heart rate variations in the LF range are reduced 
by either parasympathetic or sympathetic pharmacological blockade 
(Parati et al., 1995), and there is a weak correlation between cardiac 
norepinephrine spill-over and LF, and the LF:HF ratio (Goldstein et al., 
2011). Furthermore, heart rate variation in the LF range is also influenced 
by respiration, as slow-breath-induced low frequencies can occur during 
spontaneous breathing (Bernardi et al., 2011), although this effect can be 
controlled by paced respiration during HRV recordings. There is some 
evidence that LF is more closely correlated with BRS (Goldstein et al., 
2011). However, this has also been challenged (Martelli et al., 2014). 
Despite these limitations, practically there are few non-invasive methods of 
measuring cardiac sympathetic activity, and the use of normalised LF or 
LF:HF as an index of relative sympathetic contribution has been supported 
by the Toronto Consensus panel on Diabetic Neuropathy (Bernardi et al., 
2011).  
2.2.8.1 Heart Rate Variability Analysis 
The reliability of HRV analysis can be influenced by a number of factors, 
such as the length of recording, and the occurrence of ectopic beats and 
artefacts. HRV analysis in this study was performed in accordance with the 
recommendations of the Taskforce on Heart Rate Variability (1996), and R-
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R intervals were extracted only from annotated normal beats (NN intervals) 
using the Pathfinder Ambulatory ECG analysis system, as ectopic beats will 
distort the spectra. For reliable analysis, the ECG recording must be at least 
10 times longer than the wavelength of interest; therefore a 5 minute 
segment of successive NN intervals was selected around each reported IG 
value. HRV analysis was performed on each 5 minute ECG segment, and 
the time domain measures of SDNN and RMSSD were calculated. Spectral 
analysis of HRV was performed using the Fourier transformation. The LF 
band was defined as 0.04-0.15 Hz and the HF band as 0.15-0.4 Hz, and the 
ratio between the LF power and total power was calculated (LFnorm). 
2.2.9 Cardiac Repolarisation 
The QT interval is defined from the onset of the QRS complex, which marks 
the depolarisation of the first myocardial ventricular cell, to the end of the 
T wave, which marks repolarisation of the last ventricular myocyte. QT 
prolongation results from an increased action potential in the ventricular 
myocardium, and it remains the most widely used surface ECG marker for 
abnormal repolarisation given its ability to predict potentially fatal 
ventricular tachyarrhythmias.  
Although automatic QT detection algorithms are available, these are not 
reliable, especially when T wave morphologies are abnormal, which our 
group has shown to occur during hypoglycaemia (Marques et al., 1997). 
Thus a semi-automatic algorithm was employed which allows the manual 
verification of fudicial points on the ECG calculated by the computer 
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algorithm. First, annotated normal ECG beats were identified using the 
Pathfinder system (v.8.701, Delmar Reynolds Medical Ltd, Edinburgh and 
Hertford, UK) from the orthogonal leads I, II and V5 to represent global 
repolarisation. On each lead, a 40 Hz high pass filter was implemented to 
reduce the noise (Badilini et al., 1999), and a cubic spline interpolation was 
then applied to remove LF baseline wander without affecting the higher 
frequency ECG components. A composite wave was then generated from 
the orthogonal leads I, II and V5 to represent global repolarisation. Analysis 
of the composite wave was performed on a five minute window centred on 
each IG value.  
QT intervals from ambulatory recordings were analysed based on a 
selective beat averaging approach, as described by Badilini et al. (1999).The 
principle of selective beat averaging is to obtain higher signal-to-noise ratio 
templates for QT analysis (Badilini et al., 1999). In this method, the beats 
with a stable preceding heart rate were selected in order to respect the 
restitution properties of ventricular repolarisation. Beats that occur during 
heart rate changes may exhibit a different repolarisation shape compared 
to those occurring at a stable heart rate because the QT interval has not 
fully adapted. In this study, beats with a preceding R-R interval within ± 15 
ms and a second preceding R-R interval within ± 50 ms of the prevailing 
mean R-R across the five-minute segment were averaged.  
The composite wave was then calculated from the averaged beats derived 
from leads I, II and V5. In the composite wave, the onset of the Q wave was 
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marked as the first positive deflection from the isoelectric line above 10 
mV (Lee et al., 2003), whilst the end of the T wave was determined using 
the tangent method, whereby the tangent to the steepest downslope of 
the T wave crosses the isoelectric line (Figure 2-2). The tangent method has 
previously been employed in determining QT changes during experimental 
hypoglycaemia (Robinson et al., 2003), and has advantages over other 
methods, such as the threshold method, which require a stable isoelectric 
baseline.  All median beats were manually reviewed and the fiducial points 
adjusted if necessary by two independent observers blinded to the glucose 
values. Furthermore, all the T waves were manually classified as normal, 
notched or fusion, according to predetermined criteria described in 
Appendix 2.  
 
Figure 2-2: Tangent method of T end determination 
The peak of the T wave is identified by finding the return to the baseline of the first 
derivative, with the subsequent maximal negative dv/dt identifying the point of peak 
downslope of a positive monophasic T wave. Where the tangent intersects the baseline is 
defined as the T end. The baseline is defined by the PR segment and/or the TP segment if 
repolarisation does not interfere with the subsequent P wave (Lepeschkin and Surawicz, 
1952). 
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The QT interval is affected by the heart rate, so a heart rate correction is 
necessary to compare QT intervals at different heart rates. The QT interval 
is most commonly corrected using Bazzett’s formula:  
              
            
             
 
However, Bazett’s formula tends to overcorrect at high heart rates and 
under correct at low heart rates, and in addition, fixed correction formulae 
assume that QT/R-R relationships are uniform between individuals. It has 
been shown that there are significant inter-individual differences in QT/R-R 
relationships due to effects such as age and gender. Therefore, QT intervals 
were corrected for heart rate (QTcS) using subject-specific regression 
formulae, as has been previously employed in studies of hypoglycaemia 
(Christensen et al., 2010). Individualised linear regression formulae were 
derived that were based on all the QT/R-R values obtained for each 
individual during euglycaemia. 
2.2.10 Statistical Analysis 
2.2.10.1 Power Calculation 
This was an observational study. There was no prior information available 
as to any of these potential relationships and so a power calculation would 
have been based upon guesswork. Consequently, no power calculations 
were performed, but the numbers chosen were based upon an assessment 
of the number of patients it was possible to examine given the constraints 
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on recruitment and the projected hypoglycaemia rates of approximately 1 
in 4 patients during the study week (2007). 
2.2.10.2 Statistical analysis 
Data were inspected for normality and data that was found to follow an 
approximate normal distribution were summarised using the mean (SD), 
whilst skewed data were summarised using the median (IQR). 
Demographic data between patients who experienced at least one 
hypoglycaemic episode versus those that experienced none were 
compared using an independent t-test, Mann-Whitney U test, or Fisher’s 
exact test for the effect of the insulin regimen and insulin type on 
hypoglycaemia.  
The generalised estimated equations approach was employed to 
investigate the effect of the glycaemic status on arrhythmia counts while 
taking into account correlated measurements from individuals who 
experienced more than one episode of hypoglycaemia or hyperglycaemia. 
The Poisson model, which is usually used to analyse count data, was not 
optimal in this study as there were many individuals who did not 
experience arrhythmic events. For this reason, the data were fitted with a 
negative binomial model which takes into account the exposure time and 
the individuals experiencing no arrhythmic events. A first order 
autoregressive correlation structure was applied to adjust for the within-
individual correlation. Exponentiated regression coefficients represent the 
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incident rate ratios (IRR), and the IRR of arrhythmias during hypoglycaemia 
and hyperglycaemia compared with euglycaemia were calculated. 
 HRV parameters and QTc were compared at the glucose nadir of the 
hypoglycaemic or glucose maxima of a hyperglycaemic episode against an 
equivalent euglycaemic time point on a different day. Where there was 
more than one matching hypoglycaemic-euglycaemic episode in an 
individual participant over the course of the recording period, the mean 
from all daytime and nocturnal episodes from that individual were taken 
respectively. Data were analysed using a paired t-test and statistical 
analysis was performed using SPSS (version 20.0, IBM, Chicago, Illinois), 
with a p-value of ≤ 0.05 deemed to be statistically significant.  
2.3 Study 2: Acute and Downstream Cardiovascular Effects of 
Experimental Hypoglycaemia in Type 2 Diabetes 
2.3.1 Overview of the Study 
The aim of this study was to investigate cardiovascular responses during 
acute hypoglycaemia and downstream effects at days 1 and 7 using an 
experimental model of hyperinsulinaemic hypoglycaemia. The study was 
performed in T2DM individuals with no known CVD and an age and BMI 
matched nondiabetic group. Following the screening visit, each individual 
underwent paired euglycaemic and hypoglycaemic studies on two separate 
occasions where the rates and duration of insulin infusion were identical. 
Thus we were able to control the effects of hyperinsulinaemia. The 
advantage of this design is that each subject serves as his/her own control. 
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There is considerable intersubject variability in measures such as platelet 
reactivity and inflammation. It would be harder to match these parameters 
using a two group design where different sets of subjects undergo 
euglycaemia and hypoglycaemic studies. Euglycaemic studies and 
hypoglycaemic clamps were separated by at least four weeks to reduce the 
risk of carry over effects, but were separated by no more than twelve 
weeks. Euglycaemic studies preceded hypoglycaemic clamp studies for 
each individual. The reason for this is that interventional trials suggest 
hypoglycaemia has potential cardiovascular effects up to 90 days after the 
event and hence the clamps were not performed in a randomised fashion. 
The study was single blinded. Subjects did not know the glucose levels or 
the order with which euglycaemic and hypoglycaemic studies were 
performed. 
In the euglycaemic arm, glucose was maintained at 6 mmol/L for two 60 
minute periods in the morning and the afternoon, whilst in the 
hypoglycaemic arm, glucose was maintained at 2.5 mmol/L for two 60 
minute periods (Figure 2-3). The rationale for inducing two periods of 
hypoglycaemia was based on previously  published antecedent 
hypoglycaemia studies, which performed two 90-120 minute 
hypoglycaemic clamps on the same day in order to produce a sufficient 
stimulus (Adler et al., 2009; Davis et al., 2009).  
To examine the downstream effects of hypoglycaemia, cardiovascular 
parameters were measured at baseline, and days 1 and 7 following 
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hypoglycaemia or euglycaemia. The study visits were conducted in the 
morning to control for effects of circadian variation. Spontaneous 
hypoglycaemia in the intervening period may alter the responses under 
study, therefore the selection criteria included diabetic patients at low risk 
of hypoglycaemia (on oral agents +/- GLP-1 analogues or on insulin <2 
years), and the diabetic subjects were instructed to keep a diary of 
symptomatic hypoglycaemia during the study period. High resolution ECG 
and cardiac autonomic reflex testing was performed at baseline and days 1 
and 7. Catecholamines, cortisol, thrombotic, and inflammatory biomarkers 
were also measured at these time points in both arms of the study (Figure 
2-3). 
The response to acute hypoglycaemia was compared between morning 
euglycaemic and morning hypoglycaemic clamps.  No measurements were 
taken from afternoon clamps as the responses would have been altered by 
the hypoglycaemia induced in the morning. Blood pressure and heart rates 
were monitored every 30 minutes, and high resolution ECGs were 
performed at  0, 30, 60, 90, and 120 minutes, and following recovery (150 
minutes) (Figure 2-4). Venous blood for the analysis of urea and 
electrolytes, free insulin, and inflammatory biomarkers and counter-
regulatory hormones was sampled at the baseline and end of the clamp in 
both the euglycaemic and hypoglycaemic arms (120 minutes). Platelet 
function assays, fibrin network properties, and coagulation proteins were 
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measured at the baseline, end of the clamp and following recovery (150 
minutes). 
 
 
 
Figure 2-3: Flowchart for the hyperinsulinaemic clamp study 
In the euglycaemic (EU) arm, subjects were maintained at a glucose level of 6 mmol/L for 
60 minutes in the morning and 60 minutes in the afternoon, whilst in the hypoglycaemic 
arm, glucose was maintained at 2.5 mmol/L for 60 minutes in the morning and 60 minutes 
in the afternoon. Follow up visits were arranged in the morning on days 1 and 7. 
Abbreviations: BP-blood pressure, BRS -baroreceptor sensitivity, UE-urea and electrolytes, 
CARTs-cardiovascular autonomic reflex tests, CATAS-catecholamines. 
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Figure 2-4: Measurement of cardiovascular parameters during acute 
hypoglycaemia 
Cardiovascular parameters were measured during the morning hypoglycaemic (HYPO) 
clamp and compared against the euglycaemic (EU) clamp. Physical and biochemical 
measurements were made every 30 minutes during the clamp and after recovery. 
This experimental approach was piloted in four diabetic and four 
nondiabetic individuals, with the purpose of testing the feasibility of the 
hyperinsulinaemic clamp protocol, subject recruitment, and measurement 
time points.  During the pilot experiments, target blood glucoses were 
achieved and hence no changes were made to the hyperinsulinaemic 
clamp protocol. However, difficulty was experienced in recruiting healthy 
male volunteers and there was high screen failure of female diabetic 
participants. Consequently, recruitment of healthy volunteers was widened 
to both university and hospital staff to increase the pool of potential 
participants. Data from the pilot phase were included in the main analysis. 
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2.3.2 Study Participants and Recruitment 
Individuals with T2DM aged between 18 and 65 were recruited to the study 
and the control group consisted of an age and BMI matched group of 
nondiabetic individuals, as these factors and gender can affect cardiac 
autonomic and thrombotic parameters and counter-regulatory responses. 
The reason for matching for age and BMI factors only were due to practical 
difficulties in recruiting matched nondiabetic male volunteers which 
emerged from the pilot phase.  For reasons of safety, only participants with 
uncomplicated diabetes and no history, signs or symptoms suggestive of 
CVD were recruited. Inclusion and exclusion criteria are outlined below. 
Inclusion criteria for diabetic patients:  
 T2DM on oral medications and/or insulin for less than 2 years 
and/or GLP1 analogues 
 Age 18-65 
 Attending Sheffield Teaching Hospital/GP Practices in Sheffield  
 Most recent HbA1c 6.5-10.5% ( 48-91 mmol/mol) 
 Informed Consent  
Inclusion criteria for nondiabetic individuals: 
  Age 18-65 
  Informed Consent 
Exclusion criteria for diabetic and nondiabetic individuals: 
 Documented myocardial infarction, ischaemic heart disease, cardiac 
arrhythmia, heart failure, peripheral vascular disease, stroke, visual 
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impairment due to retinopathy, or nephropathy as demonstrated by 
elevated serum creatinine accompanied by proteinuria.  
 Abnormal resting 12 lead ECG 
 Significant symptoms suggestive of CVD 
 Pregnancy  
 Known untreated hyperthyroidism 
 Epilepsy or previous seizures  
 Patients on beta-blockers or QT prolonging drugs 
 Patients on anticoagulants or antiplatelet therapy (except aspirin) 
 Cardiac autonomic neuropathy 
 Serious intercurrent illness 
 Malignant disease 
 Previous history of deep venous thrombosis or pulmonary embolus. 
 Inability to communicate in English 
 Unwilling to self-monitor blood glucose levels (diabetic patients) 
 Family history of sudden death 
Potential diabetic participants were identified from diabetes outpatient 
clinics where an initial approach was made by their usual clinicians and 
interested individuals were provided with information about the study; this 
was the main route of recruitment. In addition, diabetes consultants, 
specialist nurses and community diabetes team were contacted and asked 
to refer any potential participants. Nondiabetic participants were recruited 
from staff, students and the general public attending Sheffield Teaching 
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Hospitals and the University of Sheffield. Advertising posters were placed 
around the diabetes centre, hospitals and the university, and the study was 
also advertised via the hospital email distribution list through which the 
majority of the nondiabetic volunteers were identified. 
2.3.3 Research Governance 
Informed consent was obtained from all participants according to the 
principles of good clinical practice. The study has received local ethics 
approval (Appendix 4). 
2.3.4 Screening 
Screening included the collection of demographic information, a full history 
and an examination, including an enquiry into cardiovascular symptoms 
and medications, a full blood count, urea and electrolytes, determination 
of fasting glucose levels, lipids and HbA1c, and the urine albumin creatinine 
ratio. Nondiabetic participants were screened for diabetes, which was 
defined as a fasting glucose >7 mmol/L or HbA1c >48 mmol/L (6.5%). A 
baseline 12 lead electrocardiogram was performed, and participants were 
screened for CAN as described for study 1. Participants with definite CAN, 
as defined by two or more abnormal tests based on published reference 
ranges, were excluded (O'Brien et al., 1986). Participants who fulfilled the 
edibility criteria were invited for the remainder of the study. 
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2.3.5 Hyperinsulinaemic Clamp Protocol 
2.3.5.1 Euglycaemic Clamp Protocol 
All the participants attended the Clinical Research Facility at 8 am having 
fasted from midnight. Diabetic patients were asked to omit their diabetic 
medications for 12 hours to check a four point capillary blood profile the 
day before the clamp. The clamp was then postponed if participants had a 
symptomatic hypoglycaemic episode or self-measured blood glucose of 
less than 3 mmol/L in the previous 24 hours as antecedent hypoglycaemia 
may modify counter-regulatory responses. Participants were advised to 
avoid smoking and caffeine on the day of the study and to avoid vigorous 
exercise for 24 hours before. Study participants were blinded to blood 
glucose levels throughout the duration of the clamp studies. 
Baseline cardiovascular and biochemical measurements were performed. 
In the case of diabetic participants, blood glucose was initially stabilised via 
a variable insulin infusion (Human Actrapid, NovoNordisk Pharmaceuticals 
LT, Crawley, West Sussex, UK) for 40 minutes to 1 hour, aiming for a target 
glucose level of between 6-7 mmol/L. 50 units of Human Actrapid was 
added to 50 mL 0.9% sodium chloride (Baxter, Baxter Healthcare Ltd, 
Norfolk, UK) and infused via a syringe driver (Alaris ® GH Guardrails, 
Cardinal Health, Rolle, Switzerland) into an intravenous cannula in the non-
dominant arm, and capillary blood glucose was monitored every 15 
minutes. Nondiabetic volunteers did not require stabilisation of their blood 
glucose through intravenous insulin, and capillary blood glucose was 
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monitored every 20 minutes for the first 40 minutes to ensure it was in the 
euglycaemic range. 
A second cannula was inserted into the opposite antecubital fossa for 
sampling of venous blood for biochemical, inflammatory and thrombotic 
measurements. These included urea and electrolytes, cortisol and growth 
hormone, and samples for platelet aggregation, fibrin clot properties and 
inflammatory cytokines.  
A retrograde cannula was inserted following the application of local 
anaesthetic cream (EMLA, Astra Zeneca, UK) to the dorsal hand or wrist 
vein of the non-dominant hand. The hand was placed in a heated chamber 
at 55oC to allow arterialisation of venous blood for glucose sampling and 
catecholamine sampling. A slow infusion of 0.9% sodium chloride was 
infused to keep the line patent.  
Due to insulin resistance, T2DM patients require a higher insulin infusion 
rate compared with published studies in T1DM patients. A primed 
continuous infusion of insulin (Human Actrapid, Novo Nordisk 
Pharmaceuticals Ltd, Crawley, West Sussex, UK) was administered at a rate 
of 120 mU/m2/minute, calculated according to the Dubois formula:  
Body surface area (m
2
) = 0.007184 × (patient height in cm)
0.725
 × (patient weight in kg)
0.425  
  
In this study, the same rates of infusion were used for diabetic and 
nondiabetic participants, so that insulin levels would be comparable. This 
was infused into the cannula in the antecubital fossa of the non-dominant 
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arm via a syringe driver (Alaris® GH Guardrails, Cardinal Health, Rolle 
Switzerland). A variable rate 20% dextrose infusion (Baxter, Baxter 
Healthcare Ltd., Norfolk UK) was administered to the same cannula via an 
infusion pump (Alaris® GP plus, Cardinal Health, 1180 Rolle, Switzerland), 
and the glucose infusion rate was adjusted according to arterialised whole 
blood glucose concentrations sampled from the retrograde cannula every 5 
minutes, which was analysed using a bedside glucose analyser (Yellow 
Spring Instruments, Ohio, USA).  Glucose infusion rates were adjusted in 
order to reach the target blood glucose concentration of 6 mmol/L over 
half an hour. Blood glucose was then maintained at the target level of 6 
mmol/L for 60 minutes.  
At the end of the euglycaemic clamp period, the insulin was switched off 
and the 20% dextrose infusion was continued for at least 30 minutes, with 
the aim of achieving a stable glucose concentration in the euglycaemic 
range of 6-8 mmol/L during the recovery period. Blood glucose was 
monitored every 5 minutes during the first half an hour of recovery and 
every 15 minutes thereafter. In diabetic participants, a variable rate insulin 
infusion (50 units Human Actrapid in 50 mL 0.9 sodium chloride) was 
started if blood glucose was greater than 9 mmol/L.  Participants also had a 
carbohydrate free midday meal and a rest period of 1 hour before the 
clamp study was repeated in the afternoon. 
In the afternoon euglycaemic clamp the Actrapid infusion rate was doubled 
at 240 mU/m2/min with a variable 20% dextrose infusion. It was necessary 
119 
to double the insulin administered in the afternoon to counteract the 
effects of increased resistance from counter-regulatory hormones 
following the hypoglycaemic clamp in the morning. To ensure that the 
insulin levels were equivalent for both the euglycaemic and hypoglycaemic 
arms, the insulin was also increased in the afternoon euglycaemic clamp. 
The clamp procedure was otherwise identical to that in the morning.  A 
target blood glucose of 6 mmol/L was maintained for 60 minutes. Heart 
rate and blood pressure was measured every 30 minutes and participants 
were attached to a 3 lead ECG for monitoring purposes only. No additional 
measurements were collected in the afternoon except arterialised blood 
glucose which was measured every 5 minutes.  
At recovery, the insulin was switched off and 20% dextrose was infused for 
a further at least 30 minutes until a minimum of 6 mmol/L was reached. 
Participants also ate a snack.  Blood glucose was monitored for a minimum 
of 1 hour following the end of the afternoon clamp until stable and within 
the euglycaemic range to ensure that the effects of insulin had worn off. 
Diabetic participants were advised to take their usual dose of medication 
and were also advised to monitor their capillary blood profile for the next 
24 hours and to keep a record of symptomatic hypoglycaemia over the 
following 7 days. 
2.3.5.2 Hypoglycaemic Clamp Protocol 
The protocol was identical to the euglycaemic visit except that blood 
glucose was lowered over 60 minutes to a target of 2.5 mmol/L. The 
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participants took part in morning and afternoon hypoglycaemic clamps 
where glucose was maintained at 2.5 mmol/L for 60 minutes. During the 
morning study they were commenced on a primed infusion of Human 
Actrapid insulin at the same rate as during the euglycaemic visit. A variable 
infusion of 20% dextrose was titrated to maintain a target glucose 
concentration of 2.5 mmol/L and the recovery procedure was identical. In 
the afternoon, Actrapid was administered at 240 mU/m2/min to overcome 
the increase in insulin resistance due to the hypoglycaemia in the morning. 
Diabetic participants were warned that their hypoglycaemic symptoms 
may be reduced in the following 48 hours. As the overall hypoglycaemic 
risk among the group of T2DM participants was low, doses of their usual 
diabetic medications were not reduced that evening. 
2.3.6 Biochemical Analyses  
2.3.6.1 Arterialised Whole Blood Glucose 
Glucose was measured from 1 mL arterialised whole blood on a bedside 
glucose analyser (Yellow Springs Instrument 2300 STAT, Ohio, USA) every 5 
minutes which employed the glucose oxidase method. Blood was sampled 
from a retrograde cannula inserted into the non-dominant hand vein and 
warmed at 55°C to aid the arterialisation of venous blood (Liu et al., 1992). 
Arterialised blood rather than venous blood glucose was measured, as 
venous glucose is variable depending on peripheral tissue consumption. 
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2.3.6.2 Free Insulin 
Whole blood (3 mL) was collected into a 6 mL lithium heparin tube and 
immediately subjected to centrifugation at 4°C, 2400 rpm for 2 minutes. of 
The resulting plasma (0.5 mL) was added to a chilled plastic tube containing 
0.5 mL polyethylene glycol (PEG) for precipitation of immune complexes 
and mixed, and the centrifugation step repeated for 30 minutes. The 
product was then stored at -80°C until analysed via an immunometric assay 
(Invitron Insulin ELISA, Invitron Ltd, Monmouth, UK), which had 100% 
cross-reactivity with Actrapid insulin. Briefly 100 µL labelled antibody 
solution and 25 µL sample was added to each well. Samples were 
incubated for 2 hours at 37oC and washed 3 times before being read in a 
luminometer. The inter-assay coefficient of variation (CV) at a 
concentration of 14.9 mU/L was 7.1%, at 81.3 mU/L was 2.4%, and at 145.5 
mU/l was 7.1%. 
2.3.6.3 Catecholamines - Adrenaline and Noradrenaline 
Whole blood (6 mL) was collected into chilled lithium heparin tubes 
containing 50 μL EGTA/glutathione as a preservative and subjected to 
centrifugation at 4oC, 3000 rpm for 10 minutes. The resulting supernatant 
was stored at -80oC until assayed via high performance liquid 
chromatography (HPLC). The inter-assay CV for noradrenaline (mean value 
1.86 nmol/L) was 6.03% and for adrenaline (mean value 0.25 nmol/L) 
15.85%. 
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2.3.6.4 Cortisol  
Venous blood (4 mL) was collected into a serum separator tube and 
samples allowed to clot for 30 minutes. The sample was subjected to 
centrifugation and the serum frozen at <-20oC until quantified using a 
commercial electrochemilluminescence assay (Cobas system, Roche 
Diagnostics, UK) at Sheffield Teaching Hospitals. 
2.3.6.5 Urea and Electrolytes  
Blood (2 mL) was collected into tubes with a clot accelerator and 
separation gel (BD Vacutainer® SST™ II Advance). Samples subjected to 
centrifugation at 3000 ×g at room temperature for 10 minutes. Assays on 
the resulting serum were performed at Sheffield Teaching Hospitals 
laboratories using an automated system (Cobas system, Roche Diagnostics, 
UK). 
2.3.7 Cardiac Autonomic Function 
2.3.7.1 Cardiovascular Autonomic Reflex Tests 
These tests were performed at screening, days 1 and 7 on participants in 
both the euglycaemic and hypoglycaemia arms, as described in section 
2.2.4. 
2.3.7.2 Heart Rate Variability 
The principles of HRV were described in section 2.2.8. Short term HRV 
recording and analysis were performed according to the recommendations 
of the 1996).  Five minutes of ECG recording was performed with the 
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subject lying supine, followed by recordings performed with free breathing 
and paced breathing at 12 breaths per minute according to a timed visual 
display to control for the effects of respiratory frequency on HF 
components. Data from a 12 lead ECG was acquired and amplified (g®.USB 
amp, g.tec Medical Engineering, GmbH, Austria) using a 24 bit resolution 
and a sampling frequency of 1200 Hz,   connected to a laptop computer 
(hp6730b) with ECG signals recorded using g.Recorder software (version 
2007-2009, g.tec medical engineering GmbH Austria). Analyses were 
performed with g®.BSanalyze software (version 3.09a, g.tec medical 
engineering, GmBH, Austria) and MATLAB® software (version 7.8.0.347, 
R2009a, The MathWorks, Inc.). QRS complexes were detected using an 
automatic algorithm as described elsewhere (Schreier et al., 2003). Manual 
editing of R-R intervals was performed together with a visual inspection of 
QRS complexes to exclude any ectopic beats (1996). Time and domain HRV 
analysis was performed and the LF band was defined as 0.04-0.15 Hz and 
the HF band as 0.15-0.4 Hz. 
2.3.7.3 Spontaneous Baroreceptor Sensitivity 
BRS may be measured by bolus injections of vasoactive drugs, neck 
suction/pressure, or by spontaneous fluctuations in heart rate and blood 
pressure. Unlike the first two methods, spontaneous BRS allows the 
continuous non-invasive assessment of BRS and does not perturb the reflex 
it is trying to measure, and has been validated against intra-arterial and 
pharmacological techniques (Omboni et al., 1993; Parati et al., 1989). In 
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this study, 12 lead ECG data was simultaneously acquired using an Ivy 
Cardiac Trigger Monitor 3000 (Ivy Biomedical systems Inc, USA) as 
described previously. Non-invasive blood pressure monitoring was 
measured via a Portapres device (TNO Biomedical Instrumentation 
Amsterdam, Netherlands), which employs infrared plethysmography to 
detect pulsation in the digital artery and uses a volume clamp technique to 
detect changes in blood pressure. An appropriately sized finger cuff was 
applied to the middle finger of the right hand and a frontend unit attached 
to the wrist. The height correction unit was nulled and the transducer was 
attached to the upper arm at the level of the heart. When the Portapres 
device was started, the finger cuff automatically inflated, and physiocal, an 
internal calibration was switched on until a steady state was achieved, 
whereupon it was switched off. Analogue blood pressure data was digitised 
with a sampling frequency of 1000 Hz and together with ECG data was 
synchronously recorded using WR TestWorks™ software for 5 minutes with 
the subject lying supine.  
Beat by beat SBP, DBP and R-R interval data was imported into the 
dedicated BRS analysis software (Nevrokard version 5.1.3, Intellectual 
Services, Slovenia) and BRS was calculated using the sequence method 
(Omboni et al., 1993; Parati et al., 1989). This method considers 
spontaneous increasing or decreasing ramps of blood pressure and its 
relationship to subsequent R-R intervals.  The 'UP' sequence was generated 
where there was an increase in SBP of at least 0.5 mmHg associated with 
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an increase in the R-R interval of at least 5 ms for three or more 
consecutive beats. A 'DOWN' sequence was identified where there was a 
reduction in SBP of at least 0.5 mmHg with a corresponding decrease in the 
R-R interval of at least 5 ms for three or more consecutive beats. Total BRS, 
measured in ms/mmHg, was calculated using the average of the regression 
coefficients for UP and DOWN sequences. 
2.3.8 Platelet Function  
Platelet activated thrombus develops in three stages: 1) initial tethering 
involving vWF, collagen and glycoproteins 1b/V/IX integrins αIIbβ3 and α2β1; 
ii) an extension phase involving platelet activation, the release of granules, 
the additional recruitment of platelets and aggregation via GpIIb/IIIa, the 
integrin receptor; and iii) a perpetuation phase characterised by platelet 
stimulation and stabilisation of clots in a fibrin mesh (Kakouros et al., 
2011). The integrin receptor αIIbβ3 is normally present in the resting state 
and agonists are able to activate a conformational change leading to high 
ligand binding affinity via ‘inside-out signalling’. 
2.3.8.1 Platelet Activation 
Platelet activation may be quantified by factors such as a change in shape 
and a tendency to aggregate, and also by measuring the levels of platelet 
metabolic products. Platelet metabolites, such as beta thromboglobulin 
and platelet factor 4, have been used as soluble activation markers; 
however, these suffer from a number of limitations.  Beta thromboglobulin 
is dependent on the venous platelet count and is raised during renal 
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failure, whilst platelet factor 4 has a short plasma half-life and is rapidly 
bound to endothelial cells (Kamath et al., 2001). P-selectin may also be 
derived from the endothelium, thus measurement of soluble P-selectin 
may not be completely specific to the state of platelet activation. Flow 
cytometry can be used with multiple fluorescent staining of platelets or in 
combination with monoclonal antibodies to measure circulating activated 
platelets.  This technique involves incubation of whole blood with 
antibodies directed against platelet glycoproteins, such as P-selectin, which 
are only expressed on activated platelets. These platelet-bound antibodies 
are then detected using streptavidin conjugated with fluorescein 
isothiocyanate (FITC) or phycoerythrin (PE). Platelets may be differentiated 
from other blood cells using antibodies to detect membrane proteins 
specific to platelets, such as GP Ib or by their light-scatter profile. The 
advantage of flow cytometry is its high sensitivity and capability for 
detecting very low levels of platelet activation (2010). However, it needs to 
be processed rapidly to avoid stasis and subsequent platelet activation.  
2.3.8.2 Platelet Reactivity 
Platelet reactivity is defined as the level of aggregation response to a given 
platelet agonist. Platelet hyperreactivity has been shown to predict a 3- to 
5-fold increase in major cardiovascular events over five years (Gorog and 
Fuster, 2013). Platelet reactivity has traditionally been measured using light 
transmission aggregometry. The extent of aggregation of platelets is 
detected and quantified by the amount of light that passes through  
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platelet-rich plasma in comparison to platelet free plasma in response to 
the addition of agonists. The disadvantage of this technique, apart from 
being laborious, is the requirement of plasma rich plasma which can cause 
artefactual distortion of the sample.  
Impedance aggregometry was developed by Cardinal and Flower (1980) 
and detects platelet aggregation in whole blood. This technique measures 
the change in electrical resistance on a sensor wire due to platelet 
aggregation and has advantages over light transmission aggregometry in 
that it measures platelet aggregation in the fluid phase. The technique is 
rapid and can be used in a point-of-care setting. Impedance aggregometry 
relies on constant smooth stirring of the platelet sample and can be 
affected by cellular composition, such as the haematocrit (2010). However, 
impedance aggregometry is insensitive to small platelet aggregates as they 
cause minimal changes in electrical impedance. Therefore, impedance 
aggregometry is primarily suited for conditions in which there are high 
levels of platelet activation where it is able to detect variation in platelet 
macroaggregation to different agonists.  
Platelet microaggregation, the formation of small aggregates of 2-4 
platelets, is better detected with particle counting aggregometry methods, 
such as whole blood single platelet counting (2010). Platelet 
microaggregation may be particularly important in T2DM patients as it has 
been shown to be the predominant type of platelet aggregation event 
(Matsuno et al., 2004) . 
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When considering the choice of agonists, hypoglycaemia has been shown 
to potentiate aggregation as a result of a wide range of agonists, such as 
ADP, thrombin and platelet activating factor in vivo, that are likely to be 
mediated through alpha-2 adrenoreceptors (Trovati et al., 1986). Agonists 
all signal via G protein coupled receptors (GPCR) that converge on common 
intracellular signalling pathways, such as phosphlipase C and intracellular 
calcium. Several GPCR subfamilies are expressed in platelets (Gq, Gi, 
G12/13), and it is thought that co-stimulation of at least two subfamilies of 
GPCR are necessary for full platelet activation and aggregation. With 
current knowledge of receptor signalling, one mechanism by which 
adrenaline can potentiate responses to other agonists is through co-
stimulation of different GPCR pathways (Figure 2-5). The alpha-2-
adrenoreceptor is coupled to Gz which is part of the Gi subfamily. Gi 
supplements other GPCR signalling pathways, such as Gq, which alone is 
insufficient to stimulate full platelet reaction. In this study, the effect of 
hypoglycaemia on 5-hydroxytriptamine (5HT) induced platelet aggregation, 
which acts exclusively through the Gq coupled 5HT2A receptor, was 
investigated, as it has been shown that there are synergistic effects of 5HT 
and epinephrine co-stimulation that may occur through the 
PLC/Ca2+signalling cascade (Shah et al., 1999). ADP acts via both the Gi 
coupled P2Y12 receptor and the Gq coupled P2Y1 receptor. To investigate 
whether potential activation of alpha-2 adrenoceptors during 
hypoglycaemia can substitute the requirement for P2Y12 Gi signalling 
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during ADP-induced aggregation, cangrelor, a P2Y12 antagonist was 
applied.  
 
Figure 2-5: Potential pathways by which adrenaline can potentiate platelet 
responses to agonists 
AC-adenyl cyclase, PI3K-phosphoinositide 3 kinase, MAPK-Mitogen-activated protein 
kinase, IP3-inositol triphosphate, DAG-diacylglycerol, PKC-protein kinase C, CALDEGGEF1-
calcium and DAG regulated GEF1 
Hypoglycaemia may also potentiate signalling through major platelet 
adhesion receptors, such as collagen.  Collagen is regarded as a strong 
agonist, which in itself is sufficient to lead to platelet degranulation and 
aggregation. Collagen interacts with the GpVI receptor of the 
immunoglobulin family and activates PLC gamma and downstream 
thromboxane A2 synthesis, granule secretion and integrin activation (Li et 
al., 2010). Hypoglycaemia may potentiate a platelet response to collagen 
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via potentiation of cytosolic calcium release due to adrenaline (Ardlie et al., 
1987). 
In summary, previous literature has suggested that hypoglycaemia can lead 
to various alterations in platelet activation and aggregation which require 
investigation using complementary platelet function assays. Platelet 
activation was investigated by P-selectin expression using flow cytometry. 
The effect of hypoglycaemia on platelet macroaggregation was 
investigated by impedance aggregometry using ADP and collagen as 
agonists, while the effect of hypoglycaemia on platelet microaggregation to 
ADP was investigated using whole blood single platelet counting. Platelet 
reactivity to 5HT and ADP (with and without P2Y12 inhibition) was 
investigated by P-selectin expression via flow cytometry. 
2.3.8.3 Impedance Aggregometry 
Materials: 
1 x 3 mL Multiplate hirudin tube 
31 x 1 µM ADP 
31 x 1 ug/mL collagen (Kollagenreagens Horm® Takeda Austria GmH, 
Austria) 
Platelet aggregation was measured using impedance aggregometry 
(Multiplate®, Verum Diagnostica GmBH, Munich, Germany). Venous blood 
(2.7 mL) was collected and carefully transferred into a 3 mL hirudin tube 
(Multiplate®) avoiding any agitation of the sample. Recombinant hirudin 
anticoagulates the blood by direct thrombin inhibition, such that platelet 
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function was assessed under physiological calcium conditions. The samples 
were transported to the Cardiovascular Biomedical Research laboratory, 
Northern General Hospital, immediately after the venepuncture was 
performed in order to maximise the chances of observing a catecholamine 
effect. Aliquots of 300 μL saline and 300 μL hirudin-anticoagulated blood 
were added to a cuvette and incubated at 37°C for 3 minutes. Agonists (20 
μL in total, ADP 1 µM and collagen 1 µM) were added and the assay 
commenced. The area under the curve (AUC) was measured which 
represents the level of platelet aggregation. 
2.3.8.4 Whole Blood Single Platelet Count 
Materials: 
1 x 4.5 mL Citrate tube (BD Vacutainer) 
25 x 1 µmol/L ADP 
25 x 3 µmol/L ADP  
Solution A (60 mL 0.077 M EDTA, 100 mL 4% Formalin, 40 mL PBS, 200 mL 
distilled water, 600 mL saline) 
Cell Pack (Sysmex) 
Whole blood single platelet counting (WBSPC) was used to determine 
platelet microaggregation responses to agonists. Citrated blood venous 
blood (4.5 mL) was taken and incubated at 37oC. Aliquots of whole blood 
(480 µL) were placed in polystyrene tubes with a magnetic stirrer bar and 
20 µL ADP at 1 or 3 µM as agonists.  Samples were stirred at 1000 rpm for 4 
minutes at 37°C prior to  fixing in saline with 1 mL of Solution A [4.6 mM 
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sodium EDTA, 4.5 mM Na2HPO4, 1.6 mM KH2PO4 and 0.16% (w/v) 
formaldehyde, pH7.4] and counting using a Sysmex KX21 haematology 
analyser (Sysmex corporation, Illinois, USA).  To a 460 µL cell pack, 60 uL of 
the fixed sample was added and single platelet and red cell counting 
performed using the haematology analyser in the pre-diluted mode. Total 
cell counts were obtained using 4 mM EDTA instead of ADP.  The adjusted 
platelet count was then determined as: 
                                               
                  
                   
  
Data are presented as percentage platelet aggregation which was 
calculated as follows:  
                                
  
                                
          
      
2.3.8.5 P-selectin Expression 
Materials: 
25 x 1 µmol/L ADP 
25 x 3 µmol/L 5-hydroxytryptamine (5HT) 
25 x 1 µmol/L cangrelor (AR-C69931MX mwt952) 
PE Cy 5™ Mouse IgG1k isotype control (BD Pharmigen) 
PECy ™Mouse Antihuman CD62P (BD Pharmigen) 
PE Mouse Anti-Human CD41a (BD Pharmigen) 
FACSfix (1.25 mL formaldehyde (38% v/v) in 100ml PBS)  
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HT buffer (1 L Millipore high grade water, 7.56 g NaCl, 0.75 g NaHCO3, 
0.209 g KCl, 0.109 KH2PO4, 1.02 g dextrose, 2.39 g HEPES) 
1 x 3 mL Multiplate hirudin tube 
Blood flow cytometry was used to determine the activation state of 
circulating platelets binding to the activation dependent monoclonal 
antibody CD62P in order to assess the reactivity of circulating platelets in 
vitro to ADP and 5HT. Cangrelor was used to assess the effect of P2Y12 
blockade on platelet reactivity. 
Hirudinised blood (192 µL) was added to 8 µL saline or 8 µL 25x1 µmol/L 
cangrelor for 2 minutes at room temperature. Aliquots of blood (5 µL) were 
then added to 33 µL HT buffer, 5 µL CD6 PECY5 for P-selectin, 5 µL CD41PE 
as a platelet marker, and either 2 µL 1 μmol ADP or 3 µmol 5HT as agonists 
or 2 µL saline (unstimulated).  PE Cy 5™ Mouse IgG1k (5 µL) was added 
instead of CD62P PECY5 as an isotype control. Samples were incubated at 
room temperature in the dark for 20 minutes followed by the addition of 
0.5 mL FACSfix. Flow cytometry was performed and forward light scatter, 
side scatter, and FITC fluorescence was measured (BD Accuri C6, BD 
Biosciences, UK). A gate was positioned around the platelet region to 
exclude any red cells. P-selectin expression was quantified as: 1) the 
percentage of cells with CD62P fluorescence greater than the fluorescence 
of the mouse IgG control (% positive events); and 2) the median CD62P 
fluorescence intensity of the platelet population.  
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2.3.9 Fibrin Polymerisation Characteristics 
Although platelets are important in the initial formation of a platelet plug, 
subsequent stabilisation of a clot is due to the activation of a complex 
network of coagulation proteins that normally exist in the fluid phase. A 
summary of the coagulation and fibrinolysis pathways are shown in Figure 
2-6. Of these, fibrinogen is of critical importance, as when converted by 
thrombin into fibrin, it is a key structural component of the fibrin clot. 
Increased plasma fibrinogen levels are associated with CVD (Kannel et al., 
1987; Kaptoge et al., 2007), and there is evidence in mouse models that 
artificially elevated levels of fibrinogen shortened the time to carotid artery 
occlusion in response to injury, increased clot density and also resistance to 
clot lysis (Ariëns et al., 2014). Fibrinogen is an acute phase protein whose 
production is stimulated by IL-6 and other cytokines. 
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Figure 2-6: Summary of coagulation and fibrinolysis pathways 
TF-tissue factor, PAI-1-plasminogen activator inhibitor-1, Tpa-tissue plasminogen activator 
Although there is a strong association between fibrinogen and thrombotic 
risk, there is good evidence that apart from quantitative levels of the 
coagulation protein, the final product of the coagulation pathway, the 
fibrin clot structure itself, is also associated with an increased CVD risk 
(Fatah et al., 1996). Two aspects of the fibrin clot structure, its viscoelastic 
properties and resistance to lysis, may be linked to the overall propensity 
for thrombosis in an individual (Ariëns et al., 2014). With regards to the 
latter, the ability of fibrinolytic proteins to diffuse through the fibrin 
network, the incorporation of inhibitors of fibrinolysis to the fibrin clot, and 
differences in the way the fibrin matrix supports the conversion of 
plasminogen to plasmin, can influence resistance to clot lysis (Ariëns et al., 
2014). Multiple factors influence the structure and function of a fibrin clot, 
as shown in Figure 2-7. In the diabetic individual, increased glycation 
fibrinogen itself can alter clot structure, independent of absolute levels of 
fibrinogen (Ariëns et al., 2014). Moreover, complement component C3 has 
recently been identified amongst other inflammatory proteins to influence 
clot structure in individuals with diabetes. Increased amounts of C3 were 
shown to be incorporated into clots of individuals with T1DM which 
prolonged clot lysis times (Hess et al., 2012a), and C3 was found to be 
independently associated with prolonged clot lysis time in the Edinburgh 
T2DM cohort, and operating via different pathways to PAI-1 (Hess et al., 
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2014). C3 was also associated with a 3-fold increase in coronary artery 
disease after adjustment for traditional risk factors (Ajjan et al., 2005).  
 
Figure 2-7: Factors influencing fibrin clot structure and function 
Fibrin clot structure is influenced by fibrinogen and thrombin concentrations. Factor XIIIa 
is responsible for cross-linking of fibrin, and genetic factors, such as fibrinogen 
polymorphisms and acquired factors, such as glycation and acetylation can modulate 
fibrin clot structure. Proteins incorporated into the clot, such as of factor XIIa, α2-
antiplasmin and C3 may increase resistance to lysis. Modified from (Ariëns et al., 2014).  
The overall thrombotic potential is also influenced by the fibrinolytic 
pathway. PAI-1  is the main inhibitor of fibrinolysis and acts by binding to 
tPA and forming the PAI-1/tPA complex. PAI-1 is secreted by a large 
number of cells, including endothelial cells, vascular smooth muscle cells, 
adipocytes and the liver. As discussed earlier, elevated levels of PAI-1 are 
present in T2DM, and elevated levels are strongly implicated in an 
increased thrombotic risk (Alzahrani and Ajjan, 2010). 
In the present study, plasma levels of key coagulation factors, fibrinogen 
and fibrinolysis inhibitor PAI-1, were measured. However, as global fibrin 
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clot properties are not dictated by absolute levels of these factors alone, a 
turbidity and lysis assay was performed on ex vivo plama clots to provide 
an indicator of the fibrin network density and fibrinolysis potential. Using 
this method, the maximum clot absorbance, an indirect measure of clot 
density, and the time to 50% clot lysis have both been shown to predict 
cardiovascular risk (Fatah et al., 1996). To complement these methods, 
scanning electron microscopy of ex vivo clots made from purified 
fibrinogen may elucidate changes in fibrin diameter and the fibrin network 
density (Alzahrani et al., 2012). C3 levels were also measured as this could 
potentially be elevated secondary to proinflammatory effects of 
hypoglycaemia, and be a mechanism of increased thrombosis.  
2.3.9.1 Fibrinogen Assay: Clauss Method 
Materials: 
Veronal buffer pH 7.35 ( 9.714 g sodium acetate 3H2O, 14.714 g sodium 5,5 
diethylbarbiturate, HCl) 
Thrombin (Sigma) 10 U/mL diluted in imidazole buffered saline (IBS) 
Fibrinogen reference plasma (Biomereux) 
venous blood (4.5 mL) was collected in a citrated tube (BD Vacutainer Glass 
Citrate Tube containing 3.2% buffered sodium citrate solution), subjected 
to centrifugation at 2770 ×g for 30 minutes at 4oC and the resultant plasma 
stored at -80oC. Samples were diluted using Veronal buffer at a 1:10 
dilution and incubated at 37°C. Samples (100 µL) were added to 
coagulometer cuvettes (KC 10, Amelung GmbH, Lemco, Germany) in 
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duplicate and incubated for 30 seconds. of Thrombin (100 μL) was added 
and the time for clot formation measured; if less than 7 seconds, samples 
were repeated at a 1:20 dilution. A standard calibration curve was 
generated using 1:6 to 1:24 dilutions of the reference plasma. The time 
taken for the clot to form was compared to the calibration curve and the 
fibrinogen concentration (g/L) deduced. 
2.3.9.2 Plasminogen-Activator 1  
Materials: 
PAI1 (SERPINE1) Human SimpleStep ELISA™kit (Abcam ab184863) 
10 x PAI1 Capture Antibody 
10 x PAI 1 Detector Antibody 
PAI1 Lyophilized Recomibinant Protein 
Antibody Diluent 4I 
10 x Wash Buffer PT 
TMB Subtrate 
Stop Solution 
Sample Diluent NS 
Sample Diluent 25BP 
SimpleStep Pre-Coated 96 Well microplate 
Plate seal 
Phosphate Buffered Saline (1.4 M KH2PO4, 8 M Na2HPO4, 140 mM 
NaCl, 2.7 mM KCl, pH7.4) 
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Venous blood (4.5 mL) was collected in a citrated tube (BD Vacutainer 
Glass Citrate Tube 4.5 mL containing 3.2% buffered sodium citrate 
solution), subjected to centrifugation at 2770 ×g for 30 minutes at 4°C and 
the resultant plasma stored at -80 oC. PAI-1 lyophilised recombinant 
protein standard was reconstituted in 500 µL sample diluent 25BP and 
serially diluted to final concentrations of 94, 188, 375, 750, 1500, 300 and 
6000 pg/mL respectively. To each well 50 µL of the sample or standard was 
added, followed by 50 µL of an antibody cocktail consisting of 300 µL 10x 
capture body, 30 uL 10x detector antibody with 2.4 mL antibody diluent 
4BI. The plate was sealed and incubated for 1 hour at room temperature 
on a plate shaker set to 400 rpm. Each well was washed three times with 
350 µL of 1x wash buffer before adding 100 µL TMB Substrate to each well 
and incubating for 10 minutes in the dark on a plate shaker set to 400 rpm. 
100 µL of Stop Solution was added to each well and the plate replaced on a 
plate shaker for 1 minute to mix.  The optical density of each well was 
recorded at 450 nm and a standard curve was constructed and the protein 
concentration of the samples interpolated. The overall assay CV was 0.92%.  
2.3.9.3 Complement  C3 
Materials: 
Complement C3 ELISA kit (Biosource, San Diego, USA)  
 Assay plate 
 Standard 
 Antibody 
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 HRP-conjugate 
 Wash Buffer 
 Substrate A 
 Substrate B 
 Stop solution 
Plasma was collected in EDTA tube, subjected to centrifugation for 20 
minute at 3000 ×g at room temperature, and samples stored at -80o C prior 
to being assayed. To each well 50 µL of the sample or standard (0, 12.5, 
37.5, 115, 250 or 500 µg/mL) was added, then 50 µL of HRP-conjugate, 
followed by 50 µL of antibody. The plate was mixed and incubated for one 
hour at 37°C. The well was washed three times using 20 µL wash buffer and 
50 µL of substrate A and 50 µL of substrate B was then added to each well 
and mixed before incubating the plate at 37°C for 15 minutes.  Stop 
solution (50 µL) was then added to each well and the optical density at 450 
nm measured using a microplate reader.  The concentrations of the 
samples were interpolated from the standard curve constructed.  The 
overall assay CV was 1.33%. 
2.3.9.4 Turbidimetric and Lysis Assay 
Materials: 
CaCl2 
Thrombin (Calbiochem, Merck Millipore, USA) 
tPA (Technoclone, Vienna, Austria) 
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Permeation Buffer (12.12 g Tris, 11.68 g NaCl dissolved in distilled water, 
pH 7.4) 
Venous blood (4.5 mL) was collected in citrated tube (BD Vacutainer Glass 
Citrate Tube 4.5 mL containing 3.2% buffered sodium citrate solution), 
subjected to centrifugation at 2770 ×g for 30 minutes at 4° C and the 
resultant plasma stored at -80oC. Citrated plasma (25 μL) was added to 75 
μL assay buffer (0.05 mol/L Tris-HCl, 0.1 mol/L NaCl, pH 7.4) and 50 μL of 
activation mix (final concentrations: 0.03 U/mL thrombin and 7.5 mmol/L 
calcium in assay buffer) was added to each column of a 96-well plate using 
a multichannel pipette at 10 sec intervals. The time of addition of the 
activation mix was recorded to enable the plate reader times to be 
adjusted to the start of clot initiation. Plates were shaken and read at 340 
nm every 12 seconds for 1 hour in a BIO-TEK ELx-808 microplate reader. 
The turbidimetric lysis assay was carried out as above but with the addition 
of 12.5 ng of tPA (Technoclone) to the 75 μL assay buffer (83 ng/mL final 
concentration) before the addition of the activation mix; this concentration 
of tPA resulted in complete lysis of pooled normal plasma within 1 hour. 
Plates were read at 340 nm every 12 seconds for 1 hour and subsequently 
every 2 minutes for up to 9 hours.  
Maximum absorbance (MA) was taken as the maximum optical density 
during the clotting assay at which three consecutive readings were 
identical.  Clot lysis time (LT) was calculated as the time from the initiation 
of clot formation to the time at which a 50% fall in absorbance from 
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maximum absorbance occurred. The inter-assay CVs for MA was 8% and  LT 
7%. 
2.3.9.5 Scanning Electron Microscopy 
Materials: 
Recombinant fibrinogen 
Thrombin 
CaCl2 
Sodium cacodylate buffer 
2% glutaraldehyde 
Venous blood (4.5 mL) was collected in a citrated tube (BD Vacutainer 
Glass Citrate Tube 4.5 mL containing 3.2% buffered sodium citrate 
solution), subjected to centrifugation at 2770 ×g for 30 minutes at 4°C, and 
the resultant plasma stored at -80oC. Recombinant fibrinogen (1.3 μM) was 
clotted upon addition of 0.5 U/mL thrombin and 2.5 mM CaCl2 in specially 
devised small, perforated plastic vessels. Samples were incubated at room 
temperature in a moist chamber for 2 hours then washed with sodium 
cacodylate buffer and subsequently fixed overnight in 2% glutaraldehyde. 
Clots were recovered and further processed by a stepwise dehydration 
technique using an acetone gradient and sputter coated with platinum 
palladium. Samples were viewed and photographed using a field-emission 
scanning electron microscope (LEO1530 FEGSEM, Leo Electron Microscopy, 
Cambridge, United Kingdom) across ten different areas of each clot. Images 
were captured using Leo 32 version 03.0210 software (Leo Electron 
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Microscopy) and cropped using Paintshop Pro version 8.0 (Corel, 
Minneapolis, MN). Fibre diameters of all the clots were measured using the 
image analysis software package ImageJ 1,23y (National Institutes of 
Health, Bethesda, MD). In all, 160 fibrin fibres per sample were measured 
with the operator blinded to the sampling time point. 
2.3.10 Inflammatory Cytokines 
Inflammation is a critical component in the determination of plaque 
stability, and is orchestrated by multiple cell types, including endothelial 
cells, monocytes and macrophages that secrete cytokines and chemokines 
to amplify the inflammatory response. Among inflammatory biomarkers, 
hsCRP has the strongest evidence for predicting cardiovascular mortality in 
primary prevention cohorts and following ACS.  CRP is produced by the 
liver in response to IL-6 and to a lesser extent by TNF-α and IL-1 at local 
sites of inflammation.  IL-6 is a pleiotropic cytokine produced by multiple 
cell types, including the liver, fibroblasts, monocytes, lymphocytes and 
neural tissues (Stoner et al., 2013). IL-6 is important in the induction of the 
acute phase response, leading to the production of CRP and fibrinogen, the 
latter an important modulator of thrombosis. IL-6 is produced by human 
adipocytes and thus implicated in subclinical inflammation in obesity. IL-6 
is a hormonally regulated cytokine that can be stimulated by 
catecholamines and insulin in adipocytes in vitro (Vicennati et al., 2002). 
The effect of hypoglycaemia on hsCRP and IL-6 has been investigated in 
T1DM and normal individuals but has yielded inconsistent results; 
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however, no studies have been performed in T2DM patients (Gogitidze Joy 
et al., 2010; Wright et al., 2010). 
Acute hypoglycaemia has previously been shown to increase a number of 
proinflammatory molecules, including ICAM-1, VCAM, TNFα and CD40L in 
T1DM and normal individuals (Gogitidze Joy et al., 2010; Wright et al., 
2010). Decreases in anti-inflammatory cytokines have also been shown to 
predict ACS (Stoner et al., 2013). However, few studies have looked at the 
effect of anti-inflammatory cytokines, such as interleukin 10 (IL-10), during 
hypoglycaemia. The effect of hypoglycaemia on monocytes has not been 
studied. MCP-1 is highly expressed in atherosclerotic plaques and is an 
important mediator for the migration of monocytes and macrophages to 
atherosclerotic lesions. Deletion of MCP-1 in ApoB-/- mice protects against 
leukocyte recruitment to plaques (Stoner et al., 2013), and MCP-1 has been 
shown to predict SCD and mortality following ACS (Gonzalez-Quesada and 
Frangogiannis, 2009).  
IL-6, IL-1 and MCP-1 were assayed using a cytometric bead array (CBA). 
This array detects the analyte using immobilised antibody capture and uses 
fluorescence detection by flow cytometry for reporting and quantification. 
The advantages of CBA over ELISA include fewer sample dilutions, smaller 
sample volumes and that multiple analytes can be assayed at the same 
time, thereby increasing efficiency (Elshal and McCoy, 2006). Although 
there is a risk of cross-reactivity between analytes, this can generally be 
avoided by adhering to cytokine combinations as specified by the 
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manufacturer. In published studies, cytokines assayed by CBA generally 
show good correlations of >90% when compared to ELISA (Elshal and 
McCoy, 2006). 
2.3.10.1 High Sensitivity C Reactive Protein  
Whole blood (1 mL) was collected into a serum gel tube (Vacutainer ® BD 
SST™ Advance) and analysed using an immunoturbidimetric assay (Cardiac 
CRP (latex) high sensitivity, Roche Diagnostics, Indianopolis, USA) in 
Sheffield Teaching Hospitals Immunology laboratories. The within-run CV 
at 2.5 mg/L was 6%.   
2.3.10.2 IL-6, IL-10 and MCP-1 
Materials: 
Human IL-6, IL-10 and MCP-1 Flex Sets (BD Biosciences, UK) containing 
Capture beads 
PE detection reagent  
Standards  
PE Positive Control Detector 
FITC positive Control Detector 
Buffer reagents 
Wash Buffer  
Assay Diluent 
Serum Enhancement buffer 
Venous blood (5 mL) was collected in EDTA tubes (BD Vacutainer™ K3E), 
subjected to centrifugation at 3000 ×g for 20 minutes and the resulting 
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supernatant stored at -80oC.  During the assay the cytokine standards were 
serially diluted from 1:2 to 1:256 for use as controls.  Wash buffer (100 µL) 
was added to each well of the filter plate and then the well was aspirated 
and dried before adding 50 µL of mixed capture beads and 50 µL of the 
sample or standard to each well. The plate was incubated for 1 hour at 
room temperature on a non-absorbent dry surface. Mixed PE detection 
reagent (50 µL) was added to each well followed by a further incubation 
period of 2 hours, before adding 150 µL of wash buffer and mixing to 
resuspend the beads. Samples were then acquired on a BD FACSarray flow 
cytometer (BD Biosciences, Oxford, UK ) and the data analysed using 
FACSarray software (BD Biosciences, Oxfordm UK ). Standard curves for 
each analyte was constructed using five parameter logistic equations from 
which median fluorescence values were converted into cytokine 
concentrations in pg/mL for each sample. 
2.3.11 Statistical Analysis 
Power calculations were performed based on change in high frequency 
HRV as the primary outcome measure The sample size calculation took 
into account the repeated measure design, assuming a correlation of 0.5 
between repeated measures (Frison and Pocock, 1992). A sample size of 12 
had 80% power to detect a clinically important difference of 35% (1.38 
ms2) in overall log high frequency power  between glycaemic arms with a 
type 1 error rate of 0.05. This assumes a SD of 1.28  ms2, based on a 
previous study of T2DM patients (Sacre et al., 2012). 
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The statistical analyses for study 2 are described individually for each sub-
study in the respective chapters which describe the studies in detail.  
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Chapter 3 - Electrophysiological Response to 
Spontaneous Hypoglycaemia in Type 2 Diabetes 
Patients with Cardiovascular Risk 
3.1 Summary 
Hypoglycaemia might cause arrhythmias through effects on cardiac 
repolarisation and changes in cardiac autonomic activity. The aim of this 
study was to examine the risk of arrhythmias during spontaneous 
hypoglycaemia in T2DM patients with cardiovascular risk. 
Twenty-five insulin treated patients with T2DM and a history of CVD or two 
or more risk factors underwent simultaneous continuous IG and 
ambulatory ECG monitoring. The frequency of arrhythmias, HRV and 
markers of cardiac repolarisation were compared between hypoglycaemia 
and euglycaemia, and between hyperglycaemia and euglycaemia matched 
for time of day. 
In total, there were 134 hours of recording at hypoglycaemia, 65 hours at 
hyperglycaemic, and 1258 hours at euglycaemia. Bradycardia, atrial and 
ventricular ectopic counts were significantly higher during nocturnal 
hypoglycaemia compared to euglycaemia, and arrhythmias were more 
frequent during nocturnal versus daytime hypoglycaemia. Excessive 
compensatory vagal activation following the counter-regulatory phase may 
account for bradycardia and associated arrhythmias. QTc >500 ms and 
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abnormal T wave morphologies were observed during hypoglycaemia in 
some participants.  
Hypoglycaemia, which is frequently asymptomatic and prolonged, may 
increase the risk of arrhythmias in patients with T2DM and high 
cardiovascular risk. This is a plausible mechanism that could contribute to 
increased cardiovascular mortality during intensive glycaemic therapy. 
3.2 Introduction 
Hypoglycaemia has been strongly associated with an increased 
downstream risk of vascular events and death but evidence of a direct 
causal link is lacking (Zoungas et al., 2010). Hypoglycaemia, including 
nocturnal episodes, was associated with increased risk of arrhythmias in 
the ORIGIN trial where patients with T2DM were randomised to treatment 
with insulin glargine (Mellbin et al., 2013) versus conventional therapy. 
There have been sporadic case reports of supraventricular and ventricular 
arrhythmias associated with hypoglycaemia. Among supraventricular 
arrhythmias, transient atrial fibrillation is the most frequently reported 
(Celebi et al., 2011), and there have also been a number of reports of 
bradycardia during severe hypoglycaemia in diabetic and nondiabetic 
patients (Bolognesi et al., 2011). In a study of experimental hypoglycaemia 
in six patients with T2DM and no cardiac disease, one patient developed a 
severe bradyarrhythmia and another developed frequent VPB (Lindström 
et al., 1992). Reports of ventricular arrhythmias associated with 
150 
hypoglycaemia are rare, perhaps because events are generally fatal if 
uncorrected. 
Hypoglycaemia may be proarrhythmic via a number of mechanisms 
(Nordin, 2014) including a  direct effect of low glucose on the hERG ion 
channel (Zhang et al., 2003b), hypokalaemia and catecholamine release 
prolong cardiac repolarisation, increasing the risk of early 
afterdepolarisations and ventricular arrhythmias (Robinson et al., 2003). 
Experimental hypoglycaemia has been previously shown to prolong the QT 
interval in individuals with T1DM and T2DM (Marques et al., 1997). Since 
arrhythmias can be triggered by a transient change in the sympathovagal 
balance, it seems worthwhile exploring the effect of hypoglycaemia on 
autonomic tone. Previous studies have reported inconsistent effects of 
acute experimental hypoglycaemia on cardiac autonomic activity (Koivikko 
et al., 2005; Laitinen et al., 2008), and our group has previously shown that 
CAN may modify the relationship between hypoglycaemia and cardiac 
repolarisation (Lee et al., 2004). 
The aim of this study was to examine the frequency of arrhythmias during 
spontaneous hypoglycaemia and hyperglycaemic compared to euglycaemia 
in patients with T2DM at high cardiovascular risk. The effect of glucose on 
cardiac autonomic tone and repolarisation were further explored as 
potential mechanisms. 
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3.3 Research Design and Methods 
The research methods have been described in detail in Section 2.2 and are 
outlined in brief below. 
Twenty-five individuals with T2DM on insulin treatment for at least 4 years 
were recruited from Sheffield Teaching Hospitals diabetes outpatient 
clinics. All had a history of CVD (ischemic heart disease, peripheral vascular 
or cerebrovascular disease) and/or two additional cardiovascular risk 
factors: hypertension, dyslipidaemia (both defined as requiring 
medication), current smoker and obesity. Those on QT prolonging drugs 
were excluded from the study, as were all patients with permanent atrial 
fibrillation or a bundle branch block on baseline ECG.  
3.3.1 Baseline Assessment  
Cardiovascular autonomic reflex tests were performed as previously 
described (O'Brien et al., 1991) in accordance with the latest consensus for 
the diagnosis of CAN.  Patients were classified as definite CAN if two or 
more cardioreflex tests were below the age adjusted reference range 
(O'Brien et al., 1986; Tesfaye et al., 2010). HbA1c was measured using ion 
exchange HLPC. 
3.3.2 Monitoring  
All patients underwent five days of simultaneous 12 lead Holter and CGM. 
Patients carried on with their usual daily activities and diabetes treatments. 
Twelve lead ambulatory ECGs (Lifecard 12, Spacelabs Healthcare, Hertford, 
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UK) were recorded at a sampling rate of 128 Hz with electrodes in a 
Mason-Likar configuration. Patients also had a time-synchronised CGM 
attached (Freestyle Navigator Continuous Glucose Monitoring System, 
Abbott Diabetes Care, Maidenhead, UK). Calibrations were performed at 
least four times during the study week according to manufacturer's 
instructions. Patients were also asked to keep a record of any symptomatic 
hypoglycaemia. An episode of low IG < 3.5 mmol/L on CGM without 
simultaneous self-reporting of symptoms was regarded as asymptomatic. 
3.3.3 Continuous Glucose Monitoring Analysis  
Hypoglycaemia was defined as IG ≤ 3.5 mmol/L in accordance with 
previously published studies (Gill et al., 2009) and hyperglycaemia was 
defined as IG ≥ 15 mmol/L. A valid hypoglycaemic episode consisted of an 
IG below the threshold for ≥ 20 minutes (2007). The first reading of IG 
≤ 3.5 mmol/L marked the start of the hypoglycaemia and the first reading 
of IG ≥ 3.5 mmol/L signified the end of the episode. The lowest IG within 
the hypoglycaemic episode was designated the glucose nadir. Each episode 
was matched with a euglycaemic period, equivalent in duration, at the 
same time of day (within 20 minutes) on a different day. Hyperglycaemic 
episodes were identified an IG above the 15 mmol/L threshold for more 
than 20 minutes. The highest IG within the episode was designated as the 
maxima and matched euglycaemic periods on a different day were 
identified. 
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3.3.4 Arrhythmia Analysis  
The 12 lead ambulatory ECG data was analysed with a Pathfinder 
Ambulatory ECG analysis system (v. 8.701, Delmar Reynolds Medical Ltd, 
Edinburgh & Hertford, UK). Leads I, II and V5 were used for analysis as they 
represented the orthogonal leads. Arrhythmic events, including atrial 
ectopic beats, bradycardia (defined as four or more consecutive beats at 
less than 45 beats per minute), VPB and complex VPB (bigeminy, trigeminy, 
couplet, Salvos and VT) were identified by the software and manually 
verified for accuracy. Hourly counts for each type of arrhythmia were 
paired against the hourly mean IG, which was categorised as 
hypoglycaemia (IG ≤ 3.5 mmol/L), hyperglycaemic (IG ≥ 15 mmol/L) or 
euglycaemia (5 mmol/L < IG < 10 mmol/L). Analyses were separated into 
day and night (2300-0700 hours) to take into account diurnal variation. 
3.3.5 Hate Rate Variability Analysis  
R-R intervals were extracted from annotated normal beats (NN intervals) 
using the Pathfinder Ambulatory ECG analysis system. A 5 minute segment 
of successive NN intervals was selected around each reported IG value, and 
spectral analysis was performed on each segment using the Fourier 
transformation. The LF band was defined as 0.04-0.15 Hz and the HF 
bandas 0.15-0.4 Hz. The ratio between the LF power and total power was 
calculated (LFnorm), as this has previously been suggested to indicate the 
level of sympathetic modulation in HRV (Bernardi et al., 2011; Montano et 
al., 1994). 
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3.3.6 Repolarisation Analysis  
Analysis of QT intervals was performed using custom-built, semiautomatic 
software based on a selective beat averaging approach (Badilini et al., 
1999). Annotated normal ECG beats were identified using the Pathfinder 
system (v.8.701, Delmar Reynolds Medical Ltd, Edinburgh and Hertford, 
UK), and following pre-processing, a composite wave was then calculated 
from averaged beats derived from leads I, II and V5. On the composite 
wave, the onset of the Q wave was marked as the first positive deflection 
from the isoelectric line above 10 mV, and the end of the T wave was 
determined using the tangent method. QT intervals were corrected for 
heart rate (QTcS) using subject-specific regression formulae generated 
from QT/R-R values during euglycaemia (Christensen et al., 2010). 
3.3.7 Statistical Analysis 
This was an observational study hence no formal power calculations were 
performed. Demographic data was compared between patients who 
experienced at least one hypoglycaemic episode versus those who 
experienced none using an independent t-test, Mann-Whitney U test, or 
Fisher’s exact test for the effect of the insulin regimen and insulin type on 
hypoglycaemia. The IRR of arrhythmias during hypoglycaemia and 
hyperglycaemic compared with euglycaemia were calculated using 
generalised estimated equations (Hanley et al., 2003). HRV parameters and 
QTc were compared at the glucose nadir of the hypoglycaemic or glucose 
maxima of the hyperglycaemic episode against an equivalent euglycaemic 
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time point on a different day. Where there was more than one matching 
hypoglycaemic-euglycaemic episode in an individual participant over the 
course of the recording period, the mean from all daytime and nocturnal 
episodes for that individual were taken respectively. Data were analysed 
using a paired t-test. Statistical analysis was performed using SPSS (version 
20.0, IBM, Chicago, Illinois), and a p-value ≤ 0.05 was deemed statistically 
significant.  
3.4 Results 
3.4.1 Participant Characteristics 
A total of 2323 hours of valid simultaneous ECG and glucose recordings 
were obtained from 25 patients. Participants were similar in age, BMI and 
the prevalence of cardiovascular risk to the population in the ACCORD trial, 
with a history of CVD in one third of the participants (Gerstein et al., 2008) 
(Table 3-1). Two out of the 25 patients were on cardioselective beta-
blockade. Out of the 25 patients, 14 experienced at least one episode of 
hypoglycaemia and 12 experienced at least one episode of hyperglycaemia. 
Demographic data, duration of diabetes, and prevalence of CVD were 
similar between patients who experienced hypoglycaemia versus those 
who did not (Table 3-1); however, a higher proportion of patients who 
experienced hypoglycaemia were on biphasic and human insulins. The 
duration of insulin therapy and baseline QTc were slightly longer in those 
who experienced hypoglycaemia but the difference did not reach statistical 
significance.  
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Table 3-1: Comparison of participant characteristics between those who 
experienced hypoglycaemia versus those who did not 
Data are mean ± SD except for age, duration of diabetes and duration on insulin which are 
expressed as medians (interquartile range). The p-value indicates the comparison of 
participant characteristics between HYPO and no HYPO groups via parametric or 
nonparametric testing (see text). HYPO – hypoglycaemia, HbA1c – glycated hemoglobin, 
SBP – systolic blood pressure, DBP – diastolic blood pressure, CVD – cardiovascular 
disease, CAN – cardiac autonomic neuropathy. 
 TOTAL 
n=25 
HYPO 
n=14 
NO HYPO 
n=11 
p-value 
Age (years) 64 (61-71) 68 (59-74) 64 (60-66) 0.26 
Male    n (%) 13 (52%) 8 5 0.82 
Duration of diabetes (years) 17 ± 6 18 (12-21) 17 (15-21) 0.76 
Duration on insulin (years) 9 ± 5 10 (7-16) 7 (5-11) 0.14 
Insulin regimen    0.12 
     Twice daily biphasic n (%) 14 (56%) 10 4  
     Basal-prandial n (%) 11 (44%) 4 7  
Insulin type    0.02 
     Human   n (% ) 18 (72%) 13 5  
     Analogue    n (%) 7 (28%) 1 6  
BMI (kg/m
2
) 32 ± 5 33 ± 6 32 ± 4 0.49 
HbA1c (%) 7.5 ± 1.0 7.4 ± 1.2 8.1 ± 1.0 0.15 
            (mmol/mol IFCC) 58.0 ± 10.9 57.0 ± 13.1 65.0 ± 10.9  
SBP (mmHg) 142 ± 23 141 ± 26 143 ± 20 0.83 
DBP (mmHg) 72 ± 9 72 ± 10 72 ± 9 0.99 
Heart rate (bpm) 74 ± 11 76 ± 12 73 ± 11 0.51 
Baseline QTc (ms) 434 ± 23 437 ± 25 425 ± 16 0.20 
CVD    n (%) 8 (32%) 5 3 0.65 
CAN    n (%) 4 (16%) 3 1 0.40 
 
3.4.2 Glucose Profiles during Hypoglycaemia 
In total, there were 134 hours of recording at hypoglycaemia and 1258 
hours at euglycaemia with the remainder outside this range. Twenty 
matched day hypoglycaemic episodes in 11 participants and 14 matched 
nocturnal episodes from 10 participants were analysed. There were diurnal 
differences in the duration and depth of hypoglycaemia. The mean±SD 
duration of daytime episodes was 62 ± 42 minutes, whereas the mean 
duration of nocturnal episodes was prolonged at 170 ± 112 minutes with a 
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lower glucose nadir (1.9 ± 0.7 mmol/L versus 2.8 ± 0.5 mmol/L). At night, 
glucose exhibited an undulating profile in contrast to daytime 
hypoglycaemia, where there was a single descent to the nadir followed by 
a brisk counterregulation (Figure 3-1). Of 34 hypoglycaemic episodes that 
were identified by CGM, three were symptomatic 
 
Figure 3-1: Mean interstitial glucose values during day versus night 
hypoglycaemic episodes 
Mean IG profiles are shown for 20 day-time episodes from 11 participants and 14 
nocturnal episodes from 10 participants.  The mean duration of daytime hypoglycaemia 
was 62 ± 42 minutes with a mean IG at the nadir of 2.8 ± 0.5 mmol/L. The mean duration 
of nocturnal hypoglycaemia was 170 ± 112 minutes with a mean IG at the nadir of 1.9 ± 
0.7 mmol/L. The hypoglycaemic nadir is shown as episode time 0, with negative time 
values indicating a change from the beginning of the hypoglycaemic episode and positive 
values from the nadir to recovery from hypoglycaemia. Data are mean ± SD. 
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3.4.3 Arrhythmias 
The incident rate of arrhythmias during hypoglycaemia versus euglycaemia 
was compared. The minimum heart rate observed during nocturnal 
hypoglycaemia was 34 beats per minute, with the longest bradycardic 
period being 156 consecutive beats. Bradycardia was 8-fold higher during 
nocturnal hypoglycaemia when compared with euglycaemia (IRR 8.42; 95% 
CI 1.40 to 51.0) (Table 3-2). Bradycardia did not occur during the day under 
either glycaemic condition. Atrial ectopic activity was nearly 4-fold higher 
during nocturnal hypoglycaemia (IRR 3.98; 95% CI 1.10 to 14.4), but was 
not significantly different during daytime episodes. VPB were more 
frequent during hypoglycaemia for both day (IRR 1.31; 95% CI 1.10 to 1.57) 
and night (IRR 3.06; 2.11 to 4.44), but there were no differences in the 
incidence of complex VPB. Some examples of arrhythmias include sinus 
bradycardia with ventricular bigeminy at IG 2.7 mmol/L and atrial bigeminy 
at IG 2.8 mmol/L (Figure 3-2). The data was also analysed with the two 
patients on beta blockers excluded. The risk of bradycardia, atrial ectopics 
and VPB during nocturnal hypoglycaemia remained significantly elevated 
(data not shown). 
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Table 3-2: Incident rate ratios of arrhythmias during hypoglycaemia compared 
with euglycaemia during daytime and nocturnal periods 
IRR and 95% CI of arrhythmias during hypoglycaemia versus euglycaemia as analysed using 
generalised estimated equations. VPB – ventricular premature beat.  
 DAY NIGHT 
 IRR 95% CI p-value IRR 95% CI p-value 
Bradycardia - - - 8.42 (1.40 to 51.0) 0.02 
Atrial ectopic 1.35 (0.92 to 1.98) 0.13 3.98 (1.10 to 14.40) 0.04 
VPB 1.31 (1.10 to 1.57) < 0.01 3.06 (2.11 to 4.44) < 0.01 
Complex VPB 1.13 (0.78 to 1.65) 0.52 0.79 (0.22 to 2.86) 0.72 
 
 
 
Figure 3-2: Examples of arrhythmias during hypoglycaemia 
Sinus bradycardia with ventricular bigeminy at IG 2.7 mmol/L (above) and atrial bigeminy 
at IG 2.8 mmol/L (below) 
3.4.4 Heart Rate Variability 
The changes in HRV during hypoglycaemia were explored compared to 
matched euglycaemia. During the day, it was found that there was 
cardioacceleration (decrease in NN interval Δ -66 ± 55 ms, p = 0.001) at the 
glucose nadir accompanied by a decrease in total power (Δ -0.59 ± 0.83, p = 
0.02) and HF power (Δ -0.62 ± 0.59, p = 0.003). Normalised LF was not 
significantly different (Table 3-3). During the night, analysis of all the 
episodes showed no significant differences in NN interval or any of the HRV 
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indices at the glucose nadir (Figure 3-2). However, the glucose response 
was more heterogeneous (Figure 3-1).  
Table 3-3: Differences in heart rate variability parameters at the glucose nadir 
between hypoglycaemia and matched euglycaemia during daytime and 
nocturnal periods 
HRV parameters (Mean ± SD) during the hypoglycaemic nadir (HYPO) versus euglycaemia 
(EU). Data from 11 participants recorded during the day (DAY) and 10 participants 
recorded during the night (NIGHT) are presented. Paired differences (Mean ± SD) and p-
values from paired t-tests are shown. Total spectral power, high frequency power (HF) and 
low frequency power (LF) of HRV series are expressed as natural logarithms (ln). NN – 
normal to normal beat R-R interval, LFnorm – LF / Total power ratio. 
  HYPO EU Paired difference p-value 
DAY NN (ms) 775 ± 167 841 ± 185 -66 ± 55 0.001 
(n = 11) Total power 4.98 ± 1.10 5.57 ± 0.59 -0.59 ± 0.83 0.02 
 HF 3.45 ± 1.01 4.08 ± 0.77 -0.62 ± 0.59 0.003 
 LF 4.56 ± 1.42 5.18 ± 0.85 -0.61 ± 0.92 0.03 
 LFnorm 0.73 ± 0.21 0.73 ± 0.20 -0.00 ± 0.08 0.95 
 LF/HF 4.41 ± 2.86 4.05 ± 2.28 -0.36 ± 2.94 0.66 
NIGHT NN (ms) 937 ± 171 929 ± 139 8 ± 71 0.72 
(n = 10) Total power 6.01 ± 1.40 6.34 ± 1.32 -0.33 ± 0.68 0.16 
 HF 4.94 ± 1.16 5.03 ± 1.43 -0.09 ± 0.84 0.75 
 LF 5.36 ± 1.78 5.76 ± 1.56 -0.40 ± 0.66 0.09 
 LFnorm 0.59 ± 0.23 0.64 ± 0.26 -0.06 ± 0.09 0.08 
 LF/HF 2.53 ± 2.20 3.85 ± 3.30 -1.32 ± 2.00 0.07 
 
Closer examination of individual episodes revealed a pattern, whereby 
counter-regulatory responses were accompanied by transient vagal 
withdrawal, with a concomitant rise in normalized LF (LFnorm) reflecting 
increased sympathetic contribution (Figure 3-3). This was followed by a 
compensatory increase in vagal activity and a relative decrease in 
normalised LF. Bradycardia was observed in this period of heightened vagal 
activity. Further examples of this phenomenon are shown in the Appendix 
5. The data was again reanalysed with the patients on beta-blockers 
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excluded, and it was shown that the NN interval and HRV indices decreased 
to a similar extent under hypoglycaemic and euglycaemic conditions, 
therefore this made no significant difference to the conclusions. 
 
Figure 3-3: Phasic changes in HRV during a prolonged nocturnal hypoglycaemic 
episode 
Glucose, heart rate, high frequency HRV power (HF) and normalised low frequency power 
(LFnorm) across a nocturnal hypoglycaemic episode in a single patient are illustrated. The 
initial fall in glucose to 2.5 mmol/L (N1) was followed by a brief counter-regulatory 
response (C1), panel A. There was transient cardioacceleration (panel B), withdrawal in HF 
power (panel C) and increase in LFnorm (panel D) at C1. This was followed by a 
subsequent increase in vagal activity (HF) and relative decrease in LFnorm, leading to 
bradycardia (45 bpm) up to fifty minutes later. Glucose further decreased to 1.8 mmol/L at 
N2. Glucose counter-regulation occurred (C2) which again was accompanied by a transient 
increase in heart rate and LFnorm with HF withdrawal. HF power is expresses as the 
natural logarithm (ln). 
3.4.5 Cardiac Repolarisation 
QTcS was compared between hypoglycaemia and euglycaemia for 20 
matched day episodes in 11 participants and 14 nocturnal episodes in 10 
participants. During the day, mean QTcS was longer during hypoglycaemia 
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(402 ± 49 ms) compared with euglycaemia (384 ± 36 ms, mean paired 
difference 18 ± 27 ms, p = 0.05), whilst at night, mean QTcS was 440 ± 43 
ms during hypoglycaemia and 432 ± 16 ms during euglycaemia, and a 
paired comparison showed no significant difference between the groups (8 
± 44 ms, p = 0.60). Two individuals had a QTcS > 500 ms during 
hypoglycaemia. There was maximal prolongation of 100 ms at the glucose 
nadir, which was accompanied by flattening of the T wave (Figure 3-4) and 
emergence of U waves.  
 
Figure 3-4: Abnormal QT prolongation and T wave morphology during 
hypoglycaemia in a single patient 
Glucose and QTc change over the course of a hypoglycaemic episode are shown in the top 
two panels. In this participant, QTcS was prolonged from 456 ms at euglycaemia to 547 ms 
at the glucose nadir of 2.51 mmol/L. The change in complex morphology with absolute 
time is shown in the bottom panel. There is progressive flattening of the T wave with the 
fall in glucose. 
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3.4.6 Symptomatic versus Asymptomatic Hypoglycaemia 
There were only three symptomatic episodes in three participants out of 
the total of 34 matched episodes identified, two of which occurred in the 
day. No arrhythmias were observed during the symptomatic episodes. The 
mean HRV indices at the glucose nadir between symptomatic versus 
asymptomatic episodes were also compared. There was a trend towards 
higher heart rates during symptomatic episodes, as shown by decrease in 
the NN interval (ΔNN -32 ± 37 ms vs 1 ± 87 ms). There was also a trend 
towards greater vagal withdrawal during symptomatic episodes (ΔlnHF -
0.53 ± 0.79 vs -0.19 ± 0.79 and Δln [Total power] -0.64 ± 0.67 vs -0.27 ± 
0.77), although due to the small numbers the uncertainty is large. 
3.4.7 Effect of Depth and Duration of Hypoglycaemia  
The role of the depth and duration of hypoglycaemia was explored by 
analysing HRV and QT changes in episodes with glucose nadirs < 2.5 
mmol/L vs ≥ 2.5 mmol/L and episodes < 120 minutes versus ≥ 120 minutes. 
Episodes with a glucose nadir above 2.5 mmol/L were associated with a 
greater degree of QT prolongation when compared with episodes with a 
lower glucose nadir (42 ± 69 ms versus 2 ± 14 ms, p = 0.04), whilst 
prolonged episodes were associated with a smaller degree of QT change, 
although this did not reach statistical significance (16 ± 42 ms vs 30 ± 62 
ms, p = 0.51). It is of note that prolonged episodes also had lower glucose 
nadirs. Similarly, longer and deeper episodes tended to be associated with 
a trend of a slowing of heart rate (increase in NN) and decreased 
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sympathetic contribution manifested as decreased ΔLFnorm and  ΔLF/HF 
values. 
3.4.8 Hyperglycaemia versus Euglycaemia 
Hyperglycaemic episodes were observed predominantly during the day; 
there were a total of 22 daytime and 3 nocturnal hyperglycaemic events in 
12 patients, 5 of whom were in the ‘no hypoglycaemia’ group. No 
significant arrhythmias were observed during nocturnal hyperglycaemic 
episodes, of which there were very few. Daytime hyperglycaemia was 
associated with lower rates of atrial ectopics (IRR = 0.41, p < 0.01) and 
complex VPB (IRR = 0.28, p < 0.01) when compared to euglycaemia, 
although there appeared to be a higher risk of VPB (IRR = 1.44, p < 0.01) 
(Table 3-4). There were no significant differences in HRV parameters during 
hyperglycaemia compared with matched euglycaemia and no significant 
differences in QTcS between hyperglycaemia and euglycaemia (paired 
difference 0.65 ± 21.0 ms, p = 0.92, two tailed paired t-test).   
Table 3-4: Incident rate ratios of arrhythmias during daytime hyperglycaemia 
compared with matched euglycaemia 
IRR and 95% CI of arrhythmias during hyperglycaemia versus euglycaemia as analysed 
using generalised estimated equations. VPB – ventricular premature beat. 
 IRR 95% CI p-value 
Bradycardia - - - 
Atrial ectopic 0.41 0.33 to 0.50 < 0.01 
VPB 1.44 1.15 to 1.80 < 0.01 
Complex VPB 0.28 0.17 to 0.46 < 0.01 
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3.5 Discussion 
This study demonstrates that hypoglycaemia is associated with an 
increased risk of cardiac arrhythmia in patients with T2DM and a history of 
CVD or at high cardiovascular risk. In this study, participant characteristics 
and CVD status were similar between patients who experienced 
hypoglycaemia versus none. Yet this observational data showed an 
increase in bradycardia, atrial and ventricular ectopic activity that was 
coincident with hypoglycaemic periods. The patterns of arrhythmia were 
consistent with those from anecdotal case reports (Bolognesi et al., 2011), 
previous studies of experimental hypoglycaemia in T2DM (Lindström et al., 
1992) and  ambulatory data in T1DM (Gill et al., 2009).  
Potential mechanisms were explored by studying the effect of 
hypoglycaemia on heart rate, which is linked to cardiac autonomic activity, 
and repolarisation, which determines the propensity for non-driven cardiac 
action potentials and arrhythmogenesis. The analysis was separated into 
day and night due to diurnal differences in glucose counterregulation, 
autonomic fuction and QTc. In this study there was transient cardio-
acceleration at the glucose nadir and vagal withdrawal during daytime 
episodes, consistent with studies of hypoglycaemia in patients with T1DM 
(Koivikko et al., 2012; Russell et al., 2001). However, what is striking is the 
difference in heart rate response and an 8-fold higher incidence of 
bradycardia during nocturnal hypoglycaemia. Defective counter-regulation 
during nocturnal hypoglycaemia is well known, and is characterised by 
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blunted and delayed adrenaline responses (Banarer and Cryer, 2003). 
Nocturnal hypoglycaemia is often prolonged with an undulating glucose 
profile with multiple nadirs that may occur as a result of repeated 
counterregulatory attempts to resist the glucose lowering effects of 
injected insulin.  
During nocturnal episodes there was a pattern of transient 
cardioacceleration with each glucose nadir, followed by a phase of 
heightened vagal counteraction up to 40-50 minutes later that was 
associated with bradycardia. It was therefore speculated that the 
occurrence of bradycardia may be linked to increased vagal counteraction 
following sympathetic neural activation. This view is supported by studies 
of experimental hypoglycaemia with autonomic blockade (Fisher et al., 
1990; Lloyd-Mostyn and Oram, 1975). When hypoglycaemia was induced 
with concomitant beta-adrenergic  blockade, a late bradycardia was 
observed 45 minutes after the acute sympathetic reaction at the glucose 
nadir (Fisher et al., 1990) with heart rates below that on propranolol alone. 
This decrease in heart rate was abolished by atropine, confirming the role 
of heightened vagal tone (Fisher et al., 1990). The dampened nocturnal 
sympathoadrenal response in nocturnal hours may be analogous to the 
effect of adrenergic blockade in these experimental studies, such that 
while heart rate may be restored to the normal range during the day, the 
rate slowing effects would be more profound at night, when sympathetic 
responses are weakened and circadian vagal tone is high. Furthermore, 
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nocturnal hypoglycaemia is likely to be driven by basal insulin, where the 
relatively slow decline in glucose may be linked with a weaker sympathetic 
response, in contrast with a faster decline secondary to rapid acting insulin 
during the day. There may also be an additional contribution due to 
impaired sympathetic responses in those who experience repeated 
episodes of hypoglycaemia (8 of 14 patients in this study).  
The effect of hypoglycaemia on cardiac repolarisation with QT as a marker 
of action potential duration length was also investigated. The degree of QT 
prolongation was smaller than that reported in previous experimental 
studies and ambulatory studies in T1DM, only achieving significance during 
the day (Gill et al., 2009; Landstedt-Hallin et al., 1999; Marques et al., 
1997). This may reflect attenuated sympathoadrenal responses in this 
advanced T2DM group, who were older and had a relatively long disease 
duration (Segel et al., 2002). In this study, QTc was prolonged to over 500 
ms with abnormal T wave morphology in two individuals during 
hypoglycaemia, a level that can strongly predispose to Torsade de pointe 
and ventricular tachyarrhythmias. These two individuals also had the 
longest baseline QTc in the group (456 ms in a male patient, 484 ms in a 
female patient). It is possible that individuals with a decreased 
repolarisation reserve, related to coronary heart disease or structural 
abnormalities, may be particularly predisposed to arrhythmias during a 
hypoglycaemic challenge.  
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It has been suggested that abnormal repolarisation associated with 
hypoglycaemia may be mediated by catecholamines, hypokalaemia 
(Robinson et al., 2003) or low glucose (Zhang et al., 2003b). However, in 
the absence of simultaneous biochemical measurements, the mechanism 
involved can only be speculated upon. Hypoglycaemic episodes which 
reached a higher glucose nadir (over 2.5 mmol/L) were associated with a 
greater QT prolongation in contrast to episodes with nadirs under 2.5 
mmol/L. This can be interpreted to suggest that the degree of QT 
prolongation may be linked to the sympathoadrenal response, rather than 
absolute glucose per se. During clinical episodes of spontaneous 
hypoglycaemia (in contrast to hypoglycaemia induced experimentally), 
episodes of hypoglycaemia with a higher glucose nadir might generally 
reflect a stronger sympathoadrenal response. Conversely, in individuals 
with impaired counter-regulation, glucose may fall to a lower nadir due to 
reduced sympathoadrenal activation. Thus, one explanation of the data is 
that greater QT prolongation occurred in episodes that were less deep due 
to greater sympathoadrenal activation. Table 3-4 illustrates a 
hypoglycaemic episode with a higher glucose nadir (> 2.5 mmol/L), where it 
was possible that the combination of sympathoadrenal activation and 
inherent repolarisation abnormalities resulted in significant QT 
lengthening. This remains speculative and also an additional role for 
hypokalaemia cannot be excluded as this is also linked to adrenaline 
release. 
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In the present study, only 3 out of 34 hypoglycaemic episodes were 
accompanied by symptoms and no arrhythmias were observed during 
these episodes. The high prevalence of asymptomatic hypoglycaemia is 
striking, probably reflecting diminished counter-regulatory responses 
associated with long disease duration and nocturnal episodes where 
hypoglycaemia occurred during sleep in a supine posture. Asymptomatic 
hypoglycaemia can contribute to an excess of arrhythmic risk, and these 
episodes may be frequent and go unnoticed. The data from this study 
indicates a trend for a lower heart rate and greater vagal tone (especially at 
night) during asymptomatic compared with symptomatic hypoglycaemia. 
However, it is difficult to draw any firm conclusions from such small 
numbers. 
This study suggests that hypoglycaemia is a proarrhythmic condition with a 
risk higher than during euglycaemia or hyperglycaemic. The 
electrophysiological conditions during hypoglycaemia could contribute to 
the initiation of ventricular tachyarrhythmias in a number of manners. 
During the day, QT prolongation may lead to increased triggered activity in 
the form of early afterdepolarisations. Sympathetic activation and an 
increase in cytosolic calcium can similarly lead to delayed 
afterdepolarisation and premature beats (Nordin, 2014). Both mechanisms 
can contribute to increased ventricular ectopic activity, which was 
observed during daytime hypoglycaemia. However, rates of arrhythmia 
were even higher at night, where sympathoadrenal responses are 
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attenuated. Arrhythmias during spontaneous nocturnal hypoglycaemia 
may be explained by alternate mechanisms, in contrast to strong 
sympathoadrenal activation and QT prolongation that is typically observed 
during experimental hypoglycaemia. During a state of vagal dominance, a 
slow sinus rate may reveal latent pacemakers, particularly under conditions 
of enhanced automaticity (Verrier and Josephson, 2009). This may explain 
the excess atrial and ventricular ectopic activity that was observed during 
nocturnal hypoglycaemia. Ventricular bigeminy during bradycardia 
occurred at low glucose levels in this study and the consequent long-short 
activation intervals are a common trigger for Torsade de pointe (El-Sherif 
and Turitto, 2004; Farkas et al., 2008). QT prolongation during bradycardia 
can also increase the frequency or risk of long-short intervals. Although this 
combination did not occur in patients during this study, it has previously 
been reported in a patient with T2DM during a hypoglycaemic coma 
(Bolognesi et al., 2011). Thus, hypoglycaemia has the potential to trigger a 
fatal arrhythmic event through more than one mechanism during 
spontaneous hypoglycaemia in patients at high cardiovascular risk. 
Most of the arrhythmias that were observed in this study may be well 
tolerated by young healthy individuals, but could be clinically relevant in 
those with T2DM. A previous study has examined symptoms of ischemic 
heart disease in adults with T2DM undergoing CGM and reported a higher 
frequency of chest pain during hypoglycaemic episodes (Desouza et al., 
2003). The authors did not separate their periods of recording into night 
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and day but it is conceivable that if their patients were generally reporting 
symptoms during the day (as is most likely), this might reflect the transient 
cardioacceleration during hypoglycaemia (causing subsequent angina), as 
observed in this study. Ischemia may further enhance hypoglycaemia-
associated repolarisation abnormalities.    
There are limitations to CGM concerning its accuracy at low glucose values 
and a time lag due to diffusion of glucose between the blood and 
interstitial compartments. Although there are reports that CGM glucose 
may be falsely low during hypoglycaemia in T1DM (McGowan et al., 2002), 
in T2DM CGM glucose has been reported to be falsely high due to 
differences in glucose distribution in the interstitial space (Choudhary et 
al., 2011). Therefore, there can be reasonable confidence that IG ≤ 3.5 
mmol/L as detected by CGM in this study represents true biochemical 
hypoglycaemia. Since it would be unethical to perform experimental 
hypoglycaemia studies in these patients at high cardiovascular risk, CGM 
remains, at the moment, the best available tool to study clinical 
hypoglycaemia in an ambulatory setting. 
3.6  Conclusions 
In conclusion, I have shown that hypoglycaemia is associated with an 
increased susceptibility to cardiac arrhythmias in patients with T2DM at 
cardiovascular risk. Changes in cardiac autonomic tone and abnormal 
repolarisation are potential contributory mechanisms. These findings may 
also be relevant to the ‘dead-in-bed’ syndrome in T1DM, which also occurs 
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at night, typically in individuals with recurrent asymptomatic 
hypoglycaemia, where an arrhythmic mode of death has been suggested 
(Heller, 2002). This study confirms that clinical hypoglycaemia is common 
and is frequently unrecognised in patients with advanced T2DM, even 
when glycaemic control is not as aggressive as that in recent interventional 
trials. Hypoglycaemia may contribute towards increased cardiovascular 
mortality through arrhythmic mechanisms in this vulnerable group. 
 
Chapter 4 - Effect of Acute Hypoglycaemia on Cardiac 
Autonomic Regulation in Type 2 Diabetes 
4.1 Summary 
Spontaneous hypoglycaemia has been associated with an increased risk of 
arrhythmias in T2DM patients. These changes could reflect differential 
changes in autonomic tone, which may differ according to the duration of 
hypoglycaemia. The aim of this study was to measure changes in cardiac 
autonomic function during sustained experimental hypoglycaemia. 
Twelve adults with T2DM and normal cardiac autonomic function tests and 
eleven age and BMI-matched nondiabetic controls underwent paired 
hyperinsulinaemia clamps separated by four weeks. Glucose was 
maintained at 6.0 mmol/L for 2 hours during euglycaemia, while during 
hypoglycaemia glucose was lowered to 2.5 mmol/L over 1 hour and 
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maintained for a further hour. Heart rate, blood pressure and HRV and BRS 
were assessed at 30 minute intervals.  
In subjects with diabetes, the heart rate increased maximally from 72±10 
to 77±10 bpm after 30 minutes at hypoglycaemia (T90), but then fell to 
71±8 bpm despite continued hypoglycaemia at 1 hour (T120). HF power 
decreased transiently but returned towards baseline at T120, suggesting 
vagal reactivation. In nondiabetic controls, there was an earlier increase in 
heart rate at T60 (from 62±9 to 66±13 bpm) which remained elevated 
throughout hypoglycaemia. HF power was persistently lower indicating 
continued vagal inhibition.  
 Cardiac autonomic regulation during hypoglycaemia appears time-
dependent and different in T2DM and nondiabetic subjects. In individuals 
with T2DM, the initial heart rate increment to hypoglycaemia is delayed 
and there is reactivation of vagal activity during more sustained 
hypoglycaemia. These mechanisms might contribute to tachy- and 
bradyarrhythmias during clinical hypoglycaemic episodes. 
4.2 Introduction 
Recent studies of intensive insulin therapy in T2DM have shown a higher 
risk of fatal arrhythmic death associated with severe hypoglycaemia 
(Gerstein et al., 2012). One mechanism by which hypoglycaemia could 
promote arrhythmias is through changes in cardiac autonomic activity. 
During insulin-induced hypoglycaemia in nondiabetic and T1DM 
174 
individuals, studies have reported a transient beta-adrenergic mediated 
increase in heart rate (Fisher et al., 1990), while the role of cardiac vagal 
activity is less clear (Koivikko et al., 2005; Laitinen et al., 2008; Schachinger 
et al., 2005). Another study has reported increased stroke volume with a 
fall in total peripheral resistance secondary to beta and alpha adrenergic 
stimulation (Fisher et al., 1990). To date, few studies have examined the 
cardiac autonomic responses to acute hypoglycaemia in individuals with 
T2DM. 
During ambulatory monitoring, a transient increase in heart rate was 
observed coinciding with vagal withdrawal during daytime hypoglycaemia 
in T2DM subjects as described in Chapter 3 (Chow et al., 2014). However, 
during nocturnal hypoglycaemic episodes, where glucose was generally 
lower and episodes more prolonged, there was a phasic response, whereby 
initial increases in heart rates were followed by a relative bradycardia.  It 
was hypothesised that this may be due to diurnal differences in the depth 
and duration of hypoglycaemia, which result in differential sympathetic 
and parasympathetic stimulation over time. However, in spontaneous 
clinical episodes neither the depth nor duration can be controlled, and it is 
not possible to measure levels of circulating catecholamines or 
electrolytes. Therefore the aim of this study was to examine in detail 
cardiac autonomic regulation using an experimental model of 
hypoglycaemia in patients with T2DM and to compare this to a nondiabetic 
control group.   
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4.3 Research Design and Methods 
These were described in detail in Section 2.3 and are outlined in brief 
below. 
4.3.1 Participants 
Twelve individuals with T2DM and no known CVD were recruited from 
Sheffield Teaching Hospitals diabetes outpatient clinics. Patients were on 
one or more oral hypoglycaemic agents and/or a GLP-1 analogue or insulin 
<2 years. Eleven nondiabetic age and BMI matched controls were recruited 
from staff at the University of Sheffield and Sheffield Teaching Hospitals. 
Patients taking beta-blocking agents were excluded. Written informed 
consent was obtained from all participants and the study received local 
ethics approval. 
4.3.2 Baseline Assessment 
Cardiovascular autonomic reflex tests were performed as previously 
described (O'Brien et al., 1986) according to the recent consensus 
statement on the diagnosis of CAN (Tesfaye et al., 2010). All patients were 
euglycaemic at the time of autonomic function testing. Results were 
compared against age-adjusted normal reference ranges (O'Brien et al., 
1986) and those below the 95% CI were considered abnormal. Participants 
with established CAN, as defined by two or more abnormal cardiovagal 
tests, were excluded. All participants had a normal 12 lead ECG at baseline, 
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and the control group had normal fasting serum glucose (<7 mmol/L) and 
HbA1c <6.5% (< 48 mmol/mol) at baseline.  
4.3.3 Hyperinsulinaemic Clamp Protocol 
All subjects participated in paired hyperinsulinaemic euglycaemic and 
hypoglycaemic studies separated by at least four weeks. Details of the 
hyperinsulinaemic clamp protocol are described in Section 2.3.5. During 
the clamp, a primed continuous intravenous insulin infusion was 
administered at 120 mU/m2/min, along with 20% dextrose at a variable 
rate and adjusted according to arterialised blood glucose concentrations, 
which were measured every five minutes. In the hypoglycaemic clamp, 
glucose was lowered from euglycaemia to 2.5 mmol/L over 60 minutes (T0 
to T60), and thereafter maintained at 2.5 mmol/L for a further 60 minutes 
(T60-T120). In the euglycaemic clamp, arterialised whole blood glucose was 
maintained at 6 mmol/L for the duration of the study (T0-T120).  
4.3.4 Heart Rate Variability and Blood Pressure 
ECG recordings were performed at 30 minute intervals during the clamp 
study (Baseline, T30, T60, T90, T120). HRV was determined from five 
minute resting recordings with the participant supine and free breathing. 
Normal R-R intervals (NN) were extracted for HRV analysis performed in 
accordance with the recommendations of the 1996). The time domain 
measures the SDNN and the RMSSD of NN were analysed.  Fast Fourier 
transformation was applied to R-R intervals for spectral analysis. The LF 
band was defined as 0.04-0.15 Hz and the HF band was defined as 0.15-0.4 
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Hz. The ratio between the LF power and total power was calculated 
(LFnorm), which is believed to indicate the level of sympathetic modulation 
in HRV (Bernardi et al., 2011; Montano et al., 1994). The HF power is an 
indicator of cardiac vagal activity.  
Blood pressure was measured every 30 minutes using an automatic 
oscillometric sphygmomanometer (DINAMAP ®GE Medical Systems 
Information technologies, Inc.) after lying supine for five minutes. Pulse 
pressure was defined as the SBP minus the DBP, whilst mean arterial 
pressure (MAP) was calculated as DBP + 1/3 (SBP-DBP) in mmHg. 
4.3.5 Spontaneous Baroreceptor Sensitivity  
Spontaneous cardiovagal BRS was measured using a Portapres (TNO 
Biomedical Instrumentation, Amsterdam, Netherlands). BRS was recorded 
for five minutes following internal calibration once a steady state was 
achieved. BRS analysis was performed using dedicated software using the 
sequence method (Nevrokard V 5.1.3, Intellectual Services, Slovenia) 
(Parati et al., 1988). An ‘UP’ sequence was generated when there was an 
increase in SBP of at least 1 mmHg associated with an increase in R-R 
interval of at least 5 ms for three or more consecutive beats. A ‘DOWN’ 
sequence was generated where there was a reduction in SBP of at least 1 
mmHg with an accompanying reduction in R-R interval of at least 5 ms for 
three or more consecutive beats. The total BRS, measured in ms/mmHg 
was calculated by averaging the regression coefficients of the RR/BP 
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relationship of the UP and DOWN sequences with correlation coefficients 
greater than 0.85.     
4.3.6 Biochemical Analysis 
Biochemical parameters were measured at baseline and after 120 minutes 
in the euglycaemic and hypoglycaemic arms in both groups. For 
catecholamines, 6 mL of whole blood was collected into a chilled lithium 
heparin tubes containing 50 μL of EGTA/glutathione preservative and 
subjected to centrifugation at 4oC and 3000 rpm for 10 minutes. The 
resulting supernatant was stored at -80oC until assayed by HPLC. Plasma 
free insulin was analysed by an immunometric assay (Invitron Insulin ELISA, 
Invitron Ltd, Monmouth, UK) following precipitation with PEG. Serum 
potassium was analysed using an automated system (Cobas® modular 
anlalyzer, Roche Diagnostics, West Sussex, UK). 
4.3.7 Statistical Analysis 
Data that followed an approximate normal distribution were summarised 
using the mean (SD) unless otherwise stated, whilst skewed data were 
summarised using the median (interquartile range). Baseline characteristics 
between the diabetic and control groups were compared using an 
independent t-test, Mann Whitney-U or Fisher’s exact test. 
Catecholamines, glucose and potassium were compared at T120 under 
euglycaemic and hypoglycaemic conditions using a one way ANOVA with 
planned contrasts for the effect of the group (diabetes versus controls). 
The nonparametric Kruskal-Wallis test was used to compare free insulin 
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levels at T120 for euglycaemia versus hypoglycaemia and between the 
groups. 
Spectral HRV parameters were logarithmically transformed to approximate 
a normal distribution. A two-way ANOVA with repeated measures was 
used to study the main effects of time, glucose, group, and interaction 
between factors on changes in heart rate, blood pressure, HRV and BRS 
parameters. Data were checked for sphericity using Mauchly’s test, and 
where sphericity was violated the Greenhouse-Geisser correction was 
applied.  Statistical analysis was performed using SPSS (version 20.0, IBM, 
Chicago, Illinois) and a p-value ≤ 0.05 was deemed statistically significant.  
4.4 Results 
4.4.1 Participant characteristics 
Participant characteristics are shown in Table 4-1. T2DM patients had a 
median age of 54 (range 37-64) years with HbA1c 7.8±1.3% (62±14 
mmol/mol). Five patients were taking oral hypoglycaemic agents only, five 
were taking a combination of oral hypoglycaemic agents and a GLP-1 
analogue, and two had been taking oral hypoglycaemic agents and basal 
insulin for less than two years. Only two diabetic patients were on ACE 
inhibitors. Nondiabetic subjects were similar in demographics with  median 
age 52 (range 34-63) years and BMI 31±8 kg/m2. 
The baseline measurements showed that diabetic subjects had higher 
baseline heart rates and blood pressure, but lower HRV and BRS. None of 
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the subjects had clinical CAN as defined by cardiovascular autonomic reflex 
tests below the normal reference range (Table 4-2).  
 
 
 
 
 
 
 
Table 4-1: Participant characteristics 
Data are mean ± SD except age which is the median value (range). p-value indicates a 
comparison of the two groups via parametric or nonparametric testing. HbA1c-glycated 
haemoglobin, SBP-systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass 
index 
 T2DM 
n=12 
Nondiabetic 
n=11 
Age (years) 54 (37-64) 52 (34-63) 
Male    (M/F) 9/3 5/6 
BMI (kg/m
2
) 34 ± 5 31 ± 8 
Duration of diabetes (years) 11 ± 7 n/a 
HbA1c (%) 7.8 ± 1.3 5.5 ±0.3  
             (mmol/mol IFCC) 62 ± 14  34±10  
SBP (mmHg) 135 ± 15 131 ± 15 
DBP (mmHg) 82 ± 10 72 ± 11 
Heart Rate (bpm) 78 ± 8 64 ±6 
 
Table 4-2: Baseline cardiac autonomic function in T2DM patients and 
nondiabetic subjects 
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Data mean ±SD. Independent t-test of baseline variables was used to compare the T2DM 
and nondiabetic groups. HRV- heart rate variability, HF-high frequency, BRS-baroreceptor 
sensitivity, E:I -expiration:inspiration ratio 
 T2DM 
n=12 
Nondiabetic 
n=11 
p-value 
Cardiovascular autonomic reflex tests    
E:I ratio 1.24±0.20 1.27±0.23 0.74 
Valsava ratio 1.51±0.29 1.81±0.41 0.05 
Standing ratio 1.28±0.17 1.58±0.28 0.005 
Heart rate variability    
SDNN 27.4±11.8 48.2±14.6 0.001 
RMSSD 15.5±7.94 32.9±15.3 0.002 
Log Total power  2.34 ± 0.36 2.90±0.36  0.001 
Log HF 1.85± 0.37 2.32±0.48 0.02 
LFnorm 0.65±0.14 0.70±0.14 0.40 
BRS  8.59±4.08 11.51±7.65 0.26 
 
4.4.2 Blood Glucose and Insulin 
Target arterialised blood glucose levels were achieved and are shown in 
Figure 4-1. Blood glucose concentrations at 120 minutes were similar 
between diabetic and nondiabetic groups in the euglycaemic arm (5.81± 
0.29 mmol/L versus 5.96± 0.18 mmol/L, p=0.15, respectively) and in the 
hypoglycaemic arm (2.56± 0.22 mmol/L versus 2.56± 0.09 mmol/L, p>0.99, 
respectively). 
Free insulin levels at 120 minutes were median (IQR) 576 (468-627) pmol/L 
during euglycaemia and 689(477-1076) pmol/L during hypoglycaemia in 
the diabetic group. In the nondiabetic group they were 865 (509-952) 
pmol/L in the euglycaemic and 665(468-967) pmol/L in the hypoglycaemic 
arms. A comparison of insulin levels between the groups under both 
euglycaemic and hypoglycaemic conditions were found to be not 
statistically different (p = 0.23). 
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Figure 4-1: Arterialised blood glucose during hyperinsulinaemic euglycaemic 
and hypoglycaemic clamps 
Open circle: euglycaemia (EU) nondiabetic control group; Open square: hypoglycaemia 
(HYPO) in nondiabetic control group; Closed circle: EU arm in diabetic group; Closed 
square: HYPO in diabetic group.  Data are Mean (SE)   
4.4.3 Heart Rate  
During euglycaemia there were no significant changes in heart rate within 
the diabetic group nor in the nondiabetic subjects (p=0.19 and p=0.11, 
respectively for time by one way ANOVA) (Figure 4-2a). Conversely, the 
heart rate changed significantly during hypoglycaemia in the diabetic group 
(p = 0.03 for time by one way ANOVA). In the diabetic group, there was an 
initial maximal increase in heart rate from 72±10 to 77±10 bpm (Δ5±2 bpm, 
p=0.03 versus baseline) after 30 minutes of hypoglycaemia (T90) (Fig. 4-
2a); however, this subsequently returned towards baseline 71±8 bpm (Δ-
1±2 bpm) after an hour (T120) despite maintained hypoglycaemia (Figure 
4-2a). In the nondiabetic group, there was a trend for an increase in heart 
rate during hypoglycaemia (p=0.20 by one way ANOVA), but the maximum 
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increase in heart rate occurred earlier at T60 (from 62±9 to 66±13 bpm, 
Δ4±5 bpm) and remained higher than baseline after 1 hour (T120, 64±10 
bpm).  The response was different to that during euglycaemia, as shown by 
a significant interaction between time and glucose (p=0.04). The absolute 
maximum increment in heart rate was similar between the groups but the 
time to maximum occurred later in diabetic subjects (Table 4-3). 
 
Figure 4-2: Heart rate and change in heart rate variability during hypoglycaemia 
in T2DM and nondiabetic subjects 
(a) shows the heart rate during hypoglycaemia versus euglycaemia in diabetic and 
nondiabetic groups. The period at which glucose was maintained at the target levels 
during euglycaemia (6 mmol/L) and hypoglycaemia (2.5 mmol/L) are shown. (b) shows the 
hanges in normalised low frequency (LFnorm) and log HF (high frequency) power during 
hypoglycaemia in diabetic patients and nondiabetic controls. Data are mean (SE).  
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Table 4-3: Maximum change and time to maximum for cardiovascular 
parameters during hypoglycaemia in diabetic and nondiabetic subjects 
Maximum change (Mean ±SD); time to maximum change; median (interquartile range), 
log HF high frequency heart rate variability, LFnorm-normalised low frequency HRV,  SBP-
systolic blood pressure, DBP-diastolic blood pressure, PP-pulse pressure 
 Nondiabetic  
(n=11) 
Diabetes  
(n=12) 
 
Max change 
Time to max 
change 
Max change 
Time to max 
change 
Heart 
Rate  
5.26±4.65 
bpm 
60 (60-90) min 
5.69±6.66 
bpm 
90 (60-90) min 
logHF -0.45±0.21 
ms
2 60 (60-90) min 
-0.45±0.34 
ms
2 90 (60-120) min 
LFnorm 0.13±0.10 ms
2 
60 (30-90) min 0.13±0.13 ms
2 
75 (52.5-97.5) min 
SBP 13±20 mmHg 60 (30-90) min 14±15 mmHg 90 (60-90) min 
DBP -13 ±7 mmHg 120 (105-120) min -11 ±7 mmHg 90 (82.5-90) min 
PP 21±15 mmHg 90 (60-105 )min 19 ±8 mmHg 75 (60-90) min 
 
4.4.4 Heart Rate Variability 
4.4.4.1 Spectral Analysis 
High frequency power 
Log HF did not change significantly during euglycaemia in diabetic and 
nondiabetic groups (Figure 4-2b). During hypoglycaemia in diabetic 
185 
subjects there was an overall change in log HF (p=0.05 for time). There was 
a decrease in HF power (logHF) maximally at T90, suggesting vagal 
withdrawal, coincident with the maximal increase in heart rate during 
hypoglycaemia (Figure 4-2b). However, after one hour (T120), logHF 
returned towards baseline levels suggesting restoration of vagal tone. In 
the control group, logHF decreased during hypoglycaemia maximally at T60 
and remained decreased up to T120. This was significantly different from 
euglycaemia (p=0.02 for glycaemic arm). The maximum decrease in logHF 
occurred earlier in the nondiabetic group but the magnitude of change was 
similar in both groups (Table 4-3). 
Total power 
Total power did not change significantly during euglycaemia in diabetic 
subjects. However, there was a trend towards a decrease in total power up 
to T90 during hypoglycaemia (p=0.10 for time). There was no significant 
difference between the glycaemic arms among diabetes subjects and in 
nondiabetic subjects there was no significant change during euglycaemia or 
hypoglycaemia. 
Normalised low frequency power 
LFnorm did not change significantly during euglycaemia within the diabetic 
group (Figure 4-2c), and similarly, there were no significant changes in 
LFnorm for during hypoglycaemia. In the nondiabetic group there was a 
trend towards a decrease at T60 during euglycaemia which then returned 
towards baseline (p=0.06 for time). LFnorm increased during 
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hypoglycaemia (p=0.04 for time) to a maximum at T30; however, the 
difference compared with euglycaemia did not reach statistical significance 
(p=0.23 for glucose, p=0.16 for interaction between time and glucose by 
two-way ANOVA) (Figure 4-2c).  
Time domain analysis 
RMSSD did not change during euglycaemia in either subject group. In 
diabetic subjects, RMSSD showed a trend towards a decrease during 
hypoglycaemia at T60 and T90, but returned to above the baseline level 
following hypoglycaemia at T120, exhibiting similar trends to HF power 
(p=0.11 for time) (Table 4-4). The pattern of change was different between 
hypoglycaemia and euglycaemia (p=0.03 for the interaction between 
glycaemic arms and time by two way repeated measures ANOVA). 
However, in nondiabetic subjects, RMSSD did not change during 
hypoglycaemia and there was no significant difference between the 
glycaemic arms (Table 4-4).  
SDNN did not change during euglycaemia in diabetic subjects but tended to 
increase at T120 after hypoglycaemia (Table 4-4). There was a difference in 
change over time between glycaemic arms (p=0.04). There were no 
significant changes in SDNN in either glycaemic arm in the nondiabetic 
group. 
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Table 4-4: Time domain measures of Heart rate variability during 
hypoglycaemia and euglycaemia 
EU-euglycaemia HYPO-hypoglycaemia, SDNN-standard deviation of NN intervals, RMSSD-
root mean squared of successive standard deviations of NN; Data are mean ±SD.  
 Time 0 30 60 90 120 
Diabetic (n=12) 
RR (ms) EU 844±183 816±164 811±189 826±161 830±152 
 HYPO 849±171 835±145 815±167 794±163 855±126 
SDNN (ms) EU 33.0±12.5 29.1±12.6 29.1±13.0 29.4±14.5 29.2±12.9 
 HYPO 31.0±14.9 33.9±16.8 30.3±14.7 34.0±18.1 40.4±26.9 
RMSSD (ms) EU 18.6±9.7 15.6±8.2 15.6±6.9 17.7±11.4 16.8±7.7 
 HYPO 20.0±13.0 19.6±14.2 15.0±8.2 16.2±13.4 22.9±22.2 
Nondiabetic (n=11) 
RR (ms) EU 983±164 978±157 1008±164 968±161 976±136 
 HYPO 982±148 1009±178 958±203 968±172 958±154 
SDNN (ms) EU 48.7±19.7 61.8±27.7 53.2±19.1 53.7±10.8 59.3±23.4 
 HYPO 55.9±26.7 57.6±16.2 47.1+17.4 51.0±19.7 59.2±40.4 
RMSSD (ms) EU 30.6±18.2 33.3±16.0 32.0±15.8 28.9±10.8 30.9±12.4 
 HYPO 35.0±18.9 34.1±17.3 28.7±17.4 33.7±21.2 36.0±36.2 
 
4.4.5 Blood Pressure 
4.4.5.1 Systolic Blood Pressure 
SBP did not change significantly during euglycaemia in the diabetic group 
or nondiabetic group. In T2DM subjects there was a non-significant trend 
towards increased SBP maximally at T90, (Δ 8±20 mmHg) but this fell to 
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below baseline (Δ-2±13) during sustained hypoglycaemia at T120 (p=0.21 
for time) (Figure 4-3). The response was not significantly different 
compared with that for euglycaemia (p=0.80 for glucose, p=0.54 for 
interaction between time and glucose).  SBP did not change significantly 
during hypoglycaemia in the nondiabetic group.  
4.4.5.2 Diastolic Blood Pressure 
There were no changes in DBP during euglycaemia in diabetic or 
nondiabetic subjects. During hypoglycaemia, DBP tended to decrease from 
the baseline (77±7 mmHg up to 71±12 mmHg) at T90 in the diabetic group 
(Δ -6.0±10 mmHg) and then plateaued (Figure 4-3) (p =0.06 for time by one 
way ANOVA), and there was an interaction between time and the 
glycaemic arm (p=0.04).  
In the nondiabetic group, DBP fell progressively from 74±9 mmHg to 62±10 
mmHg (Δ-11.3±5.93 mmHg) up to T120 (Figure 4-3) (p<0.001 for time). 
There was a significant difference between the glycaemic arms (p=0.001) 
and the interaction between time and the glycaemic arm (p=0.006) by two 
way repeated measures ANOVA. The time to minimum DBP occurred later 
in the nondiabetic group (T120 (105-120) versus T90 (82.5-90) in the 
diabetic group (p=0.01). 
4.4.5.3 Mean Arterial Pressure 
MAP did not change during euglycaemia in either subject group. During 
hypoglycaemia, MAP remained steady between baseline to T90 minutes 
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but there was a trend towards a decrease at T120 in both diabetic and 
nondiabetic subjects (Fig 4-3). Overall, MAP was lower during 
hypoglycaemia compared to euglycaemia in the diabetic (p=0.021 for 
glycaemic arm) and nondiabetic groups (p=0.014 for glycaemic arm by two 
way repeated measures ANOVA).  
4.4.5.4 Pulse Pressure 
Pulse pressure did not change significantly during euglycaemia in diabetic 
subjects but increased significantly during hypoglycaemia (p<0.001 for 
time). Pulse pressure at T60 and T90 were significantly higher than at 
baseline (p=0.001 and p=0.002 respectively). There was a significant 
interaction between time and the glycaemic arm (p=0.02 by two way 
repeated measures ANOVA). In the nondiabetic group, pulse pressure did 
not change significantly during euglycaemia, but increased during 
hypoglycaemia (p=0.03 for time). The differences between the glycaemic 
arms did not reach statistical significance in nondiabetic subjects. The 
maximum change in pulse pressure occurred at a median of 75 minutes in 
the diabetic group, primarily due to a rise in SBP, whereas the maximum 
change occurred later at 90 minutes in the nondiabetic group mediated 
mainly by a decline in DBP (Figure 4-3). 
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Figure 4-3: Blood pressure during hypoglycaemia and euglycaemia in T2DM and 
control subjects 
Systolic blood pressure (SBP); diastolic blood pressure (DBP); mean arterial pressure 
(MAP) Data are mean (SE). Closed square – HYPO DM, open square  - EU DM, Closed circle 
– HYPO control, Open circle – EU control 
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4.4.6 Baroreceptor Sensitivity 
In the diabetic group during euglycaemia, BRS significantly decreased 
(p<0.001 for time) from within 30 minutes of the insulin infusion and 
remained lower at T120. However, there were no significant changes 
during hypoglycaemia (Figure 4-4). The difference between the glycaemic 
arms did not reach statistical significance (p=0.29 for glucose). In the 
nondiabetic group, there were no significant changes in BRS in both 
euglycaemic and hypoglycaemic arms. 
 
Figure 4-4: Baroreceptor sensitivity during hypoglycaemia and euglycaemia in 
T2DM and control subjects 
Data are Mean (SE) 
4.4.7 Biochemical Measurements 
No significant changes in adrenaline and noradrenaline occurred during 
euglycaemia in both groups. 
In the diabetic group, plasma adrenaline increased significantly from 
baseline, from 0.12±0.09 to 3.05±2.46 nmol/L at the end of the 
hypoglycaemic clamp (p=0.002). In the nondiabetic group, plasma 
adrenaline increased from 0.15±0.07 nmol/L to 3.83±2.83 nmol/L at the 
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end of hypoglycaemia (p=0.001 versus baseline). However, peak adrenaline 
levels were not significantly different between the groups during 
hypoglycaemia (p = 0.48).  
During hypoglycaemia, plasma noradrenaline increased from 1.25±0.53 to 
2.37±0.82 nmol/L in the diabetic group and 1.46±0.5 to 2.69±1.45 nmol/L 
in the nondiabetic group (both p<0.01 compared with baseline), but there 
was no significant difference between the groups (p=0.52). 
Serum potassium decreased during both euglycaemia and hypoglycaemia, 
as expected due to the effects of insulin. In the diabetic group, potassium 
was significantly lower at the end of the hypoglycaemic clamp compared 
with euglycaemia (3.30±0.32 mmol/L versus 3.70±0.43 mmol/L, p=0.02). In 
the nondiabetic group levels of serum potassium during hypoglycaemia 
and euglycaemia were not statistically different (3.48±0.39 mmol/L versus 
3.65±0.45 mmmol/L respectively, p = 0.36).  
4.5 Discussion 
The main findings of this study are as follows. 1) In T2DM subjects 
hypoglycaemia resulted in transient increases in heart rate with coincident 
vagal withdrawal, followed by a relative decrease in heart rate during more 
sustained hypoglycaemia of one hour accompanied by vagal reactivation, 
as shown by HF power and RMSSD. In nondiabetic subjects this did not 
occur and there was continued vagal inhibition during hypoglycaemia. 2) 
During hypoglycaemia, there was a decrease in DBP, a non-significant 
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change in SBP, a slight decrease in MAP and an increase in pulse pressure 
in both groups. There was a progressive decline in DBP maximally after 60 
minutes of hypoglycaemia in nondiabetic subjects but this decline 
plateaued after 30 minutes in diabetic subjects. 
In T2DM patients there was an initial increase in heart rate followed by a 
subsequent decrease during sustained hypoglycaemia after 1 hour.  A 
similar phasic response was observed during spontaneous prolonged 
hypoglycaemia in T2DM patients during ambulatory monitoring (Chow et 
al., 2014) (see Chapter 3), and there was a transient cardioacceleration 
followed by subsequent decreases in heart rate up to fifty minutes later. It 
was hypothesised that this was secondary to a rebound in vagal activity, as 
shown by increased HF power, a phenomenon that has been observed in 
other studies of nondiabetic individuals ((Fisher et al., 1990; Lloyd-Mostyn 
and Oram, 1975). The extent of bradycardia was not as profound as that 
observed during spontaneous nocturnal hypoglycaemia, where episodes 
were generally more prolonged and at lower glucose values. However, 
since the experiments were conducted during the day, the differences in 
changes in heart rates may reflect circadian effects and a lower daytime 
vagal tone. Due to ethical reasons, the duration (60 minutes) and depth 
(2.5 mmol) of hypoglycaemia was limited to what can be induced in the 
laboratory safely, particularly in individuals with T2DM. It is conceivable 
that more prolonged hypoglycaemia of over two hours, as seen during 
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spontaneous episodes, would have led to continued vagal counteraction 
and similar decreases in heart rate. 
There was a delayed increment in heart rate in diabetic patients compared 
with the nondiabetic subjects which only occurred after 30 minutes of 
hypoglycaemia. Russell et al. (2001) also reported a delayed increment in 
heart rate during hyperinsulinaemic hypoglycaemia in adults with T1DM 
compared to control subjects. In support of this finding, we also observed a 
delayed and lower magnitude of increase in normalised LF power in the 
nondiabetic group which is an indicator of the degree of sympathetic 
activity as a proportion of the overall autonomic balance. However, 
absolute noradrenaline and adrenaline levels during hypoglycaemia were 
similar in diabetic and nondiabetic subjects. 
The decline in DBP during hypoglycaemia is consistent with previous 
studies (Fisher et al., 1990). Systemic or limb vascular resistance were not 
assessed due to the difficulties in performing additional invasive 
measurements, especially in diabetic subjects. Therefore we could only 
infer that the decrease in DBP during hypoglycaemia may be partly related 
to a decline in systemic vascular resistance secondary to predominant 
beta-2 adrenergic stimulation by adrenaline over noradrenaline (Fisher et 
al., 1990). DBP progressively declined up to the end of the hypoglycaemic 
period in the nondiabetic group, whereas in diabetic subjects, the declined 
plateaued after 30 minutes of hypoglycaemia. This is less likely to be 
explained by resistance to vasodilatory effects of insulin, as the changes in 
195 
DBP during hyperinsulinaemic euglycaemia were similar between the two 
groups. Adrenaline levels were slightly lower in diabetic subjects but not 
significantly different. Instread the attenuated decline in DBP in T2DM 
patients may reflect increased adrenergic sensitivity to noradrenaline-
enhanced vasoconstriction in resistance arteries (Cipolla et al., 1996). 
Insulin itself is sympathoexcitatory via central mechanisms, and 
intravenous administration is associated with vasodilatory effects. The 
cardiovascular changes that were observed during hyperinsulinaemic 
euglycaemia are consistent with those previously reported. These include 
an early increase in heart rate within 30 minutes of infusion, decreases in 
total power, and a sympathetic shift in autonomic balance (Emdin et al., 
2001; Muscelli et al., 1998). Previous studies have shown that intravenous 
insulin infusions, at physiological doses, increased muscle and lumbar 
sympathetic nerve activity (Cassaglia et al., 2011) and also a gain of the 
baroreflex as measured by the relationship between DBP and muscle 
sympathetic nerve activity (Young et al., 2010). This effect is diminished in 
the presence of insulin resistance. However, the same study reported 
unchanged cardiovagal BRS during intravenous insulin infusions as 
measured by the relationship between spontaneous SBP/heart rate 
fluctuations.  
In the present study, there were no changes in cardiovagal BRS during 
hyperinsulinaemic euglycaemia in nondiabetic subjects and a decrease in 
BRS in subjects with diabetes. The reasons for this decline in BRS during 
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euglycaemia in the diabetic group are unclear; however, the relationship 
was consistent across subjects. There were no changes in cardiovagal BRS 
during hypoglycaemia in diabetic and nondiabetic groups. Fagius and Berne 
(1991) measured BRS during insulin–induced hypoglycaemia in a small 
group of nondiabetic subjects, and similar to the findings here, they 
reported no change in BRS but a rapid resetting of the baroreflex working 
range.  
One of the key findings of this study was that the decrease in heart rate 
and vagal reactivation at 1 hour (T120) only occurred in the diabetic group, 
whilst in contrast the nondiabetic group demonstrated continued vagal 
inhibition throughout the period of hypoglycaemia. Reasons for these 
differences are unclear but could conceivably relate to differential changes 
in blood pressure. A decline in mean arterial pressure is normally 
accompanied by decreases in baroreceptor firing and vagal inhibition.  
Hypoglycaemia was accompanied by more abrupt increases in pulse 
pressure between 60-90 minutes in diabetic subjects, whereas in 
nondiabetic individuals changes in pulse pressure were more gradual 
(Figure 4-3). Baroreceptors are also sensitive to the rate of change in 
arterial pressures. During hypoglycaemia, more abrupt rises in pulse 
pressure, even without significant changes in MAP, can increase 
baroreceptor firing and vagal activation (Bell, 2013). Furthermore, acute 
baroreceptor resetting is absent or blunted when the pressure is pulsatile 
and this can promote the reflex inhibition of sympathetic activity, both by 
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sensitising the baroreceptors and by centrally facilitating the reflex 
(Chapleau et al., 1988). 
One of the strengths of this study is the inclusion of a hyperinsulinaemic 
euglyacemic control arm to account for the effects of insulin. In this study, 
changes in heart rate, HRV and blood pressure during hypoglycaemia have 
been demonstrated that are different when compared to those observed 
during hyperinsulinaemic euglycaemia. In addition, cardiovascular 
parameters have been measured at multiple time points during 
hypoglycaemia. Previous studies have yielded inconsistent results on the 
effect of hyperinsulinaemic hypoglycaemia on cardiac autonomic function 
(Koivikko et al., 2005; Laitinen et al., 2008; Schachinger et al., 2004), 
perhaps due to  measurements at a single, uncontrolled time-point. 
Koivikko et al. (2005) induced hypoglycaemia in T1DM and healthy 
volunteers in a stepwise manner from euglycaemia to 2.0-2.5 mmol/L, and 
reported an increase in heart rate and a progressive decrease in HF power, 
indicating vagal withdrawal. In contrast, another study concluded that 
hypoglycaemia did not increase the heart rate and was associated with 
higher vagal power when measured after 65 minutes of hypoglycaemia 
(Schachinger et al., 2004).  This study suggests that changes in cardiac 
autonomic regulation are phasic and are dependent on the duration of 
hypoglycaemia.  
The depth and frequency of breathing during HRV recordings was not 
controlled for in this study, and this is known to affect the HF component 
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of HRV (Bernardi et al., 2011). In the original protocol, subjects were asked 
to perform paced breathing at 12 breaths/minute by following a timed 
visual display. However, subjects were unable to follow this reliably at 
hypoglycaemic levels due to impaired concentration. The respiratory 
frequencies were extracted from the ECG recordings during free breathing 
and it was found that the mean respiratory frequencies across the five 
minutes of recording were consistently situated in the middle of the HF 
frequency band, around 0.25 Hz. There was a slight increase in the 
respiratory frequency during both clamps but these increases were too 
small to significantly affect the HRV spectra  (data shown in Appendix 
6).Thus, it is believed that the HRV analyses as shown here are due to the 
effects of hypoglycaemia itself on heart rate rather than indirect influences 
via respiration. 
A further limitation was the higher number of males in the diabetic group. 
This was an unintended consequence of the larger number of screen 
failures and withdrawals by female diabetic patients. Men have stronger 
sympathoadrenal responses compared to women in response to 
hypoglycaemia (Amiel et al., 1993). Thus smaller increments (and possibly a 
further delay) in heart rate and smaller changes in SBP and DBP compared 
to the nondiabetic subjects might have been expected, had the diabetic 
group been better gender balanced.  Limitations of normalised LF HRV as 
an indicator of relative sympathetic contribution have been discussed in 
the methods section. However, other measurements of cardiac 
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sympathetic activity, such as noradrenaline spillover are invasive and 
difficult to perform during hyperinsulinaemic clamp studies. Spontaneous 
BRS does not evaluate the entire sigmoidal baroreceptor curve throughout 
its working range, and the number of spontaneously increasing or 
decreasing blood pressure ramps may limit the number of valid sequences 
suitable for analysis. BRS analysis from this study was also repeated using 
spectral methods, which showed largely similar results to those obtained 
using the sequence method (data not shown). 
The current findings support the notion that hypoglycaemia may 
contribute to the risk of cardiac arrhythmias through alterations in cardiac 
autonomic responses. Thus, hypoglycaemia could induce arrhythmias by 
different mechanisms depending on the duration of hypoglycaemia and 
autonomic balance. Sympathetic activation can lead to ventricular 
tachyarrhythmias via the effect of catecholamines on the myocardial 
calcium influx, leading to delayed afterdepolarisations (Nordin, 2010).  
During continuous glucose and Holter monitoring in T2DM patients, a 
higher number of ventricular arrhythmias were seen in patients with 
severe hypoglycaemia (Stahn et al., 2014). In animal studies, ventricular 
arrhythmias during insulin induced hypoglycaemia were abolished by beta 
adrenergic blockade (Reno et al., 2013).  Vagal reactivation during 
sustained hypoglycaemia might protect against sympathetic mediated 
ventricular tachyarrhythmias.  Alternatively, excessive vagal counteraction 
could lead to bradycardia and the unmasking of ectopic foci under 
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conditions where background vagal tone is high, such as at night.  This can 
predispose to Torsade de pointe, particularly in combination with 
hypokalaemia and abnormal repolarisation (Bolognesi et al., 2011; Nordin, 
2014). In a previous study, a higher number of ventricular and atrial ectopic 
activities during spontaneous nocturnal hypoglycaemia were observed 
coinciding with conditions of high vagal tone (Chow et al., 2014). 
An alteration in autonomic tone is not the only mechanism by which 
hypoglycaemia may be proarrhthmic. The risk of arrhythmias is further 
enhanced when combined with abnormalities such as hypokalaemia, QT 
prolongation, hypertension and hypothermia (Tsujimoto et al., 2014).  
Whilst it is impossible to study diabetes patients with manifest CVD for 
ethical reasons, it might be expected such patients may be at even greater 
risk of arrhythmia, whereby hypoglycaemia-related ischaemia may further 
predispose patients to fatal events. 
In conclusion, it has been demonstrated that cardiac autonomic regulation 
during hypoglycaemia appears to be time-dependent. There were 
differences between those with T2DM and nondiabetic subjects which may 
be explained by differential haemodynamic effects and an impaired decline 
in DBP in response to hypoglycaemia. In T2DM, the initial heart rate 
increment to hypoglycaemia is delayed and there is reactivation of vagal 
activity during more sustained hypoglycaemia. These mechanisms could 
contribute to arrhythmias that have been reported in clinical 
hypoglycaemic episodes, and provides further evidence to support a 
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possible relationship between hypoglycaemia and increased cardiovascular 
mortality in T2DM.  
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Chapter 5 - Effect of Acute Hypoglycaemia on Cardiac 
Repolarisation in Type 2 Diabetes 
5.1 Summary 
Hypoglycaemia has been associated with increased cardiovascular 
mortality during trials of intensive glycaemic control. Increased risk of 
arrhythmias and QT prolongation during clinical hypoglycaemic episodes in 
patients with T2DM has previously been reported. The aim of this study 
was to explore the mechanisms underlying abnormal repolarisation using 
an experimental hypoglycaemic model. 
Twelve T2DM subjects with no CVD and 11 age and BMI matched 
nondiabetic subjects underwent paired hyperinsulinaemic euglycaemic 
(glucose 6 mmol/L) and hypoglycaemic clamps (glucose 2.5 mmol/L) 
separated by at least four weeks. Identical insulin infusion rates were used 
across all the experiments. Twelve lead high resolution ECG recordings 
were made at baseline and after 60 minutes of euglycaemia or 
hypoglycaemia. Corrected QT interval and T wave symmetry were 
determined along with serum potassium and plasma catecholamines. 
QTc increased by mean±SD Δ76±70 ms in the diabetic group during 
hypoglycaemia compared to Δ54±16 ms in the nondiabetic group. In 
contrast, T wave symmetry decreased to a greater extent during 
hypoglycaemia compared with euglycaemia in diabetic subjects (Δ -
0.56±0.43 versus Δ -0.20±0.18, p<0.001) but were similar under both 
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conditions in nondiabetic subjects. Potassium was lower at the end of 
hypoglycaemia compared with euglycaemia in diabetic subjects (3.30±0.32 
versus 3.70±0.43 mmol/L, p=0.02) but was similar between glycaemic arms 
in nondiabetic subjects. Peak adrenaline levels during hypoglycaemia were 
3.05±2.46 and 3.83 ±2.83 nmol/L in diabetic and nondiabetic groups, 
respectively (p= 0.48). 
Individuals with T2DM showed greater repolarisation abnormalities for a 
given hypoglycaemic stimulus despite comparable sympathoadrenal 
responses. This may reflect increased metabolic adrenergic sensitivity 
leading to lower potassium levels. This is a potential mechanism by which 
hypoglycaemia can predispose to cardiac arrhythmias during intensive 
glycaemic control. 
5.2 Introduction 
Abnormal cardiac repolarisation is strongly associated with an increase in 
cardiovascular mortality (Straus et al., 2006). Greater heterogeneity of 
repolarisation increases early afterdepolarisation and risk of ventricular 
arrhythmias (Nordin, 2010). In Chapter 3 we reported prolonged QT 
interval in acute spontaneous hypoglycaemia during the day. In selected 
individuals with a reduced repolarisation reserve, QT increased to over 500 
ms during hypoglycaemia with concurrent abnormalities in T wave 
morphology. Studies from our group and others have also demonstrated 
repolarisation abnormalities during hypoglycaemia in patients with T1DM 
and nondiabetic individuals (Gill et al., 2009; Marques et al., 1997; 
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Robinson et al., 2003). However, few studies have examined the effect of 
hypoglycaemia in T2DM on repolarisation (Landstedt-Hallin et al., 1999; 
Marques et al., 1997) and these have not involved a nondiabetic control 
group.  
It has been hypothesised that changes in QT during hypoglycaemia are 
secondary to increases in catecholamines. Robinson et al. (2003) 
demonstrated that the prolongation in QT during hypoglycaemia was 
abolished in the presence of beta-adrenoreceptor blockade, while 
maintenance of normokalaemia only partially attenuated QT prolongation. 
Thus it was concluded that changes in QT during hypoglycaemia are 
mediated by sympathoadrenal activation but not limited to adrenaline-
mediated hypokalaemia. Simultaneous measurements of catecholamines 
and electrolytes at the time of the hypoglycaemic event could not been 
recorded in ambulatory monitoring as described in Chapter 3. 
Furthermore, the depth, duration and environmental conditions 
surrounding a hypoglycaemic episode could not be controlled. Thus the 
aim of this study was to examine in detail the mechanisms underlying 
abnormal cardiac repolarisation during experimental hypoglycaemia in 
T2DM individuals and to compare their responses to those of nondiabetic 
subjects. Although QT remains the most widely accepted measure of 
repolarisation, QT measurement is influenced by heart rate. Therefore 
other electrophysiological measures of cardiac repolarisation were also 
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investigated to capture T wave morphology, including T amplitude and T 
symmetry that are rate independent. 
5.3 Research Design and Methods 
These are described in detail in Section 2.3 and are outlined in brief below. 
5.3.1 Participants 
Twelve individuals with T2DM and no known CVD were recruited from 
Sheffield Teaching Hospitals diabetes outpatient clinics. Patients were on 
one or more oral hypoglycaemic agents and/or GLP-1 analogues or insulin 
< 2 years. Eleven nondiabetic age and BMI matched controls were 
recruited from staff at the University of Sheffield and Sheffield Teaching 
Hospitals. Patients taking beta-blocking agents were excluded. Written 
informed consent was obtained from all participants and the study 
received local ethics approval. 
5.3.2 Baseline Assessment 
Cardiovascular autonomic reflex tests were performed as previously 
described (O'Brien et al., 1986) according to a recent consensus statement 
on the diagnosis of CAN (Tesfaye et al., 2010). All patients were 
euglycaemic at the time of autonomic function testing. Results were 
compared against age-adjusted normal reference ranges (O'Brien et al., 
1986) and those below the 95% CI were considered abnormal. Participants 
with established CAN, as defined by two or more abnormal cardiovagal 
tests, were excluded. All participants had a normal 12 lead ECG at baseline 
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and the nondiabetic group had normal fasting serum glucose (<7 mmol/L) 
and HbA1c <6.5% (< 48 mmol/mol) at baseline.  
5.3.3 Hyperinsulinaemic Clamp Protocol 
All subjects participated in paired hyperinsulinaemic euglycaemic and 
hypoglycaemic studies separated by at least four weeks. Details of the 
hyperinsulinaemic clamp protocol are described in Section 2.3.5. During 
the clamp study, a primed continuous intravenous insulin infusion was 
administered at 120 mU/m2/min, along with 20% dextrose at a variable 
rate and adjusted according to arterialised blood glucose concentrations, 
which were measured every five minutes. In the hypoglycaemic clamp, 
glucose was lowered from euglycaemia to 2.5 mmol/L over 60 minutes (T0 
to T60), and then maintained at 2.5 mmol/L for a further 60 minutes (T60-
T120). In the euglycaemic clamp, arterialised whole blood glucose was 
maintained at 6 mmol/L for the duration of the study (T120).  
5.3.4 High Resolution ECG Recording 
High resolution 12 lead ECGs were recorded for five minutes with the 
subject lying supine in a Mason-Likar configuration. To minimise mains 
electrical interference, all non-essential electrical equipment were 
switched off during the recording period. Signals were acquired at 1200 Hz 
and amplified using g®.USBamp (g.tec Medical Engineering, GmbH, Austria) 
and connected to a hp 6730 laptop computer with g.®Recorder software 
(g.tec Medical Engineering, GmbH, Austria) as previously described. All pre-
processing and data analysis was performed using g.®BSAnalyze software. 
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Recordings were made at baseline, T60, T120 minutes and during recovery 
(30 minutes after the end of the clamp). 
5.3.5 Repolarisation Analysis 
The ECG signal was pre-processed with bandpass filtering between 0.2 and 
40 Hz. R peaks were detected using automated software and manually 
verified. Signal averaging was then performed using correlation methods to 
improve the signal to noise ratio. Beat selection was performed by 
template matching (correlation coefficient > 0.95) and the mean beat was 
calculated using the selected beats. The repolarisation analysis was based 
on a composite wave, calculated from leads I, II and V5. The QT interval, 
from Q onset to T end, was based on the tangent method and Bazett 
correction of the QT interval was applied. As the Bazzett correction may 
overcorrect at higher heart rates, QT was also corrected according to the 
nomogram method (Karjalainen et al., 1994) which has been validated for 
heart rates between 40 to 120 beats per minute. T wave amplitude was 
defined from the isoelectric line to maximum T wave amplitude. This was 
expressed as the normalised T wave amplitude defined as the ratio of the T 
wave amplitude at the end of the clamp relative to the baseline. T wave 
symmetry was defined as the area under the T wave from T onset to T peak 
divided by the T wave area between T peak to T end (Merri et al., 1989) 
(Figure 5-1). 
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Figure 5-1: Description of T wave morphology measurements 
Tp-T peak, T end, Qo-Q onset, To-Tonset; QT was defined as Q onset (first negative 
deflection from the isoelectric line) to T end defined using the tangent method. A tangent 
is fitted to the point of maximum gradient on the downward slope of the T wave and 
where it crosses the isoelectric line is defined as T end. T amplitude was defined from the 
isoelectric line to the maximum T amplitude at T peak in microvolts. T wave symmetry was 
defined as the area under the T wave from T onset to T peak divided (Area A) by the T 
wave area between T peak to T end (area B). 
5.3.6 Biochemical Analysis 
Biochemical parameters were measured at baseline and T120 in the 
euglycaemic and hypoglycaemic arms in both groups. For catecholamines, 
6 mL whole blood was collected into chilled lithium heparin tubes 
containing 50 μL of EGTA/glutathione preservative and subjected to 
centrifugation at 4oC, 3000 rpm for 10 minutes. The resulting supernatant 
was stored at -80oC until assayed by HPLC. Plasma free insulin was analysed 
by an immunometric assay (Invitron Insulin ELISA, Invitron Ltd, Monmouth, 
UK) following precipitation with PEG. Serum potassium was analysed using 
an automated system (Cobas® system, Roche Diagnostics, West Sussex, 
UK). 
Tp Tend To 
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5.3.7 Statistical Analysis 
Data that followed an approximate normal distribution were summarised 
using mean±SD unless otherwise stated, whilst skewed data were 
summarised using the median (interquartile range). The effect of time and 
glycaemic arm on repolarisation measures were analysed using a two-way 
ANOVA with repeated measures within each subject group. Data were 
checked for sphericity using Mauchly’s test, and where sphericity was 
violated the Greenhouse-Geisser correction was applied. Catecholamines, 
glucose and potassium at T120 were compared under euglycaemic and 
hypoglycaemic conditions using a one way ANOVA with planned contrasts 
for the effect of the group (diabetes versus nondiabetic). A nonparametric 
Kruskal-Wallis test was used to compare free insulin levels at T120 under 
euglycaemia versus hypoglycaemia and between groups. Statistical analysis 
was performed using SPSS (version 20.0, IBM, Chicago, Illinois) and a p-
value ≤ 0.05 was deemed statistically significant.  
5.4 Results 
5.4.1 Baseline Characteristics 
Participant characteristics are as previously described in Table 4-1. T2DM 
patients (9 male, 3 female) had a median age of 54 (range 37-64) years, 
with an HbA1c of 7.8±1.3% (62±14) mmol/mol. Nondiabetic subjects (5 
male, 6 female) were similar in demographics with a  median age 52 (34-
63) years and BMI 31±8 kg/m2. Baseline repolarisation measures are shown 
in Table 5-1. Baseline heart rates were higher and T wave amplitude lower 
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in the diabetic group at baseline compared with nondiabetic subjects; 
however, other measures, including QTc and T wave symmetry, were 
similar. 
Table 5-1: Baseline repolarisation measures in diabetic and nondiabetic 
subjects 
QTcB – corrected QT by Bazzett’s formula; QTcN – corrected QT by nomogram method; 
Data are mean ± SD  
 Diabetes 
n=12 
Nondiabetic 
n=11 
Heart Rate (bpm) 78 ± 8 64 ±6 
QT (ms) 381±26 406±31 
QTcB (ms) 417±6 411±7 
QTcN (ms) 406±15 410±23 
T wave amplitude (µV) 399±121 466±278 
T wave symmetry 1.55±0.06 1.44±0.04 
5.4.2 Blood Glucose and Insulin 
Target blood glucoses were achieved (Figure 5-2). Blood glucose 
concentrations at 120 minutes were similar between the diabetic and 
control groups in both the euglycaemic arm (5.81± 0.29 mmol/L versus 
5.96± 0.18 mmol/L, p=0.15) and hypoglycaemic arms (2.56± 0.22 mmol/L 
versus 2.56± 0.09 mmol/L, p>0.99). 
Free insulin levels at 120 minutes were had a median value of 576 (IQR: 
468-627) pmol/L during euglycaemia and 689 (IQR: 477-1076) pmol/L 
during hypoglycaemia in the diabetic group. In the nondiabetic group, 
levels were 865 (IQR: 509-952) pmol/L in the euglycaemic arm and 665 
(IQR: 468-967) pmol/L in the hypoglycaemic arm. A comparison of the 
insulin levels between the groups under both euglycaemic and 
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hypoglycaemic conditions was found to not be statistically different (p = 
0.23). 
 
Figure 5-2: Arterialised blood glucose during hyperinsulinaemic euglycaemic 
and hypoglycaemic clamps 
Closed circle EU arm in diabetic group, Closed triangle HYPO in diabetic group, Open circle 
EU in control group, Open triangle HYPO in control group. Data are mean (SE)   
5.4.3 Heart Rate 
During euglycaemia there were no significant changes in heart rate within 
the diabetic group nor in the nondiabetic subjects (p=0.19 and p=0.11, 
respectively for time by one way ANOVA). In the diabetic group, there was 
an initial maximal increase in heart rate from 72±10 to 75±10 bpm at T60, 
however, this subsequently returned towards baseline 71±8 bpm (Δ-1±2 
bpm) after an 1 hour (T120). In the nondiabetic group, heart rate increased 
at T60 (from 62±9 to 66±13 bpm, Δ4±5 bpm) and remained higher than 
baseline after 1 hour (T120, 64±10 bpm).   
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5.4.4 QTc Interval 
QTcB using Bazett’s correction increased to a greater extent in the diabetic 
group during acute hypoglycaemia  (Δ76±70 ms) at T120 compared to 
during euglycaemia (Δ15±15 ms, p=0.04 for glycaemic arm, p =0.002 for 
interaction between time and glycaemic arm). QTc also increased 
significantly in the nondiabetic group (Δ54±16 ms) during acute 
hypoglycaemia at end of clamp, but there was no significant change in the 
euglycaemic arm (p =0.002 for interaction between glycaemic arm and 
time) (Figure 5-3). The change in QTc during hypoglycaemia did not differ 
significantly between diabetic and nondiabetic groups (p = 0.32 by two 
group t-test). 
 
Figure 5-3: Changes in corrected QT interval (QTc) during hypoglycaemic and 
euglyacemic clamps in diabetic and nondiabetic subjects 
Corrected QT using Bazzett’s correction. Data mean (SE)  
Changes in QTc using the nomogram method were also compared. QTcN 
did not change end of the euglycaemic clamp (Δ 9±10 ms) in T2DM subjects 
compared to an increase of Δ68±65 ms at the end of the hypoglycaemic 
clamp. In nondiabetic subjects, QTcN did not change during the 
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euglycaemic clamp but increased b7 Δ 56±18 ms at the end of 
hypoglycaemia. 
Among diabetic subjects, QTc increased to >600 ms at the end of the 
hypoglycaemic clamp in two individuals, and the ECG waveform of one of 
these subjects is shown in Figure 5-4. This showed progressive T wave 
flattening, a decrease in T wave amplitude, a prolonged QT, and an 
increase in T wave symmetry. QTc returned to near baseline levels at 
recovery but T amplitude remained lower than at baseline. 
 
Figure 5-4: Composite ECG waveform showing abnormal repolarisation 
morphology with QTc >600 ms in one diabetic participant during 
hypoglycaemia 
Black - baseline (QTc 397 ms), Blue (60 minutes) QTc 433 ms, Red (120 minutes) – QTc 605 
ms, Green (Recovery) – QTc 444 ms  
214 
5.4.5 T Amplitude 
The normalised T amplitude decreased during both hypoglycaemia and 
euglycaemic clamps from 60 minutes and persisted to recovery. In the 
diabetic group, the normalised T amplitude decreased to 46±18% of its 
baseline value during hypoglycaemia at T120. However, this was not 
significantly different compared to during euglycaemia, when it decreased 
to 60±12% of its baseline value (p= 0.11 for glycaemic group). In the 
nondiabetic group, the normalised T amplitude decreased to 66±50% of its 
baseline value at T120 during hypoglycaemia  versus a decrease to  61±18% 
during euglycaemia  (p=0.95 for glycaemic arm) (Figure 5-5). 
 
Figure 5-5: Normalised T amplitude during hypoglycaemia and euglycaemia in 
diabetic and nondiabetic subjects 
Normalised T amplitude expressed as a ratio to baseline (1.0). Data mean (SE) 
5.4.6 T Symmetry  
The T symmetry decreased (Δ= -0.56±0.43) at the end of hypoglycaemic 
clamp, returning to baseline at recovery. This contrasts with no overall 
change during the euglycaemic clamp and a significant interaction between 
glycaemic arm and time (p=0.02) (Figure 5-6). In the nondiabetic group, T 
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symmetry decreased to a similar extent in both glycaemic arms from T60 
and persisting to the recovery period (p =0.98 for glycaemic arm).  
 
Figure 5-6: T wave symmetry during hypoglycaemia versus euglycaemia in 
diabetic and nondiabetic subjects 
TSI-T wave symmetry; EU-euglycaemia; HYPO-hypoglycaemia; Data mean (SE) 
5.4.7 Biochemical Measurements 
No significant changes in adrenaline and noradrenaline occurred during 
euglycaemia in both groups. In the diabetic group, plasma adrenaline 
increased significantly from baseline, from 0.12±0.09 to 3.05±2.46 nmol/L 
at the end of the hypoglycaemic clamp (p=0.002), while in the nondiabetic 
group, plasma adrenaline increased from 0.15±0.07 nmol/L to 3.83±2.83 
nmol/L at the end of hypoglycaemia (p=0.001 versus baseline). However, 
peak adrenaline levels were not significantly different between the groups 
during hypoglycaemia. 
During hypoglycaemia, plasma noradrenaline increased from 1.25±0.53 to 
2.37±0.82 nmol/L in the diabetic group and 1.46±0.5 to 2.69±1.45 nmol/L 
in the nondiabetic group (both p<0.01 compared with baseline). These as 
no significant difference between the groups (p=0.52). 
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Serum potassium decreased during both euglycaemia and hypoglycaemia 
as expected due to the effects of insulin. In the diabetic group, potassium 
was significantly lower at the end of the hypoglycaemic clamp compared 
with euglycaemia (3.30±0.32 mmol/L versus 3.70±0.43 mmol/L, p=0.02). In 
contrast, in the nondiabetic group the concentrations were not statistically 
different (3.48±0.39 mmol/L versus 3.65±0.45 mmmol/L) during 
hypoglycaemia and euglycaemia (p = 0.36 ). Serum potassium decreased to 
a greater extent in diabetic (Δ – 1.03±0.28 mmol/L) compared with 
nondiabetic subjects (Δ- 0.85±0.41 mmol/L) during hypoglycaemia, though 
this difference did not reach statistical significance. 
There was a significant correlation between the change in serum potassium 
and the change in T symmetry during hypoglycaemia (r = -0.46, p =0.03) in 
diabetic and nondiabetic subjects (Table 5-2). However, there were no 
significant correlations between adrenaline and QTc, T amplitude and T 
symmetry.  
 
Table 5-2: Correlation between change in biochemical parameters and 
repolarisation parameters 
Pearson correlation coefficients r between change in adrenaline and potassium (K
+
) versus 
change in corrected QT interval (QTc), normalised T amplitude (Tamp) and T symmetry 
(TS). Significant correlations are shown in italics. 
 ΔQTc ΔTamp ΔTS 
Δ  Adrenaline r = -0.10 r = 0.33 r =0.26 
 p= 0.66 p = 0.13 p = 0.24 
ΔK
+
 r =0.27 r = -0.25 r =  -0.46 
 P = 0.66 p = 0.13 p = 0.03 
217 
 
5.5 Discussion 
The main findings of this study are as follows. 1) QTc was prolonged to a 
greater extent during hypoglycaemia compared to euglycaemia in both 
groups but there were larger changes in QTc in subjects with T2DM.  2) T 
amplitude and symmetry decreased during hypoglycaemia compared with 
euglycaemia in diabetic subjects, but there were no differences between 
the glycaemic arms in nondiabetic subjects. Peak catecholamine levels 
were similar in both groups during hypoglycaemia, but potassium 
decreased to a greater extent during hypoglycaemia in diabetic compared 
with nondiabetic subjects. 
These findings are similar those reported in previous studies of 
hyperinsulinaemic hypoglycaemia in subjects with T2DM. Landstedt-Hallin 
et al. (1999) performed hypoglycaemic clamps in T2DM subjects with blood 
glucose maintained at 2.5-3.0 mmol/L for 60 minutes and reported 
comparable increases in QTc of 61 ms. In a study by Marques et al. (1997), 
QTc increased by a median value of 128 (range: 16-166) ms. However these 
subjects were male, younger, and had a shorter disease duration compared 
with T2DM subjects in this study. Thus they may be expected to show 
stronger sympathoadrenal responses during hypoglycaemia and hence 
greater QTc changes. The change in QTc during spontaneous 
hypoglycaemia in the ambulatory study described in Chapter 3, were 
smaller (Δ18ms) compared to those observed in this clamp study. This is to 
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be expected, as experimental hypoglycaemia is associated with greater 
counterregulatory responses in addition to hypokalaemic effects of 
supraphysiological doses of insulin. Furthermore, subjects in the 
ambulatory study tended to be older and had a longer duration of diabetes 
compared with clamp participants, thus sympathoadrenal responses may 
be diminished. 
Previous studies have shown that QTc changes were smaller during 
hypoglycaemia in T1DM compared with nondiabetic individuals, which was 
attributed to diminished sympathoadrenal responses (Koivikko et al., 
2008). However, this study has shown larger increases in QTc in T2DM 
subjecst compared with nondiabetic individuals (Δ76 ms versus Δ54 ms). A 
stronger sympathoadrenal response is unlikely to be the primary 
explanation as the peak adrenaline levels were similar and if anything 
slightly lower in the diabetic group. Furthermore, there were no significant 
correlations between changes in catecholamines and changes in QTc. 
Prolonged QTc is unlikely to be explained by factors related to a correction 
in heart rate, and heart rates at the end of clamp were similar to baseline. 
QT correction has been explored via several methods and did not appear to 
make any major differences to the pattern of findings.  
Our group has previously suggested that QT changes during hypoglycaemia 
are mediated by catecholamines that are independent of its potassium 
lowering effects in nondiabetic subjects (Robinson et al., 2003). No 
significant relationships could be identified between adrenaline and 
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changes in QT or T wave parameters observed in both groups when 
combined. However, as the numbers were small these observations should 
be interpreted with caution. In the present study, only T symmetry was 
found to be significantly correlated with changes in serum potassium. 
Potassium decreased to a greater extent during hypoglycaemia in diabetic 
compared to nondiabetic subjects. However, adrenaline levels tended to 
be similar between groups during hypoglycaemia. This may be explained by 
a metabolic adrenergic hypersensitivity leading to a greater beta-
adrenoreceptor mediated fall in potassium, analogous to that observed in 
other processes, such blood glucose and FFA production (Hilsted et al., 
1987). However, this relationship does not imply causation and 
mechanisms need to be confirmed in experimental studies involving 
potassium clamping or adrenergic blockade. 
Spatial heterogeneity of repolarisation is an important determinant of risk 
of EAD and the risk of arrhythmogenesis (Antzelevitch, 2007). Earlier 
studies have shown that there is an increase in QTd during hypoglycaemia 
in T2DM subjects (Landstedt-Hallin et al., 1999).  However, QTd is no 
longer widely used due to inaccuracies in determining the T end across 
multiple leads and poor correlation against experimental models in canine 
hearts (Laguna et al., 2009). Additional information can be obtained by 
examining the morphology of the T wave, which also describes the 
dispersion of repolarisation but is free of the rate induced methodological 
limitations of QT measurements.  T wave symmetry, flatness and amplitude 
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have been shown to reliably discriminate between patients with LQTS and 
normal subjects (Struijk et al., 2006).  Increased dispersion of repolarisation 
has been shown to correlate with increased symmetry of T waves in cell to 
ECG simulation models (Xue et al., 2009).  
In the present study, T amplitude decreased to a similar extent during 
hypoglycaemia and euglycaemia in both T2DM and nondiabetic groups, 
which suggests that the effect is primarily due to insulin.  Koivikko et al. 
(2008) also showed that T amplitude decreased by 50% during 
hyperinsulinaemic hypoglycaemia similarly in T1DM and nondiabetic 
subjects, which was correlated with potassium levels. Similarly, other 
authors have shown decreases in T amplitude during hyperinsulinaemic 
hypoglycaemia in healthy subjects (Laitinen et al., 2008). Fewer studies 
have examined the effect of hypoglycaemia on T symmetry. In this current 
study, T wave symmetry decreased to 1.00 in the diabetic group indicating 
a near symmetrical T wave at the end of hypoglycaemia, but there was no 
change during euglycaemia. This suggests that the dispersion of 
repolarisation is greatly enhanced during hypoglycaemia in T2DM subjects 
which may be proarrhythmic. 
Ventricular bigeminy occurred during hypoglycaemia in one female subject 
that was likely to have a ectopic focus originating from the right ventricular 
outflow tract. This subject had no known CVD or risk factors and no history 
of palpitations. The subject subsequently underwent further evaluation, 
including a twenty four hour tape which showed rare ectopic activity, and 
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also exercise tolerance testing which did not provoke any arrhythmias. 
Benign VT originating from the right ventricular outflow tract is commonly 
associated with increases in sympathetic cardiac activity, such as exercise 
(Yoshida et al., 1998). These events suggest that hypoglycaemia may act as 
a transient stimulus to unmask occult arrhythmias. It is noteworthy that an 
arrhythmic event was observed in a nondiabetic rather than a diabetic 
subject, suggesting that this is mediated via the sympathoadrenal drive, 
although diabetic subjects on average, exhibited greater repolarisation 
abnormalities during hypoglycaemia.  
This appears to be the first study comparing the effects of hypoglycaemia 
on cardiac repolarisation in T2DM patients against nondiabetic individuals. 
Euglycaemic and hypoglycaemic clamp studies were performed on 
separate occasions rather than serial euglycaemic-hypoglycaemic clamps. 
Insulin infusion rates were identical and thus potassium lowering effects 
were secondary to changes associated with hypoglycaemia rather than 
hyperinsulinaemia alone. One of the strengths of this study is that 12 lead 
ECG high resolution ECG (1200 Hz) were employed in contrast with 
previous studies that used a lower resolution (Koivikko et al., 2008). The 
higher signal to noise ratio allowed for a more robust determination of 
fudicial points and QT measurements. The semi-automatic method meant 
that all fudicial points were manually verified, which is particularly 
important in the presence of abnormal T wave morphology. 
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However, this study also had a number of limitations. The sample size was 
small and thus it may not have been relatively under-powered to 
demonstrate significant differences between diabetic and nondiabetic 
groups. Previous studies have shown that the spatial QRS-tangle and T 
wave loop measures were abnormal during hypoglycaemia in T1DM 
patients (Koivikko et al., 2008). Principle component based QT 
measurements and T wave morphologies may be superior as it improves 
the signal-to-noise ratio, although these are computationally more 
demanding (Lipponen et al., 2010) but may be worthy of exploration in 
future studies.  
Two diabetic individuals in this study experienced QTc prolongation in 
excess of 600 ms during hypoglycaemia. The baseline QTcB was 433 and 
415 ms, respectively, which was in the normal range, and catecholamine 
levels were not particularly high at the end of hypoglycaemia (2.97 and 
1.45 nmol/L, respectively). However, they did have the lowest potassium 
(2.9 mmol/L) concentrations in the group. This level of QTc prolongation is 
strongly associated with an excess of ventricular arrhythmias. It is 
conceivable that a similar magnitude of QT change may be observed during 
severe hypoglycaemia in T2DM subjects. Tsujimoto et al. (2014) studied a 
retrospective cohort of 414 cases of T1DM and T2DM patients presenting 
to the emergency room with severe hypoglycaemia. In their study, 50% of 
T1DM patients and 60% of T2DM patients had a QTcB in excess of 440 ms 
at presentation, with 14% of T2DM patients presenting with a QTc >500 
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ms. The authors also found that T2DM patients with QTc >500 ms were 
significantly more likely to develop new onset atrial fibrillation.  
Interestingly, in this study, 42% of T1DM and 36% of T2DM patients also 
had hypokalaemia (<3.5 mmol/L) at presentation.   This confirms the 
clinical relevance of our observations made using an experimental model.  
In conclusion, patients with T2DM showed prolonged QTc and abnormal 
cardiac repolarisation in response to acute hypoglycaemia, which was 
more marked than in nondiabetic subjects. T2DM patients experienced 
greater decreases in potassium during hyperinsulinaemic hypoglycaemia. 
Thus, abnormal repolarisation in combination with autonomic changes 
during acute hypoglycaemia may be sufficient to precipitate arrhythmic 
events via mechanisms which include abnormal automaticity and triggered 
activity (Nordin, 2010). These observations add to the evidence linking 
increased cardiovascular mortality during intensive glycaemic control in 
T2DM patients with high cardiovascular risk. 
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Chapter 6 - Effect of Antecedent Hypoglycaemia on 
Cardiac Autonomic Function in Type 2 Diabetes 
6.1 Summary 
Intensive glycaemic therapy is associated with excess cardiovascular death 
in T2DM patients at high cardiovascular risk and severe hypoglycaemia 
predicts increased cardiovascular mortality in the weeks following an 
event. Decreased cardiac vagal function predisposes to arrhythmias and 
SCD.The aim was to investigate the effect of hypoglycaemia on cardiac 
autonomic function for up to 7 days following an experimental 
hypoglycaemic episode. 
Twelve adults with T2DM and 11 age and BMI matched nondiabetic 
subjects underwent paired hyperinsulinaemic clamps at least one month 
apart. Glucose was maintained at euglycaemia (6 mmol/L) and 
hypoglycaemia (2.5 mmol/L) for two 60 minute periods in each arm. HRV, 
spontaneous BRS and cardiac autonomic reflex tests were measured at 
baseline, one and seven days after clamps in both glycaemic arms. 
In the hypoglycaemic arm the heart rate increased Δ6±3 bpm at day 1 and 
remained increased at day 7  Δ5±2 bpm ( p=0.03 for time) in diabetic 
subjects. RMSSD, a measure of vagal activity, decreased following 
hypoglycaemia at day 7 compared with no change following euglycaemia 
(p=0.04 for glycaemic arm). In nondiabetic subjects, log HF, an indicator of 
vagal activity, was decreased at day 1 following both euglycaemia (ΔlogHF -
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0.21±0.12) and hypoglycaemia (Δ-0.18±0.09). However, this returned to 
baseline at day 7 in the euglycaemic arm but remained decreased following 
the hypoglycaemic clamp. There were no significant changes in normalised 
LF power, an indicator of relative sympathetic contribution, or BRS 
following either glycaemic condition in both groups.  
Hypoglycaemia influenced cardiac vagal function, an effect that persisted 
beyond the episode for at least one week.  This suggests a potential 
mechanism which could contribute to increased cardiovascular mortality 
following hypoglycaemia.  
6.2 Introduction 
Severe hypoglycaemia has been strongly associated with CV mortality with 
an elevated risk persisting at 90 days (Duckworth et al., 2009; Zoungas et 
al., 2010). Antecedent hypoglycaemia may impair cardiac autonomic 
function for at least 24 hours in nondiabetic individuals, whilst in healthy 
subjects HRV, BRS and sympathetic response to hypotensive stress were 
found to be attenuated one day after experimentally induced 
hypoglycaemia (Adler et al., 2009). In rats, antecedent hypoglycaemia 
similarly  impaired sympathetic responses to hypotensive stress after 
experimentally induced hypoglycaemia (Herlein et al., 2006). Impaired HRV 
and BRS are predictors of increased cardiovascular mortality following 
myocardial infarction (Kleiger et al., 1987; La Rovere et al., 1998), and are 
linked to an increased risk of arrhythmias (La Rovere et al., 2001). No study 
to date has examined the effect of antecedent hypoglycaemia in humans 
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with T2DM, and these individuals may have cardiac autonomic dysfunction 
which might compound impaired autonomic responses. 
The aim of this study was to examine the effect of antecedent 
hypoglycaemia on cardiac autonomic function in patients with T2DM 
versus nondiabetic controls. Given that an increased risk of cardiovascular 
mortality persists over the weeks and months following a severe 
hypoglycaemic episode, downstream changes in autonomic function at day 
1 and 7 following experimental hypoglycaemia were investigated and 
compared to following hyperinsulinaemic euglycaemia. 
6.3 Research Design and Methods 
6.3.1 Participants 
Twelve patients with T2DM aged between 18-65 and no history or signs or 
symptoms of CVD were recruited from Sheffield Teaching Hospitals 
outpatient clinics. All patients were on oral hypoglycaemic agents and/or 
GLP-1 analogues and/or insulin for ≤ 2 years. These patients were included 
as they were at low baseline risk of clinical hypoglycaemia. Eleven age and 
BMI matched nondiabetic individuals were recruited as a control group. 
Patients on beta blockers or QT prolonging drugs were excluded from the 
study. All participants gave their written informed consent and the study 
was approved by the local research ethics committee. 
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6.3.2 Baseline Assessment 
All subjects had a normal full blood count, renal function and ECG at 
baseline. Subjects underwent cardiovascular autonomic reflex testing, 
including three tests of cardiovagal function (heart rate to deep breathing, 
the Valsava manoeuvre, heart rate response to standing) and blood 
pressure response to standing as previously described (see Section 2.2.5) 
(O'Brien et al., 1986) .  Results were compared against age-adjusted normal 
ranges and values below 95% CI were regarded as abnormal (O'Brien et al., 
1986). The presence of two or more abnormal cardiovagal tests were 
defined as definite CAN and these subjects were excluded (Tesfaye et al., 
2010). 
6.3.3 Hyperinsulinaemic Clamp Protocol 
All diabetic and nondiabetic subjects participated in paired 
hyperinsulinaemic euglycaemic and hypoglycaemic studies separated by at 
least four weeks but no more than eight weeks. In the hypoglycaemic arm, 
glucose was maintained at 2.5 mmol/L for 60 minutes in the morning and 
60 minutes in the afternoon. In the euglycaemic arm, arterialised blood 
glucose was maintained at the target level of 6 mmol/L for 60 minutes in 
the morning and 60 minutes in the afternoon. The hyperinsulinaemic 
clamp study protocol is as described in detail in Section 2.3.5. 
Diabetic participants continued on their usual diabetic medications at 
stable doses following the clamp studies and were asked to report any 
spontaneous hypoglycaemia throughout the study period. 
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6.3.4 Cardiac Autonomic Testing 
Autonomic measurements were conducted in the morning to control for 
diurnal variation. Blood glucose was concurrently measured to ensure that 
participants were euglycaemic during these tests. All participants were 
asked to avoid caffeine or smoking on the day of the tests and vigorous 
exertion for 24 hours prior. HRV, spontaneous BRS, and cardiac autonomic 
reflex tests were conducted with the subject supine following at least five 
minutes of rest in a quiet room. Blood pressure was measured using an 
automatic oscillometric sphygmomanometer (DINAMAP ®GE Medical 
Systems Information technologies, Inc.) after five minutes lying supine. 
Cardiac autonomic function was assessed at baseline (in the morning prior 
to euglycaemic and hypoglycaemic clamps), and then at days 1 and 7 in 
both arms. 
6.3.5 Heart Rate Variability 
HRV was determined from five minute resting recordings with the 
participant supine. Recordings were performed with subjects free 
breathing and also with paced breathing, where subjects followed a timed 
visual display breathing at 12 breaths/minute. QRS complexes were 
detected using an automatic algorithm. Manual editing of R-R intervals was 
performed together with a visual inspection of QRS complexes to exclude 
any ectopic beats and artefacts. Normal R-R intervals (NN) were extracted 
for HRV analysis performed in accordance with the recommendations of 
the 1996). The time domain measures SDNN and RMSSD of NN were 
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analysed and fast Fourier transformation was applied to R-R intervals for 
spectral analysis. The LF band was defined as 0.04-0.15 Hz and the HF band 
as 0.15-0.4 Hz. The ratio between the LF power and total power was also 
calculated (LFnorm).  
6.3.6 Spontaneous Baroreceptor Sensitivity  
Spontaneous cardiovagal BRS was measured using Poratpres (TNO 
Biomedical Instrumentation, Amsterdam, Netherlands) as described in 
section 2.3.7. BRS analysis was performed using dedicated software using 
the sequence method (Nevrokard V 5.1.3, Intellectual Services, Slovenia) 
(Parati et al., 1988). An ‘UP’ sequence was generated when there was an 
increase in SBP of at least 1 mmHg associated with an increase in R-R 
interval of at least 5 ms for three or more consecutive beats, while a 
‘DOWN’ sequence was generated when there was a reduction in SBP of at 
least 1 mmHg with an accompanying reduction in R-R interval of at least 5 
ms for three or more consecutive beats. Total BRS, measured in ms/mmHg 
was calculated by averaging the regression coefficients of RR/BP relations 
of the UP and DOWN sequences with correlation coefficients greater than 
0.85.     
6.3.7 Biochemical Measures 
Catecholamines were assayed by HPLC. Whole blood (6 mL) was collected 
in chilled lithium heparin tubes containing 50 µL EGTA/glutathione 
preservative, subjected to centrifugation at 1000 ×g for 10 minutes, and 
the resultant plasma samples stored at -80oC prior to assaying. Free insulin 
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was analysed by an immunometric assay (Invitron Insulin ELISA, Invitron 
Ltd, Monmouth, UK). Whole blood (3 mL) was collected in a 6 mL lithium 
heparin tube and subjected to centrifugation immediately at 4°C, 2400 rpm 
for 2 minutes. A 0.5 mL aliquot of the resulting plasma was added to a 
chilled plastic tube containing 0.5 mL PEG for the precipitation of immune 
complexes and mixed. The centrifuged step was then repeated for 30 
minutes and the product at -80°C until analysed by the immunometric 
assay. Biochemical parameters were measured at baseline and at the end 
of the euglycaemic and hypoglycaemic arms in both groups, and then at 
days 1 and 7. 
6.3.8 Statistical Analysis 
Baseline demographic data is summarised as mean (SE) for parametric data 
unless otherwise stated, or median (interquartile range) for nonparametric 
data. Comparisons of baseline data between diabetic and control groups 
were made using an independent t-test for parametric data and Mann 
Whitney U test for nonparametric data.  Blood glucose and hormone 
concentrations were compared between equivalent euglycaemic and 
hypoglycaemic time points using a paired t-test or Wilcoxson signed-rank 
test.   
Autonomic function parameters were analysed using a linear mixed model 
with repeated measures. The mixed model allows for internally correlated 
measures from repeated measures (with respect to both the glycaemic arm 
and time) within an individual and also allows for missing values (Galbraith 
231 
et al., 2010). To investigate whether there was a significant change in 
autonomic parameters within  euglycaemic or hypoglycaemic arms, time 
point was specified as a fixed effect in the linear mixed model. Changes in 
autonomic function between glycaemic arms were also compared using a 
linear mixed model, where glycaemic arm, time and interaction between 
the glycaemic arm and time were specified as fixed effects.  In both 
analyses the glycaemic arm and time point were specified as repeated 
measures and fitted with an unstructured, compound symmetry or 
autoregressive 1 covariance structure. The model with the best fit (lowest 
Akaike’s information criterion) was selected. p values were obtained by 
restricted maximum likelihood estimation. A p value of <0.05 was 
considered significant. Results were analysed using SPSS Statistics (v 20.0, 
IBM, Chicago, Ilinois). 
6.4 Results 
6.4.1 Participant Characteristics 
Twelve patients with T2DM (9 male, 3 female) and 11 nondiabetic controls 
(5 male, 6 female) participated in the study. Participants with diabetes 
were similar in age 54 (50-58) years compared to the nondiabetic group, 52 
(47-59) years. The mean BMI was also comparable, 34±5 kg/m2 in the 
diabetic group versus 31±8 kg/m2 in the nondiabetic group.  Two diabetic 
patients were taking ACE inhibitors. Individuals with diabetes had higher 
baseline heart rates, blood pressure and lower HRV and BRS at baseline 
(Table 6-1).  
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Table 6-1: Baseline cardiac autonomic function in individuals with T2DM and 
nondiabetic subjects 
Data mean±SD. An independent t-test of baseline variables was used to compare T2DM 
and nondiabetic groups. RV-heart rate variability, HF-high frequency, BRS- baroreceptor 
sensitivity, E:I- expiration:inspiration  
 T2DM 
n=12 
Nondiabetic 
n=11 
p-value 
Cardiovascular autonomic reflex tests    
E:I ratio 1.24±0.20 1.27±0.23 0.74 
Valsava ratio 1.51±0.29 1.81±0.41 0.05 
Standing ratio 1.28±0.17 1.58±0.28 0.005 
Heart rate variability    
SDNN 27.4±11.8 48.2±14.6 0.001 
RMSSD 15.5±7.94 32.9±15.3 0.002 
Log Total power  2.34 ± 0.36  2.90±0.36  0.001 
Log HF 1.85± 0.37 2.32±0.48 0.02 
LFnorm 0.65±0.14 0.70±0.14 0.40 
BRS  8.59±4.08 11.51±7.65 0.26 
 
6.4.2 Heart Rate  
In T2DM patients the heart rate was higher at recovery then returned to 
baseline at day 7 in the euglycaemic arm. In the hypoglycaemic arm, the 
heart rate increased from baseline by Δ6±3 bpm at day 1 and remained 
increased at day 7  Δ5±2 bpm ( p=0.04 for time by linear mixed model) 
(Figure 6-1). There was a trend towards an interaction between the 
glycaemic arm and time (p =0.07). 
In the nondiabetic group, heart rate increased significantly at day 1 
following euglycaemia (Δ9±3 bpm) but then returned to baseline levels at 
day 7 (p =0.01 for time by linear mixed model). Conversely, there were no 
significant rises in heart rate following hypoglycaemia (p = 0.25 for time). 
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The differences between glycaemic arms did not reach statistical 
significance (p=0.18). 
  
 
6.4.3 Heart Rate Variability 
6.4.3.1 Frequency domain measures 
HF power, an indicator of vagal activity, did not change significantly 
following euglycaemia in diabetic subjects. However, Log HF was slightly 
higher at recovery then progressively decreased up to day 7 following 
hypoglycaemia from a baseline of 1.85±0.16 to 1.75±0.16 ms2 (p <0.001 for 
time) (Figure 6-1). Log HF was lower at day 7 following hypoglycaemia 
compared to euglycaemia; however, the difference in glycaemic arms did 
not reach statistical significance (p=0.17).  
 
234 
 
Figure 6-1: Change in heart rate and heart rate variability following 
hypoglycaemia versus euglycaemia in diabetic and nondiabetic subjects 
Top panel - change in heart rate (beats per minute); middle panel – change in log high 
frequency (log HF) heart rate variability; bottom panel – change in normalised high 
frequency (LFnorm) heart rate variability. Data Mean (SE). Diabetic group – hypoglycaemia 
(closed square); euglycaemia (open square); nondiabetic group – hypoglycaemia (closed 
circle); euglycaemia (open circle) 
In nondiabetic subjects, log HF was decreased at day 1 following both 
euglycaemia (ΔlogHF -0.21±0.12) and hypoglycaemia (Δ-0.18±0.09, both 
p<0.001 for time) (Figure 6-1). However, this returned to baseline at day 7 
Diabetes Nondiabetic 
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in the euglycaemic arm but remained decreased following the 
hypoglycaemic clamp, although this did not reach statistical significance 
between arms. 
There were no significant changes in normalised LF power, an indicator of 
relative sympathetic contribution, following euglycaemia or hypoglycaemia 
in diabetic or nondiabetic subjects (Figure 6-1). 
6.4.3.2 Time Domain Measures 
Time domain HRV measures are presented in Figure 6-2. SDNN did not 
change significantly in the diabetic group in either glycaemic arm. 
However, in nondiabetic subjects, SDNN significantly decreased at day 1 
following both euglycaemia and hypoglycaemia (both p<0.05).  RMSSD 
exhibited a similar trend to log HF, a measure of vagal activity.  In diabetic 
subjects, RMSSD was lower at day 7 following hypoglycaemia compared 
with euglycaemia and there was a significant interaction between time and 
glucose (p=0.04). In nondiabetic subjects, RMSSD decreased at day 1 
following both glycaemic conditions but returned to baseline following 
euglycaemia while remaining lower following hypoglycaemia at day 7 
(Figure 6-2). 
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Figure 6-2: Changes in time domain measures of heart rate variability following 
hypoglycaemia versus euglyacemia in diabetic and nondiabetic subjects 
Top: SDNN –standard deviation of NN intervals; Bottom: RMSSD root mean squared of 
standard deviation of NN intervals. HYPO-hypoglycaemia, EU-euglycaemia. Data Mean(SE) 
6.4.3.3 Effect of Respiration 
The heart rate and HRV results presented above are based on resting 
recordings with spontaneous breathing, and the mean respiratory 
frequencies during resting recordings are shown in Table 6-2. There was 
little difference between the glycaemic conditions on different days and no 
differences between the groups. HRV was also analysed with paced 
breathing (12/ breaths minute) and this showed similar trends to 
spontaneous breathing (data not shown).  
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Table 6-2: Respiratory frequencies during heart rate variability recordings at 
rest 
Mean±SD; EU- euglycaemia; HYPO- hypoglycaemia 
 Baseline Recovery Day  1 Day 7 Mean 
Diabetes 
EU 0.25±0.05 0.29±0.06 0.24±0.05 0.24±0.05 0.24±0.05 
HYPO 0.25±0.06 0.29±0.05 0.26±0.05 0.25±0.05 0.25±0.05 
Nondiabetic 
EU 0.24±0.03 0.26±0.06 0.21±0.05 0.24±0.04 0.24±0.04 
HYPO 0.24±0.04 0.26±0.06 0.26±0.06 0.24±0.04 0.25±0.05 
6.4.4 Blood Pressure 
In diabetic subjects, SBP tended to fall following both glycaemic conditions 
maximally at day 7 and there was no difference between the glycaemic 
arms (p=0.69) (Figure 6-3). Similarly DBP tended to decrease following both 
glycaemic conditions up to day 7. Both SBP and DBP did not change in the 
nondiabetic group following hypoglycaemia or euglycaemia (Figure 6-3). 
6.4.5 Baroreceptor Sensitivity 
There were no significant changes in BRS following hypoglycaemia or 
euglycaemia in either group (Figure 6-4). 
6.4.6 Cardiovascular Autonomic Reflex Tests 
The E:I ratio during deep breathing and 30:15 ratio following standing were 
similar between glycaemic arms in diabetic and nondiabetic subjects (Table 
6-3). The Valsava ratio tended to be lower at day 1 in the hypoglycaemic 
arm compared to 
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Figure 6-3: Blood pressure following euglycaemia or hypoglycaemia in diabetic 
and nondiabetic subjects 
SBP-systolic blood pressure, DBP-diastolic blood pressure. Data mean (SE) 
 
Figure 6-4: Spontaneous baroreceptor sensitivity following euglycaemia and 
hypoglycaemia in diabetic and nondiabetic participants 
Baroreceptor sensitivity (BRS) in mmHg/ms.  Data mean (SE) 
 
239 
euglycaemia in subjects with diabetes but did not reach statistical 
significance. In nondiabetic subjects, the Valsava ratio tended to be lower 
at day 1 and day 7 following hypoglycaemia compared to euglycaemia, but 
did not reach statistical significance.  
Table 6-3: Cardiovascular autonomic reflex tests following euglycaemic or 
hypoglycaemic clamps in diabetic and nondiabetic individuals 
E:I ratio expiration: inspiration ratio; 30:15 ratio to standing; Data mean(SE) 
 Euglycaemia Hypoglycaemia 
E:I ratio 
Diabetes 
       Day1 1.28±0.07 1.34±0.11 
       Day 7 1.28±0.08 1.27±0.08 
Nondiabetic 
        Day 1 1.18±0.04 1.22±0.04 
        Day 7 1.24±0.07 1.18±0.02 
Valsava ratio 
Diabetes 
        Day 1 1.61±0.13 1.51±0.08 
        Day 7 1.49+0.09 1.54±0.12 
Nondiabetic 
          Day 1 1.87±0.13 1.66±0.17 
         Day 7 1.79±0.16 1.56±0.11 
30:15 ratio 
Diabetic 
        Day 1 1.23±0.08 1.27±0.07 
        Day 7 1.23±0.05 1.27±0.08 
Nondiabetic 
        Day 1 1.42±0.05 1.55±0.04 
        Day 7 1.46±0.07 1.47±0.05 
6.4.7 Blood Glucose and Insulin 
Blood glucose concentrations at the end of the morning clamp were similar 
between diabetic and nondiabetic groups in the euglycaemic arm (5.81± 
0.29 mmol/L versus 5.96± 0.18 mmol/L, p=0.15) and hypoglycaemic arm 
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(2.56± 0.22 mmol/L versus 2.56± 0.09 mmol/L, p>0.99). Target arterialised 
blood glucose levels were similarly achieved in the afternoon (Table 6-4). 
Blood glucose was not significantly different between glycaemic arms 
except at day 1, where it was higher following hypoglycaemia in the 
diabetic group. 
Free insulin levels at the end of the clamp was median 576 (IQR: 468-627) 
pmol/L during euglycaemia and 689 (477-1076) pmol/L during 
hypoglycaemia in the diabetic group. In the nondiabetic group the median 
was 865 (509-952) pmol/L in the euglycaemic arm and 665(468-967) 
pmol/L in the hypoglycaemic arm. 
6.4.8 Plasma Catecholamines 
There were no significant changes in adrenaline following the euglycaemic 
clamp; however, adrenaline increased during hypoglycaemia clamp and 
then returned to baseline levels at day 1 and day 7 in both groups (Table 
6-4). 
In nondiabetic subjects noradrenaline increased following euglycaemia at 
day 1  then falling at day 7. Following hypoglycaemia at day 1, 
noradrenaline was similarly increased (Table 6-4). Noradrenaline levels at 
day 1 following the euglycaemic clamp were significantly higher in the 
nondiabetic group compared to T2DM individuals (3.08±1.48 versus 
1.97±0.52 nmol/L, p <0.05).  
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Table 6-4: Blood glucose during the hyperinsulinaemic clamp and plasma 
catecholamines following euglycaemia versus hypoglycaemia 
Data mean±SD *p<0.05, **p<0.01  Euglycaemia versus hypoglycaemia within each group 
at the equivalent time point †† p<0.01 denotes a significant difference between diabetic 
and control groups at equivalent euglycaemic or hypoglycaemic time points as determined 
by an independent t-test. 
 Diabetic Nondiabetic 
 EU HYPO EU HYPO 
Blood glucose (mmol/L)  
Baseline AM 6.24±1.15 6.44±1.27 5.10±0.49† 4.87±0.31† 
End of clamp AM 5.81±0.30 2.55±0.22** 5.96±0.18 2.56±0.10** 
Baseline PM 6.44±1.51 6.69±1.56 5.14±0.62 5.53±1.04 
End of clamp PM 6.01±0.30 2.70±0.17 6.03±0.27 2.61±0.12 
Recovery 6.98±1.14 6.63±1.90 6.37±0.63 8.40±1.96** 
Day 1 7.88±2.52 11.4±3.76* 5.08±0.94† 5.00±0.90† 
Day 7 9.30±2.70 10.3±0.94 5.09±0.37† 4.96±0.62† 
Adrenaline (nmol/L)  
Baseline 0.15±0.14 0.12±0.09 0.17±0.12 0.15±0.07 
End of clamp 0.16±0.16 3.05±2.46** 0.14±0.08 3.83±2.83** 
Day 1 0.23±0.43 0.17±0.21 0.17±0.11 0.20±0.25 
Day 7 0.10±0.08 0.16±0.27 0.22±0.20 0.11±0.07 
Noradrenaline (nmol/L)  
Baseline 1.23±0.47 1.25±0.53 1.56±0.51 1.46±0.52 
End of clamp 1.27±0.31 2.37±0.82** 1.56±0.40 2.69±1.45** 
Day 1 1.97±0.52 1.93±0.35 3.08±1.48† 2.32±0.72 
Day 7 2.07±0.58 2.52±1.20 2.56±0.78 2.78±1.18 
 
6.5 Discussion 
The main findings of this study are as follows. Hypoglycaemia was 
accompanied by increases in heart rate for up to seven days later in T2DM 
subjects compared to no change following hyperinsulinaemic euglycaemia. 
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This increase in heart rate was accompanied by decreases in cardiac vagal 
activity (as shown by HF HRV and RMSSD) with no apparent change in 
cardiovagal BRS or relative sympathetic contribution. In nondiabetic 
subjects, heart rates were increased and noradrenaline levels were higher 
at day 1 following hyperinsulinaemic euglycaemia but no significant 
changes in heart rate or HF HRV occurred at day seven following 
hypoglycaemia. 
These results show that impairment in cardiac vagal activity, as shown by 
HF power and RMSSD, may persist for as long as seven days after 
hypoglycaemia in T2DM subjects. It is well known that hypoglycaemia 
impairs counter-regulatory responses to subsequent hypoglycaemic 
episodes, an effect that may persist for at least several days (George et al., 
1995). Such an attenuation of sympathoadrenal responses to 
hypoglycaemia may extend to non-hypoglycaemic stimuli (Herlein et al., 
2006). Although the exact mechanism by which sympathoadrenal 
responses are attenuated following hypoglycaemia is unclear, it is thought 
to occur at the level of the central nervous system (Cryer, 2013) and it is 
tempting to speculate that impairment of cardiac vagal activity following 
hypoglycaemia may occur by related mechanisms. Cardiac vagal neurones 
are located in the nucleus ambiguous and dorsal motor nucleus of the 
vagus, which receives input from the nucleus tractus solitariuss. It has 
recently been shown that a subpopulation of GLUT-2 expressing neurones 
in the nucleus tractus solitaries may stimulate vagal activity during 
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hypoglycaemia (Lamy et al., 2014). There is further evidence that recurrent 
insulin-induced hypoglycaemia in rats reduced orexigenic transmission in 
the dorsal vagal motor nucleus via receptor down-regulation (Paranjape et 
al., 2007). 
There was a trend towards a decrease  in the Valsava ratio following 
hypoglycaemia but not in the E:I or 30:15 ratios. Although these are also 
markers of cardiovagal function, reproducibility is lower compared with 
resting HRV as it is partly dependent on participant effort (Kowalewski and 
Urban, 2003). Thus HRV may be more sensitive in demonstrating smaller 
reductions in vagal activity compared with autonomic reflex testing. 
Adler et al. (2009) showed that two episodes of antecedent hypoglycaemia 
reduced cardiac vagal activity in nondiabetic subjects after 24 hours. The 
study by Adler and colleagues also showed decreases in cardiovagal BRS 
one day after hypoglycaemia as measured by changes using the modified 
Oxford method with nitroprusside and phenylephirine. In this current study 
there was a slight reduction in spontaneous BRS at days 1 and 7 following 
both hypoglycaemia and euglycaemia in diabetic subjects but this did not 
reach statistical significance. No changes in BRS were shown following 
either glycaemic condition in the nondiabetic group. The reasons for these 
discrepancies are not clear but may relate to the method of BRS 
measurement. The measurement of BRS using the sequence method is 
limited by the number of spontaneously increasing or decreasing ramps in 
blood pressure and heart rate available for analysis. Furthermore, 
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spontaneous BRS does not evaluate the entire working range of the 
sigmoidal BRS curve, unlike pharmacological methods. However, 
pharmacological methods also have disadvantages in that they are more 
invasive and perturb the reflex that being measured. 
In the present study there was an increase in heart rate, decrease in vagal 
activity and an increase in noradrenaline at day 1 following 
hyperinsulinaemic euglycaemia in nondiabetic subjects that are believed to 
be due to sympathoexcitatory effects of insulin. Studies have shown that 
insulin acts on the arcuate nucleus where POMC neurones communicate 
with the paraventricular nucleus to elicit its sympathoexcitatory effects.  A 
number of human and animal studies have examined the effect of acute 
intravenous insulin infusions on heart rate and autonomic activity. In 
nondiabetic subjects, small increases in plasma insulin levels elicited large 
increases in sympathetic responses (Scherrer and Sartori, 1997). The 
reason why this did not occur in the diabetic group during 
hyperinsulinaemic euglycaemia may be due to resistance to the 
sympathoexcitatory effects of insulin. Sympathetic responsiveness to 
insulin infusion has been shown to be impaired in conditions associated 
with insulin resistance (Paolisso et al., 2000; Vollenweider et al., 1994).  
It is less clear how long sympathoexcitatory effects of insulin may persist 
beyond the period of infusion. Anderssen and colleagues (1992) reported 
increases in muscle sympathetic nerve activity 1.5 hours after the end of 
the infusion, when plasma insulin levels have returned to basal levels. 
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Animal studies suggest that the sympathoexcitatory effects of insulin may 
persist for at least 24 hours and, rats subjected to four days of antecedent 
euglycaemic hyperinsulinaemia had increased basal norepinephrine levels 
for at least 24 hours (Shum et al., 2001). Rats that received 
intracerebroventricular injections of insulin with no change in plasma 
glucose exhibited an enhancement of reflex tachycardia that was 
maintained for 24 hours (Okada and Bunag, 1994).  
There are a number of limitations to this study. Although HF power and 
RMSSD of HRV are widely accepted measures of vagal activity, there is no 
robust measure of cardiac sympathetic activity. Plasma noradrenaline 
levels can serve as a marker of systemic sympathetic activation but is not 
specific to cardiac sympathetic activity. Similarly, muscle sympathetic nerve 
activity reflects the state of activation in skeletal muscles which do not 
necessarily reflect the level of firing in the heart. Cardiac norepinpehrine 
spillover may be regarded as the gold standard for measuring cardiac 
sympathetic neuronal activity; however, this is relatively invasive and is 
difficult to perform in combination with hyperinsulinaemic clamps.  LF 
power, expressed as a proportion of total HRV, has been shown empirically 
to reflect the degree of cardiac sympathetic contribution to overall heart 
rate control (Pagani et al., 1986). However, others have questioned these 
observations and argued that normalised LF power may be a more complex 
measure that also reflects the baroreflex function (Goldstein et al., 2011). It 
was impossible in this study to control for all the intervening factors 
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between the clamp visit and day 7 that may impact upon cardiac 
autonomic function, although no participant experienced severe 
spontaneous hypoglycaemia outside of that induced during clamps. 
Clinically, depressed cardiac vagal function has been strongly associated 
with increased cardiovascular mortality. Low cardiac vagal activity, as 
shown by HRV on 24 hour monitoring, is associated with a 4-fold increased 
risk of SCD (Algra et al., 1993). In the ATRAMI study which examined 1071 
post-myocardial infarction patients with a low ventricular ejection fraction, 
BRS and HRV independently predicted an increase in mortality (La Rovere 
et al., 1998). In the current study, RMSSD was decreased by 20% seven 
days after hypoglycaemia in diabetic subjects who already exhibited 
impaired cardiac vagal function at baseline. Thus hypoglycaemia may 
further predispose to arrhythmias and SCD. In the NICE-SUGAR study 
where hypoglycaemia was associated with increased mortality during 
intensive glycaemic control in critical care patients, the median time from 
hypoglycaemic event to death was seven days and this mirrors the time 
course of the maximal vagal impairment in this study. It is unclear whether 
autonomic impairment persists beyond seven days and future studies 
should investigate the time course of autonomic changes beyond seven 
days following a hypoglycaemic episode.  
In conclusion, hypoglycaemia was associated with an increase in heart rate 
and impaired cardiac vagal function seven days later in T2DM subjects but 
no significant changes in spontaneous cardiovagal BRS. Impairment of 
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cardiac vagal function may be one mechanism that might predispose to 
cardiovascular mortality in the weeks following a hypoglycaemic event 
during intensive glycaemic control. 
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Chapter 7 - Effect of Hypoglycaemia on 
Platelet Function in Type 2 Diabetes 
7.1  Summary 
Increased platelet activation and reactivity are strong predictors of 
cardiovascular death in subjects with T2DM. Previous studies have 
suggested that acute hypoglycaemia can increase platelet aggregation via 
adrenergic mechanisms in T1DM and nondiabetic subjects but no study to 
date has examined the duration of these effects. The aim of this study was 
to investigate the effects of hypoglycaemia on platelet function acutely and 
downstream of the event in T2DM subjects. 
Twelve patients with T2DM and eleven age and BMI matched nondiabetic 
subjects completed paired hyperinsulinaemic clamp studies separated by 
at least four weeks. Patients were on no antiplatelet drugs except for two 
on aspirin. Glucose was maintained during hypoglycaemia (2.5 mmol/L) or 
euglycaemia (6 mmol/L) for two 60 minute periods. Platelet aggregation 
was measured at the baseline, end of the clamp, at recovery, and 1 and 7 
days later using whole blood impedance aggregometry (Multiplate), 
WBSPC, and P-selectin expression using flow cytometry. 
Platelet activation as measured by unstimulated P-selectin increased 
following acute hypoglycaemia in both groups. Platelet macroaggregation 
to collagen by impedance aggregometry increased acutely during 
hypoglycaemia in diabetic (Mean±SE Δ 9±6 U) and nondiabetic subjects (Δ 
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14±4 U) compared with decreases during euglycaemia (Δ -15±7 and Δ -9±6 
U respectively). 5HT-induced P-selectin expression increased during acute 
hypoglycaemia in both diabetic and nondiabetic subjects, returning to 
baseline at day 1 (both p <0.01 vs. euglycaemia). The percentage 
aggregation to 3 μM ADP by WBSPC decreased during euglycaemia but did 
not change in the hypoglycaemic arm, suggesting no changes in 
microaggregation.  Change in platelet reactivity following hypoglycaemia 
did not persist beyond day 1. 
Moderate experimental hypoglycaemia, frequently observed clinically, can 
increase platelet reactivity in individuals with T2DM during acute 
hypoglycaemia, although effects did not persist beyond day 1.  This is one 
potential mechanism by which acute hypoglycaemia can precipitate 
coronary thrombosis. 
7.2 Introduction 
Platelets are key contributors to the atherothrombotic process and when 
activated contribute to the activation of arterial thrombosis following 
plaque rupture. Platelets in T2DM patients are hyperactive and show 
greater aggregation responses  (Kakouros et al., 2011). Clinical studies have 
shown that high platelet reactivity, despite chronic dual antiplatelet 
therapy, was the strongest independent predictor of major adverse 
cardiovascular events in cohorts of T2DM patients with coronary artery 
disease (Angiolillo et al., 2007).  
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Early work by Hutton et al. (1979) demonstrated enhanced platelet 
aggregation to ADP as measured by Born aggregometry during 
hypoglycaemia induced by an insulin bolus. Subsequent studies have also 
shown that  platelet activation occurs in response to acute hypoglycaemia 
and leads to the release of beta-thromboglobulin from platelet granules 
(Trovati et al., 1986), as well as the expression of cell surface receptors, 
such as P-selectin (Gogitidze Joy et al., 2010). During hypoglycaemia, 
increased platelet activation is predominantly mediated via adrenaline and 
can be inhibited by alpha2-adrenoreceptor blockade (Kishikawa et al., 
1987).  
No study to date has examined the effect of hypoglycaemia on platelet 
reactivity in T2DM individuals. Furthermore, few studies have examined 
the effect of hypoglycaemia in the days after the event.  A novel aspect of 
this work was to investigate differences in both platelet macroaggregation 
and microaggregation. Platelet microaggregation, the initial formation of 
few platelet conglomerates, has been shown to be the key platelet 
aggregation event in T2DM patients that can mediate hyperreactivity 
(Matsuno et al., 2004).  Another novel aspect to this work is the effect of 
P2Y12 blockade on platelet reactivity during acute hypoglycaemia. The 
P2Y12 pathway amplifies aggregation responses to a wide range of 
agonists and P2Y12 inhibitors are used clinically as antiplatelet agents.  
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The aim of this study was to examine the effect of hypoglycaemia on 
platelet activation and platelet reactivity during and following an acute 
episode in patients with T2DM. 
7.3 Research Design and Methods 
7.3.1 Participants 
The inclusion and exclusion criteria are as previously described in Section 
2.3.2. Briefly, 12 patient with T2DM aged 18-65 and no history or signs or 
symptoms of CVD were recruited from Sheffield Teaching Hospitals 
outpatient clinics. Eleven age and BMI matched nondiabetic individuals 
were recruited as a control group. None were on antiplatelet agents or 
anticoagulants apart from two diabetic patients who were on aspirin. All 
subjects had a normal full blood count, renal function and cardiac 
autonomic function at baseline. All participants gave their written informed 
consent and the study was approved by the local research ethics 
committee. 
7.3.2 Hyperinsulinaemic Clamp Protocol 
All diabetic and nondiabetic subjects participated in paired 
hyperinsulinaemic euglycaemic and hypoglycaemic clamps separated by at 
least four weeks.  In the hypoglycaemic arm, glucose was maintained at 2.5 
mmol/L for 60 minutes in the morning and 60 minutes in the afternoon, 
whilst in the euglycaemic arm, arterialised blood glucose was maintained 
at a target level of 6 mmol/L for 60 minutes in the morning and 60 minutes 
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in the afternoon. Details of the hyperinsulinaemic clamp protocol are 
described in section 2.3.5. During the morning clamp a primed continuous 
intravenous insulin infusion was administered at 120 mU/m2/min (body 
surface area), and in the afternoon clamp at 240 mU/m2/min along with 
20% dextrose at a variable rate, and adjusted according to arterialised 
blood glucose concentrations which were measured every five minutes. 
Equivalent amounts of insulin were administered in the euglycaemic and 
hypoglycaemic arms and in diabetic and nondiabetic subjects. Platelet 
function assays were performed at the end of the clamp, at recovery (30 
minutes after the end of the clamp), and days 1 and 7 after the 
euglycaemic and hypoglycaemic clamps. Study visits were conducted in the 
morning to control for diurnal variation.  
7.3.3 Platelet Function Assays 
Detailed methods were described in section 2.3.8 but are outlined in brief 
below. 
7.3.3.1 Impedance Aggregometry 
Venous blood (2.7 mL) was collected from subjects and transferred to a 3 
mL hirudin tube (Multiplate®) carefully avoiding any agitation of the 
sample. The samples were then transported to the Cardiovascular 
Biomedical Research laboratory, Northern General Hospital immediately 
following venepuncture to maximise the chances of observing a 
catecholamine effect. Aliquots of 300 μL saline and 300 μL hirudin-
anticoagulated blood were added to the cuvette and incubated at 37°C for 
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3 minutes before adding 20 μL of the agonists ADP 1 µM and collagen 1 µM 
and commencing the assay. The AUC was measured and this represents the 
level of platelet aggregation. 
7.3.3.2 Whole Blood Single Platelet Counting 
Citrated blood venous blood (4.5 mL) was incubated at 37oC and 480 µL 
aliquots of whole blood were placed in polystyrene tubes with a magnetic 
stirrer bar and 20 µL of ADP 1 or 3 µM as an agonist.  Samples were stirred 
at 1000 rpm for 4 minutes at 37°C prior to  fixing (saline with 4.6 mM 
sodium EDTA, 4.5 mM Na2HPO4, 1.6 mM KH2PO4 and 0.16% (w/v) 
formaldehyde, pH7.4) and counting using a Sysmex KX21 haematology 
analyser. The total single platelet count was obtained using EDTA 4 mM 
instead of ADP.  The percentage aggregation was calculated as follows:  
                                  
                        
          
      
 
7.3.3.3 Platelet P-selectin Expression 
Hirudin-anticoagulated blood was anticoagulated with saline or cangrelor 1 
μM for 2 minutes at room temperature. Aliquots of blood were then added 
to tubes containing PE Cy5 mouse anti CD62P antibody and either ADP (1 
μM) or 5HT (3 μM) as agonists, and after 20 minutes incubation at room 
temperature, fixing solution was added. Flow cytometry was performed 
and forward light scatter, side scatter and FITC fluorescence were 
measured. A gate was positioned around the platelet region to exclude any 
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red cells. P-selectin expression was quantified as the percentage of cells 
with CD62P fluorescence greater than the fluorescence of the mouse IgG 
control (% positive events) and  the median CD62P fluorescence intensity 
of the platelet population.  
7.3.4 Biochemical Parameters 
For catecholamines, 6 mL whole blood was collected into chilled lithium 
heparin tubes containing 50 μL of EGTA/glutathione preservative, 
subjected to centrifugation at 4oC, 3000 rpm for 10 minutes and the 
resulting supernatant stored at -80oC until assayed by HPLC. Plasma free 
insulin was analysed by an immunometric assay (Invitron Insulin ELISA, 
Invitron Ltd, Monmouth, UK) following precipitation with PEG. The assay 
has 100% cross reactivity with Actrapid insulin. Serum potassium was 
analysed using an automated system (Cobas®system, Roche Diagnostics, 
UK). Biochemical parameters were measured at baseline and 120 minutes 
for both groups in the euglycaemic and hypoglycaemic arms. 
7.3.5 Statistical Analysis 
Data was checked for normality and data are shown as mean± SE except 
for age and duration of diabetes which was shown as medians 
(interquartile range).  Comparisons between diabetic and control groups in 
baseline data were made using an independent t-test for parametric data 
and a Mann Whitney U test for nonparametric data.  Blood glucose and 
hormone concentrations were compared between equivalent euglycaemic 
and hypoglycaemic time points using a paired t-test or Wilcoxon signed-
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rank test, and between groups at equivalent time points using an 
independent t-test. 
 Platelet parameters were analysed using a linear mixed model with 
repeated measures. The mixed model allows for internally correlated 
measures from repeated measures (with respect to both the glycaemic arm 
and time) within an individual and also allows for missing values (Galbraith 
et al., 2010). To investigate whether there was a significant change in 
platelet parameters within the euglycaemic or hypoglycaemic arms, time 
point was specified as a fixed effect in the linear mixed model. Changes in 
platelet parameters between glycaemic arms were also compared using a 
linear mixed model, where glycaemic arm, time and interaction between 
the glycaemic arm and time were specified as fixed effects.  In both 
analyses the glycaemic arm and time point were specified as repeated 
measures and fitted with an unstructured, compound symmetry or 
autoregressive 1 covariance structure. The model with the best fit (lowest 
Akaike’s information criterion) was selected. p values were obtained by 
restricted maximum likelihood estimation. Changes in P-selection 
expression in response to ADP and 5HT stimulation in the presence and 
absence of P2Y12 blockade were compared using independent t-tests. A p 
value of ≤ 0.05 was considered significant and results were analysed using 
SPSS (version 20.0, IBM, Chicago,Ilinois). 
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7.4 Results 
7.4.1 Baseline Characteristics 
Participant characteristics are as previously described in Section 4.4.1 and 
baseline platelet parameters are shown in Table 7-1. There were no 
significant differences between euglycaemia and hypoglycaemia at 
baseline. All platelet reactivity measures were generally higher in the 
diabetic subjects compared to the nondiabetic group. 
Table 7-1: Baseline platelet reactivity in T2DM subjects and controls 
Data mean ±SE. p values for diabetic versus  nondiabetic groups as determined by an 
independent t-test 
 Diabetic 
(n=12) 
Nondiabetic 
 (n=11) 
p-value 
Platelet aggregation by impedance aggregometry 
AUC ADP (U) 75±11 41±8 0.03 
AUC collagen (U) 87±8 74±6 0.21 
Platelet aggregation by WBSPC 
1 µM ADP 16.0±5.7 13.0±3.9 0.67 
3 µM ADP 40.3±10.9 54.4±6.6 0.29 
P selectin expression (CD62P MFI) 
Unstimulated 4016±1040 3236±1681 0.19 
5HT 3984±1111 2866±1488 0.07 
ADP 5629±2206 4512±2203 0.11 
P selectin expression (% CD62P positive cells) 
Unstimulated 4.45±1.42 3.16±0.81 0.43 
5HT 5.38±1.90 4.14±0.80 0.57 
ADP 28.7±4.2 36.2±4.4 0.23 
 
7.4.2 Hyperinsulinaemic Clamp 
At the end of the morning euglycaemic clamp, glucose was 5.81±0.09 and 
5.96±0.05 mmol/L in diabetic and control groups, respectively, and 
following the morning hypoglycaemia, blood glucose concentrations were 
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2.55±0.06 mmol/L in the diabetic group and 2.56±0.03 mmol/L in the 
control group, which was not significantly different between the two 
groups (Table 7-2). Blood glucose targets were also achieved during the 
afternoon clamp within each arm.  
Median  free insulin levels at 120 minutes were 576 (IQR: 468-627) pmol/L 
during euglycaemia and 689 (IQR: 477-1076) pmol/L during hypoglycaemia 
in the diabetic group. In the nondiabetic group, they were 865 (IQR: 509-
952) pmol/L in the euglycaemic arm and 665 (IQR: 468-967) pmol/L in the 
hypoglycaemic arm. A comparison of the insulin levels between the groups 
under both euglycaemic and hypoglycaemic conditions were not 
statistically different (p = 0.23). 
Counter-regulatory hormones did not change during the euglycaemic 
clamp (Table 7-2). During acute hypoglycaemia, adrenaline, noradrenaline 
and cortisol increased significantly at the end of the clamp in both groups 
(all p<0.05 versus baseline), and the peak levels were not significantly 
different between the diabetic and nondiabetic groups. 
 
7.4.3 Blood Glucose and Counter-regulatory Hormones at day 1 
and 7 
Blood glucose at day 1 and day 7 are shown in Table 7-2. Blood glucose was 
not significantly different between the glycaemic arms except at day 1, 
where it was higher following hypoglycaemia in the diabetic group. Plasma 
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adrenaline and cortisol were not significantly different from baseline at day 
1 and day 7 following euglycaemic and hypoglycaemic clamps in either 
group. However, in the nondiabetic group, plasma noradrenaline levels 
increased significantly at day 1 after the euglycaemic clamp.  
Table 7-2: Blood glucose and counter-regulatory hormones in the euglycaemic 
and hypoglycaemic arms 
Data Mean ±SE *p<0.05, **p<0.01  Euglycaemia versus hypoglycaemia within each group  
was determined by a paired t-test †† p<0.01 significant difference between diabetic and 
nondiabetic groups at equivalent euglycaemic or hypoglycaemic time points was 
determined by an independent t-test. 
 Diabetics Nondiabetics 
Euglycaemia Hypoglycaemia Euglycaemia Hypoglycaemia 
Blood glucose (mmol/L) 
Baseline 6.24±0.33 6.44±0.37 5.10±0.15† 4.87±0.09† 
End of 
clamp 
5.81±0.09 2.55±0.06** 5.96±0.06 2.56±0.03** 
Recovery 6.98±0.33 6.63±0.55 6.37±0.19 8.40±0.59** 
Day 1 7.88±0.84 11.4±1.09* 5.08±0.28† 5.00±0.29† 
Day 7 9.30±0.78 10.3±1.04 5.09±0.13† 4.96±0.21† 
Adrenaline (nmol/L)  
Baseline 0.15±0.04 0.12±0.03 0.17±0.03 0.15±0.02 
End of 
clamp 
0.16±0.04 3.05±0.71** 0.14±0.02 3.83±0.86** 
Day 1 0.23±0.12 0.17±0.06 0.17±0.03 0.20±0.08 
Day 7 0.10±0.02 0.16±0.08 0.22±0.06 0.11±0.02 
Noradrenaline (nmol/L)  
Baseline 1.23±0.14 1.25±0.15 1.56±0.15 1.46±0.16 
End of 
clamp 
1.27±0.09 2.37±0.24** 1.56±0.12 2.69±0.43** 
Day 1 1.97±0.15 1.93±0.10 3.08±0.44† 2.32±0.21 
Day 7 2.07±0.17 2.52±0.34 2.56±0.24 2.78±0.34 
Cortisol 
Baseline 277±25 329±37 338±43 300±39 
End of 
clamp 
253±25 726±36** 256±33 656±45** 
Day 1 243±35 178±28 312±35 230±29 
Day 7 243±16 198±30 285±28 233±22 
 
259 
7.4.4 Platelet Count 
There were no changes in platelet count during the euglycaemic clamp 
(Table 7-3). In the diabetic group, the platelet count tended to increase 
during hypoglycaemia and returned to baseline at recovery. In the 
nondiabetic group the platelet count increased during hypoglycaemia from 
211±12 to 236±27 x109/L  at the end of the clamp but fell to 188±16 x109/L 
at recovery (p=0.01 for time). There were no significant changes in platelet 
count downstream at day 1 or day 7 following hypoglycaemia or 
euglycaemia in either group.  
Table 7-3 Platelet count following euglycaemic or hypoglycaemic clamps in 
diabetic and nondiabetic groups 
Data Mean±SE x 10
9
/L   
 Diabetes  
(n=12) 
Nondiabetic  
(n=11) 
  Euglycaemia Hypoglycaemia Euglycaemia Hypoglycaemia 
Baseline 198±11 219±23 206±18 211±12 
End of clamp 204±15 256±21 190±15 236±27 
Recovery 215±12 214±25 185±11 188±16 
Day 1 221±16 224±25 207±19 215±14 
Day 7 219±18 234±28 219±20 232±24 
 
7.4.5 Platelet Activation 
In diabetic subjects, platelet activation as measured by unstimulated P-
selectin expression (CD62P median fluorescence intensity (MFI)) decreased 
following euglycaemia maximally at day 1 compared to an increase 
following hypoglycaemia (p=0.04 for the glycaemic arm) (Figure 7-1). In 
nondiabetic subjects, no significant changes in platelet activation occurred 
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during euglycaemia. However, platelet activation tended to increase at the 
end of the hypoglycaemic clamp (as shown by increases in CD62P MFI and 
% CD62P positive cells) and at day 1 but there was no overall difference 
between the euglycaemic and hypoglycaemic arms (Figure 7-1). 
 
 
Figure 7-1: Changes in platelet activation following euglycaemia and 
hypoglycaemia in diabetic and nondiabetic groups  
Data mean (SE). † Change in CD62P median fluorescence intensity (MFI) top and change in 
percentage CD62P positive cells (bottom) p<0.05. Euglycaemia (open circle) vs. 
hypoglycaemia (square) at equivalent time points. p values determined by a linear mixed 
model for differences between glycaemic arms and the interaction between time and 
glycaemic arm. 
7.4.6 Platelet Reactivity 
7.4.6.1 Impedance Aggregometry 
In diabetic subjects, platelet aggregation to collagen decreased during the 
euglycaemic clamp but had returned to baseline at day 1. Platelet 
macroaggregation to collagen by impedance aggregometry increased 
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acutely during hypoglycaemia in diabetic ( Δ 9±6 U) and nondiabetic 
subjects (Δ 14±4 U) compared with decreases during euglycaemia (Δ -15±7 
and Δ -9±6 U respectively,  p=0.05 for the glycaemic arm). Platelet 
aggregation to collagen returned to baseline at day 1 and 7 after 
hypoglycaemia (Figure 7-2).  
Platelet aggregation to ADP also decreased during euglycaemia compared 
with an increase at the end of the hypoglycaemic clamp (p =0.03 for the 
difference between glycaemic arm). Platelet aggregation to ADP remained 
higher at day 1 and day 7 after hypoglycaemia (Figure 7-2). 
 In nondiabetic subjects, there was a non-significant decrease in platelet 
aggregation to collagen during euglycaemia, whilst platelet aggregation to 
collagen increased during the hypoglycaemic clamp but had resolved at 
recovery. There were further increases in platelet aggregation to collagen 
and ADP at day 1 following both euglycaemia and hypoglycaemia but these 
fell again at day 7 (Figure 7-2). 
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Figure 7-2: Platelet aggregation by impedance aggregometry to a) collagen 1 µM 
and b) ADP 1 µM 
Data mean (SE), area under the curve (AUC). p values are determined by a linear mixed 
model for the fixed effects of glycaemic arm and the interaction between time and the 
glycaemic arm * p<0.05 versus baseline †p<0.05 †† p <0.01 euglycaemia (EU) versus 
hypoglycaemia (HYPO)  
7.4.6.2 WBSPC 
In the diabetic group, the percentage platelet aggregation to 3 µM ADP 
decreased at the end of the euglycaemic clamp, Δ- 26±40% (Figure 7-3), 
before returning towards baseline by day 1 and day 7. % platelet 
aggregation to ADP 3 µM did not change significantly during the 
hypoglycaemic clamp. In the nondiabetic group, the percentage platelet 
aggregation decreased during euglycaemia and hypoglycaemia up to 
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recovery to a similar extent but returned towards baseline levels at day 1 
and day 7 (Figure 7-3) (p=0.001 for time, p=0.26 for glycaemic arm). 
 
Figure 7-3: Percentage platelet aggregation to 3 µM ADP by whole blood single 
platelet counting in the euglycaemic and hypoglycaemic arms 
Data mean (SE) Change in percentage platelet aggregation, EU-euglycaemia, HYPO-
hypoglycaemia   
7.4.6.3 P-selectin Expression 
5HT 
In the diabetic group there was a general trend towards a decrease in P-
selectin expression to 5HT (3 µM) in the euglycaemic arm which was 
maximal at day 1. Platelet reactivity to 5HT as measured by CD62P MFI 
increased during the hypoglycaemic clamp but returned to baseline at 
recovery (Figure 7-4). 
In the nondiabetic group there were no changes during euglycaemia. P-
selectin expression measured by the percentage of CD62P positive cells 
and CD62P MFI increased acutely during hypoglycaemia and returned to 
baseline at recovery. There were significant differences in the percentage 
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of CD 62P positive cells following euglycaemia versus hypoglycaemia (p = 
0.04 for glycaemic arm). 
 
 
Figure 7-4: P-selectin expression to 5HT (3 µM) by flow cytometry following 
euglycaemia and hypoglycaemia in diabetic and nondiabetic groups 
Data mean (SE) Change in percentage CD62P positive cells (top) and CD62P median 
fluorescence intensity (bottom).  p values as determined by a linear mixed model for the 
glycaemic arm and interaction between time and glycaemic arm as fixed factors 
ADP 
In the diabetic group, P-selectin expression to ADP tended to decrease at 
day 1 after euglycaemia (CD62P MFI Δ-1179±634) compared to no change 
in the hypoglycaemic arm (Figure 7-5), but the differences between the 
glycaemic arms did not reach statistical significance. In the nondiabetic 
group, P-selectin expression to 1 µM ADP similarly decreased at day 1 
following the euglycaemic clamp but returned towards baseline at day 7. In 
the hypoglycaemic arm there was an increase at day 1 but this returned to 
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baseline at day 7 (Figure 7-5). There was a significant interaction between 
the time point and glycaemic arm (p=0.04). 
 
Figure 7-5: P-selectin expression to 1 µM ADP following euglycaemia and 
hypoglycaemia in diabetic and nondiabetic groups 
Data Mean (SE) change in CD62P median fluorescence intensity (MFI). Closed square- 
Diabetes HYPO, open square – Diabetes EU; closed circle – nondiabetic HYPO; open circle- 
nondiabetic EU 
Effect of P2Y12 blockade on P-selectin expression to ADP and 5HT 
During the euglycaemic clamp in diabetic and nondiabetic subjects, the 
decrement in P-selectin expression tended to be attenuated in the 
presence of cangrelor to both ADP and to a lesser extent to 5HT (Figure 
7-6a).  
During the hypoglycaemic clamp, the increment in 5HT-induced P-selectin 
expression as measured by CD62P MFI was non-significantly attenuated in 
the presence of cangrelor in the nondiabetic group but did not change in 
the diabetic group (Figure 7-6b). In contrast, there was a decrease in P-
selectin in response to 1 µM ADP at the end of the hypoglycaemic clamp in 
both diabetic and nondiabetic subjects. This decrement was reversed in the 
presence of cangrelor, as shown by increases in CD62P MFI (Figure 7-6b). 
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Similarly, the percentage of CD62P positive cells at the end of 
hypoglycaemia decreased with ADP alone (-Δ5.46±2.72 versus Δ0.10±0.51) 
in the presence of cangrelor (p = 0.05) among diabetic subjects, and in 
nondiabetic subjects the percentage of CD62P positive cells decreased with 
ADP alone (-Δ4.50±3.09% versus Δ 0.31±0.95%) in the presence of 
cangrelor (p = 0.15).  
 
Figure 7-6: Effect of P2Y12 inhibition with cangrelor on P-selectin expression to 
1 µM ADP and 3 µM 5HT in the euglycaemic and hypoglycaemic arms 
(a) Change in CD62P median fluorescence intensity (MFI) at the end of the euglycaemic 
clamp compared to the baseline in response to 1 µM ADP, ADP and cangrelor (ADP+CAN), 
3 µM 5HT, 5HT and cangrelor (5HT+CAN).  (b) Change in CD62P median fluorescence 
intensity (MFI) at the end of the hypoglycaemic clamp compared to baseline in response 
to 1 µM ADP, ADP and cangrelor (ADP+CAN), 3 µM 5HT, 5HT and cangrelor (5HT+CAN). 
Data mean (SE).  
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7.5 Discussion 
The main findings of this study are as follows: 1) platelet activation as 
shown by P-selectin expression increased during and after hypoglycaemia 
in diabetic and nondiabetic groups; 2) there were increases in platelet 
macroaggregation to collagen during hypoglycaemia which decreased 
following euglycaemia in both groups; 3) There were no increases in 
platelet microaggregation during hypoglycaemia in either group; and 4) 
P2Y12 inhibition influenced 5HT and ADP induced P-selectin expression 
during both euglycaemia and hypoglycaemia.  
During euglycaemia which reflects the effect of insulin alone, acute 
decreases in platelet macroaggregation to collagen and ADP and platelet 
microaggregation to ADP in both groups were observed. In vitro studies 
have shown contradictory effects of insulin on platelet function, as insulin 
may inhibit platelet aggregation at physiological concentrations but 
increases aggregation at supraphysiological levels (Anfossi et al., 1996). In 
vivo studies have generally shown inhibitory effects of insulin on platelet 
aggregation (Trovati et al., 1988), where insulin may act directly via the 
insulin receptor substrate-1 (IRS-1) through tyrosine phosphorylation, 
which results in calcium mobilisation and inhibition of Gi activity and P2Y12 
inhibition (Ferreira et al., 2003). Alternatively, insulin may rapidly activate a 
constitutive NO NOS3 via the PI3K/Akt pathway to increase NO release in 
platelets (Trovati et al., 1988). Insulin can also reduce platelet aggregation 
via indirect mechanisms, such as increases in prostaglandin I2 production 
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from endothelial cells (Kahn et al., 1991). In particular, platelet activation 
as shown by unstimulated P-selectin expression remained decreased at day 
1 after euglycaemia, suggesting persistent anti-inflammatory mechanisms 
may be pertinent. Greater decreases in platelet aggregation in diabetic 
compared to nondiabetic subjects were observed, and these findings differ 
from previous work which reported diminished anti-aggregatory effects of 
insulin among obese versus non-obese subjects (Westerbacka et al., 2002), 
although the reasons for these differences are unclear.  
During the hypoglycaemic clamp, there were trends towards an increase in 
platelet count in diabetic and nondiabetic groups. Hutton et al. (1979) 
reported increases in platelet counts in 3 out of 10 nondiabetic subjects 
during insulin-induced hypoglycaemia but no overall change in 7 subjects. 
The increase in platelet count could relate to the increase in adrenaline 
(Kjeldsen et al., 1995), which mobilises splenic reserves of platelets 
(Bakovic et al., 2012). 
Platelet activation increased following hypoglycaemia as shown by P-
selectin expression via flow cytometry. There was an acute increase in 
overall P-selectin expression in the total platelet population in both groups 
but increases in the percentage of P-selectin positive cells were seen in 
nondiabetic subjects only. Similar to a study by Trovati et al. (1986), 
platelet factor 4 and beta thromboglobulin were significantly higher at the 
hypoglycaemic nadir following an insulin bolus in nondiabetic individuals, 
suggesting platelet activation. Takeda et al. (1988) induced hypoglycaemia 
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using an insulin bolus in T2DM individuals and found increases in beta 
thromboglobulin were prevented by midaglizole, suggesting 
hypoglycaemia-related platelet activation is mediated via alpha 2 –
adrenoreceptors. 
This study demonstrated increased platelet aggregation to collagen and 
ADP, as measured by impedance aggregometry in both diabetic and control 
groups during acute hypoglycaemia. 5HT-induced P-selectin expression, as 
measured by flow cytometry, also increased acutely during hypoglycaemia. 
Earlier studies have demonstrated increases in platelet reactivity as 
defined by platelet aggregation to Born aggregometry in platelet rich 
plasma (Trovati et al., 1986). Dalsgaard-Nielsen et al. (1982) also induced 
transient hypoglycaemia in seven nondiabetic and 8 T1DM individuals. The 
study found that platelet sensitivity to ADP was significantly increased as 
measured by turbidimetric assays. The increase in platelet sensitivity to 
agonists, including ADP and thrombin, during hypoglycaemia was abolished 
by an alpha blockade, implicating alpha-2 adrenoreceptors in mediating 
this effect (Trovati et al., 1986). Adrenaline on its own is a weak agonist but 
it has been shown to potentiate platelet aggregation to other agonists, 
such as ADP, collagen and thrombin, both in vitro and in vivo (Trovati et al., 
1986). Furthermore, in vitro studies have shown that adrenaline can 
neutralise the inhibitory effects of insulin by blocking the tyrosine 
phosphorylation of both Giα2 and the insulin receptor β subunit (Ferreira et 
al., 2003). 
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In contrast to the changes demonstrate by impedance aggregometry, 
platelet microaggregation to ADP as measured by single platelet counting 
did not change during acute hypoglycaemia in diabetic individuals. In the 
nondiabetic group, the percentage aggregation decreased during acute 
hypoglycaemia to a similar extent to euglycaemia. Impedance 
aggregometry is influenced by platelet counts and  correlates linearly with 
platelet counts even in the normal range (Femia et al., 2013). Thus an 
increase in platelet macroaggregation by impedance aggregometry may in 
part be explained by trends in increased platelet counts during acute 
hypoglycaemia. The net effect on platelet microaggregation may reflect a 
balance between pro-aggregatory effects of adrenaline versus anti-
aggregatory effects of insulin. However, other groups have also reported a 
lack of potentiation by epinephrine on ADP/5HT platelet aggregation in 
vitro when assessed by the disappearance of single platelets (Kerry and 
Scrutton, 1985).   
During euglycaemic clamps there was a decrease in P-selectin expression 
as expressed by the percentage of CD62P positive platelets to ADP and 5HT 
in both groups. This decrement was attenuated in the presence of 
cangrelor, suggesting the anti-aggregatory effects of insulin are partially 
mediated via a P2Y12 dependent pathway. Insulin has previously been 
shown to inhibit ADP-induced calcium mobilisation via Gi pathways 
(Ferreira et al., 2003). During hypoglycaemic clamps 5HT-induced P-selectin 
expression increased but was attenuated in the presence of cangrelor in 
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nondiabetic subjects. Inhibition of P2Y12 may reduce the ability of secreted 
ADP to amplify aggregatory responses in response to 5HT analogous to 
other platelet agonists. It has been shown, for example, that adrenaline 
potentiates platelet responses to thrombin that were dependent on 
secreted ADP (Selheim et al., 2000).  
Conversely, there was a decrease in P-selectin expression in response to 1 
µM ADP at the end of the hypoglycaemic clamp in both diabetic and 
nondiabetic subjects. This decrement was reversed in the presence of 
cangrelor and reasons for this are uncertain. It is possible that exposure to 
adrenaline and stimulation via alpha2-adrenoreceptors in vivo cross-
desensitises ADP-mediated aggregation pathways.  It is known that 
desensitisation of platelet responses to adrenaline occurs following an 
insulin-induced hypoglycaemia after an insulin infusion for 60 minutes 
(Trovati et al., 1990). It has also been shown that there is cross-
desensitisation between thrombin and ADP pathways, such that pre-
activation of one receptor may heterologously desensitise aggregation 
responses to the other mediated via protein kinases (Barton et al., 2007). 
One potential explanation is that desensitisation of alpha 2 
adrenoreceptors (Gi subfamily) after hypoglycaemia can lead to cross-
desensitisation of P2Y1 mediated P-selectin expression (Gq) but not P2Y12. 
The fact that P2Y12 antagonism can reverse the inhibition suggests that the 
mediator of this desensitisation may be a downstream effector that is 
common to all three pathways. There is accumulating evidence that graded 
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activation of the Gi subfamily, including P2Y12 and alpha 2-
adrenoreceptor, regulates platelet aggregation response and controls the 
release of platelets from a state of tonic inhibition, whereas signalling via 
Gq coupled receptors, including P2Y1 and 5HT2A, are necessary for 
initiation of aggregation responses (Maayani et al., 2001). 
One of the strengths of this study is the inclusion of a euglycaemic arm to 
control for the effects of hyperinsulinaemia. All the platelet function assays 
were processed as soon as possible within two hours of collection in order 
to minimise the chances of observing a catecholamine effect. Platelet 
reactivity was analysed using different assays that measured both platelet 
macroaggregation and microaggregation effects at a single platelet level. 
However, the study also has a number of limitations. The number of 
participants are relatively small.   Another potential limitation is the slightly 
higher number of males in the diabetic group. Most of the subjects were 
not on any antiplatelet treatment apart from two diabetic subjects who 
were on aspirin. This can affect collagen-induced platelet aggregation via 
inhibition of the formation and release of thromboxane A2.  However, 
these subjects remained on aspirin throughout the study in both arms and 
displayed similar patterns of collagen-induced platelet aggregation to the 
rest of the group (data not shown). For ethical reasons, hypoglycaemia was 
not induced in individuals with known CVD.  Intensive glucose lowering 
exerts greater cardiovascular benefits in patients with low cardiovascular 
risk compared to those with established CVD (Holman et al., 2008; Reaven 
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et al., 2009). What is not known is whether the deleterious effects of 
hypoglycaemia may be exaggerated and the protective effects of insulin 
attenuated in patients at high cardiovascular risk. 
The findings of this study are relevant to intensive glycaemic control, 
particularly in the setting of ACS, where platelets play an important role in 
early disease. Vivas et al. (2011) compared the effect of intensive glycaemic 
control (4.4-6.6 mol/L) versus conventional control (<10 mmol/L) with 
intravenous glucose/insulin/potassium infusion for 24 hours in ACS 
patients. Hypoglycaemia (blood glucose <3.8 mmol/L) occurred 
significantly more often in intensively treated patients (37 vs 2%). 
Nevertheless, the study demonstrated significant reductions in platelet 
activation (P-selectin and GPIIb/IIIa expression) and reduction in platelet 
aggregation to ADP, collagen, adrenaline and thrombin at 24 hours.  
Worthley et al. (2007) compared the effects of intravenous versus 
subcutaneous insulin administration on platelet responsiveness in 76 ACS 
patients. They demonstrated that intravenous insulin infusion improved 
platelet responsiveness to NO and reduced superoxide production. 
However, in both studies it was not possible to demonstrate whether 
better glucose control or higher insulin doses per se were responsible for 
improvements in platelet function. Intensive glycaemic control had short 
term effects on platelet reactivity which did not persist at long term follow 
up (Vivas et al., 2014). This echoes findings in this study that reductions in 
platelet macroaggregation is limited to the period of acute 
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hyperinsulinaemic euglycaemia and do not persist beyond day 1. Taken 
together, this would support the benefits of intensive glycaemic control in 
ACS, however, hypoglycaemia may mitigate antiaggregatory effects of 
insulin. 
In summary, increases in platelet activation and platelet reactivity were 
observed in response to hypoglycaemia in T2DM and controls. This 
contrasts with the anti-aggregatory effects of euglycaemic 
hyperinsulinaemia. Acute hypoglycaemia, via increases in platelet 
activation and reactivity, may predispose to acute coronary thrombosis and 
cardiovascular mortality. 
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Chapter 8 - Effects of Hypoglycaemia on Fibrin clot 
properties and Inflammation in Type 2 Diabetes 
8.1 Summary 
Altered fibrin clot characteristics, impaired fibrinolysis, and subclinical 
inflammation can predispose to acute coronary events in individuals with 
T2DM. This has previously  been attributed to increased glucose levels but 
recent work has shown that hypoglycaemia can increase pro-coagulant 
factors, proinflammatory cytokines and inhibit fibrinolysis in nondiabetic 
and T1DM subjects. The aim of this current study is to investigate the 
effect of hypoglycaemia on fibrin-related thrombosis risk acutely and up to 
7 days after an experimental hypoglycaemic episode in individuals with 
T2DM.  
A total of 12 T2DM and 11 nondiabetic subjects underwent paired 
hyperinsulinaemia euglycaemic (blood glucose 6 mmol/L for two 60 minute 
periods) and hypoglycaemic clamps (2.5 mmol/L for two 60 minute 
periods) on separate occasions.  Ex vivo fibrin clot properties and 
fibrinolysis was investigated using a validated turbidimetric assay. Fibrin 
clot ultrastructure was further studied using laser scanning electron 
microscopy.  Fibrinogen, PAI-1, complement component C3, hsCRP and 
inflammatory cytokines were measured at the end of the clamp to 
elucidate mechanisms for altered fibrin clot properties. 
276 
In diabetic subjects, hypoglycaemia increased fibrin clot density (mean 
±SE), peaking at day 7 (clot maximum absorbance Δ from baseline 
0·030±0.016 AU), but decreased after euglycaemia (Δ –0·039±0·025 AU, 
p=0·007). Clot lysis times were prolonged after hypoglycaemia for up to 
day 7 but decreased after euglycaemia (Δ 66 ±32 vs Δ –52±29 sec; 
p=0·006). There were no changes in clot density or lysis times following 
hypoglycaemia in nondiabetic subjects. The fibre network density 
decreased during euglycaemia and increased following hypoglycaemia for 
up to 7 days in both groups, whereas an increase in fibre diameter was only 
evident following hypoglycaemia in diabetic subjects. Fibrinogen, C3 and 
hsCRP, but not PAI-1, increased after hypoglycaemia up to day 7 in diabetic 
subjects.  
Hypoglycaemia had sustained prothrombotic, hypofibrinolytic, 
proinflammatory effects for at least one week in individuals with T2DM. 
This may provide a potential mechanism for downstream increases in 
cardiovascular mortality associated with hypoglycaemia observed in 
interventional trials. 
8.2 Introduction 
Hypoglycaemia has been associated with an increase in cardiovascular 
deaths (Duckworth et al., 2009; Zoungas et al., 2010). In the previous 
chapters, it has been suggested that hypoglycaemia may enhance 
thrombotic risk via an increase in platelet reactivity acutely. However, in 
interventional trials, hypoglycaemia was associated with increased 
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mortality for up to 90 days after the event (Duckworth et al., 2009). 
Mechanisms by which hypoglycaemia is linked to increased cardiovascular 
mortality downstream of the event are unclear. 
Hypoglycaemia has been associated with an increase in coagulation 
activity, as shown by a rise in coagulation factor VIII activity during insulin-
induced hypoglycaemia in nondiabetic individuals (Grant et al., 1987). 
Receptor blockade with propranolol prevents the rise in factor VIII 
associated with hypoglycaemia, which suggests that this is also mediated 
by adrenergic control (Grant, 1990). vWF, an endothelial-derived factor 
that promotes thrombosis, is increased in response to hypoglycaemia 
(Fisher et al., 1991). In addition, a reduction in APTT has been reported 
following insulin-induced hypoglycaemia (Dalsgaard-Nielsen et al., 1982).  
In contrast, some studies have suggested that the fibrinolytic system is 
activated in response to hypoglycaemia induced by an insulin bolus. An 
increase in tPA and plasminogen activator activity and decrease in 
inhibitory factors such as PAI-1  have been reported during hypoglycaemia 
(Fisher et al., 1991; Wieczorek et al., 1993). However, these earlier studies 
lacked a euglycaemic control arm and it is unclear if the observations were 
due to the effects of insulin per se or due to low glucose.  Impaired 
fibrinolysis has been observed during more sustained hypoglycaemia and 
recent studies have found increases in PAI-1 and clot lysis times during 
hyperinsulinaemic hypoglycaemia maintained for more than an hour (Ajjan 
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et al., 2009). PAI-1 was also found to be increased during hypoglycaemia in 
nondiabetic but not T1DM subjects (Gogitidze Joy et al., 2010).  
Thrombosis and inflammation are interlinked; for example, IL-6 is known to 
increase fibrinogen as part of an acute phase response (Ray, 2000). 
Hypoglycaemia induces acute increases in inflammatory cytokines in 
nondiabetic and T1DM subjects. A study by Galloway et al. (2000) has 
shown that CRP increases for 24 hours after insulin induced hypoglycaemia 
in T1DM and healthy volunteers. Acute hypoglycaemia has also been 
associated with an acute rise in markers of inflammation, including soluble 
CD40 ligand, VCAM and ICAM (Gogitidze Joy et al., 2010; Wright et al., 
2010). No study to date appears to have examined the effect of 
hypoglycaemia on markers of thrombotic risk in T2DM individuals who are 
known to have an elevated risk of atherothrombotic events secondary to 
insulin resistance and other metabolic factors. Furthermore, no previous 
studies have examined markers for thrombosis risk, either acutely or in the 
days after an event when an elevated cardiovascular risk may persist. 
Therefore it was hypothesised that hypoglycaemia might oppose the 
cardiovascular benefits of intensive glycaemic control by modulating fibrin-
related thrombosis risk.   
The aim of this study was to delineate the effect of acute and downstream 
effects of hypoglycaemia on fibrin clot properties and inflammation in 
patients with T2DM versus nondiabetic controls. 
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8.3 Research Design and Methods 
These are described in detail in Section 2.3 and are outlined in brief below. 
8.3.1 Participants 
Twelve individuals with T2DM and no known CVD were recruited from 
Sheffield Teaching Hospitals diabetes outpatient clinics. Patients were on 
one or more oral hypoglycaemic agents and/or GLP-1 analogue and insulin 
<2 yrs. Eleven nondiabetic age and BMI matched controls were recruited 
from staff at the University of Sheffield and Sheffield Teaching Hospitals. 
Patients taking beta-blocking agents were excluded. Written informed 
consent was obtained from all participants and the study received local 
ethics approval. 
8.3.2 Hyperinsulinaemic Clamp Protocol 
All diabetic and nondiabetic subjects participated in paired 
hyperinsulinaemic euglycaemia and hypoglycaemia studies separated by 4-
8 weeks. In the hypoglycaemic arm, glucose was maintained at 2.5 mmol/L 
for 60 minutes in the morning and 60 minutes in the afternoon. In the 
euglycaemic arm, arterialised blood glucose was maintained at the target 
level of 6 mmol/L for 60 minutes in the morning and 60 minutes in the 
afternoon. Details of the hyperinsulinaemic clamp protocol are described in 
section 2.3.5. To investigate the effect of acute hypoglycaemia versus 
euglycaemia, prothrombotic and inflammatory markers were measured at 
the end of the morning clamp and at recovery (30 minutes after end of 
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clamp). To investigate downstream effects, thrombotic and inflammatory 
markers were also measured at 1 and 7 days after the euglycaemic and 
hypoglycaemic clamp visits.  Study visits were conducted in the morning to 
control for diurnal variation.  
8.3.3 Turbidimetric and Lysis Assay 
Ex vivo fibrin polymerisation characteristics of plasma samples were 
investigated using a turbidimetric clotting assay. The turbidimetric assay 
was performed as previously described (Carter et al., 2007). Blood was 
collected into tubes containing 3.2% sodium citrate on ice. Briefly, one 
volume of plasma was treated with 3 volumes of activation mix containing 
0.03 U/mL of thrombin and 7.5 mmol/L calcium. Turbidity was monitored 
in a 96 well plate every 12 seconds using a microplate reader to measure 
optical density. A turbidimetric lysis assay was conducted as above in the 
presence of tPA at a final concentration of 83 ng/mL. Clot maximum 
absorbance and lysis time (time for the initiation of clot formation to  fall 
50% in maximum absorbance) were calculated. Plasma clot maximum 
absorbance (MA) reflects the fibrin clot density, and lysis time the 
fibrinolytic potential (Alzahrani et al., 2012). 
8.3.4 Markers of Fibrin Dynamics and Inflammation 
Fibrinogen was measured using a validated Clauss method.  PAI-1 was 
assayed using an ELISA (PAI1 (SERPINE 1) Human SimpleStep ELISA Kit, 
Abcam), and  hsCRP using an immunoturbidimetric assay  (Cardiac CRP 
(Latex) high sensitivity, Roche Diagnostics, Indianopolis, USA). Levels of IL-
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6, MCP-1 and IL-10 were determined using a CBA (Human Il6, MCP-1, IL-10 
Flex sets, BD Biosciences, Oxford, UK). Complement C3 plasma levels, a 
protein that is incorporated into the fibrin clot and modulates fibrinolysis 
(Hess et al., 2012a), were determined by ELISA (Biosources, San Diego, 
USA). 
8.3.5 Scanning Electron Microscopy 
Pooled samples of plasma were analysed from 10 diabetic and 10 
nondiabetic subjects. Fibrin clots were made as previously described 
(Hooper et al., 2012)  and fixed overnight in 2% glutaraldehyde with clots 
recovered and further processed via stepwise dehydration with an acetone 
gradient and sputter coated with platinum palladium. Samples were 
viewed and photographed using a field-emission scanning electron 
microscope (LEO1530 FEGSEM, Leo Electron Microscopy, Cambridge, 
United Kingdom) across four different areas of each clot. Images were 
captured using Leo 32 version 03.0210 software (Leo Electron Microscopy) 
and cropped using Paintshop Pro version 8.0 (Corel, Minneapolis, MN). 
Fibre diameters of all the clots were measured using the image analysis 
software package ImageJ 1,23y (National Institutes of Health, Bethesda, 
MD). In all, 160 fibrin fibres per sample (40 fibres in four clot areas) were 
measured with the operator blinded to the sampling time point. The fibre 
network density was estimated by counting the number of fibres crossing 
an arbitrary line of fixed length drawn through a single optical section. 
Three lines were drawn per image and this was analysed on four different 
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micrographs from different areas of a clot for each sample (Hethershaw et 
al., 2014). 
8.3.6 Biochemical Analysis 
Catecholamines were assayed by HPLC. Whole blood (6 mL) was collected 
in chilled lithium heparin tubes containing 50 µL EGTA/glutathione 
preservative, subjected to centrifugation at 1000 ×g for 10 minutes, and 
the supernatant plasma removed and stored at -80oC prior to assaying. 
Free insulin was analysed by an immunometric assay (Invitron Insulin 
ELISA, Invitron Ltd, Monmouth, UK). Whole blood (3 mL) was drawn into 6 
mL lithium heparin tubes, subjected immediately to centrifugation at 4oC, 
2400 rpm for 2 minutes. A 0.5 mL aliquot of the resulting plasma was 
added to a chilled plastic tube containing 0.5 mL PEG for precipitation of 
immune complexes and mixed and the centrifugation step was repeated 
for 30 minutes. The product was then stored at -80oC until analysed by 
immunometric assay, where the inter-assay coefficient variation was 7.1%. 
The assay has 100% cross reactivity with Actrapid insulin. Serum cortisol 
was measured using a commercial electrochemilluminescence assay 
(Cobas, Roche Diagnostics, UK). Biochemical parameters were measured at 
baseline and at the end of the euglycaemic and hypoglycaemic arms in 
both groups. 
8.3.7 Statistical Analysis 
Baseline demographic data and prothrombotic and inflammatory markers 
are summarised as mean (SE) for parametric data unless otherwise stated, 
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or median (IQR) for nonparametric data. hsCRP and IL-6 were 
logarithmically transformed and expressed as geometric means (95% CI) 
due to a skewed distribution. Comparisons between diabetic and control 
groups in baseline data were made using an independent t-test for 
parametric data and Mann Whitney U test for nonparametric data.  Blood 
glucose and hormone concentrations were compared between equivalent 
euglycaemic and hypoglycaemic time points using a paired t-test or 
Wilcoxon signed-rank test.  
Fibrin thickness and fibrin network density from pooled samples were 
analysed using a two way repeated measures ANOVA for each subject 
group. Clot lysis, clot maximum absorbance, inflammatory and coagulation 
protein levels were analysed using a linear mixed model with repeated 
measures.  The mixed model allows for internally correlated measures 
from repeated measures (with respect to both the glycaemic arm and time) 
within an individual and also allows for missing values (Galbraith et al., 
2010). To investigate whether there was a significant change in 
prothrombotic markers over time within the glycaemic arms, time point 
was specified as a fixed effect in the linear mixed model. To analyse 
differences between glycaemic arms within each subject group, the 
glycaemic arm, time and interaction between glycaemic arm and time were 
specified as fixed effects.  In both analyses, the glycaemic arm and time 
point were specified as repeated measures. Repeated measures were 
fitted with an unstructured, compound symmetry or autoregressive 1 
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covariance structure and the model with the best fit (lowest Akaike’s 
information criterion) was selected. P values were obtained using a 
restricted maximum likelihood estimation and a p value of ≤ 0.05 was 
considered significant. Results were analysed using SPSS (version 20.0, IBM, 
Chicago, Illinois). 
The sample size calculation took into account the repeated measure 
design, assuming a correlation of 0.5 between repeated measures (Frison 
and Pocock, 1992). A sample size of 12 had 80% power to detect a clinically 
important difference of 25% in overall clot lysis times between glycaemic 
arms with a type 1 error rate of 0.05. This assumes a SD of 200 ms, based 
on a previous study of T2DM patients (Alzahrani et al., 2012) . 
8.4 Results 
8.4.1 Baseline Characteristics 
The demographics of the participants are as previously described. Twelve 
patients with T2DM (9 male, 3 female) and 11 nondiabetic controls (5 
male, 6 female) participated in the study. Participants with diabetes were 
similar in age, 54 (50-58) years compared to the nondiabetic group, 52 (47-
59) (p= 0.90), and the mean BMI was also comparable, 34±1 kg/m2 in the 
diabetic group versus 31±2 kg/m2 in the nondiabetic group (p=0.18). The 
median duration of diabetes was 10 (8-12) years and mean HbA1c was 
7.8±0.4% (62±4 mmol/mol). 
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Baseline prothrombotic and inflammatory markers are shown in Table 8-1. 
Clot lysis time tended to be shorter, whilst fibrinogen, hsCRP and IL-6 were 
higher in diabetic subjects. There was no statistically significant difference 
between euglycaemic and hypoglycaemic baselines for the prothrombotic 
markers (data not shown). 
Table 8-1: Baseline fibrin clot properties and inflammatory markers in diabetic 
and nondiabetic subjects 
Data presented are mean ±SEM. hsCRP expressed as geometric mean (95% CI)  p values shown are 
the comparison between group as determined by an independent t-test   
 Diabetic 
(n=12) 
Nondiabetic 
(n=11) 
p value 
Fibrin clot properties 
Clot MA (AU) 0.30±0.03 0.32±0.04 0.84 
Clot lysis time (s) 617±48 744±66 0.13 
Fibrin diameter (mm) 54±1 65±4  
Fibre network density 
fibres/µm
2 
5.52±.54 4.44±0.2  
Acute phase protein and inflammatory biomarkers 
Fibrinogen (mg/mL) 3.01±0.32 2.60±0.21 0.31 
PAI-1 (pg/mL) 3289±400 2435±378 0.14 
C3 (mg/mL) 1.04±0.04 1.02±0.07 0.79 
hsCRP (mg/L) 1.57 (0.66-3.73) 1.01 (0.37-2.77) 0.44 
 
8.4.2 Hyperinsulinaemic Clamp 
At the end of the morning euglycaemic clamp, glucose was 5.81±0.09 and 
5.96±0.05 mmol/L in the diabetic and nondiabetic groups, respectively, and 
following morning hypoglycaemia, blood glucose concentrations were 
2.55±0.06 mmol/L in the diabetic group and 2.56±0.03 mmol/L in the 
nondiabetic group. These were not significantly different between the 
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groups (Table 8-2). Blood glucose targets were also achieved during 
afternoon clamps within each arm.  
Median free insulin levels at 120 minutes were 576 (IQR: 468-627) pmol/L 
during euglycaemia and 689 (IQR: 477-1076) pmol/L during hypoglycaemia 
in the diabetic group. In the nondiabetic group it was 865 (IQR: 509-952) 
pmol/L in the euglycaemic arm and 665 (IQR: 468-967) pmol/L in the 
hypoglycaemic arm. A comparison of insulin levels between the groups 
under both euglycaemic and hypoglycaemic conditions was found not to be 
statistically different (p = 0.23). 
Counter-regulatory hormones did not change during the euglycaemic 
clamp (Table 8-2 ). During acute hypoglycaemia, adrenaline, adrenaline and 
cortisol increased significantly at the end of clamp in both groups (all 
p<0.05 versus baseline), although the peak levels were not significantly 
different between the diabetic and nondiabetic groups. 
8.4.3 Blood Glucose and Counter-regulatory Hormones at day 1 
and 7 
Blood glucose was not significantly different between the glycaemic arms 
except at day 1, where it was higher following hypoglycaemia in the 
diabetic group (Table 8-2). Plasma adrenaline and cortisol were not 
significantly different from baseline at day 1 and day 7 following the 
euglycaemic and hypoglycaemic clamps in either group (Table 8-2). 
However, in the nondiabetic group, plasma noradrenaline levels increased 
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significantly at day 1 after the euglycaemic clamp with a smaller non-
significant rise similarly following hypoglycaemia. 
 
 
 
Table 8-2: Blood glucose and counter-regulatory hormones during euglycaemia 
and hypoglycaemia in diabetic and nondiabetic subjects 
Data Mean ±SE *p<0.05, **p<0.01 euglycaemia versus hypoglycaemia within each subject 
group at the equivalent time point † † p<0.01 denotes significant difference between 
diabetic and control groups at equivalent euglycaemic or hypoglycaemic time point by 
independent t-test 
 Diabetic Nondiabetic 
Euglycaemia Hypoglycaemia Euglycaemia Hypoglycaemia 
Blood glucose (mmol/L) 
Baseline 6.24±0.33 6.44±0.37 5.10±0.15† 4.87±0.09† 
End of clamp 5.81±0.09 2.55±0.06** 5.96±0.06 2.56±0.03** 
Recovery 6.98±0.33 6.63±0.55 6.37±0.19 8.40±0.59** 
Day 1 7.88±0.84 11.4±1.09* 5.08±0.28† 5.00±0.29† 
Day 7 9.30±0.78 10.3±1.04 5.09±0.13† 4.96±0.21† 
Adrenaline (nmol/L) 
Baseline 0.15±0.04 0.12±0.03 0.17±0.03 0.15±0.02 
End of clamp 0.16±0.04 3.05±0.71** 0.14±0.02 3.83±0.86** 
Day 1 0.23±0.12 0.17±0.06 0.17±0.03 0.20±0.08 
Day 7 0.10±0.02 0.16±0.08 0.22±0.06 0.11±0.02 
Noradrenaline (nmol/L) 
Baseline 1.23±0.14 1.25±0.15 1.56±0.15 1.46±0.16 
End of clamp 1.27±0.09 2.37±0.24** 1.56±0.12 2.69±0.43** 
Day 1 1.97±0.15 1.93±0.10 3.08±0.44† 2.32±0.21 
Day 7 2.07±0.17 2.52±0.34 2.56±0.24 2.78±0.34 
Cortisol 
Baseline 277±25 329±37 338±43 300±39 
End of clamp 253±25 726±36** 256±33 656±45** 
Day 1 243±35 178±28 312±35 230±29 
Day 7 243±16 198±30 285±28 233±22 
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8.4.4 Fibrin Clot Properties 
8.4.4.1 Clot Lysis Time 
In diabetic subjects, clot lysis times decreased during euglycaemia versus 
an increase following hypoglycaemia up to day 7 (p=0.001 for glycaemic 
arm). Clot lysis times decreased Δ-81±25 s at the end of the euglycaemic 
clamp. Conversely, clot lysis times were prolonged at the end of the 
hypoglycaemic clamp Δ42±24 s returning to baseline at recovery. Clot lysis 
further increased at day 1 (Δ71±44 s) and day 7 (Δ67±30 s) (Figure 8-1). 
In nondiabetic subjects, clot lysis times decreased at the end of the 
euglycaemic clamp from Δ146±33 (p=0.02 versus baseline). Unlike diabetic 
subjects, there were no changes in clot lysis times in the hypoglycaemic 
arm in nondiabetic subjects.  
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Figure 8-1: Effect of euglycaemia and hypoglycaemia on clot density and clot 
lysis times by turbidimetric and lysis assay 
Diabetic euglycaemia (EU)- open square, diabetic hypoglycaemia (HYPO)- closed square, 
nondiabetic euglycaemia- open circle, nondiabetic hypoglycaemia - closed circle.† p<0.05  
†† p<0.01 euglycaemia versus hypoglycaemia at equivalent time points * p<0.05 versus 
baseline, ** p<0.01 versus baseline. Differences between glycaemic arm and the 
interaction between glycaemic arm and time by a mixed model with repeated measures 
are shown. Data mean (SE). Abbreviations: AU arbitrary units, MA maximum absorbance.  
8.4.4.2 Clot Maximum Absorbance  
In diabetic subjects, hypoglycaemia increased clot maximum absorbance, 
peaking at day 7 (Δ from baseline 0·030±0.016 AU), but decreased after 
euglycaemia (Δ –0·039±0·025 AU, p=0·007). In nondiabetic subjects, clot 
maximum absorbance decreased at the end of the euglycaemic clamp (Δ-
0.05±0.01 AU) but did not change significantly at the end of hypoglycaemia 
(Δ-0.02 ±0.05 AU) (Figure 8-1). There was a significant difference in the 
responses between the glycaemic arms (p=0.02).  
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8.4.5 Scanning Electron Microscopy 
8.4.5.1 Fibrin Diameter 
Fibrin diameter did not change significantly during euglycaemia or 
hypoglycaemia in the nondiabetic group (Figure 8-2). In the diabetic 
subjects, there were no changes in fibrin fibre diameter during 
euglycaemia, but this increased from Δ from baseline 28±2mm at day 1 and 
30±3mm at day 7 following hypoglycaemia (p<0.0001 for time). There was 
a significant difference between glycaemic arms (p<0.0001) and the 
interaction between time and glycaemic arm (p<0.0001 by two way 
repeated measures ANOVA). 
 
Figure 8-2: Fibre thickness following euglycaemia versus hypoglycaemia at 
baseline, day 1 and day 7 in diabetic and nondiabetic subjects 
Fibrin thickness following euglycaemia (EU) (black) versus hypoglycaemia (HYPO) grey. 
Fibre thickness was measured for a total number of 160 fibres (40 fibres measured from 4 
different clot areas at each time point)  ** p<0.01 by paired t-test between euglycaemia 
versus hypoglycaemia  Data mean (SE) 
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8.4.5.2 Fibrin Network Density 
In the nondiabetic group, fibre network density decreased Δ 1.82±0.27 
fibres/µm2 at day 1 after euglycaemia (p<0.0001), and the fibrin network 
density increased from Δ 1.15±0.28 fibres/µm2 at day 7 following the 
hypoglycaemic clamp (p<0.01) (Figure 8-4). 
In the diabetes group, the fibre network density decreased Δ-1.68±0.24 
fibres/µm2 at day 7 following euglycaemia (p<0.001), whilst following 
hypoglycaemia, there was an increase in the fibre network density Δ 
0.53±0.36  at day 1 fibres/µm2 and Δ1.43±0.24 fibres/µm2 at day 7 (p<0.01) 
(Figure 8-4). There were significant differences between the glycaemic 
arms and the interaction between glycaemic arm and time in both the 
diabetic and nondiabetic groups (both p<0.0001). Examples of scanning 
electron micrographs of pooled fibrin clots are shown in Figure 8-3.  
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DIABETIC    NONDIABETIC 
Baseline      Baseline 
 
 Euglycaemia day 7        
 
Hypoglycaemia day 
 
   
 
Figure 8-3: Scanning electron micrographs of fibrin clots following euglycaemia 
versus hypoglycaemia in diabetic and nondiabetic subjects  
Visualisation of ex vivo fibrin clots from pooled plasma samples in diabetic (n=10) and 
nondiabetic (n=10) subjects. There is a decrease in the fibre network following 
euglycaemia in both groups as opposed to an increase in the network density following 
hypoglycaemia at day 7. 
3µm 
Euglycaemia day 1 
Hypoglycaemia day 7 
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Figure 8-4: Fibrin network density following hypoglycaemia versus euglycaemia 
in diabetic and nondiabetic subjects 
Fibrin fibre density following euglycaemia (EU) (black) versus hypoglycaemia (HYPO) grey. 
* p<0.01, ** p<0.01, ****p<0.0001 between euglycaemia versus hypoglycaemia.  Data 
mean (SE) 
8.4.6 Coagulation Proteins 
8.4.6.1 Fibrinogen  
Euglycaemic and hypoglycaemic clamps had different effects on plasma 
fibrinogen levels in the diabetic group (p=0.05) (Figure 8-5). Fibrinogen did 
not change during euglycaemia but increased Δ 0.20±0.10 mg/mL at day 1 
and Δ0.85±0.69 mg/mL at day 7 following hypoglycaemia. In the 
nondiabetic group, fibrinogen tended to decrease at the end of the clamp 
and recover similarly in both glycaemic arms (Figure 8-5). 
8.4.6.2 Plasminogen Acivator-1 
In diabetic subjects, PAI-1 decreased significantly from baseline Δ -811 
±204 pg/mL at the end of the euglycaemic clamp (p<0.001 versus baseline) 
and remained lower at day 7. PAI-1 decreased to a similar extent during 
the hypoglycaemic clamp (Δ-888±256, p=0.001 versus baseline) with no 
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significant differences detected between the glycaemic arms (p=0.99). PAI-
1 also decreased in the nondiabetic group during euglycaemia and 
hypoglycaemia (both p<0.01 for time) with again no significant difference 
between the glycaemic arms (p=0.66). PAI-1 decreased to a similar extent 
in both diabetic and control groups during euglycaemia and hypoglycaemia 
(Figure 8-5). 
 
 
Figure 8-5: Effect of euglycaemia and hypoglycaemia on coagulation proteins in 
diabetic and nondiabetic subjects  
Diabetic euglycaemia (EU)-open square, diabetic hypoglycaemia (HYPO)-closed square, 
nondiabetic euglycaemia-open circle, nondiabetic hypoglycaemia-closed circle. † p<0.05  
†† p<0.01 euglycaemia versus hypoglycaemia at equivalent time points * p<0.05 versus 
baseline, ** p<0.01 versus baseline. Differences between glycaemic arm and the 
interaction between glycaemic arm and time by a mixed model with repeated measures 
are shown. Data mean (SE). Abbreviations: C3, complement component C3, PAI-
1,plasminogen activator 1, 
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8.4.7 Inflammatory Proteins 
8.4.7.1 hsCRP  
In diabetic subjects, hsCRP decreased following euglycaemia at day 7 (log 
hsCRP - Δ0.11±0.01 p=0.02 versus baseline) but tended to increase 
following hypoglycaemia (log hsCRP Δ0.06±0.01 at day 7) and this was 
significant between the glycaemic arms at day 7 (p=0.002) and there was 
also a significant interaction between time and glycaemic arm (p=0.04). In 
nondiabetic subjects, hsCRP increased similarly at day 1 following 
euglycaemia and hypoglycaemia, with no significant differences between 
the glycaemic arms (Figure 8-6). 
8.4.7.2 Complement Component C3 
C3 levels did not change during euglycaemia in the diabetic group but 
showed a trend towards an increase at day 7 following hypoglycaemia 
(from 99±5 to 108±4 mg/mL, p=0.10 versus baseline) (Figure 8-6). There 
were significant differences in the change in C3 at day 7 between the 
glycaemic arms (p=0.02). In the control group, C3 levels were similar during 
euglycaemia and hypoglycaemia and did not change significantly. 
 
8.4.7.3 Interleukin 6, interleukin 8 and interleukin 10 
In the diabetic group, IL-6 did not change during the euglycaemic arm, 
although there was a trend towards an increase in IL-6 following 
hypoglycaemia at day 7. In the nondiabetic group, IL-6 was higher at day 1 
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following euglycaemia but did not change significantly following 
hypoglycaemia (Table 8-3). 
In the diabetic group, IL-8 demonstrated a trend to increase from 
6.10±0.84 pmol/L to 8.64±1.33 pmol/L at day 7 following hypoglycaemia 
are compared with no change after euglycaemia.  There was a significant 
interaction between the glycaemic arm and time (p= 0.03).  IL-10 tended to 
increase during euglycaemia in the diabetic group (Table 8-3) and also 
increased following hypoglycaemia at day 7 (p=0.04 for time). IL-8 and IL-
10 did not change within the euglycaemic or hypoglycaemic arm in 
nondiabetic individuals (Table 8-3). 
 
Figure 8-6: Changes in hsCRP and C3 following euglycaemia versus 
hypoglycaemia in diabetic and nondiabetic subjects 
Data mean (SE) ** p<0.01 euglycaemia vs hypoglycaemia at equivalent time points 
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Table 8-3: Inflammatory cytokines following euglycaemia and hypoglycaemia 
arms in diabetic and nondiabetic subjects 
IL-6 interleukin 6, IL-8 interleukin 8, IL-10 interleukin 10 * p<0.05 versus baseline. Data 
mean±SE 
 Baseline End of clamp Day 1 Day 7 
IL-6 (pg/mL) 
Diabetic 
Euglycaemia 3.99±1.22 4.08±0.81 4.36±0.58 3.97±0.86 
Hypoglycaemia 4.93±0.96 4.97±0.65 5.02±0.79 5.30±2.43 
Nondiabetic 
Euglycaemia 3.34±0.72 3,73±0.94 5.07±0.81* 4.75±0.95 
Hypoglycaemia 3.62±1.37 3.89±1.22 3.40±0.79 4.03±1.01 
IL-8 (pg/mL) 
Diabetic 
Euglycaemia 5.81±1.18 4.87±0.91 7.74±1.25 6.65±1.18 
Hypoglycaemia 6.10±0.84 6.77±1.30 5.92±0.75 8.23±1.33 
Nondiabetic 
Euglycaemia 4.56±0.85 4.80±0.80 4.97±0.80 4.86±0.86 
Hypoglycaemia 3.59±0.59 5.01±1.58 4.19±0.99 4.73±1.03 
IL-10 (pg/mL) 
Diabetic 
Euglycaemia 1.37±0.32 1.54±0.22 1.68±0.23 1.92±0.33 
Hypoglycaemia 1.65±0.29 1.88±0.21 1.53±0.25 2.11±0.35 
Nondiabetic 
Euglycaemia 1.37±0.22 1.37±0.18 1,52±0.27 1.62±0.25 
Hypoglycaemia 1.43±0.13 1.71±0.29 1.50±0.22 1.72±0.22 
 
8.5 Discussion  
A number of novel findings have emerged from this study : 1)  
hypoglycaemia was associated with the formation of fibrin clots that are 
resistant to fibrinolysis, with these effects occurring acutely and persisting 
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for at least a week; 2) hypoglycaemia-induced changes in the fibrin 
network structure which were more prominent in diabetic subjects 
compared to nondiabetic subjects; and 3) increased levels of fibrinogen 
and C3 are likely to contribute to changes in fibrin clot structure and lysis, 
whereas PAI-1 does not appear to be a mediator.   
The antithrombotic, profibrinolytic and anti-inflammatory response of 
euglycaemic hyperinsulinaemia is in agreement with previous human 
studies (Chaudhuri et al., 2004). In this study hyperinsulinaemic 
euglycaemia acutely reduced clot density, as shown by falls in clot 
maximum absorbance in diabetic and nondiabetic groups. Such effects may 
have two mechanistic explanations. The first is related to the dilutional 
effect of infusing fluid and insulin, whereas the second mechanism is 
related to the ability of insulin to suppress fibrinogen levels  (Barazzoni et 
al., 2003). The attenuated decrement in fibrinogen and clot density in 
diabetic individuals may reflect insulin resistance or altered hepatic 
fibrinogen synthesis in T2DM subjects (Barazzoni et al., 2003). Notably in 
this study, hyperinsulinaemic euglycaemia was associated with a reduced 
fibrin network density up to a week later. Previous work has shown that 
the treatment of T1DM patients with continuous subcutaneous insulin 
therapy increases clot porosity, regardless of the effect of glycaemic 
control (Jörneskog et al., 2014). 
Hyperinsulinaemic euglycaemia also decreased clot lysis times. This may be 
mediated by decreases in PAI-1 levels, consistent with earlier studies 
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conducted in individuals without diabetes (Landin et al., 1991). An 
attenuated rise in PAI-1 has also been observed in patients with diabetes 
with myocardial infarction who were infused with intravenous insulin for 
48 hours to maintain euglycaemia (Chaudhuri et al., 2004). However, other 
studies have suggested that insulin induces PAI-1 gene expression and 
increases PAI-1 plasma levels in insulin resistant and normal subjects 
(Stegenga et al., 2006). The reasons for these discrepancies in these 
observations are unclear but may be because higher doses of insulin were 
infused in the present study. The mean plasma insulin level in the study by 
Stegenga and colleagues was 400pmol/L which is 1.5 times lower than our 
clamps. 
Insulin has anti-inflammatory effects that are independent of its glucose 
lowering effects. Diabetic myocardial infarction patients who received 
continuous insulin infusion to maintain euglycaemia for 48 hours showed 
an attenuated increase in CRP  (Chaudhuri et al., 2004), a finding that has 
been replicated by other groups (Wong et al., 2004). Previous studies have 
shown decreases in sCD40L, cell adhesion molecules, and IL-6 during 
hyperinsulinaemic euglycaemia in T1DM and nondiabetic subjects 
(Gogitidze Joy et al., 2010; Wright et al., 2010). Insulin induces the 
expression of NO synthetase in the endothelium via  the PI3/Akt pathway 
(Aljada and Dandona, 2000).  Insulin also inhibits NFκB and MCP-1 
expression in human aortic endothelial cells (Aljada et al., 2001). The onset 
of action of the anti-inflammatory effect of insulin has been shown to be 
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rapid, occurring within two hours (Dandona et al., 2009). Relatively few 
studies have explored the effects of euglycaemic hyperinsulinaemia 
beyond the period of acute administration. In an endotoxaemic model, rats 
that were administered with subcutaneous insulin showed reduced 
inflammatory responses in serum IL-6, TNFα and IL1-β for up to 7 days 
(Jeschke et al., 2004). Interestingly, in the present study, the anti-
inflammatory cytokine IL-10 was increased for up to 7 days following 
hyperinsulinaemic euglycaemia and hypoglycaemia in the diabetic group, 
but not in nondiabetic subjects. Insulin has been shown to specifically 
antagonise proinflammatory signalling at the level of the adipocyte 
(Andersson et al., 2007) and this may underlie the more pronounced anti-
inflammatory effects in the diabetic group. 
With regards to the acute effects of hypoglycaemia, the results of this 
study differ from those of previous studies which have shown that 
hypoglycaemia induced by insulin resulted in the enhancement of 
fibrinolysis, with decreases in PAI-1 activity and increases in tPA 
(Dalsgaard-Nielsen et al., 1982; Fisher et al., 1991). Previous authors have 
not included a euglycaemic control arm and hence this may reflect 
profibrinolytic effects of insulin. 
A novel and intriguing observation is the ongoing effect of hypoglycaemia 
on clot density that persisted 7 days after hypoglycaemia. Hypoglycaemia 
increased fibre density in both diabetic and nondiabetic subjects. However, 
hypoglycaemia only increased fibre thickness in subjects with T2DM but 
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the nondiabetic subjects, with no change during hyperinsulinaemic 
euglycaemia. This may be explained by the increase in fibrinogen which did 
not occur in the nondiabetic subjects.  There is evidence that dysregulated 
fibrinogen synthesis occurs in patients with T2DM (Tessari et al., 2006). 
Hypoglycaemia had a hypofibrinolytic effect for at least 7 days in diabetic 
subjects. Clot lysis times increased for up to 7 days after hypoglycaemia 
and were prolonged to a greater extent in diabetic compared to 
nondiabetic subjects. Denser fibre networks were observed in both groups 
and an increase in fibre thickness was observed in diabetic subjects but not 
nondiabetic subjects. These differences cannot be explained by changes in 
PAI-1 which was similarly depressed in the euglycaemic arm. However, 
levels of complement component C3 were increased, and this has been 
associated with increased resistance to clot lysis, particularly in clots 
composed of diabetic fibrinogen compared to those in healthy subjects 
(Hess et al., 2012a), 
The mechanisms driving sustained changes in fibrin clot density and 
fibrinolysis following hypoglycaemia are unclear. However, it can be 
hypothesised that this may be driven by subclinical inflammation, which 
exhibited similar trends to fibrin clot properties. There were modest rises 
in markers of subclinical inflammation (hsCRP, IL-6, IL-8, C3 and fibrinogen) 
following hypoglycaemia up to day 7 in diabetic subjects and this did not 
occur in nondiabetic individuals. The importance of C3 as a contributor to  
hypofibrinolysis has recently been confirmed in a T2DM cohort (Hess et al., 
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2014).   Aggravation of atherothrombosis has also been shown to occur 
follow AMI in mouse models, where it is thought that sympathetically 
mediated rise in the mobilisation of haemopoetic stem cells may promote 
proinflammatory responses in the weeks after the event (Dutta et al., 
2012). Furthermore, chronic hyperglycaemia has been shown to prime the 
innate immune system for an exaggerated inflammatory  response to 
physiological challenges, which may explain why such changes occurred 
following hypoglycaemia in T2DM subjects but not the nondiabetic 
subjects (Gyurko et al., 2006). 
The present study had some limitations as the number of participants, 
while adequate to demonstrate changes in clot density, may be short of 
power to identify subtle differences between diabetic and nondiabetic 
groups.  It was necessary to administer high doses of insulin (120 
mU/m2/min in the morning and 240 mU/m2/min afternoon) in order to 
induce hypoglycaemia in insulin resistant individuals and it was intended as 
part of the study design to give equivalent amounts of insulin between the 
glycaemic arms and between groups. Such supraphysiological doses are 
markedly higher than during routine clinical use and this might 
artefactually limit prothrombotic and proinflammatory changes due to 
hypoglycaemia.  Another potential limitation is the slightly higher number 
of males in the diabetic group. For ethical reasons, hypoglycaemia was not 
induced in individuals with known CVD, although studies have shown that 
intensive glucose lowering exerts greater cardiovascular benefit in patients 
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with low cardiovascular risk compared with those with established CVD 
(Holman et al., 2008; Reaven et al., 2009).  
This data supports a causal role for hypoglycaemia in increasing 
cardiovascular mortality, mitigating the benefits of intensive glycaemic 
control, and intensive insulin therapy. This is of clinical relevance in several 
contexts; in the use of intensive insulin therapy in critically care and during 
intensive glycaemic control in T2DM patients. In the NICE-SUGAR study, 
critically ill   patients randomised to intensive insulin therapy to achieve 
tight glycaemic targets exhibited excess mortality (Finfer et al., 2009). Post 
hoc analysis showed a strong association between death and 
hypoglycaemia that persisted despite adjusting for confounding factors.  In 
the study, the median time to death from the occurrence of a 
hypoglycaemic event was 7 days for moderate hypoglycaemia and 8 days 
for severe hypoglycaemia, and this time course closely matches the 
findings from this study  of a worsening thrombotic profile one week after 
hypoglycaemia (Finfer et al., 2012). 
An alternative explanation for the lack of improvement in mortality with 
intensive insulin therapy in some studies is that the insulin dose was not 
sufficiently high to achieve beneficial anti-inflammatory, antithrombotic 
effects. In the study by van den Berghe et al. (2001) which demonstrated a 
reduction in mortality and morbidity in critically care patients receiving 
intensive insulin therapy, significantly higher doses were used (71 units/day 
versus 30-50 units/day) compared with other studies that did not 
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demonstrate any benefit (Brunkhorst et al., 2008; Finfer et al., 2009). The 
dose and also the duration of insulin infusion may be relevant, as insulin 
given for three or more days reduced mortality in medical intensive care 
patients but not in those who received insulin for less than 3 days (Van den 
Berghe et al., 2006). 
The current findings provide a putative mechanism by which 
hypoglycaemia may increase the risk of cardiovascular death in the weeks 
and months following an episode of severe hypoglycaemia during intensive 
glycaemic control in patients with T2DM.  The prothrombotic and 
proinflammatory effects of hypoglycaemia, although modest, may be 
sufficient to predispose individuals at high risk to an acute coronary event.  
In  the Northwick Park study, fibrinogen was Δ0.35 g/L higher (2.90 g/L 
versus 3.25 g/L) in men who subsequently died of CVD in the following 5 
years (Meade et al., 1986), differences which are of a similar magnitude to 
those observed in this study. 
In conclusion, it has been shown that hypoglycaemia has acute 
prothrombotic effects in both nondiabetic and T2DM subjects. It has also 
been demonstrated that the impact of moderate, short-lived 
hypoglycaemia is maintained for at least 7 days after the event, with 
adverse effects on fibrin clot properties, fibrinolysis and subclinical 
inflammation, and these effects were more prominent among individuals 
with T2DM. These effects oppose the beneficial anti-thrombotic, anti-
inflammatory and fibrinolytic properties of intravenous insulin 
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administered under euglycaemic conditions. Thus potential mechanisms 
have been identified whereby hypoglycaemia could increase the risk of 
cardiovascular events during and after an episode, thereby counteracting 
the benefits of intensive glycaemic control.  
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Chapter 9 - Final Discussion 
9.1 Summary of Findings 
The aim of this work was to explore the potential mechanism by which 
hypoglycaemia can increase the risk of SCD in patients with T2DM in the 
context of intensive glycaemic therapy. SCD is a multifactorial process 
involving distal factors promoting atherogenesis, transition to an 
inflammatory plaque, development of acute coronary thrombosis, and a 
transient trigger leading to fatal arrhythmia and sudden death. In this 
work, potential mechanisms have been demonstrated that can increase 
the risk of SCD using ambulatory and experimental models of 
hypoglycaemia in T2DM patients. The main findings of this work can be 
summarised into four main points: 
1. Hypoglycaemia has acute proarrhythmic effects, as manifest by 
altered autonomic balance and abnormal repolarisation. 
Hypoglycaemia is also prothrombotic, acutely due to enhanced 
platelet reactivity, and downstream of the event due to altered 
fibrin clot properties and hypofibrinolysis. 
2. There are differential cardiovascular effects of hypoglycaemia 
dependent on the state of sympathoadrenal activation. 
3. Hyperinsulinaemic euglycaemia has beneficial cardiovascular effects 
that may be opposed by hypoglycaemia 
4. The adverse cardiovascular effects of hypoglycaemia on fibrin clot 
properties and inflammation are enhanced in T2DM patients  
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9.1.1 Hypoglycaemia Predisposes to Sudden Cardiac Death via 
Proarrhythmic and Prothrombotic Pathways 
Acute hypoglycaemia may have proarrhythmic effects via changes in 
sympathovagal balance and prolongation of cardiac repolarisation. Here 
we demonstrate transient vagal withdrawal followed by vagal reactivation 
during sustained hypoglycaemia in T2DM individuals. QTc is prolonged 
during acute hypoglycaemia in both spontaneous and experimental 
settings. The combined electrophysiological effects may serve as a 
transient trigger for supraventricular and ventricular arrhythmias via 
abnormal automaticity and triggered activity (Fig 9-1). 
The balance between prothrombotic and profibrinolytic factors dictates 
the propensity for coronary thrombus formation following plaque rupture. 
Here it has been demonstrated that acute hypoglycaemia causes increases 
in platelet activation and platelet reactivity. The present study also 
demonstrated that hypoglycaemia has sustained adverse effects on clot 
density and depresses fibrinolysis for up to seven days after an episode 
that are more pronounced in T2DM subjects. Figure 9-1 illustrates a revised 
hypothetical model which integrates the findings from both studies.  
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Figure 9-1: Revised model of potential mechanisms of hypoglycaemia-related 
SCD 
Acute effects of hypoglycaemia with associated sympathoadrenal activation and 
hypokalaemia can cause abnormal repolarisation, increasing the risk of ventricular 
arrhythmias. Autonomic balance can further enhance this arrhythmic risk. Acute 
hypoglycaemia is also prothrombotic and enhances platelet aggregation via adrenaline 
release. However, hypoglycaemia may have longer lasting effects on the cardiovascular 
system in the days and weeks following an event. A suppression of cardiovagal function 
leading to unrestrained sympathetic nervous system activity (SNS) can mediate 
proinflammatory changes and atherothrombotic changes. This might increase the 
propensity for plaque rupture, acute coronary thrombosis, and SCD. 
9.1.2 Differential Cardiovascular Effects of Hypoglycaemia Depend 
on the state of Sympathoadrenal Activation 
In the ambulatory study, daytime hypoglycaemia was associated with a 
transient cardioacceleration and vagal withdrawal. During nocturnal 
prolonged hypoglycaemia where sympathoadrenal activation was weak, 
there was a phasic cardiac response, whereby initial vagal withdrawal and 
sympathetic activation was followed by excessive vagal counteraction that 
led to relative bradycardia. Therefore the cardiovascular effects of 
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hypoglycaemia may significantly differ according to the state of 
sympathoadrenal activation (Figure 9-2). 
 
Figure 9-2:  Differential cardiovascular effects of hypoglycaemia depending on 
the strength of sympathoadrenal activation 
In situations where there is a strong sympathoadrenal response, as in the case of 
symptomatic daytime hypoglycaemia or in populations, QT prolongation and increases in 
platelet reactivity are likely to occur due to catecholamine release. This is in contrast with 
situations where there is diminished sympathoadrenal activation and high vagal tone, 
such as in nocturnal hypoglycaemia or in those with hypoglycaemia unawareness, where 
phasic changes in sympathovagal balance occur. 
Furthermore, there is considerable heterogeneity in counter-regulatory 
responses to hypoglycaemia in T2DM patients. In patients with advanced 
T2DM and long duration on insulin, sympathoadrenal responses to 
hypoglycaemia may be diminished. They are more likely to experience 
frequent hypoglycaemia but these episodes are also more likely to be 
asymptomatic. These hypoglycaemic episodes are likely to be associated 
with blunted sympathoadrenal responses and increased vagal 
counteraction (see Figure 9-2).  
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In contrast, T2DM patients with early disease and intact counter-regulatory 
responses are at lower risk of clinical hypoglycaemia. Hypoglycaemic 
episodes should be infrequent, except under iatrogenic circumstances, 
such as during rapid intensification of glucose therapy (Gerstein et al., 
2008). These episodes are therefore likely to be associated with strong 
sympathoadrenal responses. Acute sympathoadrenal activation results in 
cardiac repolarisation prolongation and cardioacceleration. Acute releases 
of catecholamines may promote increases in platelet aggregation, as 
shown in experimental models of hyperinsulinaemic hypoglycaemia. What 
is unknown is whether downstream proinflammatory, prothrombotic 
changes after an episode, as observed in our data, are related to the 
strength of sympathoadrenal activation at the time of the event. It was 
hypothesised that hypoglycaemia, analogous to other stressors, results in a 
rise in splenic mobilisation proinflammatory cells as a consequence of 
heightened sympathetic activity (Dutta et al., 2012). 
The impact of differential sympathoadrenal responses to hypoglycaemia on 
cardiovascular outcomes need to be considered, particularly in the 
interpretation of relationships between reported and asymptomatic 
hypoglycaemia and cardiovascular events in clinical trials (Seaquist et al., 
2012) 
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9.1.3 Beneficial Cardiovascular Effects of Hyperinsulinaemic 
Euglycaemia may be mitigated by Hypoglycaemia 
The original aim of the euglycaemic arm was to serve as a control for the 
effects of insulin. However, this has shed light on the actions of insulin in 
both normal and T2DM subjects. It has been confirmed that 
hyperinsulinaemic euglycaemia has acute anti-aggregatory, antithrombotic 
properties when administered intravenously and may have sustained anti-
inflammatory effects some days later. These potentially beneficial effects 
of insulin are opposed by the adverse effects of hypoglycaemia. For 
example, in the case of platelet aggregation, adrenaline neutralised the 
anti-aggregatory effects of hyperinsulinaemia blocking the insulin receptor 
β subunit and affecting G protein coupled pathways (Ferreira et al., 2003).  
This is of importance when understanding the risk–benefit balance of 
intensive glycaemic control within clinical settings. 
9.1.4 Adverse Cardiovascular Effects of Hypoglycaemia on Fibrin 
Clot Properties and Inflammation are enhanced in Type 2 
Diabetes  
This work has highlighted a number of similarities between T2DM and 
nondiabetic subjects in responses to hypoglycaemia. For example, there 
was increase in platelet macroaggregation and initial cardioacceleration to 
acute hypoglycaemia in both groups.  However, there were also differences 
between T2DM and nondiabetic subejcts. In diabetic patients, vagal 
reactivation occurred during sustained hypoglycaemia leading to cardiac 
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slowing which did not occur in nondiabetic subjects. Diastolic blood 
pressure declined to a smaller extent during hypoglycaemia in T2DM 
compared with nondiabetic subjects. In earlier discussions, it was 
hypothesised that the differential responses may conceivably relate to 
differences in baroreceptor and haemodynamic function. It was reasoned 
that the abrupt increases in pulse pressure during hypoglycaemia  in 
diabetic subjects can increase baroreceptor firing and vagal activation (Bell, 
2013; Chapleau et al., 1988), however, these observations are in need of 
further investigation.   
In addition, there were increases in fibrin clot density and hypofibrinolysis 
up to seven days after hypoglycaemia in T2DM patients compared with no 
change in nondiabetic controls. This was mirrored by increases in markers 
of subclinical inflammation for at least seven days after hypoglycaemia in 
diabetic subjects but not nondiabetic subjects. T2DM subjects in the clamp 
study did not have overt CVD; however, they did exhibit higher levels of 
subclinical inflammation, higher levels of prothrombotic markers including 
higher platelet reactivity, increased fibrinogen and PAI-1, as well as denser 
clots that were resistant to fibrinolysis.  There are suggestions that chronic 
hyperglycaemia may prime the innate system to exaggerate inflammatory 
changes in response to physiological challenges, potentially explaining why 
adverse effects of hypoglycaemia on inflammation  and thrombosis may be 
enhanced in T2DM (Gyurko et al., 2006).   However, this remains 
speculative. The precise mechanisms may be challenging to disentangle in 
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human studies alone, and might require complementary studies using 
animal models. 
9.2 Future Directions 
The current research poses a number of questions and the aim of future 
work should be to provide deeper mechanistic insight into cardiovascular 
effects of hypoglycaemia and to translate the current findings into areas of 
potential therapeutic benefit. Several potential avenues for exploration will 
be described below.  
9.2.1 Mechanistic Studies 
9.2.1.1 Effect of Hypoglycaemia on Inflammatory Pathways and the 
Relationship with Thrombosis 
In this study it has been shown that hypoglycaemia is capable of inducing 
sustained changes in fibrin clot properties, increases in clot density, and 
reduced clot lysis up to seven days later in T2DM patients. Mechanisms 
underlying this are uncertain but it is hypothesised that subclinical 
inflammation, which increased after hypoglycaemia, may underlie the 
worsening thrombotic profiles. To investigate this hypothesis, 
collaborations with experts in immune and vascular biology have been 
established and further preliminary data has been developed 
demonstrating the effects of hypoglycaemia on monocyte function. This 
has led to the successful funding of a project currently under way to 
investigate the effects of hypoglycaemia on inflammatory pathways. 
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In this experimental study, changes in immune cell function and 
inflammatory cytokines following an episode of insulin-induced 
hypoglycaemia will be probed using a low-dose endotoxin challenge model 
in healthy volunteers. Downstream effects will be investigated at seven 
and thirty days. In the current study, it was more difficult to demonstrate 
more modest but clinically important changes with a small sample size, and 
the priming effects of endotoxin may help to elucidate changes in 
subclinical inflammation following hypoglycaemia by enhancing the 
immune response.  
9.2.1.2 Effects of Hypoglycaemia on Atherosclerotic Plaques 
Results from interventional trials have shown that intensive glycaemic 
control had neutral or favourable effects on those with a low 
atherosclerotic burden; however, in patients with a high cardiovascular 
burden, intensive control was associated with adverse cardiovascular 
outcomes (Reaven et al., 2009).  Although  the electrophysiological effects 
of hypoglycaemia in patients with T2DM and high cardiovascular risk an in 
ambulatory setting were studied, it was impossible to examine thrombotic 
mechanisms using experimental hypoglycaemia in this  population due to 
safety and ethical considerations. It would be of value to examine the 
effect of hypoglycaemia on the atherosclerotic plaque, particularly 
concerning whether this could lead to the transition to unstable plaques; 
however, this would be challenging to examine in human models. 
Therefore, in collaboration with other groups with expertise in murine 
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models of atherosclerosis and animal models of hypoglycaemia, a 
proposed study is under way to investigate the effect of hypoglycaemia on 
changes in atherosclerotic plaques. In the planned study, hypoglycaemia 
will be induced in ApoE-/- mice and changes in plaque composition will be 
quantified along with changes in inflammatory cytokines and compared 
with euglycaemic counterparts. 
 
9.2.1.3 Physiology of Nocturnal Hypoglycaemia and Relationship 
with Autonomic Control 
The frequency of asymptomatic nocturnal hypoglycaemia among insulin-
treated T2DM patients was much higher than expected.  In the ambulatory 
study, an undulating pattern of glucose was demonstrated during 
prolonged nocturnal hypoglycaemia that has previously been reported only 
in a few studies in T1DM patients (Matyka et al., 1999). The physiological 
mechanisms underlying this are unclear. Further we reported phasic 
responses in cardiac autonomic function that parallel changes in glucose 
during spontaneous nocturnal hypoglycaemia.  
To corroborate findings from the ambulatory study, a two-part human 
experimental study is proposed to investigate glucose, counterregulatory 
and cardiac autonomic responses to nocturnal hypoglycaemia in a 
laboratory setting.  The advantage is that HRV and blood sampling for 
determination of catecholamines and electrolytes can be performed at 
regular intervals. Measurements of blood glucose, as opposed to IG, will 
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avoid problems of interstitial lag and inaccuracies in the hypoglycaemic 
range. In the first part of the study, insulin-treated T2DM subjects will be 
recruited to study counter-regulatory and cardiac autonomic responses 
during spontaneous nocturnal hypoglycaemia. Given the high frequency of 
nocturnal hypoglycaemia in the ambulatory cohort of insulin-treated T2DM 
patients (14 out of 25 subjects), it may be feasible to capture sufficient 
spontaneous episodes based on two overnight visits per subject. The 
second part of the study would involve sustained hyperinsulinaemic 
hypoglycaemia induced overnight with continuous ECG monitoring for 
assessment of HRV.  Pharmacological adrenergic and parasympathetic 
blockade may be administered at the end of the hypoglycaemic clamp to 
further probe the interaction between sympathetic and vagal arms.  A 
schematic diagram of the proposed studies is shown in Figure 9-3. 
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Figure 9-3: Schematic diagram for the proposed studies to investigate 
autonomic and counter-regulatory responses to nocturnal hypoglycaemia in 
T2DM subjects 
EU-euglycaemia; HYPO-hypoglycaemia, HRV-heart rate variability, CAT- catecholamines 
(see text for details). 
9.2.1.4 Computer Simulation of Cardiac Electrophysiological 
Changes during Hypoglycaemia in the Presence of Ion 
Channel Mutations 
SCDs are stochastic events, and given that hypoglycaemia is relatively 
common and arrhythmias and sudden deaths are relatively rare, additional 
factors must determine the risk of arrhythmias in response to the transient 
physiological challenge of hypoglycaemia. It has been demonstrated that 
individuals with a reduced repolarisation reserve displayed highly abnormal 
repolarisation during spontaneous hypoglycaemia. It is increasingly 
recognised that genetic or acquired mutations in cardiac ion channels may 
be responsible for abnormal cardiac repolarisation. For example, it has 
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been shown that changes to the persistent sodium current in diabetes may 
be responsible for QT prolongation in diabetes (Lu et al., 2013).  
Furthermore, low glucose itself has been suggested to affect HERG channel 
function (Zhang et al., 2003b). The effect of ion channel mutations on ECG 
waveforms have been simulated using a computerised model based upon 
human ventricular tissue (K.Q. Wang, 2006). Similar computerised 
simulations have been applied in other contexts (Xia et al., 2006), such as in 
silico cardiac models which have been applied in risk stratification of LQT1 
syndrome patients by predicting complex changes in channel function on 
the risk of arrhythmic events (Hoefen et al., 2012). One idea currently 
under development is to simulate physiological effects of hypoglycaemia, 
with a combination of graded hypokalaemia and sympathoadrenal 
activation, in the presence of mutated ion channels (SCN5A and HERG) in 
computerised cardiac models. The impact of hypoglycaemia on 
accentuating repolarisation abnormalities in the presence of existing ion 
channel mutations can be explored. Computer models may in future help 
stratify T2DM patients at high risk of developing arrhythmias during 
hypoglycaemia, with the possibility of prophylactic measures in the form of 
medical therapy, ablation or implantable cardiac defibrillators. 
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9.2.2 Observational Clinical Studies 
9.2.2.1 Effect of spontaneous severe hypoglycaemia on thrombotic 
risk in Type 2 diabetes 
In the present work, we have reported increases in platelet reactivity at the 
time of experimental hypoglycaemia and alteration in fibrin clot properties 
downstream. However, the transferability of these experimental 
observations to  spontaneous hypoglycaemia in a clinical setting is 
unknown.  Tsujimoto et al. (2014)  have examined a retrospective cohort of 
patients presenting to the emergency room with severe hypoglycaemia 
and demonstrated similar QT prolongation and hypokalaemia to what we 
observed experimentally. It would therefore also be of value to investigate 
thrombotic effects of hypoglycaemia in a multi-centred prospective cohort 
of T2DM patients presenting with severe hypoglycaemia to the emergency 
services. The main outcome measures would include indices of platelet 
reactivity, determined using point-of-care devices at presentation with 
hypoglycaemia. Furthermore, changes in inflammation, fibrin clot 
properties and platelet reactivity seven days later may be determined and 
compared against a matched T2DM ambulatory cohort without a history of 
hypoglycaemia.  However, this study may be logistically challenging to 
identify and recruit individuals presenting to the emergency services in a 
timely manner.  
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9.2.2.2 Changes in cardiac autonomic function following 
hypoglycaemia in critically ill patients 
The second study area of interest is concerned with the long term effects 
of hypoglycaemia in critically ill patients. During trials of intensive 
glycaemic control, the increase in mortality was not apparent during  the 
period of intensive care stay but instead rose post ICU/hospital discharge 
and remained evident at 90 days (Deane and Horowitz, 2013; Finfer et al., 
2012). One hypothesis following from the experimental observations in this 
study is that depressed cardiac autonomic function could mediate long 
term increases in cardiovascular mortality.  It has been established that 
impaired cardiac autonomic function and HRV predict subsequent 
mortality up to 60 days in patients who have experienced multiorgan 
dysfunction (Schmidt et al., 2005; Schmidt et al., 2008). Therefore, it is 
hypothesised that hypoglycaemia during intensive glycaemic therapy may 
further impair cardiac autonomic function in these patients leading to an 
increase in arrhythmic death in the short to medium term. To explore this 
possibility, collaborations are underway with an international group to 
study changes in autonomic function and the impact of glycaemic control 
in a prospective cohort of T2DM patients admitted to critical care. 
Autonomic function, as measured by HRV and cardiac autonomic function 
tests, will be performed in the period post ICU discharge and compared 
against ambulatory T2DM patients. This will be accompanied by Holter 
monitoring to assess the frequency of arrhythmias in the post-discharge 
period. 
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9.2.3 Clinical Implications 
9.2.3.1 Intensive Glucose Control with Hyperinsulinaemic 
Euglycaemia in Critical Care Patients 
This present work confirms that hyperinsulinaemic euglycaemia has anti-
aggregatory, anti-inflammatory, profibrinolytic properties that may confer 
cardiovascular protection. However, clinical trials of intensive glucose 
control in critical care settings and ACS have produced equivocal results, 
with improvements in mortality in some (Malmberg et al., 1995; van den 
Berghe et al., 2001) and no benefit or increases in mortality in others 
(Finfer et al., 2009; Malmberg et al., 2005).  
It is believed that the reasons for these are threefold. Firstly, occurrence of 
hypoglycaemia may oppose beneficial effects of intensive insulin therapy, 
as it has consistently been shown that a hypoglycaemia is one of the 
strongest independent predictor of subsequent mortality (Finfer et al., 
2012). Secondly, the occurrence of hyperglycaemia and the failure to 
achieve pre-designated targets may account for the lack of benefit, 
particularly in trials of glucose-insulin-potassium infusions in ACS. The final 
reason may be due to the fact that insulin doses were not sufficiently high 
to confer cardiovascular benefits associated with insulin action. For 
example, in the Leuven-1 trial subjects received around 70 IU insulin/day 
(with concomitant intravenous dextrose in the first 24 hours) and survival 
benefits were demonstrated with intensive control (van den Berghe et al., 
2001). This is in contrast with the NICE-SUGAR study, where daily doses of 
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around 50 units of insulin were used and this was not associated with 
improvements in clinical outcomes (Finfer et al., 2009). Similarly, other 
studies of low dose glucose-insulin-potassium infusions have had negative 
results in ACS patients (Ceremuzynski et al., 1999). 
One area where intensive glucose control has been used for many years 
and been shown to improve mortality is perioperatively during cardiac 
surgery. Rackley et al. (1981) have developed a regime for a perioperative 
hyperinsulinaemic euglycaemic clamp for cardiac surgery. In this regimen, 
following a priming bolus of insulin, intravenous insulin is administered at a 
rate of 5m U/kg/min with 20% dextrose at a variable rate to maintain 
arterialised blood glucose at 4-6 mmol/L.  Such a regime has been 
successfully applied in clinical settings with a low risk of hypoglycaemia. It 
has been shown to improve cardiac enzymes and myocardial function 
through inhibiting ischaemic-reperfusion injury (Carvalho et al., 2011) and 
attenuating the systemic inflammatory response (Visser et al., 2005).  
Therefore testing a similar hyperinsulinaemic euglycaemic clamp protocols 
in critical care patients versus conventional glucose control (<10mmol/L) 
on morbidity and mortality outcomes maybe feasible. In this present work, 
it has been demonstrated that maintaining glucose at 6.0 mmol/L still had 
favourable effects on thrombosis and inflammation. Thereofre a glycaemic 
target of between 4-8 mmol/L, compared to a narrow range as used in 
previous trials (4.5-6.0 mmol/L) may be safer and still confer benefit   
(Finfer et al., 2009).  The challenges are to design a suitable 
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hyperinsulinaemic euglycaemic clamp regime in critical care patients. This 
may be based on hyperinsulinaemic clamp protocols and doses of insulin 
according to body weight as used in this research study, but will require 
modification. The feasibility of a lower frequency of blood glucose testing, 
e.g. every 15 minutes when a steady-state is reached, will require 
investigation, as this is one of the limiting factors for translating to use in a 
clinical setting. There are groups that have trialled the use of interstitial 
CGM in critical care areas (Lee et al., 2011); however, it is unlikely that this 
can replace blood glucose monitoring due to the limited accuracy of CGMS 
in the hypoglycaemic range and also the interstitial lag that will influence 
the accuracy of insulin adjustments. Initial studies could focus on 
comparing the effects of hyperinsulinaemic euglycaemic regimes versus 
conventional glucose control on surrogate measures, such as inflammatory 
indices (hsCRP) and markers of thrombosis (fibrinogen) as a proof-of-
concept. This should lead to definitive randomised controlled trials to look 
at hard outcomes on length of intensive care stay, short and medium term 
morbidity, and mortality. 
9.2.3.2 Intensive Glucose Control in Acute Coronary Syndrome in  
Patients with Type 2 Diabetes 
Glucose-insulin-potassium infusions in ACS without glycaemic control have 
shown no mortality benefit (Zhao et al., 2010). However the value of 
insulin-glucose infusions to achieve normo-glycaemic targets in diabetic 
patients with ACS remains open to debate. In the DIGAMI-1 study, there 
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were long term survival benefits apparent at one year and even at 20 year 
follow up as recently repored, where the median survival in the intensive 
group was 7 years as opposed to 4.7 years in the conventionally treated 
group (Ritsinger et al., 2014). It remains unresolved as to whether the 
benefits seen in the DIGAMI-1 study were related to the acute insulin-
glucose regimen or subsequent control with subcutaneous insulin. 
Furthermore, the benefits of insulin-glucose regimens need to be 
evaluated in the modern era of primary percutaneous coronary 
intervention. 
There is a need for a well-designed, well-conducted trial of intensive 
glucose control in AMI in diabetic patients.  The first step would be to 
evaluate isolated effects of acute insulin-glucose therapy in the immediate 
infarct period. Pilot phases should explore safe doses of intravenous insulin 
and dextrose to be used. In a subset analysis of the Hyperinsulinaemia-
Intensive Insulin and Infarction study (HI-5), achieving a mean blood 
glucose <8 mmol/L in the first 24 hours with insulin-dextrose infusion was 
associated with a significant reduction of in-hospital,  three and  six month 
mortality  (Cheung et al., 2006). Therefore the value of a more stringent 
glucose target of 4-8 mmol/L could be explored. The optimal timing of 
insulin–glucose therapy in relation to the onset of AMI and reperfusion 
therapy needs to be investigated. This will hopefully eventually lead to 
randomised controlled trials of intensive-glucose therapy in diabetic 
patients in a clinical setting. In addition to mortality and cardiovascular 
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event rates, secondary outcomes should include effects on inflammation, 
platelet reactivity, cardiac enzymes and myocardial function. 
9.2.3.3 Intensive Glycaemic Control in Type 2 Diabetes Patients and 
Cardiovascular Outcomes 
The final question relates to the original population of interest, the value of 
intensive glycaemic control in T2DM patients in cardiovascular mortality. In 
the post ACCORD era, there has been a shift away from a ‘glucocentric’ 
view of macrovascular disease prevention, and the risk-benefit of any anti-
diabetic regimen has to be weighed against potential microvascular 
benefits versus the risk of hypoglycaemia. A third important factor to be 
taken into consideration is the glucose-independent cardiovascular profile 
of glucose lowering agents. A lesson has been learnt from the withdrawal 
of rosiglitazone following post-marketing studies demonstrating an 
increased risk of myocardial infarction and cardiovascular death (Nissen 
and Wolski, 2007). In contrast, protective effects of metformin have been 
suggested by the UKPDS study and subsequently been confirmed by meta-
analyses which showed lower cardiovascular mortality when used in 
overweight patients (Selvin et al., 2010). Recent post-marketing studies of 
DPP-4 inhibitors have shown that they may be ‘cardiovascular neutral’ with 
no evidence of an increase in cardiovascular deaths (Scirica et al., 2013; 
White et al., 2013). However, the safety of GLP-1 analogues are still to be 
confirmed in ongoing trials.  As the present study has highlighted, insulin 
itself has numerous glucose-independent effects. While it may have anti-
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aggregatory, anti-inflammatory, profibrinolytic, vasodilatory effects at high 
doses with intravenous infusion, it can also have sympathoexcitatory 
effects that can worsen, for example, platelet function.  It is emerging that 
pleiotropic effects of these glucose lowering agents can have complex 
influences on overall cardiovascular outcomes. 
Nevertheless, the present work has underlined the importance of the 
minimisation of hypoglycaemia while maintaining good glycaemic control, 
which remains important in reducing microvascular complications (Ismail-
Beigi et al., 2010). There are two aspects of choice for a suitable glycaemic 
regimen – a suitable ‘glycaemic target’ and the choice of glucose lowering 
agent. The current guidelines of the European Association for the Study of 
Diabetes and the American Diabetes Association recommend an 
individualised approach to decisions regarding glycaemic targets  (Inzucchi 
et al., 2012). Less stringent targets have been advocated in individuals at 
higher risk of hypoglycaemia, or those with advanced macrovascular 
disease, or limited life expectancy. Traditionally, glycaemic targets have 
equated with ‘HbA1c’ targets. However, observational studies suggest that 
there is not a clear linear relationship between HbA1c and the number of 
hypoglycaemic events; in fact, a U-shaped relationship has been shown, 
where patients with HbA1c <6% and above 9% were both at higher risk of 
hypoglycaemia (Lipska et al., 2013).  This current study showed that the 
high prevalence of asymptomatic hypoglycaemia was only detected on 
CGMS in insulin treated T2DM patients. Part of the problem is that 
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intensive self-monitoring of blood glucose is often impractical in this group 
of patients given that they are often elderly with multiple comorbidities 
and complications. Other studies have confirmed the value of CGMS in 
detecting asymptomatic hypoglycaemia in T2DM patients (Chico et al., 
2003), and there may be a role for CGMS as a clinical tool to aid treatment 
adjustment which will require confirmation in larger studies of T2DM 
subjects (Kim et al., 2014). 
The choice of glucose lowering agents is also of importance. Metformin 
and incretin based therapies are associated with lower hypoglycaemic 
potential among oral hypoglycaemic agents; however, insulin-treated 
patients are the most vulnerable to hypoglycaemia. Both the regimen and 
type of insulin has some effect on the risk of hypoglycaemia. The 4T study 
which compared different regimens of analogue insulins showed that 
prandial regimes were associated with the highest risk of hypoglycaemia, 
followed by premixed insulin, whilst basal insulin was associated with the 
lowest risk of hypoglycaemia (Holman et al., 2009). In the present 
ambulatory study, the only difference between T2DM patients who 
experienced hypoglycaemia was in the type of insulin used. Out of 14 
patients who experienced hypoglycaemia, thirteen were on human insulin 
and only one on analogue insulin (p=0.02). Systematic reviews of 
randomised controlled trials have shown that basal analogue insulins are 
associated with a lower risk of nocturnal hypoglycaemia compared with 
human isophane insulin (Monami et al., 2008). Similarly, in studies of 
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premixed human versus premixed analogue insulins, there was a difference 
in the rate of nocturnal hypoglycaemia as captured on CGMS (McNally et 
al., 2007). A question which remains unanswered is whether there are any 
differences between analogues versus human insulins on overall 
cardiovascular risk when controlled for HbA1c.  There is evidence from 
observational cohorts that patients on analogue insulin as opposed to 
human regular insulin had a lower incidence of cardiovascular outcomes 
(Rathmann and Kostev, 2012). However, the type of insulin regime will 
influence more than one glucose variable, so it is difficult to attribute 
whether differences are due to reduced hypoglycaemia alone or other 
aspects of glucose variability. 
9.3 Conclusions 
It is encouraging that a nationwide study has demonstrated that there has 
been a dramatic reduction in cardiovascular complications in the past 
decade (Gregg et al., 2014). The most marked reduction has been in the 
incidence of AMI, which fell by 67%. This has partly been brought about by 
improvements in revascularisation techniques, but also early disease 
detection and multifactorial risk factor modification. However, the rates of 
CVD remain significantly higher among diabetic patients. For example, the 
relative risk of AMI remains 2-fold higher than in nondiabetic individuals, 
although it was nearly 4-fold higher in the previous decade (Gregg et al., 
2014). The question for the future is how to further reduce macrovascular 
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risk with the armoury of glycaemic, lipid lowering, antithrombotic and 
cardiovascular therapies.  
Hypoglycaemia remains a limiting factor for intensive glycaemic therapy in 
T2DM patients and the magnitude of the problem of hypoglycaemia in 
T2DM has previously been underestimated. The message from this current 
work is to alert physicians to the potentially harmful effects of 
hypoglycaemia, which may not be limited to the acute hypoglycaemic 
episode but persist in the days and weeks after an event. Such 
proarrhythmic, prothrombotic effects, may in concert, ultimately lead to an 
increased propensity for SCD. It is hoped that this current work will 
stimulate new ideas and new thinking about the role of glucose lowering in 
CVD prevention in T2DM. This could lead to new paths of research that 
may change the picture of glycaemic management for the 21st century for 
the benefit millions of T2DM patients worldwide and  in generations to 
come.  
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Appendix 1: Event definitions for arrhythmia analysis in 
the Pathfinder ECG Analysis system 
N: Normal beat 
A: Aberrant beat 
Atrial ectopic 
A normal beat (N) followed by a normal beat, such that the R-R interval 
between these two beats is less than 66% of the prevailing NN interval. 
Ventricular premature beats (VPB) 
Any beat followed by an aberrant (A) beat, such that the R-R interval 
between these two beats is less than 66% of the prevailing NN interval. 
Bradycardia 
Run of any 4 beats at a rate of less than 45 bpm 
Complex VPB 
Trigeminy: repeated ANN sequence 
Bigeminy: repeated AN sequence  
Couplet: NAAN sequence 
Salvo: NAAAAN sequence 
Ventricular tachycardia: AAAAA…N, sequence of ≥ 5 aberrant beats at > 
100 bpm, terminated by a normal beat  
364 
Appendix 2: Classification of abnormal T wave 
morphologies 
Normal (Figure i)   
G1 Notched T (T1 apex >T2 apex) (Figure ii) 
G2 Notched T (T1 apex <T2 apex)  
 
QTU Fusion 
 
 
  
i) ii) 
Figure a: F0: No QTU 
fusion (No fusion between 
T and U wave)   
Figure b: F1: 1st degree 
fusion (nadir<25% of T1 
peak)  
Figure c: F2: 2nd degree 
fusion (nadir 25-50% of T1 
peak) -  
Figure d: F3: 3rd degree 
fusion (nadir>50% of T1 
peak)  
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Appendix 3: Ethics approval for Study 1: Cardiac 
electrophysiological responses to spontaneous 
hypoglycaemia in type 2 diabetes 
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Appendix 4: Ethics approval for Study 2: Cardiovascular 
responses to experimental hypoglycaemia in type 2 
diabetes 
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Appendix 5: Example of phasic changes in HRV during 
nocturnal hypoglycaemic episodes in two further 
participants  
In both instances, following falls in glucose at N1 or N2, there was glucose 
counter-regulation (C1) and (C2) (top panels). There was a decrease in ln 
HF (middle panels) indicating vagal withdrawal at C1 and C2, followed by a 
subsequent rise in ln HF within 20 minutes, similar to the example in Figure 
2. The bottom panels illustrate the reciprocal changes in normalised LF 
power.  
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Appendix 6: Respiratory frequencies during heart rate 
variability recordings  
Respiratory frequencies (Hz) mean ±SD during euglyacemic and 
hypoglycaemic clamp studies in diabetic and control groups 
Time  0 30 60 90 120 
Diabetes EU 0.25±0.05 0.27±0.07 0.26±0.05 0.29±0.06 0.24±0.05 
 HYPO 0.25±0.06 0.25±0.07 0.26±0.08 0.31±0.06 0.29±0.05 
Controls EU 0.24±0.03 0.25±0.05 0.24±0.04 0.26±0.05 0.26±0.07 
 HYPO 0.24±0.04 0.26±0.04 0.27±0.06 0.30±0.08 0.27±0.08 
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Appendix 7: Platelet aggregation to 3 µM ADP by whole 
blood single platelet counting in euglycaemic and 
hypoglycaemic arms 
Data for mean (SE) change in percentage platelet aggregation.  
 
EU – euglycaemia, HYPO - hypoglycaemia 
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